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Abstract
The work described in this thesis involves the production and characterisation of 
antibodies and recombinant antibodies to aflatoxin Bi (AFBi), a potent mycotoxin 
and carcinogen. The antibodies produced were then applied for use in a surface 
plasmon resonance-based biosensor (BIAcore), which measures biomolecular 
interactions in ‘real-time’. Production of hapten-protein conjugates of the 
organophosphate pesticides chlorpyrifos and pirimiphos, and characterisation of anti- 
chlorpyrifos antibodies were also successfully performed.
Rabbit polyclonal and single chain Fv (scFv) antibodies were produced to aflatoxin 
Bi. The scFv’s were produced from an established phage display system, which 
incorporated a range of different plasmids for scFv expression. Both sets of 
antibodies were used in the development of competitive ELISA’s and also for the 
development of BIAcore-based inhibition immunoassays. The antibodies were also 
used in the detection of AFBi in spiked grain samples by ELISA and BIAcore. Both 
the polyclonal and scFv antibodies were found to be suitable for the detection of 
AFBi, and the assays were reproducible.
The production of an activated form of the organophosphate pirimiphos for the 
production of a pirimiphos-protein conjugate was attempted. However it was not 
possible to conjugate this pesticide by any suitable means. Chlorpyrifos-BSA 
conjugates were produced with different molar substitution ratios, and were used for 
the development of a competitive ELISA with polyclonal anti-chlorpyrifos 
antibodies.
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Chapter 1
Introduction
i
1.1. The immune system
Throughout a lifetime, the mammalian vertebrate immune system encounters a large 
variety of infectious microbial agents such as viruses, bacteria, fungi, and parasites. 
These organisms can cause pathological damage, and if they are allowed to multiply 
unchecked, they will eventually kill their host. The immune system has evolved a 
powerful range of separate but inter-linked mechanisms for identifying and 
combating such pathological organisms. The two functional divisions of the immune 
system, which incorporate these protective mechanisms, are the innate system and the 
adaptive immune systems.
Innate immunity acts as the first line of defence, and consists of a series of physical 
and physiological barriers. The skin and mucous membranes are the body’s first line 
of defence against infection. Physiological factors such as pH, temperature, and 
degradative substances such as lysozyme act in addition to this. If an organism 
penetrates the epithelial surface it encounters phagocytic cells, which come from 
monocytes/macrophages. These break down non-specifically by a process known as 
phagocytosis (Roitt et al., 1989). This involves engulfing foreign particles, and 
breaking them down using potent intracellular enzymes and chemicals. The 
inflammation caused when tissue damage occurs also contributes to the innate 
immune system by facilitating the emigration of phagocytes and the lysis of 
pathogenic microorganisms.
The adaptive immune system differs from the innate system, as it is directed against 
specific molecules, and it possesses an ‘immunological memory’. The system can be 
further divided into cell-mediated immunity and humoral immunity.
1.1.1. Cell mediated immunity
The key components of cell mediated immunity are T-lymphocytes, or T-cells, which 
complete their maturation in the thymus. These mature T-cells migrate from the 
thymus to the lymphoid organs such as the lymph nodes and the spleen. The two 
main types of T-cells are cytotoxic T-cells (Tc), and T-helper cells (Th). T-cells
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cannot normally be activated by free antigens present in body fluids. Instead they 
only respond to antigenic epitopes displayed on the surface o f the body’s own cells. 
These epitopes are known as the major histocompatibility complex (MHC), and they 
act like a red flag calling the T-cells into action against cells infected by the pathogen 
represented by that particular antigen (Davey, 1992). Th-cells recognise antigen in 
conjunction with MHC II proteins and are responsible for the release of a group of 
chemicals called cytokines. Cytokines play a crucial role in the regulation of the 
immune response, as their secretion regulates neighbouring cells. Th cells are made 
up o f two distinct populations, which are differentiated by the cytokines they secrete- 
Th-1 and Th-2 cells. Th-1 cells are primarily responsible for the activation of Tc- 
cells by secreting the cytokines interleukin-2 (IL-2), interferon gamma (LFN-y) and 
tumour necrosis factor beta (TNF-p) (Male et a l, 1996). However, they also play a 
role in the activation o f B-lymphocytes. Th-2 cells are predominantly responsible for 
the activation of B-lymphocytes by secreting the cytokines IL-4 and IL-5 (Hannigan, 
2000; Male et al., 1996). Tc-cells recognise antigen in conjunction with MHC I 
proteins, which are found on all nucleated cells of the body. When it docks on the 
surface o f an infected cell, it releases perforin, a protein that forms an open lesion on 
the cell membrane, thus leading to cell lysis. As well as destroying the host cell the 
Tc-cell also deprives the invader of a place to reproduce and exposes the pathogen to 
circulating antibodies.
1.1.2. Humoral immunity
The humoral immune response is mediated by B-cells in conjunction with Th-cells 
and their secretion o f cytokines. After a macrophage engulfs a pathogen by 
phagocytosis it breaks it down into smaller pieces, and displays pieces o f the digested 
antigen on its surface. In this context, the macrophage is known as an antigen- 
presenting cell (APC). B-cells and dendritic cells can also function as APC’s (Male 
et a l, 1996). A feature o f all APC’s is that they express MHC II proteins on their 
surface (Lydyard et a l,  2000). Degraded antigen components bind to the MHC II 
molecule within the cell and are then exported to the cell surface. Th-cells then 
recognise this self/non-self complex of MHC II and antigen. This contact activates
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the Th-cell, which proliferates and forms a clone of Th-cells keyed to the specific 
antigen. A co-stimulatory signal from the APC (secretion of the cytokine TL-1) also 
activates the Th-cells to secrete cytokines. It is these cytokines that are responsible 
for the stimulation of B-cells. IL-2 plays a key role in B-cell proliferation. Antigens 
are also processed by B-cells, although uptake is specific for a particular antigen. 
When antigen binds to antigen receptors on a B-cell, the cell takes in a few of these 
foreign molecules, and displays the antigen fragments bound to class II MHC 
markers on the cell surface. The Th-cells receptors recognise this and bind to the 
antigen-MHC-complex. This results in B-cells synthesising receptors for IL-4 (Th-2 
response) which causes their proliferation, and in-tum production of IL-5. This 
cytokine is responsible for the differentiation o f B-cells into memory and plasma 
cells. Figure 1.1 shows a schematic diagram of the sequence of events that lead to 
antibody production in the immune system. Plasma cells are responsible for the 
secretion o f large amounts o f specific antibody (2000/second), and have a lifespan of 
4-5 days (Campbell, 1993). B-memory cells do not secrete antibodies, but instead, 
remain in the body for long periods o f time with specific antibody cell-surface 
receptors primed for future exposure to the antigen. Memory T-cells also exist, and 
result from the initial encounter with antigen that generates an antigen specific T-cell 
response. Once a subsequent encounter occurs with the antigen, the memory cells are 
rapidly restimulated and proliferate to combat the antigen. One surface molecule 
found on T-cells is CD45. It has been found that this molecule changes, when a T- 
cell is activated by an encounter with an antigen. T-cells that have not yet 
encountered antigen are said to have the CD45RA molecule, while memory T-cells 
have the CD45RO molecule (Hannigan, 2000). However, it is not entirely certain 
that this distinction is completely reliable, as it is thought that cells can change CD45 
formats through other event sequences.
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phagocytosed by the APC and presented on the surface as M HCII antigen-complex. Th-cells 
bind to the MHC II antigen-complex, and become activated to produce cytokines (dotted 
arrows) such as IL-1, which triggers T-cell differentiation and proliferation by autocrine 
growth factor. Th-1 and Th-2 cells secrete different cytokines that enhance B-cell 
proliferation. However, it is the Th-2 - derived cytokines that predominantly enhance B-cell 
proliferation. B-cells with specific antigen receptors on their surface bind to antigen in 
solution, and the proliferation o f  these B-cells is stimulated by the presence o f cytokines. 
This results in differentiation into memory and plasma cells. The plasma cells are capable of 
producing large amounts o f soluble antibody following affinity maturation in the germinal 
centres.
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1.1.3. Immunogenicity
Immunogenicity is the ability of a particular molecule to provoke an immune 
response. In order for a molecule to be immunogenic, it must possess three 
properties, namely: a degree of foreignness, a large molecular weight, and a degree of 
chemical complexity. The immune system must be able to recognise the antigen as 
foreign, and therefore, the greater the genetic distance between the source species of a 
molecule and the species of the host, the greater the immune response will be. 
Molecules with a molecular weight of greater than 1 kDa are generally capable of 
provoking an immune response (Davey, 1992). Smaller molecular weight 
compounds such as drugs or pesticides are not capable of provoking an immune 
response, and therefore, need to be conjugated to a larger carrier molecule in order to 
become immunogenic. The greater the chemical complexity of a substance, the more 
immunogenic it will be. Synthetic polymers of a single amino acid generally do not 
give rise to an immune response, whereas those containing a variety o f amino acids 
are more effective immunogens.
Once an animal has been exposed to an antigen, either through immunisation or 
natural causes (e.g. injury) the immune system begins to work on combating it. The 
selective proliferation o f lymphocytes to form clones o f effector cells against an 
antigen constitutes the primary immune response. Between exposure to the antigen 
and the maximum production of effector cells, there is a lag period o f 5-10 days. 
During this lag period, the lymphocytes selected against the antigen are 
differentiating into effector T-cells and antibody producing plasma cells. If  the body 
is exposed to the same antigen at a later date, the response is faster and more 
prolonged. This is known as the secondary immune response, and is based on the 
immune systems ability to recognise previously encountered antigen i.e. 
immunological memory (Figure 1.2).
The effectiveness o f the secondary immune response is dependent on the 
immunogenicity o f the antigen used. Generally large insoluble molecules tend to be 
better immunogens than small insoluble molecules, as they can be rapidly
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Figure 1.2. Immunological memory. Initial exposure to the immunogen stimulates the 
primary immune response, with the eventual production o f  antibodies against the immunogen 
after a short time lag. A second exposure to the immunogen on day 28 produces a faster and 
greater secondary immune response, which is due to specific long-lived memory cells.
phagocytosed, and effectively processed and presented by APC’s. Administrating an 
adjuvant along with the immunogen can enhance the immune response significantly. 
An adjuvant is a substance that non-speciflcally stimulates the immune system. 
Adjuvants function in two main ways. Firstly, they protect the antigen by trapping it 
in a local deposit, and secondly, they attract macrophages and increase the local rate 
o f phagocytosis. Freund’s complete is one o f the most widely used adjuvants in 
animals. It consists o f mineral oil, emulsifying agent, and heat-killed Mycobacterium 
tuberculosis (Cooper, 1982). When the immunogen is mixed with the adjuvant and 
injected, the emulsifying agent causes the oil to form into small droplets, and results 
in the immunogen being released slowly from the injection site. The mycobacteria 
enhance macrophage activity and lead to the stimulation o f Th cells. These factors 
provoke an inflammatory response, thus giving the immune system the ‘kick-start’ to
developing a large immune response to the immunogen. Freund’s incomplete is the 
less pathogenic adjuvant, as it does not contain any mycobacteria. It is frequently 
used for second and subsequent immunisations- a process known as ‘boosting’. 
Boosting is carried out in order to achieve the secondary immune response, and 
therefore, a greater amount of specific antibody in the serum.
Dosage and route o f administration can also effect the immune response. Low doses 
of immunogen will not significantly activate the lymphocytes, while high doses can 
result in lymphocytes entering a non-responsive state. Different routes of 
administration can also be used, such as sub-cutaneous, intravenous, or intra- 
peritoneal. Sub-cutaneous injection will cause an administered substance to gather in 
the local lymph nodes, while intravenous injection carries the immunogen straight to 
the spleen. Intra-peritoneal injection is the most commonly used method for 
immunising mice with antigens. This is because of the large volume of the peritoneal 
cavity, thus allowing for larger volumes o f immunogen to be administered. It is also 
a useful route for injecting particulate antigens such as heat-killed bacteria. These 
cannot be injected intraveneously as they may cause embolisms in the mouse.
1.2. Antibody structure and function
Antibodies constitute a class of glycoproteins called immunoglobulins (Igs) that are 
produced by the immune system against foreign antigens. Five distinct classes of Ig 
exist in most higher mammals. These are IgM, IgA, IgD, IgE, and IgG (Lydyard et 
al., 2000). IgM ’s are pentameric in structure, and are the first circulating antibodies 
to appear in response to initial exposure of antigen. IgA antibodies are dimeric in 
structure, and are found in many body secretions, as they prevent the attachment of 
bacteria and viruses to epithelial surfaces. IgD antibodies are monomeric, and are 
mostly found on the external surfaces o f B-cells functioning as antigen receptors 
required for initiating differentiation of B-cells that produce antibodies against the 
antigen. IgE antibodies are also monomeric in structure, and represent only a very 
small proportion o f total antibodies in the blood. They are involved in the release of 
histamine, and other chemicals that cause an inflammatory reaction (Campbell,
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1993). IgG’s are the major immunoglobulin found in the blood system, as they 
constitute for 70-75 % of the total immunoglobulin pool (Roitt et al., 1989). The 
basic structure o f the IgG molecule is shown in Figure 1.3. It consists of two 
identical heavy (H) chains and two identical light (L) chains stabilised and linked 
together by inter-and intra-chain disulphide bonds.
The L-chains weigh about 25 kDa, and the H-chains approximately 50 kDa giving the 
total molecular weight of approximately 150 kDa for the monomeric structure. The 
H and L-chains can be further divided into domains on the basis o f the variability of 
their amino acid composition. Each L-chain has one variable (Vl) and one constant 
(Cl) domain, while the H-chain has one variable (Vh) and three constant domains 
(ChI, Ch2, Ch3). The hinge region is a short amino acid sequence situated between 
the ChI and Ch2 regions of the antibody’s heavy chains. It gives flexibility for the 
two arms of the molecule (Lydyard et al., 2000).
The constant regions o f the antibody are responsible for effector functions and 
complement binding, while the Vh and V l domains are responsible for the specific 
recognition of antigen. These domains exhibit a high variability in amino acid 
sequence. This is a highly organised process within specific areas of the variable 
region, known as hypervariable regions. These form a region complementary in 
structure to the antigen epitope, and are thus called the complementary determining 
regions (CDRs). The CDR can be further divided into three sub-regions (CDR1, 
CDR2, and CDR3), as well containing more conserved regions known as framework 
residues. The CDR sequences are exposed on the variable region of the antibody and 
form a cleft that is the antigen-binding site. The combination of the CDR sequences 
results in a precise amino acid sequence and shape o f the antigen-binding site, which 
confers an antibody’s particular specificity (Roitt et a l, 1989).
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Figure 1.3. Structure o f  the immunoglobulin IgGj molecule. The antibody is composed o f  
two identical light (25 kDa) and heavy (50kDa) chains. The H  chains comprise o f  five distinct 
domains: one variable (V^), three constant (CH1, CH2, CH3), and one hinge region. The hinge 
region provides the flexibility to allow fo r the individual antibody-binding sites to bind to 
antigen. The light chains comprise o f  a single variable (V i)  and a single constant (Cl ) 
region. Interchain disulphide bonds connect the heavy and light chains, while intrachain 
disulphide bonds exist in the variable and constant regions giving the folded globular 
structure characteristic to antibodies. The complementary determining regions (CDRs) 
confer the specificity to the particular antibody-binding site, and have a high amino acid 
sequence variability.
10
The IgG molecule can also be broken down into various fragments by means of 
enzymatic degradation, as well as being produced genetically. Figure 1.4 shows a 
structure of an IgG molecule and its various fragments. Treatment o f the IgG with 
the enzyme pepsin cleaves the two heavy chains below the interchain disulphide 
bonds and forms a F(ab')2 fragment. This consists o f two light chains, along with two 
heavy chains and the hinge region. Papain will cleave the IgG molecule above the 
disulphide bridges, giving rise to two separate Fab fragments which bind antigen 
(Roitt et ah, 1989). Protein engineering has allowed for the development Fab 
fragments as well as scFv antibody fragments. The production of scFv fragments is 
becoming increasingly popular, as they can also offer high levels o f sensitivity and 
specificity towards a given antigen compared to that of whole IgG’s. A scFv 
antibody fragment consists of one variable heavy chain and one variable light chain 
stabilised together by a synthetic peptide linker (or in some cases the insertion of 
cysteine residues to form a disulphide bridge). This results in the production of a 
more stable antibody fragment compared to that of the Fv molecule. The genetic 
production of these antibody fragments will be discussed later in this chapter.
Antibodies do not destroy antigenic invaders directly. Instead, the binding of the 
antibody-antigen complex serves the basis of many effector functions. The simplest 
of these is neutralisation, which blocks key binding sites on a particular antigen, thus 
making it ineffective. Agglutination is another method it uses, where it exploits its 
two binding sites to cross-link adjacent antigens (Lydyard et ah, 2000). Both of these 
methods enhance phagocytosis, and antigen processing and presentation. Another 
important effector mechanism of antibodies and the humoral immune response is the 
activation o f complement. Complement is a group of more than 20 plasma proteins 
that act with elements of the innate and adaptive immune system (Hannigan, 2000). 
Antibodies often combine with complement proteins, to activate complement and 
produce lesions in an invading cell’s membrane, and thus lysing it.
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Figure 1.4. Structure o f  the immunoglobulin IgGj molecule and its various fragments. The F  
(ah') 2 fragment consists o f two antigen binding fragments linked by the hinge region, while 
the Fab fragment is only one antigen binding fragment. An Fv molecule consists o f  one 
variable heavy chain and one light variable chain. The scFv molecule is an Fv stabilised by 
a synthetic linker. The Fd fragment comprises o f  a variable heavy and one constant heavy 
chain molecule, while the complementary determining region (CDR) is the smallest antigen- 
binding fragment. These various fractions o f  the whole antibody molecule may be generated 
either through genetic or enzymatic and chemical manipulation.
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1.3. Antibody diversity and its genetic basis
The variable regions of the heavy and light chains o f an antibody are what encode for 
the antibody’s diversity. Heterogeneity within these regions ensure a diverse 
repertoire of antibodies that can combat any pathogen the immune system encounters. 
Four distinct processes have been identified for the generation of this somatic 
diversity (Tonegawa, 1983), and they are namely: combinatorial diversity, junctional 
site diversity, junctional insertion diversity, and somatic mutation.
In the germ-line cells, there are three sets of genes involved in immunoglobulin 
coding. One set codes for the heavy chain genes, and two sets code for the light 
chain genes, which are designated by the Greek letters kappa ( k )  and lambda (X). 
These differ significantly in the amount of amino acid sequence in their constant 
domains. The three sets of germ line genes (heavy chain, and k  and X light chain 
genes) occur on three different chromosomes on both human and mouse cells. Figure 
1.5 shows the three immunoglobulin gene sets in human germ line cells.
Variable light chain genes are encoded by the V and J regions, while the heavy chain 
genes are encoded by the V, D, and J regions. After B-cell maturation the various 
VDJ, and VJ sequences recombine to form a complete functional gene. During the 
recombination process, when a D region is brought adjacent to a V region, a 
procedure called ‘looping out’ occurs, where the intervening gene segments are 
deleted by recombinase enzyme (Figure 1.6). As a result, joining can occur with 
various combinations on the genes, and the number o f possible permutations is the 
product of the number of V, D, and J sequences particular to each sequence.
Junctional site diversity arises at the Vl-Jl, V h-D and D-Jh junctions, because the 
joining ends are imprecise. This leads to changes in amino acid sequences at the 
junction sites, thus altering the binding site specificity.
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X light-chain genes
k  light-chain genes
heavy-chain genes
= Genes coding for the variable region of the light 
chain (VJ) or heavy chain (VJD)
= Genes coding for the constant region o f a given chain
= Represents intervening stretches o f non-coding DNA 
= Represents immunoglobulin genes that have been 
omitted from the diagram
Figure 1.5. The three immunoglobulin gene sets in human germ-line cells, prior to somatic 
recombination. These three gene sets are on different chromosomes in the human and mouse 
genome. Diagram taken from Davey (1992).
Vu V» »u
VKi !J  VkJOO  JKI — I JK5 1 CK|
'111 ! mw- Di - j -j  D m   Jin -j-J- JH4
14
Germ Line DNA
200 Variable Genes 12 D Regions 6 J Regions Constant RegionHMOOOOOOOflMOmdir
D J joining
- — OWDQ--------
Mature B- 
cellDNA
V D J  joiningHZHZHHH
Functional
GeneFigure 1.6. The two separate processes involved in the recombination o f  a heavy chain gene. 
Heavy chain gene segments are composed o f  V (variable), D  (diversity), and J  (joining) 
segments. The constant regions encode fo r the antibody isotype. The first recombination 
step involves bringing the D  and J  segments together by the process o f  ‘looping out ’ the 
intervening DNA by recombinase enzymes. These also introduce further variability at the 
point o f cleavage (junctional site diversity). The second step also involves looping out o f  
DNA genes, in order to bring the V region alongside the D J  regions. This determines the 
specificity o f  the antibody and gives rise to a functional B-cell variable heavy chain gene.
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Junctional insertion diversity only occurs in the V h-D  and D -J h junctions, where one 
to several nucleotides are inserted in between the sequences.
More variation arises after contact with antigen. Single base changes occur in the 
DNA of activated B-cells, during the process of memory-cell formation. This is 
called somatic mutation, and the V, D and J genes are particularly susceptible to this 
type of mutation that can generate a small, but significant, variation in the antibody- 
antigen binding sites. One of the consequences of somatic mutation is that some of 
the binding sites produced by the mutated DNA have a better affinity for the antigen, 
and some have a lesser affinity. This is because the mutations occur randomly in the 
DNA coding for the variable regions, and therefore, sometimes improving the 
‘goodness of fit’ between the antigen-binding site and the epitope- and also- 
sometimes reducing it. Somatic mutations mainly occur during memory B-cell 
formation, so the memory B-cell from a single clone ends up with binding-sites for 
the same antigen but with a range o f different affinities. The memory cells with the 
higher affinity antibodies on their surface will be more likely to bind the antigen upon 
a second exposure, than the lower affinity antibodies. Thus, cells producing a higher- 
affinity antibody will be selected for activation during the secondary immune 
response. This process is known as affinity maturation (Davey, 1992).
Class or isotype switching occurs in mature B-cells as a result of antigenic 
stimulation. Figure 1.5 shows that constant H-regions are found downstream of the 
variable region genes, in the sequence |J., 5, y, s, a. The C^-gene is the first one and 
codes for the constant domains of the heavy chains of the IgM class. Transcription 
always takes place in the one direction (from 5' to 3'), and as a result, the primary 
mRNA transcript made from this DNA contains the transcribed version of CH, thus 
ensuring the resulting antibodies are IgM. These are the predominant class of 
antibody secreted by B-cells for first contact with antigen. However, as the primary 
immune response proceeds, some of the V, D, and J sequences o f the B-cell undergo 
further DNA recombination with the C-genes (except for the 8 gene, which has no
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switch region). The CY is next in the order and is brought to lie immediately 
downstream of the genes coding for the variable region of the heavy chain. This will 
be then transcribed into mRNA, and the cell will switch from synthesising IgM 
antibodies to IgG antibodies (Davey, 1992). Antigen and T-cell-derived cytokines 
regulate this mechanism, and allows for the production of antibodies with unique 
specificities and effector functions to a particular antigen.
1.4. Production of antibodies
1.4.1. Hapten-carrier conjugate production
A mentioned previously in section 1.1.3, hapten-molecules such as pesticides, food 
contaminants, and drugs usually have a molecular weight of less than 1 kDa. As a 
result o f this, they generally do not elicit an immune response on their own, and need 
to be conjugated to a larger protein for immunisation purposes. The most frequently 
used carriers are highly immunogenic proteins, but lipid bilayers, polymers (e.g. 
dextran), and synthetic organic molecules have also been used (Hermanson, 1996). It 
is important for the carrier molecule to be highly immunogenic, non-toxic in vivo, as 
well as contain suitable functional groups for covalent linkage. Haptens may also 
have to be chemically modified, in order to conjugate them effectively to a protein. 
Hapten-protein conjugates are also used in the screening stages of antibody 
production. When screening for the detection of specific antibody, it is desirable to 
use a conjugate containing a different protein moiety than the immunogen, so false 
positive results o f observing non-specific binding o f antibodies produced to the 
protein part o f the conjugate are minimised. Danilova et al. (1994) recommended 
that, when dealing with very small haptens, the conjugate used for screening should 
possess a different carrier molecule and coupling chemistry than used for 
immunisation. However, in situations when it is not possible to synthesise a second 
protein conjugate for use in the screening stages, certain controls can be introduced 
into a particular assay to minimise false positives. These include incorporating the 
protein (that was conjugated to the hapten) into the antibody diluent buffer. This 
ensures that any o f the non-specific antibodies to the protein are ‘mopped up’ before
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they can bind to the protein conjugate on the plate, and thus detected in the assay. In 
order to ensure that there is sufficient protein in the diluent buffer to remove the non­
specific interactions, another control must be ensured, where the antibodies are also 
assayed against the protein with the protein in the diluent buffer. One of the most 
widely used proteins for conjugation to haptens is bovine serum albumin (BSA). 
This is highly soluble with a molecular weight of 67 kDa. It also has a variety of 
functional groups available for conjugation including -NH2, and -COOH groups.
1.4.2. Polyclonal antisera
When an animal is injected with a multivalent antigen, an immune response is 
elicited, and the titre of antibody specific for the epitopes on that antigen increase. If 
several injections o f the antigen are given over a period of weeks or months the 
specific antibody response will increase. The blood of the host animal will contain a 
heterogeneous mixture of antibodies directed against different epitopes on the 
immunogen, and binding with a variety o f affinities. This is known as polyclonal 
antiserum (Davey, 1992). The animals in which polyclonal antiserum is ‘raised’ tend 
to be the larger species of domestic animal such as rabbits, sheep, and goats. This is 
because of their relative ease o f handling, as well as the fact that it is possible to 
obtain large quantities o f serum without harming the animal.
The concept o f antibody affinity cannot be applied to polyclonal antisera due to the 
heterogeneous nature o f the population. Instead the term ‘avidity’ is used to 
described the average affinity value for the mixture of antibodies in a polyclonal 
antibody population (Davey, 1992).
While an individual antibody molecule may exhibit a high specificity o f binding for a 
particular antigen-epitope, the presence o f similar epitopes on different molecules 
(but structurally related) may result in the antibodies binding to these structurally 
related molecules. This effect is known as ‘cross-reactivity’ and is more prevalent in 
a polyclonal antibody population due to their heterogeneity. However, it may also be 
encountered when dealing with a homogenous antibody population.
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One of the main advantages in the production of polyclonal antibodies is their relative 
inexpense, as well as the relatively short time-frame in which they can be obtained. 
A possible disadvantage is that consistency between batches cannot be guaranteed, 
and therefore there may be a greater degree in variation in assays using polyclonal 
antibodies
1.4.3. Monoclonal antibodies
In order to produce a homogenous antibody population i.e. a monoclonal antibody- it 
is necessary to isolate and propagate one individual B-cell clone. B-cells can only be 
cultured in vitro for a short period o f time, after which they will die. Kohler and 
Milstein (Kohler & Milstein, 1975) reported the fusion of a B-cell to an immortalised 
myeloma cell resulting in an immortalised fusion product that could continuously 
produce monoclonal antibodies. This fusion product was called a hybridoma (hybrid- 
myeloma).
In order to produce a monoclonal antibody by somatic cell fusion, it is necessary to 
immunise a mouse or rat with the antigen of interest. After a period of time when a 
high enough antibody titre is obtained, the animal is given a final intravenous 
injection of the immunogen (without adjuvant). This results in the immunogen being 
directly carried to the spleen, where a large number of B-lymphocytes producing 
specific antibodies are present. The animal is usually sacrificed 3-4 days after this 
and the spleen removed.
A variety o f myeloma cells are available as suitable fusion partners such as X63- 
Ag8.653 or Sp2/0-Agl4 cell lines. They are tumorigenic B-lymphocytes that were 
produced from a myeloma cell line developed after injection o f mineral oil into the 
peritoneal cavity o f mice. These myeloma cells are deficient in an enzyme called 
hypoxanthine guanidine phosphoribosyl transferase (HGPRT). As a result of this, 
they are unable to proliferate in the presence of HAT (Hypoxanthine, Aminopterin, 
and Thymidine) medium. This is because aminopterin blocks de novo synthesis 
purines and pyrimidines, which are required for DNA synthesis. HGRPT deficient
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cells are incapable of using the salvage pathways for DNA synthesis as they do not 
have the requisite enzymes systems to do so.
Splenocytes carry the functional enzyme HGRPT, but are not capable of living in 
culture over a long period of time, and will die off. Therefore, once a fusion has been 
carried out, only splenocyte-myeloma cells will survive as they have the functional 
requirements to survive in HAT medium i.e. HGRPT enzyme (from the splenocyte) 
and the property of immortality (from the myeloma).
In order for a fusion to be effectively carried out, attachment and joining of both cells 
needs to be enhanced. One of the most common methods used is fusion using 
polyethylene glycol (PEG). This is a polywax, that enhances cell fusion and the 
transfer o f nuclei (Hurrell, 1985). Another method used for the generation of a 
hybridoma is electrofusion. This involves the generation of hybrid cells using high 
voltage electrical pulses to induce the fusion process. Dielectrophoresis is carried out 
first, which leads to cell-cell contact. This is followed by high voltage pulsing leading 
to the breakdown o f the adjacent cell membranes (Zimmermann et al., 1987). 
Fusion using PEG is generally more popular as it less stressful on the cells. 
However, electrofusion can increase the fusion efficiency 100-fold compared to that 
of PEG-based method.
After a number o f weeks, only hybridomas will have survived, and the culture 
supernatants are assayed for the presence o f specific antibody, and eventually only 
hybridomas derived from a single cell are produced. This is achieved by a process 
known as cloning by limiting dilution, in which the contents of positive wells are 
divided and sub-divided a number of times (Goding, 1996). A schematic diagram 
describing the generation of a monoclonal antibody is shown Figure 1.7.
The average amount of antibody in culture supernatant from conventional cell culture 
flasks is usually only between 10 and 100 fig/ml (Epstein & Epstein, 1986). In order 
to increase production of the quantity of antibodies, ascites fluid have been used.
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This entails the injection of the fused hybridoma cells into the peritoneal cavity of a 
mouse or rat, and allowing them to proliferate. The resulting ascites fluid can contain 
up to 1000 times as much specific antibody as spent cell culture medium (Galfre & 
Milstein, 1981). However, the disadvantage is that the resulting hybridomas can 
contain a high concentration of contaminating protein. More recently, there is also 
concern over the welfare of the animals using this procedure (Marx et al., 1997).
Monoclonal antibodies can also be produced to antigens following in vitro 
immunisation (Borrebaeck et al., 1983). The process involves harvesting B- 
lymphocytes from the spleen of a naive mouse (i.e. not immunised) and incubating 
them in culture with the antigen of interest for 5-9 days. Somatic cell fusion is then 
carried out on the cells after this period of time. The technique is advantageous in- 
that it offers a shorter immunisation schedule, as well as that reduced amounts of 
antigen are required. However, the shortfall is that the antibody response raised is 
primary, and therefore it is predominantly an IgM response, with reduced quantities 
of IgG. A primary in vivo immunisation can also be incorporated into the procedure 
followed by a secondary in vitro boost. This strategy has been shown to produce 
greater quantities o f IgG’s with increased affinities (De Boer et al., 1989).
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Figure 1.7. Flow diagram showing the principle steps in the production o f  a murine 
monoclonal antibody.
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1.4.4. Chimeric/Humanised, antibodies
One o f the few disadvantages of hybridoma technology has been the inability to 
extend it as a general method for the generation of human monoclonal antibodies. 
Although murine-derived monoclonal antibodies have been widely applied in clinical 
diagnostics, they have had a limited amount o f success in human therapy (Clark, 
2000). Two major problems have been encountered with the use of murine antibodies 
for therapy. Firstly, although the murine antibodies can be highly specific toward 
their target antigens, they do not always activate the appropriate human effector 
functions such as complement and Fc receptors. Secondly, when the antibodies were 
used for human therapeutic purposes, the patients immune system would recognise 
them as foreign and thus reduce their effectiveness. This is known as the human anti- 
murine-antibody immune response (HAMA). HAMA can produce several 
undesirable side-effects such as allergic reactions, as well as an increase in the 
clearance rate of the administered antibody from the serum (Iwahashi et ah, 1999).
In order to overcome HAMA, murine monoclonal antibodies were transformed into 
chimeric antibodies (Boulianne et ah, 1984). A chimeric antibody combines the 
entire variable (V) domain o f a mouse antibody with a human antibody constant (C) 
domain. Humanised antibodies have also been developed, and these consist of the 
mouse complementary determining regions being grafted onto human V-region 
framework regions and expressed with human C regions (Sung Co & Queen, 1991). 
The first fully humanised antibody, CAMPATH-1H, bound to an antigen on 
lymphocytes, and was used to treat patients with non-Hodgkin’s lymphoma (Hale et 
ah, 1988). Other strategies to overcome the immunogenicity of therapeutic 
antibodies include: selecting human antibody V-regions from phage libraries by 
affinity selection on antigen (Winter et ah, 1994), as well as constructing transgenic 
mice that have had there own immunoglobulin genes replaced with human 
immunoglobulin genes. Thus, they can produce human antibodies upon 
immunisation (Mendez et ah, 1997).
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Although the humanisation process has been relatively successful, it does have some 
problems such as reduction of the antibody affinity after humanisation (Riechmann et 
al., 1988). It is rarely sufficient to combine the CDR’s from a murine antibody with a 
completely human framework. This is because certain residues in the original murine 
framework make key contacts with the CDR’s that help maintain their conformation. 
When the murine framework is replaced with the human one, the contacts are altered, 
therefore altering the shape o f the CDR’s and reducing the affinity of the antigen 
(Sung Co & Queen, 1991). However, the reduction in affinity can be minimised by 
careful selection of framework regions that are homologous to the starting antibody, 
or by réintroduction o f important murine framework residues back into the 
engineered antibody. Sims et al. (1993) humanised a rat anti-human antibody that 
bound to CD 18, a cell surface glycoprotein that promotes the interaction of 
leukocytes with each other. They compared the rat V regions with human V region 
sequences, and the most homologous human frameworks were chosen. The 
comparison involved matching CDR length and composition, as well as framework 
identity. They found that the functional blocking characteristics of the rat antibody 
were also retained by the humanised antibody. Parajuli et al. (2001) demonstrated 
that a humanised anti-ganglioside GM2 antibody as well as its mouse-human 
chimeric counterpart could promote the lysis o f lung cancer cells by blood 
mononuclear cells of lung cancer patients. Gangliosode GM2 is widely and 
substantially expressed in human cancer cells, and is therefore, a possible target for 
cancer therapy. This shows the potential use o f humanised/chimeric antibodies for 
the treatment of cancer patients.
1.5. Applications o f monoclonal antibodies
Antibodies and antibody-based immunoassays have been extensively used as 
diagnostic tools, and today they are still one o f the fastest growing technologies for 
the analysis o f biomolecules and drugs (Fitzpatrick et al., 2000). Major trends in 
antibody-based diagnostics over the past few decades, have included increasing assay 
specificity, detection technologies and sensitivity (Borrebaeck, 2000). This has been
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achieved by the development of a number of different assay formats based either on 
competitive or non-competitive principles.
Juric (2001), report the use of a mouse monoclonal antibody that could rapidly and 
specifically target-known sites of leukemia in patients. The antibody was produced 
against CD33, a cell surface glycoprotein found on most myeloid leukemias. The 
antibody was labelled with 131Iodine (I)-M195. Subsequent trials showed elimination 
o f large leukemic burdens after treatment with higher doses o f the labelled antibody. 
A humanised version o f the antibody was also produced, and was found to display 
rapid targeting of leukemia, and pharmacology similar to that of its murine 
counterpart without significant immunogenicity. They also found that treatment with 
supersaturating doses o f the humanised antibody produced complete remissions in 
some patients with advanced myeloid leukemias.
Immunotoxins have also been applied for the treatment of cancer. An immunotoxin 
is a fusion protein consisting o f a toxin connected to a monoclonal antibody or 
growth factor. Plant- and bacteria- derived toxins work in the same way: they bind to 
the cell surface through a monoclonal antibody, internalise into an endosome, 
translocate to the cytosol, and finally, inhibit protein synthesis that leads to cell death. 
Hematologic tumours are easier to target than solid tumours, as they are easier to 
access for the immunotoxin than for intravascular tumour cells. Anti-CD 22 and anti- 
CD 19 immunotoxins have been used in the treatment o f B-cell lymphomas and 
leukemias (Funaro et al., 2000). Immunodrugs are similar to immunotoxins, as both 
of them use antibodies to carry the respective drug to the tumour target.
Presently, there are more than eight licensed monoclonal antibodies commercially 
available in Europe and the U.S. (Fitzpatrick et al., 2000). They are used for the 
treatment o f a range o f diseases such as graft rejection, rheumatoid arthritis, non- 
Hodgkin’s lymphoma, metatstatic breast cancer, and respiratory synctial virus 
infection. Some of the antibodies are either humanised or chimeric, while one of 
them, OKT3 (Orthoclone-Ortho Biotech) is a murine antibody.
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Antibodies can be produced against protein markers on cancer cells and used for 
diagnostic purposes. Antibody kits for cancer detection are predominantly used for 
the management o f cancer patients, as opposed to an initial diagnosis. The BTA 
test™, manufactured by Bion Diagnostic Sciences Inc., is used for recovering bladder 
cancer patients to monitor their risk of a relapse of cancer. The kit is lateral flow 
immunoassay that uses a monoclonal antibody specific to human complement factor 
H-related protein (hCFHrp). This is a tumour-related antigen that is secreted in urine 
by bladder cancer cells (Sarosdy et al., 1997; Kinders et al., 1998) . The test is used 
as an adjunct to cystoscopy for helping physicians assess patient progress after 
treatment.
Antibodies have been produced against a wide range o f other molecules for 
diagnostic purposes including cytokines (Yun et al., 2000), polyamines (Schipper et 
al., 1991), viruses (Shum et al., 2001), and pesticides (Bruun et al., 2001). Future 
applications for antibodies include their use in proteome analysis, which will be 
discussed later in this chapter. A recent development o f non-biological alternatives to 
antibodies are ‘plastibodies’, which may significantly improve immunoassay 
technology. Plastibodies are based on the concept o f molecular imprinting. This 
entails mimicking the binding site o f a natural antibody and moulding it directly into 
a polymer (Borrebaeck, 2000). The polymeric constructs have subsequently been 
used in so-called molecularly imprinted sorbent assays (MIA) against theophylline 
and diazepham. However, a general problem with the design of molecular 
alternatives to antibodies is that very low affinity variants are often obtained. Walshe 
et al. (1997) produced a plastibody to 7-hydroxycoumarin. The polymer was packed 
into a cartridge and used as a solid-phase extraction sorbent for 7-hydroxycoumarin 
from urine. The method was found to be linear for the extraction of 7- 
hydroxycoumarin between 10-50 (ig/ml as well as being reproducible. It highlighted 
the potential o f plastibodies as suitable alternatives to convention liquid-liquid 
extraction procedures.
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1.6. Antibody engineering
Improvements in the efficacy and the relative ease o f use o f recombinant DNA 
technology has meant it is now possible to produce specific antibody using genetic 
engineering. Recombinant antibody display technology has been utilised for the 
generation of antibody fragments from several species including human, mouse, 
sheep and rabbit. This has resulted in the engineering of antibody fragments, which 
include the Fab and scFv fragments. Due to their small size, scFv fragments have 
many applications in therapeutics, as they allow for easy access through tissues. 
Antibody fragments smaller than scFv’s can also be engineered, which have the 
ability to bind antigen; these include the Fd, and the complementary determining 
region (CDR), the smallest antibody fragment capable of binding to an antigen 
(Figure 1.4). Extensive reviews o f antibody engineering are available elsewhere 
(Kontermann & Dubel, 2001; Borrebaeck, 1992).
The genetic material coding for an antibody fragment can be obtained from a variety 
of sources. These include immunised or non-immunised animals, such as mice 
(Caton & Koprowski, 1990) and sheep (Li et al., 2000), as well as humans (McCall et 
al., 1998), or a repertoire o f naive, semi-synthetic or synthetic genes (Winter, 1998). 
The genes are isolated from cells o f the immune system, which may be found in the 
spleen, peripheral blood, bone marrow or the lymph nodes. Classical hybridomas can 
also be used as the raw material for cloning the antibody variable gene segments. 
The genes for the antibody heavy and light chains can then be amplified up for 
insertion into a vector (Orlandi et a l, 1989). A vector is used to transfer the genetic 
information into the host organism, which then produces the desired protein. 
Plasmids are naturally occurring closed circles of DNA that are commonly used as 
vectors in antibody engineering. Subsequently they may be used to transfect a range 
o f different hosts for expression (Figure 1.8). These include bacterial, yeast, 
mammalian, and insect expression systems (Verma et al., 1998). Each has their 
individual advantages, potential applications and limitations. Bacteria cannot 
assemble whole glycosylated antibodies, but are useful for the production o f antibody 
fragments. Complete antibodies can be expressed in yeast, but they can contain high-
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mannose, multiple-branched oligosaccharides and have been shown to be defective in 
effector functions. Fully functional antibodies can also be expressed in mammalian 
cells, as it takes advantage of the sophisticated refolding machinery that is located in 
the endoplasmic reticulum of these cells. Insect expression systems are advantageous 
for large-scale production of proteins as they are cost effective and have a high 
affinity of expression.
Antibody engineering has allowed for the construction of large antibody libraries that 
can be used for the in vitro selection of many different molecules. In recent years the 
selection process has been made easier with the use of surface-display vectors for 
displaying antibody fragments on the surface of bacteriophage and bacteria. Both of 
these factors combined have enabled the development of more effective strategies for 
drug and target discovery.
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F i g u r e  1.8. Summary diagram showing the different sources for isolation of antibody genes 
and the different systems that can be used for the expression of scFv antibody fragments.
1.7. Phage display technology
Bacteriophages are viruses whose hosts are bacterial cells. Discovered over 80 years 
ago, they have played a key role in the development of modern biotechnology (Marks 
&  Sharp, 2000). Bacterial phage display is by far the most important tool in the 
isolation and engineering of recombinant antibodies. Its principle entails the batch 
cloning of D NA encoding millions of variants of certain ligands (e.g. peptides, 
antibody fragments etc.) into the phage genome as a fusion to the gene encoding one 
of the phage coat proteins (pin, pVI, or pVHI) (Hoogenboom et al., 1998). When 
expressed, the coat protein fusion is incorporated into new phage particles that are 
assembled in the bacterium. This results in the ligand being presented on the phage 
surface, while its genetic material resides within the phage particle. The connection 
between ligand genotype and phenotype allows for the enrichment of specific phage 
using selection on immobilised target.
Phage display was developed in 1985 by Smith (Smith, 1985), when it was 
demonstrated that foreign DNA fragments could be inserted into filamentous phage 
gene III to create a fusion protein with a foreign sequence in the middle. The 
filamentous phage used was a member of the Ml3 family. These non-lytic phage 
infect strains of E.co li containing the F conjugative plasmid. Gene III of filamentous 
phage encodes a minor coat protein, pill, which is located at one end of the virion. 
The amino terminal half of pill binds to the F-pilus of E.co li during infection, while 
the carboxy-terminal half is buried in the virion and participates in morphogenesis. A 
foreign sequence can be inserted between the two domains without significantly 
affecting pill function. Phage particles attach to the tip of the F-pilus that is encoded 
by genes on the plasmid, and the phage genome, a circular stranded DNA molecule is 
translocated into the cytoplasm. The genome can then replicate using phage and 
host-derived proteins, and is packaged by the infected cell into a rod-shaped particle 
that is released into the media. All virion proteins undergo transport to the cell 
periplasm prior to assembly and extrusion. Figure 1.9 shows what the typical 
structure of a filamentous phage.
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F i g u r e  1.9. Structure of filamentous Fd or M l 3 phage. ScFv’s are displayed on the surface 
of the phage as a fusion with the p il l  phage coat protein. The pV III coat protein can also be 
used for display of antibody fragments on its surface. The plasmid DNA containing the 
genetic information coding for the antibody fragment is found within the phage particle. 
Production of phage particles displaying the scFv, within a bacterium, is induced by 
superinfection of a helper phage into the bacterium.
Several filamentous phage have been used for the display of ligands. Attempts to 
display Fab' fragments fused to pVIII, the phage major coat protein have also been 
successful. (Gram et al., 1992). However, although the pVIII site is popular for 
peptide phage display, it is not suitable for the efficient display of large polypeptides 
such as antibodies.
Early work also concentrated on the use of X phage, as it was a well understood 
system, with a number of suitable vectors. Huse et al. (1989) produced a 
combinatorial Fab' antibody library using such a vector. However, it was soon noted 
that methods based on X phage could only produce relatively small libraries (106), as 
well as the fact that screening procedures were poor.
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M°Cafferty et al. (1990) were the first to clone and express antibody variable 
domains on the surface of Fd filamentous phage. The antibody was a murine anti- 
lysozyme antibody with the Vh and Vl fragments linked via the (Gly-Gly-Gly-Gly- 
Ser)3 linker to the gene III of the Fd phage. This system also used a phage vector that 
carried all of the genetic information for the phage life cycle. However, presently, 
phagemids are the more commonly used vectors for display. Phagemids are small 
plasmid vectors that carry gene III with the appropriate cloning sites (for the insertion 
of cloned antibody genes) and the phage intergenic region (for rolling circle 
replication and packaging) (Benhar, 2001). The scFv may be fused to the phagemid at 
the N-terminus of an intact gene III, or at the N-terminus of a truncated gene III 
lacking the first two N-terminal domains. Phagemids have high transformation 
efficiencies, and therefore, are ideally suited for the production of very large library 
repertoires.
Most phagemids use a lacZ promoter to drive expression of the antibody gene III 
fusion product. In order to achieve display of the antibody-gene III product, glucose, 
acting in catabolite repression of the lac promoter is removed or depleted, leading to 
the upregulation of the lac promoter, and the expression of sufficient fusion product 
to generate monovalent phage particles. It is often necessary to regulate the system 
tightly, as expression mediated toxicity can be a problem with antibody fragments. 
The phagemid D N A  encoding antibody-gene III fusions is preferentially packaged 
into phage particles using a helper phage such as such as M13K07 or VCS-M13. 
These supply all of the structural proteins necessary. The helper phage genome 
encodes wild-type pHI, and as a result, over 90 %  of rescued phage display no 
antibody at all, and the majority of the rescued phage particles that do display the 
fusion product will only contain a single copy. Therefore, the use of a helper phage is 
required which supplies the necessary structural proteins needed to correctly package 
the phage particle is required. Figure 1.10 shows an example of a typical phagemid 
and the major components required for the production of functional scFv antibody 
fragments.
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F i g u r e  1.10. Example of a (hypothetical) phagemid showing the major components required 
for phage display of a scFv antibody. ScFv fragments may be displayed on phage using a 
phagemid like this that expresses the VHand VLfragments fused to a coat protein gene, gene 
III, of filamentous phage Fd. The VH and Vl fragments may be ligated separately into the 
phagemid, or alternatively, as is shown here, they may be assembled as one prior to ligation. 
Bacteria harbouring the phagemid are superinfected with helper phage to drive production 
of phage particles carrying the scFv fragment. The phagemid contains an antibiotic 
resistance gene (e.g. chloramphenicol, ampicillin) as a selective marker. Gene I I I  codes for 
phage Fd, while the amber codon (*) allows for soluble expression of antibody in non­
suppressor bacterial strains. The H6 and tag region code for a histidine stretch, and peptide 
tag that can be used for purification and detection purposes of the antibody fragment. A 
pelB leader sequence directs expressed protein to the bacterial periplasm, while the lacZ 
promoter is responsible for control and expression of scFv-gene I I I  fusion product.
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1.7.1. Construction o f an antibody phage display library
Figure 1.11 outlines the main steps taken in the construction of an antibody phage 
display library. Firstly mRNA is extracted from either hybridomas, or spleen cells 
from a mouse that was either naive or pre-immunised with antigen. The advantage of 
using spleen cells from a mouse pre-immunised with antigen means that there is a 
greater quantity of genetic material for specific antibodies produced to that antigen in 
the spleen. However, if one wanted to produce a phage display library for screening 
of a number of antigens, then a naive library is more useful. If one uses the genetic 
material obtained from a hybridoma, it will result in cloning the antibody fragment of 
the parent monoclonal antibody. Reverse transcription-polymerase chain reaction 
(RT-PCR) is carried out to reverse transcribe the messenger RNA (mRNA) to its 
complementary D N A  (cDNA) sequence. Primers are then used in the amplification of 
the heavy and light variable-genes by PCR, which are required for scFv production. 
Several sets of universal primers are available for the amplification of a large 
selection of V-genes (De Haard et al., 1998). These primers can be engineered to 
contain certain restriction sites necessary for cloning. The restriction sites chosen are 
not contained within the scFv sequence. Commonly used restriction enzymes include 
Sfil and Notl, as they rarely cut within antibody genes, on the basis of recognition of 
eight base-pairs. The amplified DNA, which encodes millions of different variations 
of the scFv, is cloned as a fusion to the gene encoding one of the phage coat proteins 
(e.g. gene III), into a particular vector. The V-genes can either be cloned in as two 
separate pieces of D N A  or alternatively, they may be annealed together using splice 
by-overlap extension (SOE)-PCR (See Section 4.1), and then cloned into the 
phagemid vector as one piece. The ligated phagemid vector is then used to transform 
a suppressor strain of E.coli, such as Xl-1 blue. Expression of scFv displaying phage 
is then carried out, with the aid of a particular helper phage required to provide 
structural proteins necessary for correct packaging of the phage. This can then be 
used in the screening process for the detection of a ‘positive’ clone.
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F i g u r e  1.11. Phage display library construction. Genetic material encoding sequences 
derived from mRNA is reverse transcribed, and amplified up using PCR. The DNA encoding 
the scFv is restriction enzyme digested and ligated to a particular vector either as one or two 
separate pieces of DNA. This is then transformed into a bacterium for the creation of an 
antibody phage display library. The scFv is displayed on the surface of the phage when fused 
to a coat protein, after super infection of the harbouring vector with a helper phage.
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Library size is a particularly important factor, when producing a phage display 
library, as the number of clones in a library is a function of its diversity and the 
affinity of the antibodies selected from it. Atypical library size would consist of 107 
clones (Hoogenboom et al., 1998). Sheets et al. (1998) produced a large naive 
human phage-display library consisting of 6,7 x 109 clones. The library was then 
used to select for scFv’s to fourteen different protein antigens. Analysis of these 
antibodies revealed high affinities for number of them.
As mentioned previously, the helper phage genome encodes wild-type pm, and 
therefore, over 90 % of rescued phage will not display any antibodies on their 
surface. Rondot et al. (2001) developed a new method for increasing the number of 
phage particles displaying scFv fragments on their surface. They have developed a 
new helper phage known as hyperphage. Hyperphage have a wild type pill 
phenotype and can therefore infect E.coli cells via their F-pilus with high efficiency. 
However, they lack a functional pill gene, which means that the phagemid-encoded 
pill antibody fusion is the sole source of pill in phage assembly. This results in a 
considerable increase in the fraction of phage particles carrying antibody fragments 
on their surface. Results using hyperphage showed a 400-fold increase in antigen- 
binding activity. After two rounds of panning (against tetanus toxoid), it was found 
that more that 50 %  of the phage were found to bind to antigen, compared to 3 %  
when conventional helper phage was used.
The majority of vectors used for antibody phage display carry a small peptide tag 
linked to the 3' end of the scFv permitting its detection by various immunological 
assays. However, these tags are not applied for the actual capture and purification of 
antibody-displaying phage particles. Usually, phage particles are isolated from 
culture supernatant by polyethylene-glycol (PEG) precipitation. A more recent 
alternative to PEG precipitation, is where a ligand-binding peptide is displayed in 
many copies on the phage surface as a fusion to the major phage coat protein pVIII. 
This peptide, which co-expresses with the scFv, antibody can then be used as an 
affinity tag for the selective concentration of displaying phage particles only.
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Berdichevsky et al. (1999) expressed an scFv antibody as an in-frame fusion protein 
with a cellulose binding domain (CBD) derived from the Clostridium thermocellum 
cellulosome. Cellulosomes are multi-enzyme complexes devoted to the efficient 
degradation of cellulose and hemicellulose by cellulolytic microorganisms. The CBD 
domain serves as an affinity tag, allowing for the rapid capture of phage, and 
concentration from crude culture supernatants. CBD retains its cellulose binding 
properties when fused to a heterologous protein. Therefore, it binds to, and can be 
eluted from cellulose under mild conditions. Functional phage displaying scFv’s 
expressing the tag can be separated from non-functional fragments by binding and 
elution with cellulose. The functional scFv’s can then be used for screening against a 
particular antigen. They found the tag to be particularly useful in the selection for 
scFv fragments from naïve libraries. Comparison of panning for a scFv-specific to a 
human Alzheimers P-amyloid peptide using the CBD tag, as well as without it, was 
carried out. They found that using cellulose treatment throughout the panning 
allowed the isolation of specific scFv antibodies, while exhaustive panning without 
cellulose treatment failed to produce any antigen positive clones.
A third method for the functional selection of specific phage is the use of selectively 
infective phage (SIP) technology (Jung el ah, 1999). SIP is particularly 
advantageous, as there is direct coupling of the antibody-antigen interaction with 
phage infectivity and amplification. It works on the principle of displaying an 
antibody library on non-infective phage particles. This is done, by deleting part of 
the gene III protein on the phage (amino terminal domains), which are essential for 
phage infectivity but not phage morphogenesis. Infection is restored by binding a 
fusion protein consisting of the cognate antigen, and the amino terminal domains of 
pill responsible for pilus binding and infection. The fusion product may be supplied 
either in vitro, or in vivo. For in vitro SIP, phage displaying the scFv and the fusion 
product need to be separately purified and combined together in defined amounts to 
yield infective phages. The fusion product is encoded on a plasmid, and the ligand 
can be either genetically fused to it, or in the case of a hapten chemically coupled to
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The in vivo system entails encoding the antibody and antigen on the same genome, 
and producing them in the same cell. Therefore, in this case the ligand can only be a 
protein.
1.7.2. Screening for scFv antibodies from a phage display library 
The feature of the display of ligands on the surface of phage is the linkage between 
phenotype (surface displayed ligand) and ligand genotype, encoded within the phage 
genome. This allows the enrichment for antigen-specific phage antibodies using 
immobilised label or antigen. Figure 1.12 outlines the screening procedure for the 
enrichment of specific phage antibodies. Phage that display a specific antibody are 
retained on a surface with coated antigen, while non-adherent phage are washed 
away. Bound phage can then be eluted from the surface and re-infected into bacteria 
for further growth and enrichment. Phage clones can be analysed for binding after 
each round of panning. A phage ELISA is the common method used for such 
analysis, where antigen is immobilised on the surface, and phage displaying a scFv 
antibody are added to the well. The phage can be detected using a secondary 
antibody specific to a tag encoded for on the phagemid vector (e.g. c-myc tag)
If a clone were found to be positive in a phage ELISA, the assay would be repeated in 
a competitive format. This is particularly important when selecting for scFv’s 
specific to small haptens, as often, during panning, scFv’s directed against the 
protein-conjugate molecule, or just the protein part of the conjugate are selected for, 
and amplified. Therefore, it is necessary to ensure the scFv recognises free hapten in 
solution. It is desirable to use more than one hapten-protein conjugate when panning 
for scFv’s to such small molecules. This ensures non-specific phage that bind to the 
protein will not be continually selected and amplified, and therefore generating high- 
absorbance non-specific signals in phage ELISA.
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F i g u r e  1.12. Cycle for the selection of phage from an antibody phage-display library. 1. 
Phage is produced from an antibody library. 2. Antigen is coated on an immunotube, and the 
library is incubated with it in solution. 3. Non-bound phage are washed away, while (4) 
specific phage are eluted from the antigen. 5. A number of phage clones are selected for 
recognition to antigen (either in a competitive or non-competitive format). 6. The phage is 
also re-infected into E.coli for (7) amplification and rescue. 8. Phage particles from the 
amplified library are used to incubate with antigen in a subsequent round of panning. 
Clones are analysed by phage ELISA after each round of panning in order to select clones 
that bind specifically to the antigen. This process of enrichment and selection increases the 
probability of selecting for ‘positive ’ clones after each round ofpanning.
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Any method that separates clones that bind to antigen, from clones that do not, can be 
used as a selection method for phage-display scFv’s. Such methods include 
biopanning on immobilised antigen coated onto solid supports, columns, or BIAcore 
sensor chips. Selection can also be carried out using biotinylated antigen, panning on 
fixed prokaryotic cells, and on mammalian cells (Hoogenboom et al., 1998). All the 
methods mentioned here are in vitro-based, and rely on a relatively large amount of 
antigen being available for the selection process. It is more difficult to select for 
phage antibodies with a limited amount of antigen. In v/vo-based screening can be 
used for selection when one has a limited amount of antigen. Johns et al. (2000) used 
in vivo selection for the selection of scFv antibodies to vascular endothelium (found 
in the thymus). It is difficult to isolate fresh endothelial cells with intact surface 
molecules and unchanged phenotype from any tissue. The procedure entails 
producing phage from a library as normal, and injecting them intravenously into a 
mouse. After a two-hour incubation period, the thymus is removed, and teased out in 
PBS. Elution buffer is added, and the phage are eluted, and re-infected back into 
bacteria. They found the method to be successful for the isolation of a scFv to an 
endothelial protein. However, characterisation of the protein antigen also needs to be 
carried out, in order to determine the exact molecule to which the antibody generated 
is specific against.
1.8. Soluble expression of scFv antibodies
Once a phage-clone is found to specifically recognise the antigen of interest, the 
DNA encoding that particular scFv can be subcloned into an enhanced expression 
vector. This may be carried out for a number of reasons such as high expression of 
phage-displaying scFv’s or soluble scFv’s (Krebber et al., 1997(a)), or expression of 
a soluble scFv attached to alkaline phosphatase for the direct detection of antigen 
(Muller et al., 1999). These enhanced expression vectors may also contain a gene 
coding for a histidine tag to aid in scFv purification and detection. Soluble expression 
of scFv’s is also enhanced by switching from a suppressor strain of E.co li (e.g. XL-1 
blue) to a non-suppressor strain of E.co li such as JM83 (Krebber et al., 1997). An 
amber codon is usually present on phagemid vectors between the antibody and the
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pill gene. In suppressor strains, this allows direct expression of the scFv as a fusion 
partner with phage coat protein. In the case of non-suppressor strains, the amber 
serves as a stop codon, which enhances soluble scFv expression. ScFv expression is 
directed to the periplasm of the bacterium, which resembles the natural route of 
antibody production in the endoplasmic reticulum of the lymphocyte (de Haard et a l,
1998). This ensures the antibody folds correctly according to its natural 
conformation. Therefore, this production route, via the endoplasmic reticulum 
enhances the chances of obtaining a functional scFv. A proportion of periplasmic 
scFv may also leak out into the culture supernatant. ScFv antibodies can also be 
produced as cytoplasmic inclusion bodies (Huston et al., 1988; Cho et al., 2000) 
followed by re-folding in vitro. However, problems can arise with refolding, as the 
formation of incorrect intramolecular disulphide bridges can occur.
Kipriyanov et al. (1997) developed a system for high-level production of scFv 
antibodies in small scale E.co li cultures. They found that the addition of sucrose to 
the culture medium greatly increased (15-25 fold) the yield of soluble scFv’s 
produced. They also found that scFv’s could be made to accumulate in the periplasm 
or be secreted into the medium by simply changing the incubation conditions and the 
concentration of the inducer. Aggregation of recombinant proteins in the periplasm 
of E.co li could be reduced by growing the cells in the presence of certain sugars such 
as sucrose. These sugars are small enough to diffuse into the periplasmic space, but 
are not metabolised. The sugars cause an increase in osmotic pressure, and therefore, 
enlarge the periplasmic space, which allows more scFv’s to be secreted into it.
Soluble scFv antibodies have also been expressed in mammalian cells (Ridder et al., 
1995), yeast (Freyre et al., 2000), plants (Longstaff et al., 1998), and insects 
(Kretzschmar at al., 1996). These systems offer advantages such as better protein 
folding pathways as in the case of yeast and mammalian cells. Insect and plant-based 
systems do not require large fermenters with sterile culture media and, therefore, the 
secreted proteins are free from mammalian viruses and bacterial endotoxins. As a
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result it could be possible to grow cells in serum-free media, that do not contain 
mammalian contaminants, thus simplifying purification.
A  more novel expression system for the production of recombinant antibodies has 
been the use of transgenic milk (Pollock et ah, 1999). The principle involves linking 
the gene for the scFv antibody to mammary gland-specific regulatory elements on a 
vector. The resulting transgene is then introduced by pronuclear microinjection into 
embryos of the selected species (e.g. goat or sheep). The embryos are then 
transferred to the uterus of a surrogate mother and carried to term. The transgenic 
offspring are identified, and when mature are either bred or hormonally induced to 
lactate. The expression level of the target protein in the milk of the transgenic 
animals is determined and a suitable founder line is chosen for the generation of a 
production herd. Dairy goats are ideal for this application, as they provide relatively 
high yields of milk (300-800 liters/3 00-day lactation), and recombinant antibody 
concentrations are quite good with 1-5 g/1 of protein being recorded (Pollock et al.,
1999). With these types of conditions, a herd of transgenic goats could yield up to 
300 kg of purified product per year. The other advantage of using goats is that it only 
takes 16-18 months from the time of initiating microinjection to full lactation. A 
number of recombinant antibodies have been expressed in transgenic milk with good 
success rates (Pollock etal., 1999).
1.9. Purification of scFv antibodies
Several methods are available for the purification of scFv antibodies. These include 
antigen affinity-chromatography (Owen et ah, 1992; Casey et ah, 1995; Cho et ah,
2000), protein A  chromatography (Mahler et ah, 1997)), cation exchange and size 
exclusion chromatography (Kretzschmar et ah, 1996), human constant light chain 
tagging (Ridder et ah, 1995; Longstaff et ah, 1998), and immobilised metal affinity 
chromatography (IMAC) (Kipriyanov et ah, 1997; Freyre et ah, 2000).
EMAC is one of the most popular methods for scFv purification, as it can ensure high 
ligand stability, high protein loading, mild elution conditions, low cost and complete
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recovery of ligand following regeneration (Arnold et al., 1991). However, it has been 
noted in our laboratory that this method is not as effective as initially thought. This 
will be further discussed in Chapter 4. IMAC involves the insertion of the genes 
coding for a histidine (His) tag, containing 4-6 histidine residues, into the scFv 
sequence. Insertion at the N  or C terminus ensures that the antigen binding site is not 
effected (Casey et al, 1995). The column consists of transition metals such as Ni2f, 
Co2+, Zn2+ and Cu2+, chelated by nitrotriacetic acid (NTA), iminodiacetic acid (IDA) 
or tris (carboxymethyl) ethylenediamine (TED) (Arnold et al., 1991; Muller et al,
1998). His-tagged proteins bind to the metal-chelate solid support, while impurities 
are eluted. Specifically bound protein is then eluted using low pH. This confers a 
positive charge on the histidine residues making them incapable of binding metal 
ions. Alternatively, imidazole can be used for elution, which competes with histidine 
for metal binding. The advantage of the imidazole-based elution system is that it 
does not denature the protein. Janknecht et al. (1991) used it to purify human serum 
response factor to greater than 95% purity. Casey et al. (1995) have utilised Cu2+-IDA 
chelated IMAC to purify a His-tagged protein to 90% purity, with a higher yield than 
that of antigen affinity chromatography (10mg/l as opposed to 2.2mg/l). Kipriyanov 
et al. (1997) have shown that IMAC can also be used to successfully purify scFv’s 
from E. coli periplasmic extracts.
1.10. Applications of scFv antibodies
The ability to produce a large number of recombinant antibodies in bacterial cells and 
to select for antibodies that bind to unique or non-dominant epitopes demonstrates the 
power of recombinant antibody technology. It has resulted in recombinant antibodies 
being produced to a large number of molecules and proteins, for use in assay 
development, antibody therapy and proteomics. A  number of these applications are 
described in the following sections.
1.10.1. Application o f scFv’s in residue analysis
The detection of food residues and contaminants has become increasingly important 
in today’s society, as there is a strong focus within the E U  for food quality and safety
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Many of the detection methods using recombinant antibody technology to date have 
been ELISA based.
Mycotoxins are a serious problem in the grain industry, as they are highly potent 
carcinogens. Yuan et al. (1997) produced a soluble scFv antibody to zearalenone 
from an anti-zearalenone hybridoma cell line. The antibody fragments could detect 
as little as 14 ng/ml for 50 %  inhibition of binding to zearalenone. This was similar 
to that of the parent monoclonal antibody in a competitive indirect enzyme-linked 
immunosorbent assay (ELISA). Yuan et al. (2000) also expressed an anti- 
zearalenone scFv antibody in Arabidposis plants. This scFv ‘plantibody’ could detect 
as little as 11.2 ng/ml for 50 %  inhibition of binding of zearalenone. The antibody 
was found to be as sensitive as its bacterially expressed scFv counterpart, as well as 
its parent monoclonal antibody. Moghaddam et al. (2001) produced scFv antibodies 
to aflatoxin Bi from human lymphocyte, and semi synthetic antibody phage display 
libraries. The scFv antibodies produced could detect as little as 14 |oM AFBi in 
solution.
ScFv’s have also been produced to pesticides for detection purposes (Longstaff et al., 
1998; Strachan et al., 2000). Stabilisation of the fragments has also been carried out 
in order to improve their tolerance in polar solvents. This is further discussed in 
section 6.1.
M cElhiney et al. (2000) isolated scFv fragments to the cyanobacterial hepatotoxin 
microcystin-LR from a naive human phage display library. Cyanobacterial toxins are 
environmental pollutants commonly responsible for human and animal poisoning 
worldwide. In a competition ELISA, the most sensitive antibody clone selected from 
the library could detect as little as 4 fxM of free microcystin-LR for 50 %  inhibition of 
binding. Other recombinant antibodies such as Fab fragments have also been 
produced to environmental toxins including botulinum toxin complex (Emanuel et 
al., 2000). This recombinant antibody was applied in a number of assay set-ups 
including ELISA, surface plasmon resonance (SPR), flow cytometry, and a hand-held
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immunochromatographic assay. The antibody was found to be sensitive in all of 
assay formats assessed, indicating encouraging signs for future applications of 
recombinant antibodies as routine detection molecules.
1.10.2. Medical applications o f scFv antibodies
Engineered antibody fragments such as scFv’s are replacing monoclonal antibodies in 
many areas, especially in medical applications such as cancer treatment and other 
forms of potential in vivo therapy. Developments in the areas of chimerisation and 
humanisation, as well as other characteristics of scFv antibodies, such as their size, 
tissue penetration and pharmacokinetic characteristics have been of great benefit. A  
number of naive human phage display libraries are available for the selection scFv’s 
specific to a particular antigen. Krebs et al. (2001) report the production and of a 
human combinatorial antibody library with 2 x 109 members, optimised for high- 
throughput generation and targeted engineering of human antibodies for various 
applications. Although recombinant antibodies provide effective and highly specific 
in vivo targeting reagents for tumours, they are cleared and removed rapidly from the 
blood due to their small size and single binding site. Covalently linked dimers or 
non-covalent dimers of scFv’s (also known as diabodies) have shown improved 
targeting and clearance properties due to their higher molecular weight (60-120 kDa) 
and increased avidity. Diabodies are constructed by two functional scFv’s joined 
together by a short 5-residue polypeptide linker. Careful selection of the linker length 
dictates the size and the valency of the scFv multimer formed. The production of a 
monomeric scFv requires that the linker employed be at least 12 residues in length. If 
one selects a linker of 3-10 residues in length, the scFv cannot fold into a functional 
scFv, and thus associates with a second scFv to form a diabody (60 kDa) (Figure 
1.13). Reducing the linker length below 3 residues forces the scFv to form triabodies 
(90 kDa) or tetramers (120 kDa) (Little et al, 2000). Molecules of diabody and 
triabody are relatively flexible from the orientation of antibody binding sites, and 
show higher functional affinity with reduced kidney clearance rates. Recombinant 
antibodies and their fragments now represent approximately 30 %  of all biological 
proteins undergoing clinical trials for F D A  approval of engineered cancer therapeutic
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antibody. Human antibodies derived from phage display have already entered phase 
II/III clinical trials for treatment of rheumatoid arthritis and ocular fibrosis (Ryu &  
Nam, 2000).
Other medical applications of recombinant antibodies include their potential role in 
diagnostics. Cho et al. (2000) produced a murine scFv antibody to human plasma 
apolipoprotein A-I. This is a major protein component of plasma high-density 
lipoproteins (HDL), which play an important role in the process of reverse cholesterol 
transport from peripheral tissues to the liver for excretion. Lower levels of 
apolipoprotein A-I and H DL cholesterol are significantly correlated with increased 
risk of cardiovascular disease. As a result, production of a recombinant antibody to 
such a protein, may be useful in a diagnostic application for prediction of 
cardiovascular disease.
V L L VH Vl L Vh
scFv Diabody
F i g u r e  1.13. S c h e m a t i c  d i a g r a m  o f  s c F v  antibody f r a g m e n t  a n d  diabodies s h o w i n g  antigen- 
binding sites. W h e n  j o i n e d  b y  a  peptide linker (L) at least 12 residues long, s c F v  antibody 
f r a g m e n t s  are m o n o m e r i c  (30 kDa). D i a b o d i e s  (60 k D a )  are f o r m e d  w h e n  a  linker between 3 
a n d  1 2  residues is used. R e d u c i n g  the linker length b e l o w  3 residues forces the s c F v  to fold 
into a  triabody (90 k D a )  or tetramer (120 kDa).
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1.10.3. Application o f scFv’s toproteomics
Proteomics can be defined as the study of protein properties (expression level, post- 
translational modification, interactions etc.) on a large scale to obtain a global, 
integrated view of disease processes, cellular processes and networks at protein level 
(Blackstock &  Weir, 1999). Recombinant antibodies now play a significant role in 
proteomics, due to considerable advances made in the construction of large antibody 
phage display libraries, with high affinity antibodies being produced to target antigen. 
They can be produced quickly and cheaply, and can theoretically be produced against 
every human protein. Such a collection, in conjunction with screening technologies 
that use high density antibody arrays to identify these differentially expressed 
proteins, are being applied to the whole field of proteomics for selection of 
differentially expressed proteins.
There are different selection methods being adapted to apply antibody phage display 
technology to the proteomics field (Holt et al., 2000). The three main areas are 
selection on complex antigen, conventional but highly parallel selection, and library 
versus library selection i.e. a library of antibodies selected against a library of 
antigens.
Selection on complex antigen entails the simultaneous selection of a library of 
antibodies against a complex antigen such as whole cells or cellular extracts. 
Although this can lead to a large panel of antibodies, phage selection generally biases 
antibodies recognising the most abundant protein present. As a result there is not a 
wide diversity of antibodies to all the targets in a given sample (Hoogenboom et al,
1999). Instead, a number of antibodies are produced to different epitopes on the most 
abundant protein.
In order to overcome the problem of selecting large numbers of antibodies to the most 
abundant antigen a more strategic approach is required. This is known as 
conventional but highly parallel selection. Instead of selection against a complex 
antigen, selection of an individual protein, peptide or expressed cDNA can be
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performed in parallel. Although this method has good potential for high-throughput 
it requires expensive robotics. It can also be problematic as the selected antibodies 
might only recognise the protein fragment used in the screening process and not the 
parental protein.
It is also possible to select a library of antibodies against a library of antigens, thereby 
allowing a large number of antibody-antigen combinations to be selected. An 
example of this system is selectively infective phage (SIP) (Krebber ei al., 1997(b)). 
As mentioned previously, SIP temporarily destroys the basic infectivity of the Ml 3 
filamentous phage, thereby enabling the direct coupling of a productive protein- 
ligand interaction to the phage. The infectivity can then be restored, allowing phage 
amplification and avoiding an elution step from a solid matrix. To date it has only 
been applied to model selections of antibody-antigen pairs, and has not yet been used 
to select antibody versus antigen libraries. The yeast two-hybrid system is another 
method of library versus library selection (Visintin et al., 1999). It entails scFv 
antibodies being linked to a transcriptional transactivation domain within a eukaryotic 
cell. These linked scFv’s can then interact with target antigen linked to a LexA-DNA 
binding domain, thereby activating a reporter gene. This method is also useful as is 
overcomes such problems as incorrect folding of antibodies in the cytoplasm. It has 
been used in a model selection where a single scFv was isolated from a mixture of 
half a million clones, indicating the procedure has the potential to capture antibodies 
of different specificities from complex mixtures.
Phage antibodies are also being applied to functional genomics using what is known 
as the ProAb™ approach (Pennington &  Dunn, 2001). Presently there is a large 
amount of information currently available in databases of short D N A  sequences 
called ‘expressed sequence tags’ or EST’s, which represent most of the expressed 
human genome. These EST’s can be translated into protein. Peptides are synthesised 
chemically to represent the protein sequence, and these peptides can then be used as 
antigens against which phage antibodies are selected. The antibodies can then be
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used as detection reagents in immunocytochemistry, thereby revealing the 
distribution and abundance of the gene product in normal and diseased tissues.
Another screening method used in proteomics is the ProxiMol™ technique 
(Pennington &  Dunn, 2001). Catalysed reporter deposition (Bobrow et al., 1989; 
Bobrow et al., 1992) was adapted to allow the isolation of phage antibodies binding 
in close proximity to a biotinylated guide molecule. When trying to screen antibodies 
to a cell surface antigen, a guide molecule (e.g. a biotinylated target ligand, or an 
HRP-conjugated antibody) is added to intact cells, together with phage from a >10" 
human antibody library. These diverse antibodies bind specifically to the ligand, to 
the target, and to all other cell surface markers. Biotin-tyramine reagent is added and 
a reactive biotin species is generated; phages binding within approximately 25nm of 
the guide ligand are covalently labelled with biotin. These phage antibodies, 
recognising the target and near neighbours, are recovered using streptavidin-coated 
magnetic beads.
Both of these methods can be successfully used in conjunction with each other, as 
antibodies selected using the ProAb™ strategy can be applied as guide molecules in 
ProxiMol™ method selections.
Immunoassay technology is limited to the analysis of a few thousand assays per day. 
When screening from an antibody phage display library the first round of phage 
selection can yield up to 107 clones. ELISA screening using 96-well plates only 
allows a small percentage of selected clones to be screened. The use of antibody 
arrays, however, can increase throughput up to several hundred times (Ekins et al., 
1990). Arraying antibodies and performing parallel screens using the same antibody 
array on different biological samples enables the identification of antibodies that bind 
to differentially expressed proteins. This form of application is useful, as antibodies 
selected against diseased samples could be screened in parallel with diseased and 
non-diseased samples. Unlike D N A  arrays, antibodies cannot be synthesised on the 
surface of chips. Instead they have to be spotted on the chips in an array format and
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coupled to a downstream high throughput detection system (Borrebaeck, 2000). 
Examples of detection systems would include fluorescent tags, nano-electrodes, and 
in the case of smaller arrays surface plasmon resonance and MALDI-TOF (matrix- 
assisted laser desorption ionization-time of flight) mass spectroscopy.
Antibody arrays take many forms from spatial patterning of just a few molecules on a 
solid support to high-density microarrays. Different supports can be used for the 
array including glass, nitrocellulose, and polyvinylidene fluoride (PVDF). Mendoza 
et al. (1999) produced a biochip that consisted of an optically flat, glass plate 
containing 96 wells formed by an enclosing hydrophobic Teflon™ mask. Each well 
contained four identical 36-element arrays comprising of eight different antigens and 
a marker protein. This 96 well microarray format was compatible with automated 
robotic systems and supported low cost, highly parallel assay format. Liu and Marks 
(2000) electroblotted the proteins ErbB2 and bovine serum albumin from SDS-PAGE 
onto nitrocellulose, and selected phage display antibodies to them. Antibodies were 
obtained with as little as 10'1 ng of antigen, and were used as reagents in both ELISA 
and Western blotting. De Wildt et al. (2000) developed a technique for high 
throughput screening of recombinant antibodies based on the creation of high-density 
antibody arrays. The method entailed the robotic picking and high-density gridding 
of bacteria containing antibody genes followed by filter-based ELISA screening to 
identify clones that express binding antibody fragments. This method was found to 
screen up to 18,342 clones at a time and simultaneously against 15 different antigens. 
Antibodies have also been used in the analysis of cellular changes occurring in 
cultured human cells, using a very small array and detected by SELDI (surface 
enhanced laser desorption/ionization) mass spectroscopy (Davies et al., 1999). The 
antibodies were used as the capture molecules on the chip array for retaining the 
target proteins from a biological sample. These proteins were then characterised 
using SELDI mass spectroscopy.
Information about gene expression at the protein level will make a great contribution 
to medicine and diagnostics in the twenty first century. Recombinant antibody arrays
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will have a wide range of applications in proteomics and will have a significant 
impact in the field.
1.11. Immunoassays
The first immunoassay was developed by Yalow and Berson in 1960 (Yalow &  
Berson, 1960), for the determination of insulin in blood. Since then, immunoassays 
have been commonly used in analytical biochemistry for the detection of a wide 
range of compounds such as hormones, drugs and viruses. Different assay formats 
are available, and these have been reviewed extensively elsewhere (Price &  Newman, 
1997).
Enzyme-Linked Immunosorbent Assay (ELISA) is one of the most common 
techniques used for measuring antibody-antigen interactions. ELISA’s are
heterogeneous assays because the antibodies or antigens are immobilised on a solid 
phase. Figure 1.14 shows a schematic diagram of a direct non-competitive ELISA. In 
this type of assay, the analyte such aflatoxin-Bi-BSA (AFBi-BSA) conjugate is 
adsorbed onto the solid support matrix primarily through hydrophobic interactions. 
After a suitable incubation time (e.g. 1 hour at 37° C) the plate is washed using 
phosphate buffered saline (PBS) solution containing 0.05 %  (v/v) tween, and 
phosphate buffered saline (3-times with each). Any remaining absorption sites on the 
plate are then blocked with casein protein dissolved in PBS, in order to reduce non­
specific binding interactions. After another one-hour incubation and washing 
procedure, various dilutions of antibody are added to the coated wells of the plate, 
and allowed to react with the immobilised analyte. After incubation, unbound 
antibodies are then washed away, and an anti-species antibody molecule conjugated 
to an enzyme is added. Following further incubation and washing, the enzyme 
substrate is added, and a coloured product is produced. The intensity of the colour 
can then be read spectrophotometrically at the appropriate wavelength. This allows 
for the quantitative measurement of antibody binding to an antigen.
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Another assay format commonly used is the indirect competitive ELISA. Figure 1.15 
shows a schematic diagram of this. It is similar to the direct non-competitive ELISA 
as analyte in the form of a hapten-protein conjugate (e.g. AFBi-BSA) is adsorbed 
onto the wells of an immunoplate and blocked in the same manner. A  solution 
containing a limiting constant amount of antibody (e.g. anti-AFBi antibody) and 
varying known concentrations of antigen (e.g. AFBi) are then applied to the wells of 
the immunoplate and allowed to incubate. The washing step removes any of the 
antibody that has bound to the free antigen in solution, and the subsequent steps in the 
assay allow for the detection of the amount of antibody bound to the immobilised 
conjugate surface. In this assay format, as the concentration of free antigen (i.e. 
AFBi) in solution increases, less-antibody is available for binding to the solid-phase 
immobilised antigen (i.e. AFBi-BSA conjugate). As a result, an inverse relationship 
exists between intensity of the coloured solution formed, and the concentration of 
free antigen in solution. The assay format can be applied for the detection of 
unknown antigen concentrations in solution, by reference to a standard curve.
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AFBr BSA conjugate
Blocking solution
A. Coat Plate
A
Affinity-purified rabbit anti-AFB, 
antibodies
W ash  P la te
D. Addition of HRP- 
labelled goat anti-rabbit 
antibody
Wash
Plate
C. Addition o f affinity- 
purified rabbit anti- 
AFBi antibodies
E. Addition of 
OPD substrate
F i g u r e  1.14. S c h e m a t i c  d i a g r a m  s h o w i n g  the principle o f  direct E L I S A .  E a c h  step requires 
a n  incubation p e r i o d  a n d  w a s h i n g  p r o c e d u r e  to r e m o v e  excess n o n - b o u n d  material. A.  
Aflatoxin B j - B S A  conjugate is u s e d  to coat wells o f  a  96-well immunoplate, a n d  sticks to the 
plate primarily b y  h y d r o p h o b i c  interactions. B. T h e  wells o f  the i m m u n o p l a t e  are then 
coated with 2-4 %  (w/v) o f  casein protein in P B S ,  to block a n y  r e m a i n i n g  absorption sites on  
the plate. C. T h e  antibody s a m p l e s  are then a d d e d  to the wells o f  the plate, a n d  allowed to 
incubate f o r  a  suitable p e r i o d  o f  time f o l lowed by washing. D. A  species-specific secondary 
enzyme-labelled antibody is added, a n d  after suitable incubation a n d  washing, substrate is 
added, w h i c h  allows for colour development. T h e  a b s o r b a n c e  is then m e a s u r e d  
spectrophotometrically at the appropriate wavelength for the substrate.
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AFB,-BSA conjugate
Blocking solution 
Free AFB(
A. Coat Plate
At
Affinity-purified rabbit anti-AFB(
antibodies
Florseradish peroxidase-labelled goat anti­
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W ash  P la te
- A *
W ash  P late
<Z>
B. Block Plate
W ash
P la te
D. Addition of HRe­
labelled goat anti-rabbit 
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Plate
free AFBi
E. Addition of 
OPD substrate
F i g u r e  1.15. Sc h e m a t i c  d i a g r a m  s h o w i n g  the principle o f  a  competitive E L I S A ,  u s e d  for the 
m e a s u r e m e n t  o f  the r a n g e  o f  detection o f  a n  antibody for a  given antigen. T h e  E L I S A  s h o w n  
here is described in the context o f  m e a s u r i n g  free A F B j .  T h e  assay is similar to the direct 
E L I S A ,  except that at step C, a  solution o f  limiting constant a m o u n t  o f  antibody a n d  varying 
k n o w n  concentrations o f  antigen are applied to wells o f  the immunoplate. Competition 
occurs b e t w e e n  free antigen in solution a n d  immobilised antigen o n  the i m m u n o p l a t e  for 
binding to the antigen-specific antibody. T h e  w a s h i n g  step r e m o v e s  a n y  b o u n d  antibody -  
free A F B i  complex. T h e  s e c o n d a r y  antibody then detects the a m o u n t  o f  antibody b o u n d  to 
the conjugate o n  the plate surface, f o l lowed b y  the addition o f  substrate for colour 
development.
C. Addition of afRnity-purified 
rabbit anti-AFBi antibodies and
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1.12. Aims of research
The aim of this project was to produce antibodies and antibody fragments to aflatoxin 
Bi, utilising well established technologies, as well as exploiting combinatorial phage 
display technology. It was also envisaged to develop different types of 
immunoassays using these antibodies for the detection of aflatoxin Bi. An additional 
aim of the project was to produce pesticide-protein conjugates and possibly generate 
antibodies using them, as well as utilise them in different immunoassay set-ups.
Chapter 3 describes the production of polyclonal antibodies to AFBi, their 
purification and use in ELISA for the detection of AFBi. It also includes cross 
reactivity studies and the application of one polyclonal antibody preparation for the 
detection of AFBi in spiked grain samples.
Chapter 4 describes the production of a combinatorial antibody phage display library 
derived from the RNA obtained from a mouse immunised with AFBi-BSA conjugate. 
Single chain Fv antibodies were produced from the library, and were applied for use 
in an ELISA for the detection of AFBi.
Chapter 5 describes the characterisation of polyclonal and scFv anti-AFBi antibodies, 
by applying them for the detection of AFBi on an SPR-based biosensor. Both 
antibodies were also applied for the detection of AFBi in spiked grain samples, and 
solution affinity analysis was carried out on the scFv antibody.
Chapter 6 describes the production of a pirimiphos-hapten molecule containing an 
amino group for conjugation to proteins. It also includes the production of 
chlorpyrifos-BSA conjugates, their spectrophotometric characterisation, and 
application on BIAcore. A competition ELISA for the detection of chlorpyrifos was 
also developed using antibodies and conjugates obtained from collaborators (IFR 
Norwich, U.K.). The development of an inhibition-based BIAcore assay for the 
detection of chlorpyrifos, using this antibody preparation was also attempted.
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Chapter 2 
Materials & Methods
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2.1. Materials and equipment
All reagents used were of analytical grade, and with the exception of those 
tabulated below, and all reagents were purchased from Sigma Chemical Co., Poole, 
England. All commercial antibody preparations were also purchased from Sigma 
unless otherwise stated.
Reagent Supplier
Acetic acid 
Hydrochloric acid 
Sodium chloride
Riedel de-Haen, Wunstrofer, Straße 40, Apartado de Correos, 
D-3016, Seelze 1, Hannover, Germany.
Arnino-dextran Molecular Probes, Eugene, Oregon, U.S.A.
Bicinchoninic acid assay (BCA) kit Pierce and Warriner (UK) Ltd., Chester, U.K.
Ci g reverse phase cartridge filter SEP-PAK®, Waters (A division of Millipore), Millipore 
Corporation, Milford, Massachusetts, U.S.A.
CM-5 Chips Pharmacia Biosensor AB, Uppsala, Sweden.
CM-Dextran
Chlorpyrifos
O-carboxymethylhydroxylamine
Fluka Chemicals, Gillingham, Dorset, U.K.
DNA Ligase Boreinnger Mannheim, Bell Lane, Lewes, East Sussex, U.K.
Epicurian coli Supercompetcnt Cells StrataGene, San Diego, California, U.S.A.
HPLC-grade solvents Lab-Scan, Stillorgan, Dublin, Ireland.
ProBond Resin 
PCR Optimiser Kit
In Vitrogen BV, 9704 CH Groningen, The Netherlands.
Sfil enzyme New England Laboratories, 73 Knowl Place, Wilbury Way, 
Hitchin, Hertfordshire, U.K.
Tryptone 
Yeast Extract 
Bacto Agar
OxoidLtd., Wade Rd., Basingstoke , Hampshire, U.K.
Wizard Plus PCR-prep kit 
Wizard Plus SV Mini-prep kit 
Reverse Transcription system 
Low-melt Agarose
5-bromo-4-chloro-3 ’ -indolyphosphate/ 
nitro blue tétrazolium chloride 
(BCIP/NBT) reagent
Promega Corporation, Madison, WI, U.S.A.
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The equipment used and its suppliers are listed below.
Equipment Supplier
3015 pH meter Jenway Ltd., Essex, U.K.
Amicon 8050 Ultrafiltration Cell Amicon Inc., Beverly, Massachusetts 01915, U.S.A.
Atto dual minislab AE-6450 
Atto AE-6100
Atto Corp., Hongo 7-Chrome, Bunhyo-Kui, Tokyo, Japan.
BIAcore 1000 
BIAcore 3000
Pharmacia Biosensor AB, Uppsala, Sweden.
Biometra PCR machine Anachem Ltd., Anachem House, Charles St., Luton, 
Bedfordshire, U.K.
BioRad wet blotter BioRad, BioRad House, Maylands Ave., Hemel Hempstead, 
Hertfordshire, U.K.
Eppendorf centrifuge (5810 R) Eppendorf AG, 10 Signet Court, Swann Rd., Cambridge,
U.K.
Eppendorf tubes Sarstedt, Wexford, Ireland.
Grant Waterbath (Y6) Grant Instruments (Cambridge) Ltd., 29 Station Rd., 
Shepreth, Royston, Hertfordshire, U.K.
Hermle Centrifuge (Z 200 M/H) Hermle Labortechnik, 78564-Wehingen, Gosheimerstr. 56, 
Germany.
Image M aster VDS Pharmacia Biotech, San Francisco, California, U.S.A.
NUNC Maxisorb plates NUNC, Kamstrup DK, Roskilde, Denmark.
Orbital incubator Gallenkamp, Leicester, U.K.
RM6 Lauda waterbath 
Millipore filtration device
AGB Scientific Ltd., Glasncvin, Dublin, Ireland.
SB1 Blood tube rotator Stuart Scientific, London, England.
Sorvall Refrigerated Centrifuge Du Pont Instruments, Newtown, Connecticut, U.S.A.
Stuart Platform shaker (STR 6) Lennox, Naas Rd., Dublin, Ireland.
Titretek Twinreader Plus 
Sterile universal containers
Medical Supply Company, Damastown, Mulhuddart, 
Dublin 15, Ireland.
Tomy Autoclave (SS 325) Mason Technology, Greenville Hall, 228 South Circular 
Rd., Dublin 8, Ireland.
UV-160A spectrophotometer Shimadzu Corp., Kyoto, Japan.
UVP ImageStore 7500 gel 
documentation system
Ultra Violet Products, Upland, California, U.S.A.
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2.2. Culture media formulations
2 X  Tiyptone Yeast extract (TY) Medium Tryptone 16 g/1 
Yeast Extract 10 g/1 
NaCl 5 g/1
Non-expression (N E ) medium 2 X  TY medium 
1% (v/v) glucose 
25 ug/ml chloramphenicol 
30 (j.g/tnl Tetracyclinc
Low-expression (LE) medium 2 X  TY medium
1% (v/v) glucose
25 ug/ml chloramphenicol
0.5 mM  isopropyl-p-D-galactopyranoside
(IPTG)
Expression medium 2 X  TY medium 
25 ug/ml chloramphenicol
Tryptonc Yeast extract (TYE) medium 2 X  TY medium
Bacteriological agar 15 g/1
Super Optimal Catabolite (SOC) medium Tryptone 20 g/1 
Yeast Extract 5 g/1 
NaCl 0.5 g/1 
KC1 2.5 mM 
MgCl2 20 mM 
Glucose 20 mM 
pH 7.0 
Glucose and MgCl2 added separately following 
autoclaving
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2.3. Antibody Production
2.3.1. Licensing
All procedures involving animals were approved and licensed by the Department of 
Health and Children, and every care was taken to minimise the level of distress 
caused to the animals.
2.3.2. Health Warning
Aflatoxin Bi is carcinogenic and should be handled with extreme care.
2.3.3. Immunisation protocol for the production o f rabbit anti-aflatoxin Bi 
antisera
Phosphate buffered saline, containing 0.15 M  NaCl, 2.5 m M  potassium chloride, 
10 m M  disodium hydrogen phosphate and 18 m M  sodium dihydrogen phosphate, 
pH 7.4, was prepared. This buffer will be referred to throughout as PBS. A stock 
5 mg/ml solution of aflatoxin Bi-BSA (AFBi-BSA) conjugate was made up in 
PBS. This was diluted to a concentration of 200 fig/ml in PBS. An equal volume 
of Freund’s Complete adjuvant was added to 200 |ag/ml of the conjugate. The 
mixture was vortexed until it formed an emulsion. 1 ml of this mixture was 
injected sub-cutaneously at several sites into a New-Zealand white rabbit. This 
procedure was repeated 21 days later, using Freund’s Incomplete adjuvant. The 
rabbit was bled from the marginal ear vein 14 days after this immunisation, and the 
cycle of reboosting and bleeding was continued until a specific antibody titre of 
greater than 1/100,000 was obtained. The rabbit was exsanguinated, and the 
serum was collected, allowed to clot for 2 h at room temperature and stored 
overnight at 4° C. It was then centrifuged at 4000 rpm for 20 minutes, and the 
supernatant collected and stored at -20° C until required for use.
2.3.4. Immunisation protocol for BALB/c mice for the production o f scFv anti- 
aflatoxin Bi antibodies from splenomic RNA
A stock 5 mg/ml solution of AFBi-BSA conjugate was prepared in PBS. This was 
diluted to a concentration of 50 (ig/ml in PBS. An equal volume of Freund’s
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Complete adjuvant was added to 50 (ig/ml of the conjugate. The mixture was 
vortexed until it formed an emulsion. 6-10 week old BALB/c mice were injected 
sub-cutaneously with 250 [xl of the immunogen at several sites. On day 21, the 
mice were re-immunised intraperitoneally with the same dose of immunogen and 
Freund’s Incomplete adjuvant. On day 28 a blood sample was taken from the tail, 
and intraperitoneal boosts, followed by blood sampling, were continued until a 
satisfactory titre of greater than or equal to 1/50,000 was obtained. 3-4 days prior 
to being sacrificed, the mice were injected with 250 (il of 50 |ig/ml AFBi-BSA 
conjugate in PBS. This was administered intravenously via the tail vein.
2.4. P reparation of serum
2.4.1. Preparation o f rabbit serum
For estimation of antibody titre, a 2 ml blood sample was collected from the 
marginal ear vein in Sterilin universal containers, and allowed to clot for 2 h at 
room temperature. The clot tightened overnight at 4° C, before being centrifuged 
at 4,000 rpm for 20 min. The supernatant (serum) was then removed and stored at 
-20° C until required for further use.
2.4.2. Preparation o f mouse serum
For the estimation of antibody titre in mouse blood, 10-20 |j,l of blood was taken 
from the tail, and allowed to clot at room temperature for 30 min. Following 
centrifugation at 13,000 rpm for 20 min the serum was removed and stored at -20° 
C until required for further use.
2.5. Polyclonal antibody purification
Rabbit serum was initially purified by saturated ammonium sulphate precipitation. 
It was then affinity-purified by protein G affinity-chromatography. Subtractive 
immunoaffinity chromatography was also carried out on the serum to remove all 
‘BSA-binding’ antibodies.
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2.5.1. Saturated ammonium sulphate precipitation
10 ml of rabbit serum was stirred on ice, and an equal volume of cold saturated - 
100% (w/v) - ammonium sulphate was added, dropwise. The mixture was stirred 
on ice for 1 h. It was then centrifuged at 3000 rpm for 20 min. The supernatant 
was removed and the pellet was washed twice in 10 ml of 45% (v/v) ammonium 
sulphate. The final pellet was dissolved in 5 ml of PBS and dialysed overnight at 4° 
C against 5 1 of PBS.
2.5.2. Protein G affinity-chromatography
The composition of the buffers used in this procedure are given in Table 2.1.
A  Protein G  column was prepared by pouring 2 ml of protein G immobilised on 
sephadex into a small column. It was allowed to settle and was equilibrated with 
20 ml of Running buffer. 2 ml of the dialysed saturated ammonium sulphate- 
treated antibody solution (obtained as described in section 2.5.1.) was added to the 
column. The effluent from the column was collected and re-applied to the column 
three times. The column was then washed with 20 ml of wash buffer. The column 
was re-equilibrated with 20 ml of running buffer. Bound immunoglobulin was 
eluted from the column by the addition of elution buffer. This was allowed to run 
into the column, and remain in it for 5 min. Fifteen 0.5 ml fractions were collected 
to which 100 nl of neutralising buffer had already been added to each tube in order 
to prevent denaturation of the eluted antibody. The collected fractions were then 
analysed at 280 nm using quartz cuvettes. The fractions containing protein were 
pooled and dialysed in 5 1 PBS overnight at 4° C. The protein G column was 
washed and stored in the recommended buffer (PBS with 20% (v/v) ethanol), at 
4°C.
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Table 2.1. Composition of running buffer, wash buffer, neutralising buffer, and
elution buffer for protein G affinity-chromatography.
R unning Buffer PBS - 0.05% (v/v) Tween, 0.15 MNaCl
W ash buffer PBS - 0.05% (v/v) Tween, 0.35 MNaCl
Neutralising buffer 2 M  Tris/HCl, pH 8.6
Elution Buffer 0.1 M  glycine/HCl, pH 2.7
2.5.3. Subtractive immunoaffinity chromatography
A BSA immobilised immunoaffinity column was obtained as a gift from Dr. 
Anthony Killard. Subtractive immunoaffinity chromatography was carried out on 
protein G-purified antibody to remove all BSA-binding antibodies from the 
antibody population. The method, as described in section 2.5.2, was used. The 
antibody solution was then sterile filtered through a 0.22 fim filter, and 0.05% 
(v/v) azide was added. It was aliquoted into 1 ml quantities, and stored at -20° C 
until required for use.
2.6. Bicinchoninic acid (BCA) protein assay
Standard protein solutions ranging in concentration from 0.01 - 1.5 mg/ml were 
prepared using purified immunoglobulin G (IgG). 10 |xl of each standard or sample 
was added, in triplicate, to wells of a 96-well plate. 190 [xl of BCA reagent was 
added to each sample. The plate was incubated for 30 min at 37° C. The 
absorbances of the wells were measured at 560 nm using a micro titre plate-reader 
(Titretek Twinreader Plus), and a standard curve was constructed from which the 
protein concentrations of the samples could be calculated.
62
2.7. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed to assess antibody purity. It was carried out using an Atto dual minislab 
AE-6450 gel electrophoresis system. The composition of gels, electrophoresis 
buffer and sample loading buffer are given in Table 2.2. Protein sample were 
diluted with sample loading buffer (4:1, sample:buffer) and boiled for 10 minutes. 
Approximately 10-15 |il of sample was loaded onto a gel. Molecular weight 
markers were also loaded onto the gel. When the gel was being used for Western 
blotting, it was necessary to use pre-stained molecular weight markers. The gel 
was electrophoresed at 20 m A  per plate and was run until the dye had migrated to 
the bottom of the gel plates.
2.8. Coomassie blue staining
Gels were stained for 30 minutes in Coomassie blue staining solution (0.2% (w/v) 
Coomassie blue R250 in 30: 10: 60 (v/v/v) methanol: acetic acid: water), and 
destained overnight in destaining solution (10: 7: 53 (v/v/v) methanol: acetic acid: 
water).
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Table 2.2. Composition of stacking gel, resolving gel, electrophoresis buffer and
sample loading buffer for SDS-PAGE.
Stacking gel 5% (w/v) acrylamide 
0.13% (w/v) bis-acrylamide 
125 m M  Tris 
0.1% (w/v) SDS
0.15% (w/v) ammonium persulphate 
0.25% (v/v) TEMED
Resolving gel 10% (w/v) acrylamide 
0.27% (w/v) Bisacrylamide 
375 m M  Tris 
0.1% (w/v) SDS
0.08% (w/v) ammonium persulphate 
0.08% (v/v) TEMED
Electrophoresis buffer 25 m M  Tris 
192 m M  glycine 
0.1% (w/v) SDS
Sample loading buffer 60 m M  Tris
25% (v/v) glycerol
2% (w/v) SDS
14.4 m M  2-mercaptoethanol
0.1% (w/v) bromophenol blue
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2.9. W estern blotting
Proteins were transferred from acrylamide gels (prepared in section 2.7) to 
nitrocellulose using a BioRad wet blotter in electrophoresis buffer containing 20% 
(v/v) methanol, for 90 minutes at 72 V. The membrane was blocked using 5% 
(w/v) non-fat milk powder, 0.01% (v/v) antifoam A, 0.02% (v/v) sodium azide in 
Tris Buffered Saline (TBS) (50 m M  Tris-HCl, 150 m M  NaCl, pH 7.4) for 2 h at 
room temperature or overnight at 4° C. Monoclonal anti-FLAG antibody was 
then added in blocking solution containing 1 m M  calcium chloride (CaCLz) for 1.5 
h at room temperature. The nitrocellulose was washed three times in TBS 
containing 1 m M  CaCL2 for 10 min each time. Alkaline phosphatase-labelled anti­
mouse IgG was added to the filter in TBS containing 5% (w/v) fat free milk 
powder and 1 m M  calcium chloride for 1.5 h while shaking at room temperature. 
Final washing consisted of four 10 min washings in TBS, containing 1 m M  CaCk, 
prior to development with ‘one-step’ 5-bromo-4-chloro-3’-indolyphosphate/ nitro 
blue tetrazolium chloride (BCIP/NBT) reagent (Promega). Colour development 
was stopped by the addition of 2 m M  ethylene diamine tetra acetic acid (EDTA) in 
PBS.
2.10. Preparation of standard  concentrations of hapten for use in 
competition ELISA
2.10.1. Aflatoxin Bj preparation
A 2 mg/ml solution of free aflatoxin Bi was prepared in methanol. Working 
standards were prepared in PBS containing 5% (v/v) methanol, at varying 
concentrations.
2.10.2. Chlorpyrifospreparation
A  50 mg/ml solution of free chlorpyrifos was prepared in methanol. Working 
standards were prepared in PBS containing 5% (v/v) methanol, at varying 
concentrations.
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2.10.3. Preparation o f grain matrix samples
AFBi samples in grain matrix were supplied as a gift from Mrs. Sue Patel, R H M  
Technology Ltd., The Lord Rank Centre, London Road, HP 12 3QR, High 
Wycombe, U.K. A blank sample of grain was extracted according to the method 
described by Scudamore and Patel (2000), and then spiked with different 
concentrations of AFBi according to the official AO  A C methods of analysis (Scott, 
1995). The samples were then diluted to a final methanol concentration of 5% 
(v/v).
2.11. Enzyme-linked im m unosorbent assay (ELISA)
A  range of different ELISA methods were used for the detection of antibodies in 
rabbit and mouse serum, and phage supernatants, for the quantitative determination 
of aflatoxin Bi, and chlorpyrifos, and for the assessment of the cross-reactivity of 
purified antibody. In addition, ELISA was also used to study regeneration 
conditions for suitability of antibody use in an immunosensor. PBS containing 
0.05% (v/v) Tween 20 was used to wash microtitre plates, and is referred to in all 
sections commencing from section 2.11 as PBST.
2.11.1. Estimation of rabbit and mouse serum antibody titres to specific 
antigens
The levels of specific antibody in serum were measured using ELISA. A 96-well 
microtitre plate was coated by adding 100 \i\ of aflatoxin Bi-BSA conjugate 
dissolved in PBS at a concentration of 50 (ig/ml to each well. Due to the 
availability of only one protein-toxin conjugate, a second microtitre plate was 
coated with BSA at a concentration 50 ng/ml in order to estimate the antibody 
response to BSA. The plates were incubated overnight at 4° C. The plates were 
emptied and washed six times, three times with PBST and three with PBS only. 
The plates were then blocked by addition of 100 nl per well of PBS containing 2% 
(w/v) milk powder and incubated for 1 h at 37° C. (For both coating and blocking 
of plates, incubation steps could also be carried out at 37° C for 1 hour or 4° C 
overnight).
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Serum from immunised rabbits or mice was then diluted (1/100 to 1/200,000 for 
rabbits; 1/300 to 1/61,400 for mice) in PBS containing 0.1% (w/v) BSA. This was 
carried out for two purposes. Firstly, to ensure that 0.1% (w/v) BSA was 
sufficient to remove the non-specific interactions, and secondly, to observe the 
specific antibody response to the AFBi part of the conjugate. The serum was also 
diluted in PBS containing no BSA, in order to observe the non-specific antibody 
response to BSA. The serum diluted in the PBS 0.1% (w/v) BSA was added to the 
AFBi-BSA coated plate, as well as the BSA coated plate. The serum diluted in the 
PBS was added to the BSA coated plate only. All samples were added to the plate 
at 100 pl/well. This was incubated for 1 h at 37° C. The plate was washed three 
times in PBST and three times in PBS. After washing, 100 fil of horseradish 
peroxidase (HRP)-conjugated-anti-rabbit or anti-mouse secondary antibody, 
diluted in PBS (1/5,000 dilution), was added to each well and incubated for 1 h at 
37° C.
After repeating the washing step, 100 |il of substrate (0.4 mg/ml 5- 
phenylenediamine (8-PD), in 0.05 M  phosphate citrate buffer, pH 5.0, and 0.4 
mg/ml of urea hydrogen peroxide) was added into each well and incubated for 30 
min at 37° C.
2.11.2. Standard checkerboard ELISA for determination o f optimal antibody 
dilution and conjugate concentration for use in a competition ELISA 
A 96-well microtitre plate was coated with different concentrations of the 
conjugate of interest (aflatoxin Bi-BSA conjugate, chlorpyrifos-BSA, chlorpyrifos- 
dextran dissolved in PBS) ranging from 0 to 50 ug/ml by adding 100 pi of 
conjugate to each well. The plates were incubated overnight at 4° C, after which 
they were emptied and washed six times, three times with PBST and three with 
PBS only. It was then blocked by addition of 100 (il per well of PBS containing 
2% (w/v) milk powder and incubated for 1 h at 37° C. Serial dilutions of the 
antibody of interest were carried out. 100 (il per well of each antibody dilution was 
added to the wells (in at least triplicate). This resulted in a set of titre curves being 
produced for each different conjugate concentration. The plate was incubated for 1 
h at 37° C. After washing, 100 |il of horseradish peroxidase (HRP)-conjugated-
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anti-rabbit secondary antibody, diluted in PBS, was added to each well and 
incubated for 1 h at 37° C. Colour was developed as described in section 2.11.1. 
From the titre curves obtained, the antibody dilution that gave half the maximum 
absorbance, and the lowest conjugate concentration that provided sufficiently high 
absorbances was chosen for use in competition ELISA.
2.11.3. Standard competitive E L IS A  using polyclonal antibodies
Microtitre plates were coated by adding 100 (il of conjugate (aflatoxin Bi-BSA 
conjugate, chlorpyrifos-BSA, chlorpyrifos-dextran dissolved in PBS) to each well. 
The plates were incubated overnight at 4° C. The plates were emptied and washed 
six times, three times with PBST and three times with PBS. They were then 
blocked by adding 100 (il per well of PBS containing 2% (w/v) milk powder, and 
incubated for 1 h at 37° C. Stock solutions were prepared for each analyte at 
varying concentrations to produce a set of standard solutions (as described in 
sections 2.10.1-2.10.3). Washing was carried out as described before, and 50 |il of 
rabbit anti-hapten antibody was added into each well with 50 (il of hapten 
standards. The plate was incubated for 1 h at 37° C, and then washed three times in 
PBST and once with PBS. 100 pl/well of URP labelled anti-rabbit IgG was then 
added, and the plate incubated for 1 h at 37° C. Colour was developed as 
described in section 2.11.1.
2.11.4. Estimation o f  cross reactivity o f  purified polyclonal anti-AFBj 
antibodies
Stock solutions of aflatoxin B2, Mi, M 2, Gi, G2, B2a, and G2a were prepared in 
methanol and diluted in PBS-5% (v/v) methanol with a range of concentrations 
from 31.25 to 500 ng/ml. The assay was carried out in the same way as that for 
the competition ELISA (2.11.3) except that standards of the other aflatoxins were 
added to the plate with the anti-AFBi antibody.
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2.11.5. Estimation o f cross reactivity o f purified polyclonal anti-chlorpyrifos 
antibodies
Stock solutions of parathion, fenitrothion, carbophenothion, etrimfos, and 
dichlorvos were prepared in methanol and diluted in PBS-5% (v/v) methanol with 
a range of concentrations from 40 to 12,500 ng/ml. The assay was carried out in 
the same way as that for the competition ELISA (2.11.3), except that standards of 
the other pesticides were added to the plate with the anti-chlorpyrifos antibody.
2.11.6. The use o f ELISA to examine the efficiency and effects o f regeneration 
on an immobilised AFBi-BSA surface
In an experiment to examine the efficiency of regenerating conjugate immobilised 
at a surface, 96-well microtitre plates were coated with 50 (ig/ml AFBi-BSA and 
blocked with PBS containing 2% (w/v) milk powder.
After washing, 100 (il/well of a 1/5,000 dilution of polyclonal anti-AFBi antibody 
in PBS was added to the plates, and was then incubated at 37° C for 1 h.
A set of solutions of 1M ethanolamine containing various percentage 
concentrations of acetonitrile was then prepared. Antibody solution was aspirated 
from the plates, which were washed three times in PBST and three times in PBS. 
100 fj.1 of each of the different ethanolamine-acetonitrile solutions was then added 
to wells, and the plates were incubated for 10 minutes at room temperature. 
Following incubation, the plates were washed three times in PBST and three times 
in PBS.
100 fil/well of HRP-labelled anti-rabbit antibody (1/5,000 in PBS) was then added, 
and the plates incubated at 37° C for 1 h. The colour was then developed as 
described in section 2.11.1. To examine the effect of the regeneration reagent 
upon the conjugate surface, the assay was repeated as before, except that the 
ethanolamine-acetonitrile solutions were added to the wells immediately after the 
blocking step. After washing the anti-AFBi antibody was added, incubated for 1 h 
at 37° C and the plate was washed as before. HRP-labelled anti-rabbit antibodies 
were then added, and the plates were washed and incubated as previously. Finally, 
colour development was carried out as described in section 2.11.1.
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2.12. Agarose Gel Electrophoresis
D N A  samples from 10 fo,l to 20 |il were prepared in 6X loading solution (with 
0.25% (w/v) bromophenol blue and 40% (w/v) sucrose). These samples were 
loaded into wells of agarose gels, (typically 0.5-2% (w/v)). Agarose gels were 
prepared using 50X TAE (242 g/1 Tris, 57.1 ml/1 glacial acetic acid, 100 ml/1 0.5 M  
EDTA pH 8.0) and type 1A agarose. Low melt agarose was used as the 
alternative when purifying specific D NA products. Ethidium bromide was added 
to the gels at 0.5 ng/ml. The samples were electrophoresed at 70V for 1 to 2 h.
2.13. Synthesis and characterisation of pesticide-protein conjugates
2.13.1. Chemical derivatisation o f  pirimiphos
A number of novel strategies were carried out in the attempt to derivatise an active 
form of pirimiphos for conjugation to proteins. These methods performed by Dr. 
Ollie Egan, and Dr. Kieran Nolan. Nuclear magnetic resonance (NMR), and 
spectroscopy analysis of the compounds were also performed by Dr. Egan and Dr. 
Nolan. Mass spectroscopy was carried out at the Department of Chemical 
Sciences, National University of Ireland (NUI), Cork.
2.13.2. Conjugation o f  amino-pirimiphos to B SA
10 mg of amino-pirimiphos was dissolved in 10 m M  HC1 and cooled on ice for 10 
min. A chilled solution of 5 ml of 0.1 M  NaN02 was added dropwise and allowed 
to mix for 30 min. This created an excess of nitrous acid, which was decomposed 
by the addition of 5 g of urea. 50 mg of BSA was dissolved in 0.2 M  borate 
buffer, pH 9.0. This was added to the reaction mixture. This was allowed to mix 
for 2 h on ice, before being dialysed overnight in 5 1 of PBS at 4° C.
2.13.3. Chem ical derivatisation and purification o f  chlorpyrifos fo r  
conjugation to a protein
An activated form of chlorpyrifos was produced for conjugation to the protein 
B SA  by the method described by Manclus et al., (1994). These methods are 
described in the following sections 2.13.3.1 to 2.13.3.3.
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2.13.3.1. Synthesis o f 0,0-Diethyl 0-[3,5-Dichloro-6-[(2-carboxyethyl)thio]-2- 
pyridyl] Phosphorothioate
3-mercapto-propanoic acid was dissolved in 3 ml of ethanol to a final molar 
concentration of 10 mM. Two equivalents of K OH were added to the solution and 
heated until dissolved. 10 m M  chlorpyrifos, dissolved in 3 ml of ethanol, was 
added, and the reaction mixture was refluxed for 1 h. After this time the reaction 
mixture was filtered and the solvent was removed under reduced pressure. 5% 
(w/v) of NaHC03 was added to the residue in order to remove any residual water, 
followed by washing with hexane (2X5 ml). The aqueous layer was acidified to 
pH 4.0 and extracted with dichloromethane (3X5 ml). The extract was dried over 
Na2SC>4 and concentrated by rotary evaporation.
2.13.3.2. Purification o f 0,0-Diethyl 0-[3,5-Dichloro-6-[(2-carboxyethyl)thio]~ 
2-pyridyl] Phosphorothioate
The activated chlorpyrifos compound was reconstituted in 4 ml of the solvent 
mixture hexane/tetrahydrofuoran (THF)/acetic acid (75: 25: 1). A Cig reverse 
phase cartridge filter was used to purify the compound. This was carried out by 
connecting the cartridge to a glass syringe, and washing it through with 
approximately 20 ml of the solvent mixture. The reconstituted chlorpyrifos 
product was injected through the column, and 500 |j,l fractions were collected. A 
further 3 ml of solvent was injected through the cartridge filter and the fractions 
collected. These fractions were then analysed by thin layer chromatography (TLC) 
using a silica plate. Fractions showing only one spot on the TLC plate (R f  0.41, 
same solvent mixture used to dissolve the chlorpyrifos) were pooled and 
concentrated by rotary evaporation.
2.13.3.3. Production o f chlorpyrifos-BSA protein conjugates
5 mg of activated chlorpyrifos was dissolved in 1 ml of ethanol and the pH was 
adjusted to 8.5 using 0.2 M  borate buffer, pH 9.0. This was placed on a stirrer and 
100 m M N H S  (N-hydroxysuccinimide) and 400 m M  EDC (N-ethyl-N- (dimethyl- 
aminopropyl) carbodiimide hydrochloride) were added to the reaction mixture. 
This was allowed to mix for 10 min. BSA was dissolved in 0.2 M  borate buffer, 
pH 9.0, at varying concentrations depending on the molar excess of hapten to
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protein required for each conjugation (50, 25, 10, and 5 molar excesses of hapten 
were used for conjugation). The BSA was then added dropwise to the reaction 
mixture, and the solution was left stirring at room temperature for 1 h. After this 
time the conjugate was dialysed in 5 1 PBS overnight at 4° C. It was sterile filtered 
through a 0.22 |j,m filter, and 0.05% (v/v) of sodium azide was added for 
preservation. The conjugate was stored at -20° C until required for further use.
2.14. Characterisation of pesticide-protein conjugates
2.14.1. Ultraviolet spectroscopy
Pesticide-protein conjugates were analysed by UV spectral analysis from 200- 
400nm. U V  spectra of similar concentrations of ‘control’ protein were also 
prepared and recorded. The UV spectra of the respective pirimiphos and 
chlorpyrifos molecules were also recorded over a similar wavelength range. Direct 
comparison of the three spectra gave putative confirmation of conjugation of the 
respective pesticide molecules to the protein molecules.
2.14.2. ELISA
ELISA was also used as a method for the characterisation of chlorpyrifos-BSA 
protein conjugates. This was carried in the same way as described in section
2.11.3. where the chlorpyrifos conjugate of interest was coated on the surface of a 
96-well microtitre plate at a concentration of 50 |J.g/ml, and serial dilutions of a 
polyclonal anti-chlorpyrifos antibody was added to the plate (either in the presence, 
or without free chlorpyrifos). Colour development confirmed recognition of the 
antibody for the pesticide-protein conjugate.
2.15. Production of a single chain Fv antibody library to aflatoxin Bi
A  pre-immunised scFv phage display library was produced according to the 
method described by Krebber et al. (1997(a)).
2.15.1 Synthesis o f AFBj-dextran conjugate
This procedure was performed according to Langone and Van Vunakis (1976) and 
involved the production of AFBi O-carboxymethylhydroxylamine, followed by
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coupling of the activated aflatoxin molecule to amino-dextran using carbodiimide 
coupling chemistry.
2.15.1.1. Preparation o f AFBi O-carboxymethylhydroxylamine
A  solution of AFBi (15 mg: 0.054 mM) and O-carboxymethylhydroxylamine 
hydrochloride (123.2 mg: 0.64 mM) were mixed in 3.53 ml of ethanol, and 0.704 
ml of aqueous NaOH (1.6 mM). This solution was refluxed for 3 h, and then 
allowed to sit overnight at room temperature. After this time the brown reaction 
mixture was concentrated to 1 ml using rotary evaporation. 5 ml of distilled water 
was added, and the pH adjusted to 9.5 with 1 M  NaOH. This was then washed 
with two 10 ml portions of ethyl acetate. The aqueous layer was acidified to pH 2 
with 6 M  HC1 and stored at 0° C overnight to yield a yellow oxime precipitate. 
This was collected by centrifugation, and vacuum dried over anhydrous calcium 
sulphate. The product was stored in 1 ml of dimethyl sulfoxide (DMSO), and 
frozen at -20° C.
2.15.1.2. Conjugation o f AFBi O-carboxymethylhydroxylamine to amino- 
dextran
10 mg of AFBi O-carboxymethylhydroxylamine in DMSO was taken, and the pH 
adjusted to 8.5 using 0.2 M  borate buffer, pH 9.0. This was placed on a stirrer and 
100 m M  NHS and 400 m M  EDC were added to the reaction mixture. This was 
allowed to mix for 10 min. 100 mg of amino-dextran was dissolved in 0.2 M  
borate buffer, pH 9.0, and was added dropwise to the reaction mixture. The 
solution was left stirring in the dark at room temperature for 1 h. After this time 
the conjugate was dialysed in 5 1 PBS overnight at 4° C. It was stored at 4° C in 
the dark until required for ftnther use.
2.15.1.3. Evaluation o f AFBi-dextran conjugate using BIAcore 
Preconcentration of the AFBi-dextran conjugate was carried out as described in 
section 2.20.1. Following this, the conjugate was immobilised on the CM-dextran 
gel surface as described in section 2.20.2. Monoclonal anti-AFBi antibody was 
injected over the immobilised conjugate surface in order to observe its binding
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capacity. The surface was regenerated using 1 M  ethanolamine containing 20% 
(v/v) acetonitrile, pH 12.0.
2.15.2. Preparation o f mouse spleen RNA
Trizol reagent is a ‘ready-to-use’ reagent for the isolation of total RNA from cells 
and tissues, based on the procedure of Chomczynski and Sacchi (1987). The 
reagent, a mono-phasic solution, contains phenol and guanidine isothiocyanate. 
Trizol reagent maintains the integrity of the RNA, while disrupting cells and 
dissolving cell components.
All glassware and reagents were prepared using diethyl-pyrocarbonate (DEPC)- 
treated ultrapure water and autoclaved at 121°C, and 15 p.s.i. for 15 min. This 
was required to remove all contamination resulting from RNAse enzymes. 
Following immunisation of mice, as described in section 2.3.4, mice were sacrificed 
by exsanguination and their spleens were removed using aseptic technique. The 
weight of the spleen was recorded. The spleen was homogenised with 1 ml of 
Trizol™ reagent and incubated at room temperature for 5 min. 200 jjl of 
chloroform per ml of Trizol was added, and this was shaken for 15 seconds before 
being allowed to incubate for 2-3 min at room temperature. This was then 
centrifuged at 14,000 rpm for 15 min. The upper aqueous phase containing the 
RNA was carefully removed, and the pellet was discarded. The RNA was 
precipitated using 500 (il of isopropanol per ml of Trizol. The precipitate was 
incubated for 10 min at room temperature, and then centrifuged at 14,000 rpm for 
10 min. The precipitate was removed, and the brown pellet remaining was washed 
with 1 ml of 75% (v/v) ethanol per ml of Trizol used. The eppendorf was inverted 
as opposed to vortexing, as vortexing would cause shearing and loss of the RNA. 
This was centrifuged at 10,000 rpm for 5 min. The ethanol was removed from the 
pellet, and the pellet was completely dried at 37° C. This was done by covering the 
eppendorf tube with parafilm, and making small perforations in it. This was then 
placed in a 37° C oven until the pellet was judged to be dry. The pellet was 
resuspended in 30 ^il of DEPC-ultrapure water.
The optical density (O.D.)26o and O.D.28o of each extract were determined. This 
was used to determine the concentration of RNA from the standard that a solution
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of RNA with an O.D.26o=1.0 contains 40 ug of RNA per ml. The purity of the 
RNA was also determined from the ratio of O.D.260 / O.D.280. This should be 
equal to 2.0. If this number was lower than 2.0 contamination of the of the extract 
with protein had occurred.
2.15.3. Reverse transcription of mouse spleen RNA
Reverse transcription was performed using the Promega polymerase chain reaction 
(PCR) - related Reverse Transcription System. The cDNA was synthesised using 
random hexamer primers (mix of 5 base fragments of varying sequence (d NTP)) 
which were obtained separately from the kit. The d NTP mix was prepared in 
sterile ultrapure water and mixed thoroughly before use. All buffers were allowed 
to completely thaw on ice and were mixed well before use. The components, and 
their concentrations for the reaction, are listed below.
Component Stock concentration Concentration in 20 [j.1 
reaction
X I
MgCl2 25 m M 5 m M 4jal
10X buffer 10X 1 X 2 |al
dNTP Mix 10 m M 1 m M 2^1
RNAase 40 U/p.1 lU/fal 0.5 ^il
Inhib
Random 0.5 j-ig/f-tl 0.2 ng/reaction* 0.4 )j,l
Primer
A M V R T 25 U/jLtl 15 U/reaction* 0.6 |xl
RNA 7-10 fag/reaction* Varied
* Total concentration per reaction NOT per reaction volume as for other 
components.
X 1= Amount used per reaction
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2.15.4. Amplification of antibody light and heavy chain genes using 
polymerase chain reaction (PCR)
2.15.4.1. PCR Primers
PCR primers were obtained from Sigma-Genosys Ltd., London Rd., Pampisford, 
Cambridge, CB2 4Ya, England. Primers used were as follows:-
Variable light chain back primers:-
LB1 5'gccatggcggactacaaaGAYATCCAGCTGACTC AGCC3'
LB2 5 'gccatggcggactacaaaGAYATT GTT CT C WCCC AGTC3'
LB3 5' gccatggcggactacaaaGAY ATT GT GMTMACT C AGT C3'
LB4 5' gccatggcggactacaaaGAYATT GTGYTRAC AC AGTC3'
LB 5 5 'gccatggcggactacaaaGAYATT GTRAT GACMC AGTC3 '
LB6 5' gccatggcggactacaaaGAY ATTMAGATRAMCC AGT C3'
LB7 5 'gccatggcggactacaaaGAYATT C AGAT GAYDC AGT C3'
LB8 5 'gccatggcggactacaaaGAY ATYCAGATGACACAGAC3'
LB9 5'gccatggcggactacaaaGAYATTGTTCTC AWCCAGTC3'
LB10 5'gccatggcggactacaaaGAY ATTGWGCTSACCCAATC3'
LB 11 5' gccatggcggactacaaaGAY ATTSTRATGACCCARTC3'
LB 12 5' gccatggcggactacaaaGAYRTTKTGATGACCCAR AC3'
LB 13 5'gccatggcggactacaaaGAYATTGTGATGACBCAGKC3'
LB 14 5' gccatggcggactacaaaGAYATT GT GAT AAC YC AGGA3'
LB 15 5 'gccatggcggactacaaaGAY ATT GT GAT GACCC AGWT3'
LB 16 5 'gccatggcggactacaaaGAYATTGTGATGACACAACC3'
LB 17 5'gccatggcggactacaaaGAYATTTTGCTGACTCAGTC3'
L B X  5 'gccatggcggactacaaaGATGCT GTTGT GACT C AGGAAT C3'
Variable light chain forward primers:-
LF1 5 'ggagccgccgccgcc(agaaccaccaccacc)2 ACGTTTGATTTCC AGCTTGG3' 
LF2 5 'ggagccgccgccgcc(agaaccaccaccacc)2 ACGTTTT ATTTCC AGCTTGG3' 
LF4 5'ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTTATTTCCAACTTTG3' 
LF 5 5 'ggagccgccgccgcc(agaaccaccaccacc)2 ACGTTTC AGCTCCAGCTTGG3'
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LFÀ- 5 'ggagccgccgccgcc(agaaccaccaccacc)2 ACCT AGGAC AGT C AGTTTGG3 '
Variable heavy chain back primers:-
H B 1 5 'ggcggcggcggctccggtggtggtggatççGAKGTRM AGCTTC AGGAGTTC3 ' 
HB2 5 'ggcggcggcggctccggtggtggtggatcçGAGGTBC AGCTBC AGC AGT C3 ' 
HB3 5'ggcggcggcggctccggtggtggtggMcçCAGGTGCAGCTGAAGS ASTC3 ' 
HB4 5'ggcggcggcggctccggtggtggtggatccGAGGTCCARCTGCAACARTC3' 
HB5 5'ggcggcggcggctccggtggtggtggatccCAGGTYCAGCTBCAGCARTC3' 
HB6 5 'ggcggcggcggctccggtggtggtggatcçC AGGT YC ARCTGC AGC AGTC3 ' 
HB7 5'ggcggcggcggctccggtggtggtggatççCAGGTCCACGTGAAGCAGTC3' 
HB 8 5 'ggcggcggcggctccggtggtggtggatççGAGGT GAASST GGT GGA AT C3 ' 
HB9 5 'ggcggcggcggctccggtggtggtggatecGAV GT G AWGYT GGT GG AGTC3 ' 
HB10 5'ggcggcggcggctccggtggtggtggatççGAGGTGCAGSKGGTGGAGTC3' 
HB 11 5'ggcggcggcggctccggtggtggtggatççGAKGTGCAMCTGGTGGAGTC3' 
HB 12 5'ggcggcggcggctccggtggtggtggatccGAGGTGAAGCTGATGGARTC3 ' 
HB 13 5 'ggcggcggcggctccggtggtggtggatcçGAGGTGCARCTTGTTGAGTC3 '
HB 14 5 'ggcggcggcggctccggtggtggtggatccGARGTRAAGCTTCTCGAGTC3 '
HB 15 5'ggcggcggcggctccggtggtggtggatccGAAGTGAARSTTGAGGAGTC3 ' 
HB 16 5 'ggcggcggcggctccggtggtggtggatçcCAGGTTACTCTRAAAGWGTS TG3 ' 
HB 17 5'ggcggcggcggctccggtggtggtggatççCAGGTCCAACTVCAGCARCC3 '
HB 18 5 'ggcggcggcggctccggtggtggtggatççGATGTGAACTTGGAAGTGTC3 '
HB 19 5 'ggcggcggcggctccggtggtggtggatcçGAGGTGAAGGTCATCGAGTC3 '
Variable heavy chain for primers:-
HF1 5 ' ggaattcggcccccgaggcCGAGGAAACGGT GACCGT GGT 3 '
HF2 5 ' ggaattcggcccccgaggcCGAGGAG ACTGT GAGAGT GGT3 '
HF3 5 'ggaattcggççcccgaggçÇGC AGAGAC AGT GACC AGAGT3 '
HF4 5'ggaattcggcccccgaggcCGAGGAGACGGTGACTGAGGT3 '
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2.15.4.2. PCR reaction
Standard multiplex PCR reaction mixture was as follows:
Component Stock
concentration
Concentration in 
a 50 pi reaction
XI
Forward Primers Varied 0.1 nmol each Varied
primer /reaction
Reverse Primers Varied 0.1 nmol each Varied
primer /reaction
10 X 10X 1 X 5.0 nl
MgCl2 25 m M 1.0 m M 2.0 pi
dNTP 20 m M 0.4 m M l.Ojxl
cDNA Varied 1.0 (j.1/ reaction
Taq Polymerase 5U/|o.l 5U/reaction 1.0 pi
Water Make up reaction
to 50 jal
XI = Amount used per reaction
The PCR thermal cycling conditions were as follows:
94° C X I  min 
63° C X  30 sec 
58° C X  50 sec 
72° C X  1 min 
repeat by 7 cycles
94° C X  lmin
63° C X  30 sec
72° C X I  min
repeat by 24 cycles
72° C X 10 min (optional)
All ramping rates were at 3°C/sec.
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After the PCR was completed, the amplified D NA was electrophoresed on an 
agarose gel as described in section 2.12. A clean 400 base pair fragment was 
observed indicating that the required specific PCR product was generated.
2.15.5. Purification of PCR reaction products
PCR reaction products were gel-purified using a Wizard PCR-prep purification kit. 
The products were electrophoresed using an Atto AE-6110 gel electrophoresis 
system. Typically a 0.5% (w/v) low-melt agarose gel was prepared as described in 
section 2.12 The PCR products were loaded onto the gel, and this was 
electrophoresed at 70 V for 1-2 h. After this time the gel was observed through a 
protective shield under ultra violet (UV) light. The fragment of interest was 
excised from the gel and placed in a 1.5 ml eppendorf tube. The gel fragment was 
then incubated in a 70° C waterbath until it had fully melted. 1 ml of resin was 
immediately added and mixed thoroughly with the melted gel for 15-20 sec. A 
Wizard minicolumn was assembled with a 5 ml syringe barrel attached to it, and 
this was placed on a 1.5 ml eppendorf tube. The gel-resin mix was pipetted into 
the barrel, and was slowly plunged through the column. The syringe was removed 
and the barrel re-attached to the column. 2 ml of 80% (v/v) isopropanol was 
pipetted into the barrel, which was used to wash the column. The syringe was 
removed and the column inserted into a fresh 1.5 ml eppendorf tube. The column 
and eppendorf tube were centrifuged at 14,000 rpm for 2 min to remove any 
remaining isopropanol from the column. The minicolumn was once again 
transferred to a fresh 1.5 ml eppendorf tube, and 20 |il of autoclaved ultrapure 
water added to the column. This was allowed to incubate for 1 min at room 
temperature before being centrifuged at 14,000 rpm for 20 sec. The DNA eluted 
from the column was stored at -20° C until required for use.
After purification, the D NA fragments were re-electrophoresed with quantitative 
molecular weight marker. The concentration of DNA in the purified fragment 
(relative to the band of known concentration in the marker) was determined 
densiometrically using the Image Master VDS system. In the case of a Promega 
100 base pair marker, the 500 base pair fragment was used as the reference for 
quantification, where 5 (il of marker contained 150 ng of DNA and 50 ng of the 
other fragments.
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2.15.6. Splice by overlap extension (SOE)-PCR amplification conditions 
The components for the SOE-PCR are as follows:
Component Stock concentration Concentration in 50 
|j,l reaction
X  1
V h As determined 10 ng/ reaction
V l As determined 10 ng/ reaction
10 X 10 X 1 X 5 pi
MgCl2 25 m M 1 m M 2 pi
dNTP 20 m M 0.4 m M 1 pi
Water Make up to 50 pi
Sc Forward Varied 0.05 nmol/reaction Varied
Sc Back Varied 0.05 nmol/reaction Varied
Taq 5 U/p.1 5 U/reaction 1 pi
XI = Amount used per reaction
The PCR thermal cycling conditions were as follows:
92° C X I  min
45° C X  50 min
72° C X  1 min
repeat X  5 cycles
pause
Add:
0.05 m M  Sc forward and Sc back primers 
5 U  Taq DNA polymerase per reaction
92° C X  1 min 
68° C X  30 sec 
72° C X  1 min 
repeat X  25 cycles
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After the SOE-PCR was completed, the amplified DNA was electrophoresed on an 
agarose gel as described in section 2.12. A clean 800 base pair fragment was 
observed indicating that the required specific PCR product was generated.
2.15.7. Plasmid purification o f pAK 100 using Wizard Plus SV miniprep DNA 
purification system
All plasmids were donated as a kind gift from Prof. Dr. Andreas Pluckthun, 
Biochemisches Institut der Universität, Zurich, CH-8057 Zurich, Switzerland.
A  single colony of Escherichia coli (E. coli) XL I-blue cells containing the plasmid 
pAK 100 was picked from an agar plate and grown in non-expression media 
overnight shaking in 37° C. The culture was then centrifuged at 7,000 rpm for 5 
min at 4° C. The supernatant was removed and the tube was placed inverted on a 
piece of tissue in order to remove any remaining supernatant. The pellet was 
thoroughly resuspended in 250 pi of cell resuspension solution. This was 
transferred to a sterile 1.5 ml eppendorf tube, and 250 ]i\ of cell lysis solution was 
added. The tube was carefully inverted four times causing the solution to clear. If 
the solution did not clear immediately it was necessary to wait up to five minutes in 
order for it to clear. After this, 10 pi of alkaline phosphatase was added and the 
tube carefully inverted four times, and incubated for five minutes. 350 pi of 
neutralisation solution was added and the tube was once again carefully inverted 
four times. The tube containing the cell lysate was then centrifuged at 14,000 rpm 
for 10 min. A spin column was inserted into a 2 ml collection tube and the cleared 
lysate was pipetted into the spin column. At this point it was important not to 
disturb the white precipitate remaining in the centrifuge tube. The spin column 
containing the lysate was centrifuged at 14,000 rpm for 1 min. The column was 
then removed from the tube and the liquid discarded. It was re-inserted into the 
tube and 750 pi of column wash solution was added. This was centrifuged again at 
14,000 rpm for 1 min at room temperature. The wash step was repeated using 250 
pi of wash solution and re-centrifuged at 14,000 rpm for 2 min. The column was 
then transferred to a sterile 1.5 ml eppendorf, and 50 pi of autoclaved ultra pure
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water was added. This was centrifuged at 14,000 rpm for 1 min in order to elute 
the DNA. The eluted DNA was stored at -20° C until required for further use.
2.15.8. Restriction enzyme digestion o f pAK 100, and the annealed Vh-Vl DNA 
The plasmids used in this recombinant phage display system are unique in that they 
only require one restriction enzyme digestion prior to ligation into the plasmid. The 
pAK vectors contain a tetracycline resistance gene bounded by Sfil sites while the 
SOE primers also incorporate an Sfil site into both ends of the fragment.
The components for restriction enzyme digestion of the Vh -Vl insert are as 
follows:
Component Volume/ Reaction
NEB buffer 2 1.5 pi
BSA 0.2 pi
Sfil 0.5 pi
Vh -V l fragment 10 JLll
Water 3.5 pi
The components for restriction enzyme digestion of the p AK vector are as 
follows:
Component Volume/ Reaction
NEB buffer 2 5 pi
BSA 0.5 pi
Sfil 1 pi
PAK vector 10 pi
Water 34pl
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Both sets of components for both reactions were incubated in a 50° C waterbath 
overnight.
After this time the digested vectors and digested VH-VL inserts were 
electrophoresed on a 1%  (w/v) low melt agarose gel as described in section 2.12. 
In the case of the pAK vector there was a clear distinction between the cut vector 
(4,300 base pairs) and the tetracycline gene cut (2,100 base pairs). However, in 
the case of the V h-V l fragment the distinction was not as apparent, with only a 
small number of base pairs being cut from the 800 base pair DNA fragment. In 
order to observe the cut more clearly in the case of the VH-VL fragment, it was 
electrophoresed on a 2-2.5 %  (w/v), agarose gel to aid separation.
The cut fragments were purified as described in section 2.15.5 and following 
purification were electrophoresed on an agarose gel in order to determine their 
concentrations densiometrically as described in section 2.15.5.
2.15.9. Insertion o f Vh-Vl fragment into pAK 100 plasmid vector
Gel purified SOE-Vh-Vl fragment was ligated into the pAK 100 plasmid vector as
follows:
Component Stock
concentration
Concentration in 
a 20 pi reaction
pAK 100 As determined 1.5 X  V h-V l
fragment*
V H -V l fragment As determined 1 X*
Ligase As supplied 10 U/reaction
5X Ligase buffer 5X IX
All reactions were made up to a final volume of 10 pi.
* Using the concentrations of VH -VL and vector digests, a sufficient volume 
was added to ensure a ratio of vector to insert of 1.5:1
Incubation was overnight at 16° C. It was preferable to use the ligated construct 
immediately, but, if necessary, it was possible to store it at -20° C.
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2.15.10. Transformation o f E.coli XLl-blue with pAK 100 plasmid vector 
containing SOE- Vh-Vl fragment
The supercompetent E.co li cells were completely thawed on ice, before being 
mixed gently by hand. 100 |il of the cells were added into each of two pre-chilled 
25 ml tubes. (One tube was for the experimental transformation and one tube was 
for the control transformation). 1.7 jj.1 of p-mercaptoethanol provided with the kit 
was added to each of the two Sterilin 25 ml tubes containing the bacteria. The 
tubes were gently swirled, and then incubated on ice for 10 min, with gentle 
swirling every 2 min. 50 ng of the ligated DNA vector was added to one of the 
aliquots and gently swirled. As a control, 1 ^il of the pUC 18 control plasmid was 
added to the other aliquot of cells and swirled gently. Both tubes were incubated 
on ice for 30 min. The tubes were then heat-pulsed in a 42° C water bath for 45 
seconds. This length of time of the heat pulse was critical for obtaining the highest 
efficiency, as there is a defined ‘window’ of the highest efficiency resulting from 
the heat pulse. The defined ‘window’ for these particular cells was between 40-50 
seconds, after which time transformation efficiencies are greatly reduced. The 
tubes were further incubated on ice for another 2 min. After this time 0.9 ml of 
preheated (42° C) SOC medium was added, and the tubes incubated at 37° C for 1 
hour with shaking at 225-250 rpm. The tubes were then centrifuged at 2000 rpm 
for 12 min and resuspended in 400 |j,l each of 2 X  TY. Serial dilutions (diluted to 
10‘10) were carried out on both transformed samples, and were plated out on 
selective TYE medium (TYE containing 25 ng/ml of chloramphenicol, and 1% 
(v/v), glucose for the experimental transformation; TYE containing 50 fig/ml 
ampicillin, and 1% (v/v), glucose for the control transformation). The remaining 
experimental transformed sample was plated out on selective medium plates for 
production of library stocks. The plates were incubated for 24 h at 37° C.
2.15.11. Production o f stocks of the antibody phage display library
After the transformed bacteria were allowed to grow overnight, the diversity of the 
library was determined from the experimental transformant dilution plates, while 
the transformation efficiency was determined from the control transformant
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dilution plates. The bacteria on the stock experimental plates were aseptically 
scraped off with 2 X  TY (using a glass spreader). The bacteria were then 
centrifuged at 4000 rpm in a bench centrifuge for 10 min. The supernatant was 
removed and the bacterial pellet containing the transformed antibody phage display 
library was resuspended in 3 ml of 2 X TY containing 15% (v/v) sterile glycerol. 
The cultures were aliquoted and “flash-frozen” using liquid nitrogen. They were 
then stored at -80° C until required for further use.
2.16. Screening for scFv phage display antibodies from a pre-immunised 
anti-AFBj phage display library
All culture media formulations used in the production of scFv displaying phages, 
and soluble scFv antibodies are described in section 2.2.
2.16.1. Production o f scFv displaying phages
50 ml of non-expression (NE) medium was inoculated with 100 (j,l of approx 105 
cells from the glycerol stock library. The culture was shaken at 37° C until O.D. 
550=0.5. The culture was then allowed to sit for 10 min at 37°C. 1011 colony
forming units (c.f.u.) of helper phage (2 (il -VCSM13 (StrataGene)) and 25 [il of 1 
M  IPTG solution was added. After 15 min incubation at 37° C the culture was 
diluted in 100 ml of low-expression (LE) medium. The culture was then shaken 
for 10 h at 26° C for phage production. Two hours after infection 30 (xg/ml of 
kanamycin was added. Phage particles were purified and concentrated 100-fold by 
two PEG/NaCl precipitations.
It was necessary to inoculate 4 ml of 2 X  TY containing 30 [xg/ml tetracycline with 
a single colony of XL-1-blue when it was intended to carry out a phage titre as 
well as PEG/NaCl precipitation the following day. This was carried out in 
duplicate (as well as a control) and incubated overnight at 37° C in a shaking 
incubator.
2.16.2. PEG/NaCl precipitation
150 ml of the E .co li XL-l-blue-library was transferred to a sterile 300 ml Sorvall 
tube and centrifuged at 10,000 rpm for 10 min at 4° C. One fifth of the volume of
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PEG/NaCl was added to the supernatant. This was mixed and incubated at 4° C 
(on ice) for at least one hour. The mixture was then centrifuged in a Sorvall 
refrigerated centrifuge at 10,000 rpm for 30 min at 4° C. The pellet was re­
suspended in 40 ml of ultrapure water and 8 ml of PEG/NaCl. This was mixed and 
incubated at 4° C for 20 min. After this time, the mix was centrifuged at 10,000 
rpm for 20 min at 4° C. The supernatant was removed and the pellet re­
centrifuged at 7,000 rpm for 10 min at 4° C. Any remaining supernatant was 
removed and the pellet was re-suspended in 2 ml of sterile-filtered PBS. The 
phage was then micro-centrifuged at 4000 rpm for 10 min at 4° C, to remove any 
bacterial debris. The phage precipitate was retained and stored at 4° C (short-term) 
or at -80° C in a 15% (v/v), sterile glycerol solution (long-term).
2.16.3. Phage titre
4 ml of 2 X  TY containing 50 ng/ml tetracycline was inoculated with a single 
colony of XL-1-blue overnight at 37° C. The E.co li XL-1-blue culture was then 
diluted 1/100 in 5 ml of 2 X  TY containing 50 ug/ml tetracycline. This was grown 
shaking at 37° C for approximately 2 h until O.D.550 = 0.5 -0.6. The culture was 
then allowed to sit at 37° C for 15 min. After this time serial dilutions (lO^ -lO'11) 
of the phage were prepared using the bacterial culture. This was then incubated 
for 30 min at 37° C without shaking. 100 (il of each dilution was spread on TYE 
plates containing 1% (v/v) glucose and 25 ug/ml chloramphenicol. The plates were 
allowed to grow overnight at 37° C. The colony forming units were counted in 
order to calculate the titre of the stock phage.
2.16.4. Selection o f antigen binders by panning
For selection, an immunotube was coated overnight at 4° C with AFBi-BSA or 
AFBi-dextran (AFBi-Dex) diluted in PBS (50-100 ug/ml). The tube was washed 
five times with PBST and five times with PBS. This was then blocked with 4% 
(w/v) milk in PBS and allowed to incubate for 1 h at 37° C. After this time the 
tube was again washed, and 1 ml of phagemid particles was added to 3 ml of PBS 
which in total contained 2% (w/v), milk. This was allowed to incubate in the 
immunotube for 2 h at room temperature, gently shaking. After washing (as 
before) bound phage was eluted from the tube by adding 800 |il 0.1 M
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glycine/HCl, pH 2.2 for 10 minutes. This was then neutralised using 48 pi of 2 M  
Tris. The phage was then used for titre, as described previously.
2.16.5. Preparation o f Library Stocks
Once phage was eluted from an immunotube (as described above), it was re­
infected into an E .co li XL-1-blue culture. 4 ml of 2 X  TY containing 50 pg/ml 
tetracycline was inoculated with a single colony of XL-l-blue overnight at 37° C. 
The E.co li XL-l-blue culture was then diluted 1/100 in 5 ml of 2 X  TY containing 
50 ug/ml tetracycline. This was grown shaking at 37° C for approximately 2 h until 
O .D .550 = 0.5-0.6. The culture was then allowed to sit at 37° C for 15 min. 
Approximately 1.5-2 .0 ml of the eluted phage was added to a 5 ml culture and was 
allowed to incubate for 15 min at 37° C. After this time the culture was centrifuged 
in a bench centrifuge at 4000 rpm for 10 min. The supernatant was discarded and 
the pellet resuspended in 400-500 pi of 2 X TY. The resuspended culture was 
then spread on TYE plates containing 1% (v/v) glucose and 25 ug/ml 
chloramphenicol (100 pi of culture per plate). The plates were allowed to grow 
overnight at 37° C. After this time the bacteria were scraped off the plates with 2 
X  TY (using a glass spreader). This was then centrifuged at 4000 rpm for 10 min. 
The supernatant was removed and the pellet was resuspended in 3 ml of 2 X  TY 
containing 15% (v/v), sterile glycerol. The cultures were aliquoted and “flash- 
frozen” using liquid nitrogen. They were then stored at -80° C until required for 
further use.
2.16.6. Preparation of clones for non-competitive phage ELISA
Individual wells of a 96 well culture plate containing 200 pi/well of 2 X  TY, 1% 
(v/v) glucose, 25 ug/ml chloramphenicol, and 30 pg/ml tetracycline were 
inoculated with single colonies from plates growing bacteria from a round of 
panning. The plate was shaken (150 rpm) overnight at 37° C and used as the 
primary ‘master’ plate to inoculate an identical plate. 30 pi of 60% (v/v) sterile 
glycerol was added to each well of the master plate and stored at -20° C. The 
second plate was grown (shaken at 150 rpm) for 6-8 h at 37° C. The plate was 
allowed to stand for 15 min at 37° C. 25 pi of 2 X TY containing 1% (v/v)
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glucose, 25 ug/ml chloramphenicol, 1.5 m M  IPTG, and 5 x 109 VCSM13 helper 
phage per ml was then added to each well, and allowed to stand at 37° C for 15-30 
min followed by shaking (150 rpm) for 1-2 h at 26° C. The plate was centrifuged 
in a bench centrifuge at 4000 rpm for 10 min. The supernatant was discarded and 
replaced with 200 pi 2 X TY containing 1% (v/v), glucose 25 ug/ml 
chloramphenicol, 1.5 m M  IPTG, 30 ug/ml kanamycin, and grown at 150 rpm 
overnight at 26° C. After the overnight incubation the plate was centrifuged in a 
bench centrifuge at 4000 rpm for 10 min. The supernatant was analysed by phage 
ELISA.
2.16.7. Non-competitive phage ELISA for the detection o f positive clones to 
AFH,
A 96-well microtitre plate was coated by adding 100 pi of aflatoxin Bi-BSA 
conjugate or AFBi-Dex conjugate dissolved in PBS at a concentration of 50 ug/ml 
to each well. The plate was incubated overnight at 4° C. The plate was emptied 
and washed six times, three times with PBST and three with PBS only. The plate 
was then blocked by addition of 100 pi per well of PBS containing 2% (w/v), milk 
powder and incubated for 1 h at 37° C. (For both coating and blocking of plates, 
incubation steps could also be carried out at 37° C for 1 h or 4° C overnight). 75 pi 
of supernatant and 25 pi of 4% (w/v), milk in PBS were added to each well for 1 h 
at 37° C. Plates were emptied and washed as described before, and incubated for 1 
h at 37° C with 1/1,000 dilution of anti-M13 antibody (anti-helper phage antibody). 
This was followed by addition of a 1/5,000 dilution of HRP-labelled anti-rabbit 
antibody. This was incubated for 1 h at 37° C followed by colour development as 
described in section 2.11.1 The enzymatic reaction was stopped by the addition of 
25 pi 4 M  H 2SO4 to each well. The absorbance of the wells at 492 nm was 
subsequently measured using a microtitre plate-reader.
2.16.8. Preparation o f clones fo r competitive phage ELISA
Positive clones recognising either AFBrBSA or AFB,-Dex in the non-competitive 
format were grown from the master plate (prepared in section 2.16.6) in 2 ml of 
NE medium at 37° C. After reaching O.D.55o= 0.3, 1 ml of NE medium
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complemented with 5 X  109 cfu VC SMI 3 and 1.5 mM IPTG was added. The 
cultures were allowed to produce scFv-displaying phages overnight at 24° C in a 
shaking incubator. The cultures were then centrifuged at 4,000 rpm for 10 min and 
the supernatant containing the phage displayed scFv’s was removed and analysed 
for recognition of free AFBi.
2.16.9 . Competitive phage ELISA for the detection of clones recognising free 
AFBi
A competitive phage ELISA was carried out on clones that recognised either 
AFBi-BSA or AFBi-Dex on a non-competitive format. The ELISA was carried 
using the same method as described in section 2.16.7 except that standards of free 
AFBi were added to the ELISA plate at same time of addition of the phage clones.
2.17. Iso la tion  and soluble expression o f  scFv anti-A F B i antibod ies
2 .17.1 . Purification and isolation o f ‘positive’ Vh-Vlfragment from pAK 100
Plasmid purification of pAK 100 containing DNA of scFv antibody recognising 
free AFBi was carried out using the Wizard Plus SV miniprep DNA purification 
system as described in section 2.15.7. The plasmid was then restriction enzyme- 
digested from the pAK 100 vector as described in section 2.15.8 and 
electrophoresed on a low-melt agarose gel as described in section 2.12. The 
fragment excised from the gel (800 base pair fragment), was then purified using the 
Wizard PCR-prep purification kit as described in section 2.15.5 prior to being 
ligated into the high expression vector pAK 400.
2 .17 .2 . Restriction enzyme digestion o f pAK 400
Restriction enzyme digestion of the soluble high expression vector pAK 400 was 
carried out in the same way as described in section 2.15.8.
2 .17 .3  Insertion o f Vh-Vl fragment into pAK 400plasmid vector
Ligation of the positive Vh -Vl fragment into the vector pAK 400 was carried out
in the same way as described in section 2.15.9.
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2.17.4 . Preparation o f fresh competent E.coli JM-83 using calcium chloride
A single colony of the non-suppressor E.coli bacteria JM 83 was used to inoculate 
5 ml of 2 X  TY containing 50 (ig/ml of streptomycin sulphate. This was grown 
overnight while shaking at 37° C. The E.coli culture was then diluted 1/100 in 100 
ml of 2 X  TY containing 50 pg/ml of streptomycin sulphate. This culture was 
grown until the O.D.55o= 0.3-0.4. The cells were cooled on ice for 10-15 min 
before being collected by centrifugation at 4° C (2,000 rpm for 20 min in a bench 
centrifuge). The cells were maintained at 4° C for the rest of the procedure. The 
supernatant was decanted off and the cells were resuspended in 20 ml of 100 mM 
MgCl2. This was re-centrifuged at 2000 rpm for 20 min, and the cells resuspended 
in 20 ml of 50 mM CaCl2. The cells were left on ice for 30 min before being 
centrifuged again at 4° C (2000 rpm for 20 min in a bench centrifuge). The 
supernatant was decanted off and the cell pellet was resuspended in 2 ml of 50 mM 
CaCl2 per 100 ml culture. The washed bacterial cells were then ready for 
transformation. If  necessary, it was possible to “flash-freeze” the cells using liquid 
nitrogen and store them at -80° C in 15%  (v/v) sterile glycerol.
2 .17 .5 . Transformation o f  E.coli JM-83 with pAK 400 plasmid vector 
containing 'positive’ VH-VLfragment
3 j-il of the ligated DNA vector was added to a 200 |il aliquot of fresh CaCl2 - 
competent E.coli JM-83 cells. As a control, 3 (J.1 of 50 mM CaCl2 was also added 
to a 200 jxl aliquot of the competent cells. The transformations were left on ice for 
60 min. After this, they were placed in a 42° C waterbath for exactly 2 min, and 
then immediately back on ice. The contents of the tubes were then added to 700 (j,l 
of 2 X  TY, and incubated for 1 h at 37° C with gentle shaking. Serial dilutions 
(diluted to 10‘8) were carried out on both transformed samples. These were plated 
out on selective TYE medium (TYE containing 25 (ig/ml of chloramphenicol, and 
1 %  (v/v), glucose). The remaining experimental-transformed sample was plated 
out on selective medium plates containing 25 Mg/ml of chloramphenicol, and 1%  
(v/v), glucose, in order to grow stocks of the library. The plates were incubated 
for 24 h at 37° C. The production stocks of the bacteria containing the ligated 
pAK 400 were made in the same way as described in section 2.15.11.
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2.17 .6 . Soluble expression of scFv fragments in pAK 400
In order to obtain soluble expression of scFv antibodies, 20-200 ml of expression 
medium was inoculated with 200 (il - 2 ml of preculture (JM 83 harbouring the 
pAK 400 expression plasmid for the anti-AFBi scFv antibody). This was grown 
while shaking at 37° C until O.D.55o= 0.5. Expression was then induced by the 
addition of 1 mM IPTG and allowed to proceed for 4 h at 24° C. The culture was 
then centrifuged at 4,000 rpm in a bench centrifuge for 15 min. The supernatant 
was removed and analysed for soluble expression of scFv antibodies .
2 .17 .7  Analysis o f the cellular distribution o f scFv antibodies 
Cell pellets were analysed for periplasmic expression of scFv by resuspending in 
100 nl -  1 ml of PBS containing 0.1% (w/v) phenyl methyl sulphonylfluoride 
(PMSF) and 1.5% (w/v) streptomycin sulphate. They were then subjected to three 
freeze-thaw cycles and centrifuged in a bench centrifuge at 3,000 rpm in a bench 
centrifuge for 10 min. Lysates were analysed for soluble expression of scFv 
antibodies by ELISA.
2.18. P u rification  and concentration  o f  so luble scF v an tib od y fragm ents
ProBond™ resin (Invitrogen) was used for the isolation of the soluble scFv 
antibodies from bacterial culture supernatant. ProBond™ resin allows for single 
column purification of expressed proteins that contain polyhistidine tags (Hemdan 
eta l, 1989).
2.18 .1 . Purification o f soluble scFv fragments by immobilised metal affinity 
chromatography (IMAC)
5 ml of ProBond™ resin was poured into a column and allowed to settle. The 
column was then calibrated with 20 ml of wash buffer (20 mM phosphate buffer 
with 500 mM NaCl, pH 7.8). 20 ml of the bacterial cell culture supernatant was 
added to the column and re-applied a number of times, in order to allow optimal 
binding of the scFv’s to the column. The column was then washed with 40 ml of 
wash buffer. 20 ml of elution buffer (wash buffer containing 300 mM imidazole) 
was added and allowed to sit in the column for 10 min, before fractions were
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collected. All of the fractions were monitored for protein content at O.D.28o, and 
elution continued until there was no more protein being eluted from the column. 
The fractions containing protein were pooled and dialysed overnight at 4° C against 
51 PBS.
2.18 .1 .1 . Stripping and recharging o f ProBond™resin
The column was washed twice with 8 ml of 50 mM EDTA to strip away chelated 
nickel ions. This was followed by washing once with 16 ml of 0.5 M NaOH in 
order to denature or elute any non-specific proteins remaining on the resin. It was 
then washed with 16 ml of sterile distilled water. The column was recharged with 
16 ml of a 5 mg/ml solution of nickel chloride (NiCl2) followed by one more 
washing with 16 ml of distilled water. The charged column was stored in water 
containing 20% (v/v) ethanol, until required for use. The resin was always used 
for the same recombinant antibody, and only used 3-4 times before disposal.
2.18.2 . Concentration o f purified scFv antibody
Soluble scFv antibodies, in PBS, were concentrated five-fold using a stirred 
ultrafiltration cell with a 76 mm diaflo ultrafiltration membrane, with a molecular 
weight cut-off of 10,000 daltons. The concentrate was sterile filtered, and 0.05% 
(v/v) sodium azide was added for preservation. It was stored at 4° C until required 
for use.
2.19. E L IS A  analysis o f  soluble scF v antibod ies
2 .19.1 . Checkerboard ELISA for determination o f optimal scFv antibody 
dilution and conjugate concentration for use in a competition ELISA
A 96-well microtitre plate was coated as described in section 2.11.2. Serial 
dilutions of the scFv antibody were carried out in PBS. 100 (j,l per well of each 
dilution of scFv antibody was added to the wells (at least in triplicate) in the 
absence of free hapten. This resulted in a set of titre curves being produced for 
each different conjugate concentration. The plate was incubated for 1 h at 37° C, 
followed by washing, and the addition of a 1/400 dilution of anti-FLAG 
monoclonal antibody, which recognises the histidine tag on the scFv antibody.
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After incubation and washing, 100 \x\ of horseradish peroxidase (HRP) - 
conjugated - anti-mouse secondary antibody, diluted in PBS, was added to each 
well and incubated for 1 h at 37° C. Colour was developed as described in section
2.11.1. From the titre curves obtained, the antibody dilution that gave half the 
maximum absorbance, and the lowest conjugate concentration that provided 
sufficiently high absorbances was chosen.
2.19.2 . Competitive ELISA using soluble scFv antibodies for the detection free 
AFBi
A competitive ELISA was carried using the same method as described in section 
2.19.1 except that the ELISA plate was coated with one concentration of 
conjugate, and standards of free AFBi were at same time of addition of the soluble
scFv antibody.
2.19.3 Estimation o f cross reactivity o f soluble anti-AFBi scFv antibodies
Cross reactivity studies were carried out in the same way as described in section
2.11.4 for the preparation of aflatoxin standards, and section 2.19.2 for the 
competition assay.
2.20. B IA core studies
CM5 research grade sensor chips were used in all cases. Running buffer for all 
BIAcore experiments was Hepes buffered saline (HBS) buffer, pH 7.4, containing 
10 mM HEPES, 150 mM NaCI, 3.4 M EDTA, and 0.005% (v/v) Tween 20. All 
solutions were filtered (0.22 |j,m) and running buffer was degassed by sonication 
prior to use.
2.20.1 . Preconcentration studies
Proteins and protein-conjugates were immobilised on the sensor surface by means 
of N-hydroxysuccinimide esterification. This allows covalent attachment of 
biomolecules via primary amine groups. In order for the coupling reaction to be 
carried out, an initial "preconcentration" step is required. At pH values greater 
than 7, the CM-dextran surface has a net negative charge (negatively charged 
carboxyl groups), while proteins at pH values below their isoelectric point (pi) will
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have a net positive charge (protonated amine groups), and will, therefore, be 
electrostatically attracted to the chip surface.
For the native form of a protein, preconcentration can be facilitated by adjusting 
the pH below the isolectric point (pi). However, modification of proteins by, for 
example, conjugation to hapten molecules often radically alters the pi. Therefore, 
when dealing with modified proteins, the correct pH for preconcentration had to be 
determined experimentally. This was done by preparing protein solutions (usually 
at a concentration of 50 ug/ml) in 10 mM sodium acetate at a range of different 
pH’s from 3.9 to 5.0. These solutions were then injected over an underivatised chip 
surface, and the degree of electrostatic binding was monitored. The highest pH at 
which satisfactory preconcentration was observed was chosen as the pH for 
immobilisation.
2 .20 .2 . Coupling reaction o f proteins and hapten-protein conjugates to cm- 
dextran gel
The carboxymethylated dextran (CM-dextran) matrix was activated by mixing 
equal volumes of 100 mM NHS (N-hydroxysuccinimide) and 400 mM EDC (N- 
ethyl-N-(dimethyl-aminopropyl) carbodiimide hydrochloride) and injecting the 
mixture over the sensor chip surface for 7 min at a flowrate of 5pl/min. The 
interactant to be immobilised (concentration: 50 - 200 ng/ml) was dissolved in 10 
mM acetate buffer (at the required pH), and injected over the surface for 20 min at 
a flowrate of 2 l^/min. The unreacted sites on the sensor chip surface were then 
capped by injection of 1 M ethanolamine, pH 8.5, for 7 minutes.
2 .20 .3 . Removal o f non-specific interactions
In certain situations non-specific interactions may occur with an inhibition assay 
format, where the antibody being injected over the immobilised conjugate surface 
may non-specifically bind to the CM-dextran surface, as well as the protein part of 
the hapten-protein conjugate. This is particularly common with a polyclonal 
antibody population due to its heterogeneous nature. The problem is overcome by 
‘spiking’ the antibody diluent buffer, when necessary, with CM-Dextran 
(~100p.g/ml) or the protein the hapten is conjugated to (~lmg/ml).
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2 .20 .4 . General surfaceplasmon resonance-based inhibition immunoassay
An indirect inhibition assay system was used for the detection of aflatoxin Bi in 
PBS and spiked grain samples. All additions of reagents and incubation steps were 
automated.
Approximately 4,000-8,000 response units (RU) of aflatoxin Bi-BSA conjugate 
was immobilised on the chip surface for each assay.
The antibodies were diluted in HBS running buffer, and depending on the non­
specific interactions, CM-dextran and/or BSA were also added. All buffers and 
solutions used were prepared using ultrapure water de-gassed and sterile filtered.
A stock solution of AFBi was made, as described in section 2.10.1, and standard 
solutions within the desired range were prepared in PBS containing 5% (v/v) 
methanol from this stock.
Each sample was incubated with an equal volume of the anti-aflatoxin antibody or 
scFv for 10 min when the system was automated, or alternatively the samples 
could be incubated for 1 h at 37° C and then passed over the surface of the chip. 
This was carried out three times for each concentration. Regeneration of the 
surface of the chip was carried out using, 10-100 mM HCl/NaOH or 1 M 
ethanolamine with 20%(v/v) acteonitrile, pH 12.0.
A calibration curve was constructed from these results by plotting the change in 
response (in RU) for each standard against the log of concentration. The intra-day 
variability of the assay was investigated by running a set of three standards across 
the linear range three times in one day, and determining the coefficient of variation 
(C.V.) between the calculated AFBi standards for each set of three.
The inter-day variability of the assay was assessed by running three sets of 
standards across the linear range on three different days, and determining the C.V. 
between the calculated AFBi concentrations for the standards from each of the 
three standard curves.
2 .20.5 . Solution affinity analysis o f scFv antibodies using BIAcore 
Approximately 5,000 RU of AFBi-BSA conjugate was immobilised as described in 
section 2.20.2. Serial dilutions of purified anti-AFBi scFv of known concentration 
were passed over the immobilised surface, and a calibration curve was constructed 
of mass bound measured in terms of response units, versus scFv concentration
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(nM). A known concentration of scFv was then incubated with varying 
concentrations of AFBi (nM), and allowed to reach equilibrium for 2 h at 37" C. 
These samples were then sequentially injected over the immobilised surface and the 
binding response calculated. The response values measured were used to calculate 
the amount of ‘free scFv’ in the equilibrium mixtures, from the constructed 
calibration curve. A  graph was then constructed of toxin concentration (nM) 
versus ‘free scFv concentration’ (nM), and using the solution phase interaction 
models inBIAevaluation 3.1 software, the overall constant could be determined.
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Production, and Applications of Polyclonal Antibodies to
Aflatoxin Bj
Chapter 3
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3.1. In trod u ction
Aflatoxins were discovered in 1960 following the deaths of several thousand turkey 
poults throughout England, due to consumption of contaminated Brazilian groundnut 
meal (Murray et a l, 1982). They are a group of highly toxic fungal secondary 
metabolites that occur in Aspergillus species (O’Kennedy et al., 1997). The fungus 
contaminates foodstuffs and feeds, as well as crops such as maize, cottonseed, 
peanuts, and tree nuts during growth but particularly while in storage. Contamination 
is most common in tropical and sub-tropical countries where humidity is high, and, 
therefore, allows favourable conditions for the fungus to grow. Aflatoxins are 
members of the coumarin family and the most significantly occurring compound is 
aflatoxin B, (AFBi) (Figure 3.1), which is produced by certain strains of Aspergillus 
flavus (A. flavus) and Aspergillus parasiticus (A. parasiticus). Other aflatoxins 
designated B2, Gi, and G2 are also produced, but AFBt is generally present in the 
largest quantity, and is the most toxic. Aflatoxin Mi (AFMi-or 4-hydroxy-AFBi) is a 
hydroxylated metabolite of AFBi, which is excreted in the milk of dairy cattle after 
they consume aflatoxin-contaminated food. AFQi and AFPi are metabolites of AFBi 
in the mouse and rhesus monkey (Dalezios et al., 1971).
3.1.1 . Aflatoxin production conditions and biosynthesis
The Aspergillus species that produce aflatoxins are widely distributed saprobic 
moulds. They grow naturally on many substances ranging from rubber to foodstuffs 
depending on the climatic conditions. A. flavus species generally infect nuts as the 
fungus is airborne, while A. parasiticus is most commonly found in the soil, so 
contamination of cereals is mainly due to this subspecies. For aflatoxin production, 
relative humidity (RH) levels need to be between 83-88 % , with levels increasing as 
the RH increases up to 99% (Gourama and Bullerman, 1995). Although A. flavus 
requires optimum growth temperatures between 36-38° C, it was found that AFBi is 
produced between 24-35° C (Gqaleni et al., 1997). Carbon dioxide levels and pH 
may also have effects on aflatoxin production. Optimum pH levels from 4 to 6 are 
particularly favourable, while increasing concentrations of carbon dioxide from 20 to 
100 %  gradually inhibits aflatoxin production.
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Figure 3.1. Chemical structure of aflatoxin Bi (AFBi) and its structural analogues.
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Aflatoxins produced by the Aspergillus species are secondary metabolites, and are 
therefore not essential for growth of the fungi. Their functional role in the producing 
fungus is not known. Acetate polyketides are the main precursors of aflatoxins, and 
their biosynthesis is long and complex. It is characterised by diverse oxidative 
rearrangement processes (Minto and Townsend, 1997). The pathway outlined in 
Figure 3.2 is for the biosynthesis of AFBi and AFB2 (Trail et al., 1995).
3.1.2. Aflatoxin biotransformation
The most serious toxic actions associated with AFBi exposure are mutagenicity and 
carcinogenicity, which result from metabolic activation. This involves oxidative 
activation in the liver and kidneys by cytochrome P 450 and its enzymes (Minto and 
Townsend, 1997). Cytochrome P 450 is associated with extra-mitochondrial electron 
transport in the liver, and is involved with drug detoxification, and mixed function 
oxidation reactions. It is the principle enzymatic system involved in the 
biotransformation of AFBi to AFBi-8-9-epoxide, referred to also as AFBi-2-3- 
epoxide, which is highly toxic. P 450 enzymes capable of activating AFBi include 
members of the 1A  2B, 2C and 3 A subfamilies (Pelkonen etal., 1997). Activation is 
essential for aflatoxin to produce its carcinogenic, mutagenic, and DNA-binding 
actions. AFBi can be activated to form either an endo-epoxide or an exo-epoxide 
(Massey et al., 1995) (Figure 3.3). Only the exo-epoxide binds to DNA. It does this 
by electrophilically attacking the N7 atom of Guanine, with the reaction producing a 
DNA lesion known as 2,3-dihydro-2-(N7-guanyl)-3-hydroxyaflatoxin Bi (AF-N7- 
Gua). This is studied as an indicator compound of genotoxic damage (Groopman et 
al., 1984). It is also thought to be the major cause of lesions on the liver that account 
for the carcinogenic and mutagenic nature of AFBi. The exo-epoxide has also been 
shown to cause G-T transversions at codon 249 of the p 53 tumour suppressor gene, 
the altered sequence of which is associated with human cancers (Woloshuk and 
Preito, 1998). Hydration of the exo-epoxide can also occur, forming the dihydrodiol 
of AFBi. This dihydrodiol inhibits protein synthesis in vitro and this may explain the 
cause of necrosis of the liver, which causes death (Gourama and Bullerman, 1995).
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3.1.3. Carcinogenicity and toxicity
AFBj is a very potent carcinogen and has been linked to human hepatocellular 
carcinoma. The international agency for research on cancer regards it as a human 
carcinogen (Ward et al, 1990). Aflatoxicosis is a very rare disease and only a few 
instances of it have been reported. Symptoms of aflatoxicosis in animals and humans 
have been categorised in two general forms.
A. Acute aflatoxicosis is produced when moderate to high levels of aflatoxins are 
consumed. Specific, acute episodes of disease ensue and may include haemorrhage, 
acute liver damage, oedema, alteration in digestion, and possibly death.
B. Chronic aflatoxicosis results from ingestion of low to moderate levels of 
aflatoxins. The effects are usually subclinical and difficult to recognise. Some of the 
common symptoms are impaired or slower food conversion rates (U.S. Food and 
Drug administration. ‘Foodborne pathogenic micro-organisms and natural toxins 
handbook’, http://vm.cfsan.fda.gov/~mow/chap41 .html).
Although a wide range of LD5o’s have been reported for different species, most are in 
the region of 0.5 -  10 mg/kg of body weight. Animal studies indicate that aflatoxins 
can cause cancer in the liver, kidney and lungs, with the liver being the most sensitive 
and principle target organ (Nawaz et al., 1995). However, it is often difficult to 
prove that aflatoxins are a cause of liver cancer, because, in tropical climates where 
aflatoxins occur most frequently, hepatitis B is very common (Chen et al, 1996). 
Immunotoxicological effects, caused by AFBi have also been reported (Silvotti et al.,
1997). In this study, piglets were fed with AFBi, and a number of effects including 
impairment of macrophage and granulocyte function were reported.
3.1.4 . Occurrences o f aflatoxin poisoning
Links between dietary exposure to aflatoxins and increased risks of primary 
hepatocellular carcinoma has been reported in several ethnic groups (Gerbes & 
Caselmann, 1993; Harrison et al, 1993). For example, in Taiwan, an ecological 
correlation study was carried out that showed an association between urinary
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aflatoxin level and hepatocellular carcinoma (hcc). Residents in an area called 
Penghu Islets, Taiwan, were reported to have the highest mortality rate caused by 
liver cancer in the country. Peanuts, the major agricultural product in this area were 
heavily contaminated by aflatoxins (Chen et al., 1996). The study found that the 
onset of hcc among residents in the Penghu Islets was 10 years earlier than in 
residents of Taiwan island, and this was at least partly attributable to aflatoxin 
exposure.
One of the most significant accounts of aflatoxicosis in humans, occurred in 
northwest India in 1974. More than 150 villages in adjacent districts of two 
neighbouring states in were affected by the outbreak. It was found that 397 persons 
were affected, of whom 108 died. In this outbreak, contaminated corn was the major 
dietary constituent, and aflatoxin levels ranging from 0.25 to 15 mg/kg were found. 
The daily aflatoxin B i intake was estimated to have been at least 55 ug/kg body 
weight for an undetermined number of days. The patients experienced high fever, 
rapid progressive jaundice, oedema of the limbs, pain, vomiting, and swollen livers. 
Histopathological examination showed extensive bile duct proliferation and periportal 
fibrosis of the liver together with gastrointestinal haemorrhages. A 10-year follow-up 
of the Indian outbreak found the survivors fully recovered with no apparent ill effects 
from the experience.
A second outbreak of aflatoxicosis was reported from Kenya in 1982. There were 20 
hospital admissions with a 60% mortality rate. Daily aflatoxin intake was estimated 
to be at least 38 ug/kg body weight for an undetermined number of days.
In a deliberate suicide attempt, a laboratory worker ingested 12 ug/kg body weight of 
aflatoxin B i per day over a 2-day period, and 6 months later, 11 ug/kg body weight 
per day over a 14-day period. There were no ill effects, except for transient rash, 
nausea and headache. Hence these levels may serve as possible no-effect levels for 
aflatoxin B i in humans. In a 14-year follow-up, a physical examination and blood 
chemistry analysis, which included tests for liver function proved to be normal (U.S.
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Food and Drug administration. ‘Foodborne pathogenic micro-organisms and natural 
toxins handbook’, http://vm.cfsan.fda.gov/~mow/chap41.html).
3.1.5 . Analysis and detection of aflatoxins
Due to the widespread occurrence of the toxin-producing fungi in cereals, major 
efforts have been made to develop rapid and sensitive methods for detection of 
aflatoxins. Thin-layer chromatography and high-pressure liquid chromatography 
have been traditional methods used (Nawaz et al., 1995), but can lack sensitivity and 
consistency due to the presence of many components in food and biological matrices 
that can interfere with physiochemical analysis. Selection of representative samples 
is a major problem, as the content of aflatoxin can vary from grain sample to sample 
due to individual ‘hot spots’ of mycotoxin production in an individual grain or nut 
consignment. Gourama and Bullerman (1995) gave an example, where in a peanut 
lot, one peanut kernel alone was reported to contain several hundred micrograms of 
AFBi. This kernel could consequently contaminate 1,000 other kernels with a high 
level of aflatoxin. This emphasises the importance of adequate sampling of grains 
and nuts. Scudamore and Patel (2000) describe in detail a survey for aflatoxin and 
other mycotoxins in maize imported to the United Kingdom. It entailed sampling 
from all the major ports as well as from maize mills. This was carried out by taking 
incremental samples each of 0.5 kg from consignments on route to mills over a 2 h 
period. In the case of sampling at the mills, 0.5 kg incremental samples were also 
taken using an automatic sampling probe. This ensured the ability to take a sample 
from the ‘centre’ of a load and not just on the surface. In order to achieve a good 
degree of uniformity within samples for accurate analysis, it is strongly recommended 
to finely grind the grain as this will aid in more equal distribution of the mycotoxin 
within the sample. Extraction can be carried out with polar solvents such as 
methanol, acetone or chloroform. However, chloroform is generally the solvent of 
choice (Patel et al., 1996). Once the aflatoxin has been extracted it can be further 
purified in one of two ways.
A. Using a column clean-up step: This entails passing the extracted sample through a 
silica column pre-washed with a solvent such as toluene. The sample is then passed
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through the column, which is washed again with toluene to remove any impurities. 
The aflatoxin is then eluted from the column using chloroform and methanol mixed 
together. The solvent can then be removed from the sample by rotary evaporation, 
and the sample dissolved in mobile phase buffer (if the sample is going to be 
analysed by HPLC).
B. Immunoaffmity clean-up can also be utilised for aflatoxin sample purification. 
Immunoaffinity columns are commercially available, and contain a monoclonal 
antibody specific for aflatoxin B i (or another mycotoxin if required). An extracted 
sample is passed through the column and the aflatoxin binds to the monoclonal 
antibody immobilised on the column. The column is washed with PBS and the 
aflatoxin is then eluted from the column under gravity, using acetonitrile. The 
acetonitrile is then evaporated, and the aflatoxin sample re-dissolved in mobile phase 
buffer.
Both of these methods are effective in their application, but also require stringent 
internal controls. This entails spiking ‘non-contaminated’ grain sample with a known 
concentration of aflatoxin, and then extracting it the same way as the unknown grain 
samples, which monitors the effectiveness of the extraction procedure. 
Immunoaffintiy columns are used for a higher degree of sample cleanup (Patel et al. 
1996) i.e. those containing high levels of co-extractives, which could not be removed 
using the silica column. The silica column method is also effective in sample cleanup 
and also offers recoveries of between 70-110 %  throughout a given study (Scudamore 
et al., 1999).
Other methods include extracting the sample as described already, evaporating off the 
solvent without a clean-up step, resuspending it in buffer and analysing it. 
Alternatively, the extracted sample could be directly diluted in buffer and analysed 
(Linskens et al., 1992). Both of these methods are more applicable for immunoassay 
analysis, which normally does not require as many sample clean-up steps. 
Immunoassays can offer high levels of sensitivity, specificity, and are capable of high 
sample throughput (Linskens et al., 1992). In order to produce antibodies to
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aflatoxins and most mycotoxins they must be covalently linked to an immunogenic 
carrier molecule such as a protein (e.g. Bovine serum albumin-BSA), which will 
elicit a strong immune response following immunisation. This is because aflatoxins 
have a low molecular weight (i.e. less than 1,000 daltons). The protein conjugate is 
also used at the screening and characterisation stages of antibody production. 
Monoclonal and polyclonal antibodies have been produced using an aflatoxin B,- 
BSA (AFBi-BSA) conjugate (Ward el al., 1990). Immunoassays (and ELISA in 
particular) have found widespread use in aflatoxin analysis. Langone and Van 
Vunakis (1976) were one of the first to develop an immunoassay to AFBi in serum, 
urine, and crude extracts of com and peanut butter supplemented with aflatoxin. 
Antibodies were produced in New Zealand white rabbits immunised with AFBi-poly-
1-lysine conjugate. Results showed that as little of 1 jig/kg of sample could be 
measured. The radioimmunoassay for AFBi was found to be at least as sensitive as 
the chromatographic and spectral techniques available.
ELISA is more widely used in present day, as radioisotopes are more expensive and 
hazardous to use. Aldao et al. (1995) developed an indirect competitive ELISA for 
the quantification of AFBi in peanuts. It was found that the assay had a limit of 
detection of 0.25 (ig/kg (ppb), which was more than satisfactory to meet international 
compulsory limits (~5 ppb) for commercial preparations of the particular food. 
Aflatoxin test kits have also been produced employing ELISA. Abouzied (1998) 
developed a highly sensitive competitive ELISA using polyclonal antibodies to 
AFBi. The assay had a limit of detection of 0.05 ng/ml (0.25 ppb), and was validated 
against high-performance liquid chromatography using corn samples. The assay was 
found to be reproducible, and the kit was stable for at least nine months when stored 
at 4° C. There are also commercially available kits for the detection of AFBi. An 
Oxford-based company called Digen Ltd., develop and sell a kit called “Ridascreen®, 
Aflatoxin TOTAL”. This is a competitive enzyme immunoassay for the quantitative 
analysis of aflatoxin in cereals, fruits nuts, spices, coffee and feeds. The assay only 
takes one and a-half-hours from start to finish. It can detect as little as 1.75 ppb, with 
a recovery rate from extraction of 85% ± 15 %.
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Dipstick assays employing antibodies for the detection of mycotoxins have also been 
developed. Schneider et al. (1995) produced a membrane-based visual dipstick 
enzyme immunoassay for the simultaneous detection of up to five mycotoxins 
including AFBi. The visual detection limit for AFBi was 2 ng/ml in buffer solution, 
while in extracted sample it was 30 ng/g. Niessen et al. (1998) also developed a 
dipstick assay for the detection of AFBi. This was a lateral flow one-step sol particle 
immunoassay (SPIA), with signals generated by colloidal carbon particles onto which 
monoclonal antibody specific for AFBi was coupled. A diagram of the SPIA is 
outlined in Figure 3.4. The capture ligand (aflatoxin Bi-BSA (AFBi-BSA) 
conjugate) was spotted onto plastic backed nitrocellulose strips in a line format. In 
the same way a control line was spotted above the test line, using secondary 
antibodies directed against the AFBi specific antibodies (used to test assay 
performance). In a research set-up, the strips (1) were mounted in a vertical position 
on a perspex bridge (2). A piece of filter paper was placed on the top end of the strip 
(3) in order to serve as a fluid drain. The bottom end of the strip was positioned to 
take a droplet (4) pipetted onto a piece of parafilm. The droplet contained a detection 
ligand (anti-AFBi antibody) coupled to colloidal carbon particles. Upon passing the 
immobilised capture ligand the detection ligand on the colloidal conjugate 
specifically bound, resulting in the formation of a visual signal, i.e. a black line. This 
assay was used for sample analysis in a competitive format. The droplet of fluid also 
contains the target molecule of interest (AFBi sample). During the run the detection 
ligand would bind the target molecule, which would result in less binding of the 
detection ligand conjugate to the capture ligand and, as a consequence, loss of signal 
intensity. Figure 3.5 shows an example of a possible format of a SPIA dipstick for 
the detection of AFBi. A detection limit of 0.1 ppb (ng/ml) AFBi could be achieved 
in buffer, while a detection limit of 10 ppb was achieved in extracts of an 
uncontaminated blank sample spiked with AFBi.
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Control Strip Test Strip
Figure 3.4. Schematic diagram for SPIA.
Figure 5.5. Visualisation of an SPIA for the detection AFB ¡. Three lines are visible on the 
strip. One of the lines is a control line, while a second one is the test line. The third line is a 
multi-analyte line for the detection of different ligands. In the case of AFB], this could be 
applied for the detection of a number of aflatoxins, providing the antibody was cross-reactive 
to various other aflatoxins.
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3.1.6. Control o f aflatoxins
Following the discovery of aflatoxins in 1960, several countries have developed 
legislation to regulate and control mycotoxins (mainly AFBi) in food and feed. The 
Food and Drug Administration (FDA) in the United States have established 
regulatory working guidelines on acceptable levels of aflatoxin in food and feeds. 
The action level for food is 20 ppb (ng/g) total aflatoxin, while the action level for 
AFMi in milk is 0.5 ppb. This low level for milk was set due to the fact that milk- 
containing AFMi may present a risk to infants (Gourama & Bullerman, 1995). 
Within the EU, the maximum residue level (MRL) for AFBi has been set at 2 ppb, 
while the U.K. Ministry of Agriculture, Fisheries and Food have proposed that nuts 
and nut products destined for human consumption should not contain more than 4 
ppb of total AFBi (Niessen etal., 1998).
From this, it is clear the aflatoxins pose a serious problem to farmers and food 
processors throughout the world, and as a result there is a great emphasis put on 
detection methods for such contaminants. Additionally there is also emphasis put on 
inhibition of Aspergillus growth in grain and nuts thus eliminating aflatoxin 
production.
3.1 .7 . Chapter outline
This chapter describes the production of polyclonal antibodies to AFBi, their 
purification and use in ELISA for the detection of AFBi. It also includes cross 
reactivities and the application of one polyclonal antibody population for the 
detection of AFBi in spiked grain samples.
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3.2. Results
3.2.1 . Production and characterisation of polyclonal anti-AFBi antibodies 
Polyclonal antibodies were produced in two rabbits (rabbits 1 & 2, respectively) 
against AFBi using a commercially available AFBi-BSA conjugate. They were 
purified by saturated ammonium sulphate precipitation and protein G affinity- 
chromatography, as well as by subtractive immunoafTinity chromatography on a 
BSA-immobilised' column. The purity of the antibodies was investigated by SDS- 
PAGE, and the working dilution for the antibodies in competitive ELISA for AFBi 
was assessed. A linear range of detection was optimised for both antibodies using a 
competition ELISA and an assessment of the cross reactivity of the antibodies was 
also made. One of the antibody populations was then applied for the detection of 
AFBi in spiked grain samples using competitive ELISA.
3.2 .2 . Estimation o f rabbit titres
New Zealand white rabbits were immunised with a commercially available AFBi- 
BSA conjugate as described in section 2.3.3. The rabbits received a sub-cutaneous 
injection of the conjugate together with an equal volume of Freund’s Complete 
adjuvant. Blood was drawn periodically to estimate the specific antibody titre, which 
was assessed by ELISA as described in section 2.11.1. One half of a 96-well 
microtitre plate was coated with AFBi-BSA conjugate, and the other half of the 
microtitre plate was coated with BSA. The plate was blocked with 2 %  (w/v) casein 
protein. Serum was then diluted from 1/100 to 1/200,000 in PBS containing 0.1% 
(w/v) BSA  The serum was also diluted in PBS containing no BSA. The serum 
diluted in the PBS 0 .1% (w/v) BSA was added to the AFBi-BSA-coated wells, as 
well as the BSA-coated wells, while the serum diluted in the PBS was added to the 
BSA-coated wells only. The antibody responses were then detected using a horse­
radish peroxidase-labelled anti-rabbit antibody followed by the addition of a 
chromogenic substrate. The titre was taken to be the highest dilution of immunised 
serum which gave a signal greater than the corresponding dilution of control serum, 
i.e. the serum diluted in PBS containing 0.1% (w/v) BSA and added to the BSA-
111
coated plate. Background levels (i.e. PBS containing 0 .1% (w/v) BSA-added to the 
BSA-coated plate) were also considered when determining the highest antibody titre. 
However, these were minimal. The final titre for serum for rabbit 1 was 1/204,800, 
while the final titre for serum for rabbit 2 was 1/102,400. Figures 3.6 and 3.7, 
respectively show these results, including the antibody responses to BSA, with or 
without BSA in the diluent buffer. The figures also demonstrate that there was a 
greater antibody response to AFBi than to BSA  as well as that 0.1 % (w/v) BSA was 
sufficient to remove non-specific binding of the serum to the BSA part of the AFBi- 
BSA conjugate.
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Figure 3.6. Final titre of serum obtained from rabbit 1. The serum was diluted in PBS as 
well as PBS containing 0.1% (w/v) BSA, and added to wells of a microtitre plate coated with 
AFBi-BSA conjugate. Diluted serum was also added to wells of a microtitre plate coated with 
BSA. The final titre recorded was in excess of 1/204,800.
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Figure 3.7. Final titre of serum obtained from rabbit 2. The serum was diluted in PBS as 
well as PBS containing 0.1% (w/v) BSA, and added to wells of a microtitre plate coated with 
AFBj-BSA conjugate. Diluted serum was also added to wells of a microtitre plate coated with 
BSA. The final titre recorded was 1/102,400.
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3.2.3. Purification o f polyclonal antiserum
The serum was initially purified by saturated ammonium sulphate precipitation as 
described in section 2.5.1. It was further purified by protein G affinity- 
chromatography as described in section 2.5.2. IgG bound to the protein G column, 
and were eluted after washing, by addition of glycine buffer. The presence of 
antibody in the collected fractions was monitored by absorbance at 280 nm. Typical 
elution profiles for serum obtained from rabbits 1 & 2 are shown in Figure 3.8. The 
profiles show that a higher protein concentration of antibody was eluted from the 
serum obtained from rabbit 1, as well as that the majority of the protein eluted in 
fewer fractions compared to that of the serum of rabbit 2. These fractions were 
pooled and dialysed. Both antibody populations were further purified by subtractive 
immunoaffinity chromatography. Figure 3.9 shows titre curves for both antibody 
populations after subtractive immunoaffinity chromatography was carried out. The 
purification was successful as it removed all of the BSA binding antibodies while not 
affecting the specific antibody titre to AFBi.
3.2 .4 . Characterisation o f purified antibodies by SDS-PAGE
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is a 
technique which separates proteins on the basis of their molecular weights. The 
purity of both polyclonal antibody populations from rabbits 1 & 2, respectively, was 
assessed by SDS-PAGE as described in section 2.7. The antibody was 
electrophoresed under reducing conditions, along with a molecular weight marker 
containing proteins of different weights. Purity was assessed as a comparison 
between serum, ammonium sulphate-precipitated antibody, and the affinity-purified 
antibody. Figures 3.10 and 3.11, respectively, show the gels obtained for both 
antibodies. Boiling the antibody samples together with mercaptoethanol causes the 
polypeptide chains of the immunoglobulins to separate, resulting in two main sample 
bands being observed. One band, with a molecular weight of ca. 50 kDa shows the 
presence of the heavy chains. A second band is barely visible at ca. 25 kDa and 
indicates the presence of the antibody light chains. The figures also demonstrate that
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the purification steps have worked effectively in the isolations of pure 
immunoglobulins from serum.
F raction N u m ber
Figure 3.8. Typical elution profiles for polyclonal anti-AFB, antibodies from a I ml protein 
G affinity column. Saturated ammonium sulphate precipitated samples were passed through 
the column, followed by 20 column volumes o f wash buffer. Bound antibody was then eluted 
using 0.1 M glycine, pH 2.7. 0.5 ml fractions were collected, and the protein content was 
measured by absorbance at 280 nm. In the case of rabbit I, fractions 2-7 were collected and 
pooled, while for rabbit 2, fractions 3-1J were used.
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Figure 3.9. Titres of serum obtained for rabbits I & 2, which were purified by saturated 
ammonium sulphate precipitation, protein G affinity-chroinatography and subtractive 
immunoaffinily chromatography. The curves indicate that subtractive immmoqffinity 
chromatography was successful in removing all of the BSA-binding antibodies, while not 
reducing the specific antibody response to AFB/-BSA.
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Figure 3.10. SDS-PAGE showing serum (B), ammonium sulphate precipitate (C), and 
affinity-purified polyclonal anti-AFB¡ antibodies (D) from rabbit 1. These were 
electrophoresed under reducing conditions. Lanes A and E contained markers consisting of 
a.2 macroglobulin (180 kDa), ¡3 galactosidase (116 kDa), fructose-6-phosphate kinase (84 
kDa), pyruvate kinase (58 kDa), fumar ase (48.5 kDa), lactate dehydrogenase (36.5 kDa), and 
triosephosphate isomerase (26.6 kDa). The purified sample in lane D has one band below 
the 48.5 kDa markers, and one less distinct one below that for the 26.6 kDa marker 
consistent with the presence of the heavy chain and the light chain of IgG. The less intense 
light chain may be due to the fact that the staining method used was not sensitive enough to 
detect it.
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Figure 3.11. SDS-PAGE showing serum (B), saturated ammonium sulphate precipitate (C), 
and affinity-purified polyclonal anti-AFB) antibodies (D) from rabbit 2. These were 
electrophoresed under reducing conditions. Lanes A and E contained markers consisting of 
the same proteins as mentioned previously. The purified sample in lane D has one band 
below the 48.5 kDa markers, and one less intense band below that for the 26.6 kDa marker 
consistent with the presence of the 50 kDa heavy chain and the 25 kDa light chain of IgG. 
The less intense light chain may be due to the fact that the staining method used was not 
sensitive enough to detect it.
118
3.2.5 . D eterm in ation  o f  w ork in g  d ilu tion  o f  antibod ies in com petitive E L ISA  for  
AFBi
A checkerboard ELISA was carried out as described in section 2.11.2 in order to 
determine the optimal antibody dilution and conjugate concentration for use in 
competitive ELISA. Rows of wells of a 96-well microtitre plate were coated with 
concentrations of AFBi-BSA ranging from 0 to 50 (ig/ml, and blocked with 2 %  
(w/v) casein protein. Dilutions of the purified polyclonal anti-AFBi antibodies from 
1/100 to 1/100,000 were prepared and added to the plate. After incubation, enzyme- 
labelled anti-rabbit antibody was added followed by chromogenic substrate. Figures 
3.12 and 3.13 show the overlaid titre curves obtained from the antibodies isolated 
from rabbit’s 1 & 2, respectively. The antibody dilution that gave half the maximum 
absorbance was chosen, and the lowest conjugate concentration that provided 
sufficiently high absorbances was chosen. For rabbit 1, a 1/10,000 dilution of 
antibody was used in the competition ELISA, with a conjugate concentration of 20 
M-g/ml. For rabbit 2, the antibody dilution used was 1/20,000 with a conjugate 
concentration used of 50 (ig/ml.
3.2 .6 . Competitive ELISA for the detection o f AFBi
A series of standards of AFBi ranging in concentration from 12-25,000 ng/ml for 
rabbit 1 and 24-1,563 ng/ml for rabbit 2 were prepared as described in section 2.10.1. 
50 p,l of each of these standards were then added to an AFBi-BSA-coated plate (see 
section 2.11.3). 50 [il/well of each of the affinity-purified anti-AFBi antibodies
obtained from rabbits 1 & 2, respectively, were prepared at the appropriate dilution 
and added to the plates. After incubation and washing, enzyme-labelled anti-rabbit 
antibody was added followed by chromogenic substrate. The linear range of 
detection for the antibodies obtained from rabbit 1 was 12 to 25,000 ng/ml, while for 
rabbit 2 it was 24 to 1,563 ng/ml. For intra-day assay variation, each concentration 
was assayed five times on the one day and the mean absorbance of bound antibody 
for each antigen concentration was plotted versus antigen concentration. Figures 3.14 
and 3.15 show the intra-day assay linear ranges of detection of AFBi for rabbit’s 1 & 
2, respectively. Tables 3.1 and 3.2 show the coefficients of variation (C.V.’s) for
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both rabbits. Intra-day percentage C.V.’s for the calibration plots of both the assays 
were below 9 % .
The inter-day assay variation was calculated by performing the assay over five 
separate days, and a separate calibration curve plotted for each normalised 
absorbance (absorbance/absorbance 0 (A/Ao)) value versus the respective AFBi 
concentration for each assay carried out on each day. The normalised mean values 
for these assays were calculated and plotted as one assay. Figures 3.16 and 3.17 
show the inter-day variability assays for each of the antibody populations obtained 
from rabbits 1 & 2. The percentage C.V.’s for each of the inter-day assays are shown 
in Tables 3.3 and 3.4, respectively. All of the percentage C.V.’s for both assays were 
no greater than 9 %  except for one concentration shown on Table 3.3 for the assay 
developed using rabbit 1 antibodies.
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Figure 3.12. Determination of optimal conjugate loading density and antibody dilution. 
Wells of a microtitre plate were coated with AFBr BSA conjugate at a range of 
concentrations between 0 and 100 jug/ml. One row on the plate was coated with 50 fjg/ml of 
BSA as a control. Serial doubling dilutions of the affinity-purified anti-aflatoxin antibody 
(Rabbit 1) were carried out and then added to the plate as described in section 2.11.3. The 
optimal conjugate concentration chosen was 20 /ug/ml, and the optimal antibody dilution (i.e. 
the one that gave half the maximum absorbance) was 1/10,000.
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Figure 3.13. Determination of optimal conjugate loading density and antibody dilution. 
Wells of a microtitre plate were coated with AFBj-BSA conjugate at a range of 
concentrations between 0 and 50 pg/ml. One row on the plate was coated with 50 /j.g/ml of 
BSA as a control. Serial doubling dilutions of the affinity-purified anti-aflatoxin antibody 
(Rabbit 2) were carried out and then added to the plate as described in section 2.11.3. The 
optimal conjugate concentration chosen was 50 fig/ml, and the optimal antibody dilution (i.e. 
the one that gave half the maximum absorbance) was 1/20,000.
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Figure 3.14, lntra-day assay variation for competitive ELISA for AFB/ using affinity- 
purified anti-AFB/ antibodies obtained from rabbit 1. The linear range of detection was 12.0 
to 25,000 ng/mL The error bars on each calibration point indicate the standard deviation of 
the mean of five measurements.
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Table 3.1. Intra-day assay coefficients o f variation for the determination offree AFBi using 
affinity-purified antibody obtained from rabbit 1. Five sets of twelve standards were assayed 
the same day, and the coefficient o f variation (C. V. ’s) were calculated as the standard 
deviation (S.D.) expressed as a percentage of the mean values for each standard.
Aflatoxin Bt concentration 
(ng/ml)
Calculated m ean ±  S.D. Coefficient of variation
(% )
25,000 0.176 ±0.003 1.73
12,500 0.246 ±  0.021 8.65
6,250 0.267 ±0.006 2.32
3,125 0.333 ±0.013 3.78
1,563 0.398 ±0.014 3.42
781 0.437 ±  0.010 2.29
391 0.499 ±0.009 1.79
195 0.551 ±0.023 4.09
98 0.593 ±0.014 2.34
49 0.629 ±0.011 1.79
24 0.658 ±0.005 0.79
12 0.694 ±0.012 1.75
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Table 3.2. Intra-day assay coefficients of variation for the determination offree AFBi using 
affinity-purified antibody obtained from rabbit 2. Five sets of seven standards were assayed 
the same day, and the C. V. ’s were calculated as the standard deviation (S.D.) expressed as a 
percentage of the mean values for each standard.
Aflatoxin Bj concentration
(ng/ml)
Calculated m ean ±  S.D. Coefficient o f variation
(% )
1,563 0 .3 1 2  ± 0 .0 0 5 1.64
781 0 .3 4 4  ±  0 .004 1.27
391 0 .3 7 4  ± 0 .0 0 9 2.43
195 0 .3 9 9  ±  0 .00 4 1.01
98 0 .4 2 9  ±  0 .0 0 4 0 .97
4 9 0 .4 5 6  ± 0 .0 0 8 1.66
24 0 .471  ±  0 .00 6 1.32
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Figure 3.15. Intra-day assay variation for competitive ELISA for AFB, using affinity- 
purified anti-AFBj antibodies obtained from rabbit 2. The linear range of detection was 24.0 
to 1,563 ng/ml. The error bars on each calibration point indicate the standard deviation of 
the mean of five measurements.
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Figure 3.16. Inter-day assay variation for competitive ELISA for AFB/ using affinity- 
purified anti-AFB/ antibodies obtained from rabbit 1. The linear range of detection was 12.0 
to 25,000 ng/ml. The error bars on each calibration point indicate the standard deviation of 
the mean of five measurements. The results were normalised by dividing the absorbance 
values (A) by the absorbance value obtained for zero concentration of antigen (Ao) in the 
assay.
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Table 3.3. Inter-day assay coefficients of variation for the determination offree AFB1 using 
affinity-purified antibody obtained from rabbit 1. Five sets o f twelve standards were assayed 
on five different days, and the C. V. ’s were calculated as the standard deviation expressed as 
a percentage of the mean normalised values for each standard.
Aflatoxin Bi concentration 
(ng/ml)
Calculated m ean ±  S.D. Coefficient of variation
(% )
25,000 0.238 ±0.022 9.08
12,500 0.321 ±0.027 8.46
6,250 0.377 ±0.059 15.59
3,125 0.431 ±0.035 8.02
1,563 0.528 ±0.039 7.36
781 0.556 ±  0.040 7.24
391 0.672 ±0.047 6.93
195 0.703 ±0.037 5.20
98 0.750 ±0.041 5.49
49 0.848 ±0.070 8.29
24 0.859 ±0.070 8.07
12 0.917 ±0.036 3.88
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Table 3.4. Inter-day assay coefficients of variation for the determination offree AFB/ using 
affinity-purified antibody obtained from rabbit 2. Five sets of seven standards were assayed 
on five different days, and the C. V. ’s were calculated as the standard deviation expressed as 
a percentage of the mean normalised values for each standard.
Aflatoxin Bi concentration 
(ng/ml)
Calculated m ean ±  S.D. Coefficient of variation 
(% )
1,563 0.520 ± 0.036 6.92
781 0.603 ± 0.043 7.17
391 0.669 + 0.013 1.97
195 0.720 +  0.016 2.16
98 0.764 ±0.007 0.95
49 0.832 ±0.018 2.21
24 0.859 ±0.026 2.99
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Figure 3.17. Inter-day assay variation for competitive ELISA for AFB] using affinity- 
purified anti-AFB] antibodies obtained from rabbit 2. The linear range of detection was 24.0 
to 1,563 ng/ml. The error bars on each calibration point indicate the standard deviation of 
the mean of five measurements. The results were normalised by dividing the absorbance 
values (A) by the absorbance value obtained for zero concentration of antigen (Ao) in the 
assay.
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3.2.7. Cross-reactivity studies
Cross reactivity studies were carried out on the antibodies obtained from rabbits 1 & 
2 to seven other structurally related aflatoxins, as described in section 2.11.4. 
Standard curves for each of the aflatoxins were produced as described in previously 
in 3.2.6. The results were normalised and plotted. The slope of the line of the 
standard curve for each toxin was expressed as a percentage of the slope of the line 
for binding to AFBi. Table 3.5 shows the cross-reactions of the afFinity-purified 
antibodies obtained from rabbits 1 & 2. Both antibody populations showed a high 
level of cross-reaction to the structurally related aflatoxins.
Table 3.5. Cross-reactions o f  affinity-purified anti-AFBj antibodies obtained from  rabbits 1 
& 2 observed to seven other aflatoxins. Standard curves were produced fo r  each o f  the 
aflatoxins in the same way as that fo r  AFBj. Each concentration fo r  each point on the 
standard curve was assayed in triplicate and the means plo tted  and normalised in order to 
construct standard curves.
Aflatoxin Rabbit 1 
%  Cross Reactivity
Rabbit 2 
%  Cross Reactivity
B, 100 100
b 2 67.5 4 7 .9
Gi 65.5 6 5 .0
g 2 50.1 2 9 .9
Mj 35 .0 3 4 .0
m 2 1.7 <1
B2a 33 .4 37 .3
G2a 15.5 <1
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3.2 .8 . Optimisation o f a competitive ELISA for the detection o f AFBi in spiked 
grain samples
The affinity-purified antibodies obtained from rabbit 1 were chosen for use in the 
detection of AFBi in spiked grain samples. Spiked grain samples were prepared as 
described in section 2.10.3, and were applied in a competitive ELISA as described in 
section 2.11.3. The linear range of detection for the detection of AFBi in spiked 
grain samples was 98 to 12,500 ng/ml. Figure 3.18 shows this result as the intra-day 
assay. This was carried out by running five sets of each concentration on the one day, 
and calculating the mean absorbance, which was plotted against concentration of free 
toxin. Table 3.6 shows the percentage C. V. ’s for the assay, which were all lower than 
7 % . Inter-day assays were also carried out by running five sets of each standard on 
five different days. The results were normalised and plotted as mean of all five sets 
of results. Figure 3.19 shows the inter-day graph plotted along with percentage
C.V.’s in Table 3.7, which were no greater than 12 % .
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Table 3.6. Intra-day assay coefficients of variation in grain samples spiked with AFB/ using 
affinity-purified antibody obtained from rabbit 1. Five sets of eight standards were assayed 
the same day, and the C. V. ’s were calculated as the standard deviation (S.D.) expressed as a 
percentage of the mean values for each standard.
Aflatoxin B( concentration
(ng/ml)
Calculated m ean ± S.D. Coefficient of variation
(% )
12,500 0.191 ± 0 .0 5 0 2 .82
6 ,250 0 .20 8  ±  0 .005 2 .17
3,125 0 .2 6 9  ±  0 .009 3 .16
1,563 0 .3 3 0  ± 0 .0 1 7 5.01
781 0 .3 7 7  ± 0 .0 1 9 5 .08
391 0 .4 2 6  ±  0 .022 5 .17
195 0 .4 7 7  ± 0 .0 3 1 6.55
98 0 .531  ± 0 .0 2 0 3 .80
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Figure 3.18. Intra-day assay variation for competitive ELISA in grain samples spiked with 
AFB], using affinity-purified anti-AFBi antibodies obtained from rabbit 1. The linear range 
of detection was 98 to 12,500 ng/ml The error bars on each calibration point indicate the 
standard deviation of the mean offive measurements.
y= -0.073Ln(x) + 0.8623 
R2 = 0.99
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Table 3.7. Inter-day assay coefficients of variation in grain samples spiked with AFBi using 
affinity-purified antibody obtained from rabbit 1. Five sets of eight standards were assayed 
on five different days, and the C. V. ’s were calculated as the standard deviation expressed as 
a percentage of the mean normalised values for each standard.
Aflatoxin Bt Concentration 
(ng/ml)
Calculated mean ±  S.D. Coefficient of variation
(% )
12,500 0.300 ±0.036 12.10
6,250 0.381 ±0.009 2.55
3,125 0.451 ±0.031 6.96
1,563 0.552 ±0.036 6.52
781 0.611 ±0.054 8.76
391 0.708 ±0.055 7.80
195 0.771 ±0.071 9.28
98 0.830 ±0.094 11.28
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Figure 3.19. Inter-day assay variation for competitive ELISA in grain samples spiked with 
AFBi, using affinity-purified anti-AFBi antibodies obtained from rabbit 1. The linear range 
of detection was 98 to 12,500 ng/ml The error bars on each calibration point indicate the 
standard deviation of the mean of five measurements. The results were normalised by 
dividing the absorbance values (A) by the absorbance value obtained for zero concentration 
of antigen (Ao) in the assay.
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3.3. D iscussion
The work presented in this chapter is concerned with the production of polyclonal 
antibodies to aflatoxin Bi, and their characterisation and application in ELISA. 
Aflatoxin Bi is a small hapten with a molecular weight of 320 Da. Due to its small 
size, the toxin needed to be conjugated to a larger protein such as BSA in order to 
elicit an immune response in an animal following immunisation. This conjugate was 
commercially available, and according to the manufacturers, consisted of 7-8 AFBi 
molecules for every BSA molecule present. Two New Zealand white rabbits were 
immunised with this protein conjugate with the aim to produce antibodies. Both 
rabbits gave high antibody titres, with rabbit 1 giving a slightly higher titre than 
rabbit 2.
Only one protein conjugate was commercially available, and because of the hazards 
involved with handling free AFBi, it was decided to use this conjugate for both the 
immunisation and analytical steps. As a result, when carrying out antibody titres 
using this conjugate, a number of controls also needed to be included. Serial 
dilutions of the serum were carried out in both PBS, and PBS containing 0.1 %  (w/v) 
BSA. The serum diluted in the PBS-BSA was added to AFBi-BSA-coated wells of a 
microtitre plate, in order to ensure specific antibody binding to AFBi was observed 
(and not to BSA). The PBS-BSA-diluted serum was also added to BSA-coated wells 
of a microtitre plate, in order to ensure that 0.1 %  (w/v) BSA was sufficient to 
remove the non-specific binding of the antibody population to BSA. The serum 
diluted in PBS only was added to BSA-coated wells, which demonstrated the non­
specific immune response to BSA. These controls worked effectively, as 0.1 %  (w/v) 
BSA was sufficient to remove the non-specific interactions, as well as showing that 
there was a greater immune response to the AFBi part, as opposed to the BSA part of 
the conjugate. This indicates that AFBi is highly immunogenic, which may be due to 
the manner in which AFBi was conjugated to the protein. Holtzapple et al. (1996) 
state that when designing an immunogen, it is preferable to introduce new functional 
groups (for attachment of the hapten to the carrier) at positions originally 
unfunctionalised compared to derivatising determinant groups that are already present
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on the molecule. They also state that antibodies generally recognise the part of the 
molecule most-distal to the point of attachment of the carrier protein than other 
regions. In the case of AFBi, an O-carboxymethylhydroxylamine linker was added 
on the carbonyl group on the cyclopentanone ring of the molecule. Holtzapple el al. 
(1996) have carried out molecular modelling studies on the structurally similar AFMi 
molecule which was linked in the same was as AFBi. They found that generation of 
an oxime at the carbonyl group on the cyclopentanone ring did not cause major 
structural damage in any of the other rings. As a result, it is possible that a similar 
situation has occurred with AFBi. O-carboxymethylhydroxylamine is also a relatively 
short linker, and as a result the hapten would be kept in close proximity to the BSA 
molecule. The molecule was not structurally changed in any significant manner 
during conjugation, and it was also held in close proximity to BSA. Both of these 
findings, coupled with the fact that there is a relatively high substitution ratio of 
hapten: protein, suggest an explanation for such a high and specific antibody titre for 
AFBi in both rabbits.
Purification of the serum was carried out by ammonium sulphate precipitation, and 
protein G affinity-chromatography. This worked effectively, with all of the bound 
immunoglobulin eluting easily from the protein G column. The low pH of the 
glycine buffer did not affect the integrity of the eluted immunoglobulins, as each 
fraction tube contained 2 M Tris, which neutralised the pH of the eluted antibodies. 
Subtractive immunoaffinity chromatography was also carried out on the antibody 
populations, in order to remove all of the ‘BSA-binding antibodies’. This was highly 
effective with only background binding observed when the purified antibodies were 
titered against BSA (Figure 3.9). Subtractive immunoaffinity chromatography has 
been used elsewhere for the isolation of anti-BSA antibodies from an anti-AFBi 
antibody population (Aldao et al, 1995). They found the technique to be successful 
in the depletion of anti-BSA antibodies from the population. SDS-PAGE was carried 
out on both antibody populations in order to determine their purity. Both antibody 
populations showed high degrees of purity, compared to that of serum or the 
ammonium sulphate precipitate. However, in both electropherograms (Figures 3.10
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and 3.11) the light chain band at 25 KDa is not very apparent. This may be due to its 
lower molecular weight as well as its lower affinity for the dye. It may also have 
migrated on the gel at a different rate to the serum and ammonium sulphate sample, 
due to both samples being in matrices of different protein concentrations.
Antibodies achieve their highest degrees of sensitivity in a competitive ELISA when 
the primary antibody concentration approaches zero i.e. when the antibody response 
in decreasing antigen concentrations is approaching the absorbance achieved for 
primary antibody binding to immobilised conjugate in the absence of free antigen on 
the microtitre plate. As a result of this, limits of detection of antibodies in a 
competitive ELISA are a function of varying antibody affinities (in the case of 
polyclonal antibodies), and the equilibrium between both free and immobilised forms 
of the antigen. Consequently, it is important to optimise conjugate loading density 
for application in a competitive ELISA, as using too much conjugate on the microtitre 
plate surface will shift the binding equilibrium in favour of binding to the ELISA 
plate, and cause reduced sensitivity to free antigen in solution (i.e. the desired 
detectable antigen). It is also necessary to optimise the antibody concentration for 
use in the assay, as too high an antibody concentration will result in an excess of free 
antibody in solution, and therefore will only be suitable to detect high concentrations 
of free antigen in solution. It is essential therefore, to optimise the concentration of 
hapten-conjugate and antibody for use in a competitive ELISA  Two separate 
checkerboard ELISA’s were carried out for both antibody populations obtained from 
rabbits 1 & 2, respectively, as described in section 2.11.2. The antibody dilution for 
rabbit 1 was 1/10,000 with a conjugate loading density of 20 |ig/ml for the assay. In 
the case of rabbit 2 the antibody dilution was 1/20,000 with a conjugate loading 
density of 50 (ig/ml.
Competition ELISA’s were optimised for both antibody populations using these 
parameters. Both assays showed good levels of sensitivity. Antibodies obtained 
from rabbit 1 gave a linear range of detection of between 12 and 25,000 ng/ml 
(Figure 3.14), while antibodies obtained from rabbit 2 had a linear range of detection
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of between 24 and 1,563 ng/ml (Figure 3.15). Inter-day assay variation studies were 
carried out by analysing five sets of standards across the respective linear ranges on 
five different days and calculating the C.V.’s as the standard deviation expressed as a 
percentage of the mean normalised values for each standard.
Both assays were reproducible over five different days and the C.V.’s for them are 
shown in Tables 3.3 and 3.4, respectively. The C.V.’s for both assays are well within 
the acceptance limits, as they are all less than 10 % . One point in the rabbit 1 assay 
was above 10 % , which was possibly due to a pipetting error when the assay was 
being carried out on one of the given five days. Both assays are quite sensitive, with 
the assay optimised with rabbit 1 antibodies being the more sensitive. It had a limit 
of detection of 12 ng/ml while the assay optimised with rabbit 2 assay had a limit of 
24 ng/ml. The assays also demonstrate good precision profiles (i.e. the quantitative 
measure of the variation between measurements, usually the C.V.’s versus the 
nominal concentration of analyte in the sample). However other assays have been 
produced that are more sensitive than these ELISA’s developed. Aldao et al. (1995) 
developed a competition ELISA with a detection limit of 25 pg/ml, while Ward et al. 
(1990) have also developed competitive assays with picogram limits of detection. 
Both of these assays were also developed using polyclonal antibody populations, and 
the same assay format was used as described here. Neither publication mentions the 
final titres obtained from the immunised rabbits. As a result, it may be that higher 
antibody titres were obtained from the rabbits and hence more sensitive antibodies for 
the detection of AFBi. Notwithstanding these factors, both assays described here are 
quite sensitive and highly reproducible and, therefore, can be used for the detection of 
AFBi in grain samples, when applying certain maximum residue levels i.e. U.S. 
maximum residue levels (M.R.L.’s)-20 ppb.
Cross-reactivity studies were also carried out on both antibody populations. Cross­
reactivity may be defined as the measure of antibody response to structurally related 
molecules, as a result of shared epitopes. The procedure is described as in section
2.11.4 and Table 3.5 shows the results of the studies. Both antibody populations
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showed high degrees of cross reactivity, especially to AFB2 and AFGi. Holtzapple et 
al. (1996) carried out molecular modelling studies on all the main aflatoxins, in an 
attempt to characterise the cross-reactivity of monoclonal anti-AFMi antibodies. 
They found that the antibody showed similar levels of reactivity towards AFBi and 
AFGi. This may be due to the fact that the conjugated protein predominantly masked 
the cyclopentanone ring where it is linked to the hapten. AFBi and AFGi only differ 
in structure on this particular ring, and the rest of the molecule is identical. From 
these findings, it is possible to extrapolate that both antibody populations showed a 
high degree of cross-reactivity to AFGi, as the only position in which they differ 
structurally was shielded by the conjugated protein. It is also thought that the 
methoxyl group on all AFB structures is immunodominant, i.e. plays a large role in 
what epitopes the antibody recognises antigen (Langone & Van Vunakis, 1976). 
This may give a reason why both antibody populations showed levels of cross­
reactivity to all of the structurally related aflatoxins. Differing ranges of cross­
reactivity of anti-AFBi antibodies has also been found elsewhere. Groopman et al. 
(1984) described a monoclonal antibody with equal specificity for aflatoxins Bi, B2, 
and Mi, while Aldao et al. (1995) produced polyclonal antibodies with a high level of 
specificity for AFGi. Although it is generally favourable to produce specific 
antibodies for a particular hapten, it can be advantageous from a regulatory viewpoint 
to produce a more ‘broad-specificity antibody’. This could be particularly useful for 
the detection of aflatoxins, as the total amount of aflatoxin in a sample is regulated, 
and thus the antibody reacting to the major forms of the toxin would be appropriate.
The antibody population obtained from rabbit 1 was deemed to be the more sensitive 
for use in competition ELISA. As a result of this, it was decided to use these 
antibodies for the detection of AFBi in spiked grain samples. Spiked grain samples 
were prepared as described in section 2.10.3, and used as samples for a competitive 
ELISA with the same format as described in section 2.11.3. The linear range of 
detection of AFBi in the spiked grain samples was 98 to 12,500 ng/ml. Figures 3.18 
and 3.19 show the intra-day and inter-day graphs for both assays while Tables 3.6 and
3.7 show the percentage C.V.’s for both assays. The precision profiles for the intra­
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day assay were excellent with C.V.’s no higher than 5 % . The inter-day C.V.’s 
showed slightly higher C.V.’s of up to 12 %  for certain concentrations on the curve. 
The assays were carried out in the same methanol concentration as that for the assays 
optimised in PBS. However, it is apparent that the grain matrix has affected the 
robustness and sensitivity of the competition ELISA. When the assay was performed 
in PBS the limit of detection was 12 ng/ml, and when it was carried out in spiked 
grain matrix the limit of detection was 98 ng/ml. These results indicate that although 
a reproducible assay was developed for the detection of AFBi in grain samples, 
further work needs to be carried out to make it more sensitive. Different international 
agencies have set maximum residue levels between 3 and 20 ppb (ng/g), and as a 
result it would be desirable to optimise the assay for the detection of such quantities 
of AFBi. Different extraction techniques could be employed which would entail the 
removal of all solvent from the samples, and re-suspend them in PBS. This may 
reduce the effects the matrix might have on the assay.
3.4. Conclusions
This chapter highlights the serious problem mycotoxins pose to the food industry, and 
the important role antibodies can play in their detection. AFBi-BSA conjugate was 
effective in the production of antibodies to AFBi in rabbits. Immunoaffinity 
chromatography proved to be a simple and effective method for the isolation of the 
polyclonal antibodies from extraneous protein found in serum. The polyclonal 
antibodies proved to be relatively sensitive and specific to AFBi as well as a number 
of structurally related aflatoxins. The assays optimised were highly reproducible, and 
demonstrated good precision. One of the antibody populations was used in the 
detection of AFBi in spiked grain samples. It showed that the grain matrix affected 
the antibody’s performance in the assay, as it was not as sensitive as the assay 
optimised in PBS. Further work in the extraction of AFBi from grain samples needs 
to be carried out in order to optimise conditions for a more sensitive assay for the 
detection of AFBi. This may have a significant impact on the future performance of 
the assay, as well as routine analysis of aflatoxins in food.
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Production and Characterisation of Murine Single Chain Fv 
Antibodies to Aflatoxin Bi derived from a Pre-Immunised 
Antibody Phage Display Library system
Chapter 4
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4.1. In troduction
In recent years, phage-display technology has become increasingly powerful, and has 
transformed the way in which we produce binding-ligands, such as antibodies or 
peptides for a given target. The technology has enabled the tailor-made design of 
repertoires of ligands ab initio, and their expression on the surface of filamentous 
phage for the selection of a ligand with the desired properties (Hoogenboom et al.,
1998). Phage-display has proven to be particularly successful for the isolation of 
monoclonal single chain Fv (scFv) antibodies, either from a hybridoma, naive spleen 
cells, or spleen cells that were pre-immunised with antigen in vivo. The enrichment 
technique of affinity selection (panning) is particularly advantageous as it allows for 
the selective amplification of phage particles carrying antibody specificities of 
interest from the rest of the population. This chapter focuses on the ‘Krebber’-based 
system (Krebber et al., 1997), which utilises phage-display technology for the 
production of soluble scFv antibodies. Mice were immunised with AFBi-BSA 
conjugate, and the RNA from their spleens was used for the construction of an 
antibody phage-display library, which was used to produce soluble scFv antibodies 
specific for AFBi.
4.1.1. The Krebber-based phage display system for the production o f scFv 
antibodies
One of the main advantages of phage-display technology is the direct link of DNA 
sequence to protein function. As a result, single clones can be rapidly screened for 
antigen binding, as well as being selected from pools in the same experimental set-up. 
Phage-display has some drawbacks, where aberrant chains are often expressed on the 
surface of phage, but are non-toxic to the bacterial cell. As a result, cells expressing 
functional scFv-gene III fusions have a growth disadvantage. This is because they 
are competing with the non-functional scFv-gene III fusions for growth nutrients, as 
well non-specifically binding in the phage ELISA assay. The scFv-gene III fusion 
protein can cause vector instability, and create deletions in the antibody fusion genes. 
These shortfalls of phage-display technology prompted the development of a 
regulatable vector system, which allowed tight product suppression during all
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propagation steps as well as controlled expression of low amounts of scFv-gene III 
fusion protein for phage display. This re-designed system has a number of 
significantly improved features.
With previous antibody phage-display systems the primer sets used were too 
restricted to amplify either particular light or heavy chains. As a result, the mouse 
primers used in this system (section 2.15.4.) have been extended and optimised, as 
they incorporate all mouse Vh, V x ,  and VK sequences collected in the Kabat data base 
(Kabat et al., 1991). It also combines the extended primer sets described by 
Kettleborough et al. (1993), 0rum et al. (1993) and Zhou el al. (1994). In addition, 
the V l back primer set encodes a shortened version of the FLAG peptide, which 
introduces only three additional amino acids at the N-terminus of Vl. This allows 
easy detection of the scFv using a commercially available monoclonal antibody with 
an appropriate label.
The amplified Vh and V l fragments are assembled by splicing-by-overlap extension 
(SOE)-PCR (Horton et al., 1989). This simplifies the restriction enzyme digestion 
step, as only one piece of DNA on the plasmid needs to be cut. In addition, ligation 
of the scFv-DNA fragment into the vector is also a simplified one-step procedure. In 
order to avoid incorrect overlaps during the SOE-PCR, the four (Gly4Ser) repeats in 
the single chain linker region are encoded by different codons, while reduction of 
dimerization of the scFv is ensured with the linker between the Vh and V l being 20 
amino acids in length rather than the usual 15 amino acid length.
Figure 4.1 shows a diagram of two of the phagemid vectors used in this system, pAK 
100, and pAK 400. The vector pAK 100 has a tetracycline resistance cassette (tetA 
and tetR; 2101kb) inserted between two different restriction enzyme (Sfil) sites which 
is used as the recipient of the scFv-DNA. Digestion with Sfil results in a vector that 
can be easily separated from uncut vector by gel-electrophoresis. The vector also has 
a strong upstream tHP terminator sequence between the lacl gene and the lac promoter 
gene. This factor, along with glucose repression of the lac promoter, completely
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abolishes background expression before induction. Hence, selection against toxic 
scFv-glll fusion proteins is avoided during the propagation steps, and plasmid 
stability is significantly improved. The lac repressor is encoded on the phagemid, 
which ensures strain-independent lac promoter repression. There is also a synthetic 
Shine-Dalgarno sequence combined with a pelB sequence, which gives only 
moderate levels of translation, and therefore only low levels of scFv-glll expression 
upon induction by IPTG.
Sfil Sfil
sr.i Sfil
p A K  4 0 0
SDT7g 10 ____
Lac p/o - Pel B Tetracycline 6 His
H ind 111
Figure 4.1. Phage-display vector pAK 100, and related vector, pAK 400. Both vectors 
contain a tet resistance cassette (tet A and tet R; 2101 bp) to facilitate the monitoring of the 
Sfil restriction-enzyme cutting. The in-frame fusion to gene 111 250-406 in pAK 100 leads 
firstly into a c-myc-tag which is used as a detector handle, followed by an amber codon 
(asterisk). It is possible to switch to soluble expression of scFvs with pAK 400 (i.e. using a 
non-suppressor strain such as JM 83) depending on the bacterial strain used. C-terminal 
his-tag fusions can be used for purification by immobilised metal-ajfinity chromatography 
(IMAC) as well as for detection by an anti-tag antibody. The expression strength of the 
antibody can be enhanced by replacing the original Shine Dalgarno (SD 2) sequence by the 
stronger SDT7gl0, as in the case of pAK 400.
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PAK 100 is engineered to achieve low levels of expression, and is therefore not 
useful for large-scale production of soluble antibody fragments. Thus, a compatible 
high-expression vector has also been engineered. PAK 400 has a stronger Shine- 
Dalgarno sequence (SDT7g10), and as a result the expression strength is greatly 
enhanced. Removal of the genelll and the absence of helper phage allows it to 
propagate as a plasmid, and soluble production of scFvs is induced in the same way 
as pAK 100 by up-regulation of the lacZ promoter. It also has a C-terminal his-tag 
fusion, which can be used for IMAC purification and detection using a labelled anti- 
his-tag antibody. Both vectors use chloramphenicol as the resistance marker, as it 
allowed more stringent selection than ampicillin. This is because the resistance 
protein does not leak into the medium. It was also found that chloramphenicol is 
more advantageous than kanamycin or tetracycline as it does not reduce phage titres 
as much (Johansen et al., 1995).
The restriction enzyme digestion used in this system is unique, as Sfil is the only 
enzyme used for directional cloning of scFv fragments into pAK 100. Sfil is a 
particularly useful restriction enzyme as it recognises eight bases, interrupted by five 
non-recognised nucleotides (5'-GGCCNNNN/NGGCC-3': where “N” is any base and 
the point of cleavage). Sfil restriction sites are, therefore, very rare in antibody 
sequences, which reduces the possibility of internal digestion of sequences. The 
enzyme is also unique as it always cuts two sites at once and therefore single-cut 
plasmids or inserts do not occur as intermediates. Two different sticky ends were 
designed to allow cloning of the scFv fragment in a directional manner. In contrast to 
the palindromic sticky ends 3 base pair overhangs derived from Sfil sites render it 
impossible to self dimerise by either insert or vector.
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Figure 4.2. Schematic diagram showing the restriction-enzyme digestion of plasmid DNA 
and SOE-PCR product using Sfil.
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Figure 4.3 (a) shows a diagrammatic representation of how an antibody phage display 
library may be produced using the Krebber-based system. The genetic material 
(mRNA) can originate from an immunised mouse if one were to produce a pre­
immunised phage display library, or alternatively a naive mouse for production of a 
naive library. It is also possible to obtain the genetic material from a hybridoma, and 
clone the scFv fragment of the parent monoclonal antibody. The mRNA is then 
reverse-transcribed to produce DNA. The Vh and V l fragments are amplified by PCR 
using the designated primers and the DNA. SOE-PCR is used to anneal the Vh-Vl 
fragments together as one. Restriction enzyme digestion is carried out on the SOE 
product as well as the vector (pAK 100), which enables ligation of the scFv fragment 
into pAK 100. This is transformed into E. coli, and results in an antibody phage 
display library. Once the bacteria are harbouring the phagemid vector, they can be 
superinfected with helper phage to drive production of phage particles carrying the 
scFv fragment, as a fusion product with the phage coat protein p ill on the surface and 
genes encoding the scFv inside the particle. Expression of the fusion product and its 
subsequent incorporation into the mature phage coat results in the ligand being 
presented on the phage surface, while its genetic material resides within the phage 
particle. This connection between ligand genotype and phenotype allows the 
enrichment of specific phage using selection on an immobilised target.
Figure 4.3 (b) shows an outline of the panning procedure, where phage-expressing 
scFv’s are exposed to (for example) hapten-protein conjugate. After a short 
incubation period, the non-specific phage are washed away, and bound phage are then 
eluted from the conjugate. The specific phage may be amplified and re-selected 
against conjugate, or alternatively they may be assayed for recognition to free hapten. 
Once a phage clone recognising free hapten has been selected, the phagemid DNA 
can be purified and the specific scFv fragment cut from the vector. The scFv 
fragment can then be re-ligated into a high expression vector such a pAK 400 for 
soluble expression of scFv fragments.
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Figure 4.3 (a). The Krebher-based system for phage display library construction. Genetic 
material from spleens or hybridomas encoding sequences derived from mRNA is reverse 
transcribed and amplified up by PCR. SOE-PCR is used to assemble the VH and VL chains as 
one. The DNA encoding the scFv is restriction enzyme-digested and ligated to a particular 
vector i.e. pAK 100. This is then transformed into E. coli. The scFv is displayed on the 
surface of the phage when fused to a coat protein, after superinfection of the harbouring 
vector with a helper phage.
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Figure 4.3(b). Schematic diagram of panning procedure for the selection of phage- 
displaying scFv antibodies recognising free hapten, and soluble expression of scFv 
antibodies. Phage ELISA is used to detect and amplify specific phage to hapten-protein 
conjugate. These phage colonies are then analysed for recognition of free hapten. Plasmid 
DNA is purified from ‘positive’ clones, restriction enzyme digested, and re-ligated into the 
high-expression vector pAK 400for soluble expression of scFv antibodies.
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4.2. Results
4.2.1. Estimation o f mouse titres
Two Balb/C mice were immunised with a commercially available AFBi-BSA 
conjugate as described in section 2.3.4. The mice received an intra-peritoneal 
injection of the conjugate together with an equal volume of Freund’s Complete 
adjuvant. Blood was drawn periodically to estimate the specific antibody titre, which 
was assessed by ELISA as described in section 2.11.1. One half of a 96-well 
microtitre plate was coated with AFBi-BSA conjugate, and the other half of the 
microtitre plate was coated with BSA. The plate was blocked with 2 %  (w/v) milk. 
The mouse serum was then diluted from 1/300 to 1/614,400 in PBS containing 0.1% 
(w/v) BSA. The serum was also diluted in PBS containing no BSA. The serum 
diluted in the PBS 0 .1% (w/v) BSA was added to the AFBi-BSA-coated wells, as 
well as the BSA-coated wells, while the serum diluted in the PBS was added to the 
BSA-coated wells only. The antibody responses were then detected using a 
horseradish peroxidase-labelled anti-mouse antibody followed by chromogenic 
substrate. The titre was taken as highest dilution of immunised serum which gave a 
signal greater than the corresponding dilution of control serum, i.e. the serum diluted 
in PBS containing 0 .1%  (w/v) BSA and added to the BSA-coated wells. The final 
titre for serum from mouse 1 was 1/153,600, while the final titre for serum from 
mouse 2 was 1/76,800. Figures 4.4 and 4.5, respectively, show these results, 
including the antibody responses to BSA with or without BSA in the diluent buffer. 
The figures also show that there was a greater antibody response to AFBi than to 
BSA, as well as that 0.1 % (w/v) BSA was sufficient to remove non-specific binding 
of the serum to the BSA part of the AFBi-BSA conjugate. The serum titrations were 
deemed high enough responses to indicate that splenomic RNA would be utilised 
following a final intravenous boost.
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Figure 4.4. Final titre of serum obtained from mouse 1. The serum was diluted in PBS as 
well as PBS containing 0.1% (w/v) BSA, and added to wells of a microtitre plate coated with 
AFBj-BSA conjugate. Diluted serum was also added to wells of a microtitre plate coated with 
BSA. The final titre recorded was in excess of 1/153,600.
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Figure 4.5. Final titre of serum obtained from mouse 2. The serum was diluted in PBS as 
well as PBS containing 0.1% (w/v) BSA, and added to wells of a microtitre plate coated with 
AFBj-BSA conjugate. Diluted serum was also added to wells of a microtitre plate coated with 
BSA. The final titre recorded was in excess o f1/76,800.
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4.2.2. Preparation o f splenonuc RNA
Splenomic RNA was isolated from the spleens o f the two mice (1 & 2) as described 
in section 2.15.2. Table 4.1 shows the yields o f RNA obtained from the two mice, 
where the spleen from mouse 1 yielded 11.74 p.g/p.1, and the spleen from mouse 2 
yielded 9.68 1.
Table 4.1. U. V.-visible readings for determination of total RNA concentration from extracted 
spleen cells. The absorbance at 260 nm indicated the amount of RNA in the sample, while 
the absorbance at 280 nm indicated the amount of background protein in the sample. The 
concentrations of RNA were calculated on the basis that A 260 = 1.0 is equivalent to 40 pg of 
RNA per pi.
A, 260 A, 280 C oncentration o f
R N A  (ng per ^1)
M ou se 1 1.174 0.672 11.74
M ouse 2 0.968 0.546 9.68
4.2.3. Amplification of mouse heavy and light chains using PCR
The V L back primer mix (LB 1-17 and LBa, representing a total o f 131 variants) 
paired with five Vl forward primers (LF 1, 2, 4, 5 and LFA,) were used to amplify the 
Vi, domains. The V H back mix (HB 1-19, representing a total o f 94 variants) coupled 
with four V H forward primers (HF 1-4) were used to amplify the V H domains. The 
domains were amplified from a mixture o f cDNA obtained from mice 1 & 2, 
respectively. Using the standard multiplex PCR protocol (section 2.15.4.2), single 
amplified bands ranging from 375-402 bp for the V l, and 386-440 bp for V H were 
achieved. Figure 4.6 shows typical bands obtained from the multiplex PCR reaction,
150
where two batches o f heavy chains were amplified, and one batch o f light chain was 
amplified.
Figure 4.7 shows an SOE-PCR where the heavy and light chains were annealed 
together to form an 800 bp fragment. In order to optimise this reaction properly, the 
heavy and light chains were analysed densiometrically to determine the concentration 
o f DNA in respective fragments. The bands shown in Figure 4.6 were analysed 
densiometrically, and the results are given in Table 4.2. 10 ng of each o f the Vh and 
Vl fragments was used to carry out the SOE-PCR.
1 2  3 4
1500 bp
500 bp Fragment 
400 bp
Figure 4.6. Amplification of murine heavy (Vh) and light chains (Vj) from a mixture of DNA 
obtained from two mice immunised with AFBj-BSA conjugate. Lane 1: 100 base pair (bp) 
ladder. Lanes 2-3: Amplified heavy chains. Lane 4: Amplified light chains. Ln the case of 
the heavy chains, a sharp band with the predicted size 375-402 bp was obtained, while for 
the light chain, a sharp band with the predicted size 386-440 bp was obtained. These bands 
were observed as expected just below the 500-bp fragment on the gel picture.
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1 2
Figure 4.7. SOE-PCR annealing the VH and VL genes. Lane 1: 100 bp ladder. Lane 2: SOE- 
PCR. A specific band is obtained for the SOE product just below the 800 bp fragment on the 
ladder, which is as expected, both the heavy and light chains annealed together.
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4.2.4. Preparation o f SOE-PCR product andpAK 100 for ligation reaction 
The SOE-PCR product was digested with the restriction enzyme Sfil as described in 
section 2.15.8. Figure 4.8 shows a gel photograph o f the digestion of the PCR 
product. Only a small change in weight is observed between undigested and digested 
product. However, there is an apparent difference between the two fragments, which 
is highlighted by the presence of the yellow line placed across the bands. This 
indicated the digestion was successful. Densiometric analysis was also carried out on 
digested SOE-PCR product, and Table 4.2 shows that 9.8 ng/(_il was present in the 
pooled samples o f Lanes 3 & 4 on Figure 4.8.
Figure 4.9 shows a gel photograph o f the restriction enzyme digestion of pAK 100. It 
is easy to differentiate between the cut vector (at approximately 4144 bp) and the 
tetracycline gene (2101 bp) which was cut from the vector. The photograph also 
shows that a small amount of the vector also remained uncut. However, there was 
sufficient vector digested to gel-purify and use for the ligation reaction. 
Densiometric analysis was also carried out on pAK 100, and Table 4.2 shows that 
14.8 ng/p.1 o f plasmid DNA was present in the sample.
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1 2 3 4
Figure 4.8. Restriction enzyme digest of SOE-PCR product using SfiL Lane 1: 100 bp 
ladder. Lane 2: Undigested SOE product. Lane 3: Digested PCR product. Lane 4: 
Digested PCR product. A yellow line has been placed through the 800 bp fragment in order 
to observe the change between the bands. Only a minor change is observed between the 
digested and undigested bands, as only a small number of base pairs are removed from the 
DNA fragment, and hence a small change in separation.
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Figure 4.9. Restriction enzyme digest of pAK 100 using Sfil. Lane 1: 100 bp ladder. Lanes 
2-5: Digested pAK 100. Both the cut tetracycline gene, and the digested plasmid can be 
observed on the gel photo. Three weak-intensity bands are also visible above cut plasmid. 
These may represent some remaining uncut plasmid as well as partially cut products.
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Table 4.2. Concentrations (ng/jul) of all of the various DNA products required for 
production of the antibody phage display library. All of the concentrations were 
densiometrically calculated from the standard ladder, where 5 /ul of the 100 bp ladder was 
equivalent to 150 ng of DNA.
DNA Product C oncentration
(ng/|il)
100 bp Ladder 150
Vh  Fragment (batch 1) 29.44
Vji Fragment (batch 2) 26.08
Vl Fragment 17.32
Digested SOE product 9.8
pAK 100 Vector 14.8
156
4.2.5 . Transformation of pAK 100 containing Vh- Vl genes into E. coli 
Supercompetent E. coli cells with a transformation efficiency o f 1 x 109 cfu/pg of 
plasmid DNA were heat-pulse transformed with the ligated plasmid DNA as 
described in section 2.15.10. This resulted in the production o f a phage display 
library consisting of 5 x 103 clones. This library was then used for subsequent 
panning procedures.
4.2 .6 . Screening for phage-display scFv antibodies to AFBi
4.2 .6 .1 . Production o f AFBi-dextran conjugate
An AFBi-dextran conjugate was synthesised for use in the panning procedure, as it is 
desirable to use more than one hapten-carrier conjugate when selecting for scFv 
antibodies to small molecules by phage display. The conjugate was produced as 
described in sections 2.15.1.1 and 2.15.1.2, and its performance was assessed by 
BIAcore analysis as described in section 2.15.1.3. An introduction to BIAcore and 
how to interpret the SPR signal is given in section 5.1. Figure 4.10 shows a 
sensorgram of a preconcentration study o f the conjugate onto a CM-dextran chip 
surface. The conjugate (concentration used-50 (ig/ml) was prepared in 10 mM 
acetate buffer at a range of incremental pH’s from 3.8 to 5.0. Each conjugate 
concentration was passed sequentially over an underivatised chip surface at 5 (il/min 
for 2 minutes as described in section 2.20.1. The differing degree of preconcentration 
was measured by the response for each conjugate solution at the various pH values, 
prior to the end of the injection. Following injection, the flow of the running buffer 
over the chip surface was sufficient to dissociate the electrostatic attraction between 
the protein and the CM-dextran gel surface. Figure 4.10 shows that an increase in 
preconcentration occurs at pH values above 4.5. The studies showed the optimal pH 
for immobilisation o f AFBi-dextran conjugate was 5.0 in 10 mM acetate buffer, and 
was thus used for immobilisation.
157
19000 
18000 
17000
3  160000£
01E 150003
§ 14000a
&K 13000 
12000
11000 -------------------t-------------------1------------------, -------------------1--------------------t-------------------f------------------t-------------------1-----------------,—  |-----------r 1
0 500 1000 1500 2000 2500 3000
Time (seconds)
Figure 4.10. Preconcentration of AFB¡-dextran conjugate onto a CM-dextran chip surface. 
Solutions of AFB i-dextr an at 50 /ig/ml in 10 mM acetate buffer at pH increments of 0.1 were 
passed over an unactivated CM-dextran surface at 5 jjl/min for 2 minutes. The low ionic 
strength of the buffer used favours the electrostatic attraction between the negatively charged 
dextran layer and the positively charged amino-dextran conjugate (i.e. below isoelectric 
point). The degree of ‘preconcentration ’ was measured from the response prior to the end of 
each sample injection. The ionic strength of running buffer (150 mMNaCl) was sufficient to 
remove the electrostatically attracted conjugate from the sensor chip surface. The optimal 
pH for immobilisation of AFB ¡-dextran onto the CM-dextran chip surface was calculated to 
be pH 5.0, and subsequently all immobilisations of AFBrBSA were carried out in 10 mM 
acetate buffer, pH 5.0.
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EDC/NHS coupling chemistry was used for activation o f  the CM-dextran gel surface 
for the immobilisation o f AFBi-dextran conjugate, as described in section 2.20.2. 
Figure 4.11 shows an immobilisation sensorgram where 2,773 RU o f  AFBi-dextran 
conjugate was immobilised onto the sensor surface after capping with 1M- 
ethanolamine hydrochloride, pH 8.5. This deactivated any remaining NHS-esters, 
and eluted any non-covalently bound material.
Affinity-purified polyclonal anti-AFBi antibodies (obtained from rabbits 1 & 2 (See 
Chapter 3)) were diluted in HBS buffer and injected over the immobilised conjugate 
surface. Figure 4.12 shows a sensorgram o f this, which resulted in 67.3 RU o f a 
1/100 dilution o f  antibody (obtained from rabbit 1) binding to the surface. 
Regeneration o f the surface was carried out using 1 M ethanolamine containing 20 % 
(v/v) acetonitrile, pH 12.0, which removed all o f  the bound antibody from the 
surface. A 1/50 dilution o f antibody (obtained from rabbit 2) was then injected over 
the surface, which resulted in 95 RU binding to the immobilised conjugate. The 
surface was once again regenerated using the same regeneration solution. These 
studies indicated that conjugation o f AFBi to amino-dextran was a successful 
procedure, although the antibody binding response was low, indicating a low 
substitution ratio o f  the hapten to the amino-dextran.
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Figure 4.11. Immobilisation of AFB¡-dextran conjugate onto a CM-dextran chip surface:
1. HBS running buffer is passed over the chip surface and a baseline measurement is 
recorded.
2. After mixing, a solution containing 0.05 MNHS and 0.2 MEDC is injected over the chip 
surface to activate it. The large increase in SPR signal is mainly due to a bulk refractive 
index change.
3. An increase of approximately 200 RU is recorded following activation of the chip 
surface.
4. A solution containing 50 /xg/ml of AFB,-dextran conjugate in 10 mM acetate buffer (pH 
5.0) is passed over the chip surface for 20 minutes.
5. The amount of bound conjugate adsorbed is recorded whilst most of the non-covalently 
bound protein has been eluted.
6. Any remaining surface NHS-esters are deactivated by the addition of 1 M ethanolamine 
hydrochloride, pH 8.5. This also elutes any non-covalently bound conjugate.
7. 2,775 RU ofAFB ¡-dextran conjugate bound to the surface following the immobilisation 
procedure.
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T im e  (s e c o n d s )
Figure 4.12. Binding curve of polyclonal antibodies binding to an immobilised AFBj- 
dextran conjugate.
1. HBS running buffer is passed over the chip surface and a baseline measurement is 
recorded.
2. A 1/100 dilution of affinity-purified polyclonal anti-AFBi antibody (obtained from rabbit
1) was injected over the immobilised chip surface resulting in 67.3 RU binding to the 
AFB rdextran surface.
3. Regeneration of the bound antibody from the conjugate surface was carried out by 
injecting a 2-minute pulse of lM-ethanolamine containing 20%(v/v) acetonitrile, pH
12.0. The large increase in SPR signal is mainly due to a bulk refractive index change.
4. The surface was completely regenerated removing an additional 50 RU from the 
immobilised conjugate surface.
5. A 1/50 dilution of affinity-purified polyclonal anti-AFBi antibody (obtained from rabbit
2) was injected over the immobilised chip surface resulting in 95.0 RU binding to the 
AFBj-dextran surface.
6. Regeneration of the bound antibody from the conjugate surface was carried out by 
injecting a 2-minute pulse of IM-ethanolamine containing 20%(v/v) acetonitrile, pH
12.0. The large increase in SPR signal is mainly due to a bulk refractive index change.
7. The surface was completely regenerated removing an additional 28 RU from the 
immobilised conjugate surface.
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4.2 .6 .2 . Panning procedure fo r  the detection o f  scFv phage display antibodies 
Table 4.6 gives a summary o f all o f  the phage titres obtained from the three rounds o f 
panning that were carried out, including the number o f  clones assayed after each 
round, and the number that recognised free toxin.
After the library was constructed, phage was produced from it (as described in section 
2.16.1) giving a titre o f  2.5 x  109 cfu/ml o f phage. The phage were then panned 
against an A FBi-BSA conjugate (concentration used was 50 (ig/ml). Stocks o f the 
panned library were prepared as described in section 2.16.5, and a phage titration was 
also carried out (section 2.16.3) which showed that 3 x 105 cfu/ml o f  phage was 
produced after one round o f panning. 96 random bacterial clones from round 1 o f 
panning were selected for analysis, and phage was produced from them. These phage 
displaying scFv antibodies were analysed by phage ELISA for recognition o f AFBi- 
B SA  conjugate. Eight clones were found to significantly recognise the conjugate. 
Table 4.4 shows the absorbances obtained from the phage ELISA, while Figure 4.13 
shows the results in the form o f a 3-D bar graph. The three clones with the highest 
absorbances were analysed for recognition to free AFBi, by competitive phage 
ELISA. However, when analysed none o f  the three recognised free AFBi. Figure 
4.14 shows the competitive phage ELISA where no competition was observed.
A  second round o f panning was then carried out. This entailed producing phage from 
the panned library stocks from round 1 o f panning. AFBi-dextran was used for this, 
where 200 (J.g/ml was coated onto an immunotube. A  phage titre o f 2.8 x 107 cfu/ml 
was obtained, and once again 96 random clones were analysed for recognition to 
AFBi-BSA conjugate. Table 4.5 shows the absorbances obtained from the phage 
ELISA, while Figure 4.15 shows the data depicted as a 3-D bar graph. Ten positives 
recognising the conjugate were obtained, and the clones with the three highest 
absorbances were analysed for recognition to free AFBi. However, the phage ELISA 
was unsuccessful, with none o f the three clones recognising free AFBi (Figure 4.16).
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Table 4.3. Data obtained from three panning rounds of an antibody phage-display library 
produced for the detection of a scFv fragment to aflatoxin Bj. The library was produced 
from RNA obtained from a mouse that was pre-immunised with the AFBr BSA conjugate 
prior to using the RNA.
C onjugate  
used for  
pannin g
P hage
T itre
cfu /m l
N o. o f  
clones  
assayed
N o. o f  
positive  
clones 
recognising  
A F B ,-B S A  
conjugate
N o. o f  
clones  
recognising  
free toxin
Phage
P roduction
- 2.5 x 109 96 0 0
R ound 1 o f  
panning
AFBRBSA
50|ig/ml
3.0 x lO 5 96 8 0
R ound 2 o f  
panning
AFBi-
Dextran
200fj,g/ml
2.8 x 107 96 10 0
R ound 3 o f  
panning
AFBi-BSA
50fog/ml
2.4 x 107 96 7 6
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Table 4.4. Phage ELISA data of 96 randomly selected clones from the pre-immunised anti- 
AFBj phage display library after one round of panning. Eight positives were detected, with 
the numbers in bold being the clones that were chosen to be assayed for recognition free 
AFB,.
1 2 3 4 5 6 7 8 9 10 11 12
A 1.112 1.043 1.215 1.077 1.018 1.073 0.976 0.905 1.206 0.977 0.85 0.269
B 0.958 1.04 1.117 1.075 1.015 0.913 1.058 1.218 0.771 0.900 1.131 1.093
C 1.09 1.18 1.07 1.043 1.143 1.072 1.045 1.117 1.072 1.157 1.378 1.115
D 1.066 1.038 1.043 1.007 1.069 1.104 1.001 0.894 0.737 1.100 1.154 1.099
E 1.092 1.077 0.864 1.138 1.073 0.94 0.899 0.913 1.096 1.123 1.16 0.949
F 1.142 1.156 0.991 1.167 1.142 1.016 1.089 0.936 1.108 1.145 1.135 1.259
G 0.893 1.02 1.024 0.75 1.261 0.857 0.894 1.008 1.135 1.297 1.137 0.834
H 0.884 1.194 0.918 0.906 1.173 0.809 0.941 0.963 1.213 1.023 1.177 1.143
1 3Absorbance (492
"m) 1.25
W ell R ow
W ell Column
Figure 4.13. Bar graph of phage ELISA analysis from the pre-imm unised anti-AFBj library. 
The bars with flags represent the eight positive clones that correlate with the clones shown in 
Table 4.4.
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C oncentration  o f  free A F B 1 (ng/m l)
Figure 4. ¡4. Competition phage-ELISA of three clones selected after one round of panning 
for recognition to free AFBt. The three clones selected, gave the highest absorbances in the 
non-competitive phage-ELISA, and were therefore selected for further analysis. None of the 
clones showed recognition for the free toxin.
I
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Table 4.5. P hage ELISA data o f  96 random ly selected  clones fro m  the pre-im m unised  anti- 
A F B i phage-d isp lay  library after two rounds o f  panning. Ten positives were detected, with 
the num bers in bo ld  being  the clones that were chosen to be assayed fo r  recognition fre e  
A F B h
1 2 3 4 5 6 7 8 9 10 11 12
A 0.748 0.728 0.661 1.007 0.922 0.623 0.573 0.669 0.724 0.623 0.632 0.813
B 0.842 0.682 0.655 0.673 0.576 0.537 1.122 0.673 0.645 0.498 0.989 1.136
C 0.726 0.795 0.771 0.144 0.749 0.584 0.658 0.888 0.570 0.498 0.678 0.896
D 1.196 0.947 0.720 0.684 0.952 0.615 0.617 0.592 0.800 0.497 0.69 0.882
E 0.913 0.881 1.262 0.595 0.714 0.980 0.951 0.889 0.543 0.603 0.617 0.941
F 0.948 1.039 0.731 0.997 0.602 0.667 0.891 0.726 0.566 0.699 0.593 0.625
G 0.73 0.646 0.558 0.722 0.613 1.056 0.611 0.697 0.524 0.568 0.536 1.004
H 0.891 0.681 0.741 0.640 0.466 0.619 0.567 0.519 0.758 0.880 0.639 0.566
Absorbance (492 
nm)
W ell R ow
6 7
W ell Column
Figure 4.15. B ar graph o f  ph ag e  ELISA analysis fro m  the pre-im m unised  anti-AFBj library. 
The bars with fla g s  represen t the ten p o sitive  clones that correlate with the clones shown in 
Table 4.5.
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Figure 4.16. Com pel it ion phuge-E LISA  o f  three clones se lected  after two rounds o f  pann ing  
fo r  recognition to fi-ee AFB/. The three clones selected, gave the highest absorbances in the 
non-com petitive pliage-ELISA, a n d  were therefore selected  fo r  fu r th e r  analysis. None o f  the 
clones show ed recognition fo r  the fr e e  toxin.
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A third round of panning was subsequently carried out, as the previous two rounds 
yielded no clones recognising free AFBi. This was carried out using the stocks 
produced after round two of panning. This pan was carried out using an AFBi-BSA 
conjugate (50 (ig/ml) and yielded a phage titre o f 2.4 x 107 cfu/ml o f phage. 96 clones 
selected from this round were grown, and phage was produced from them. These 
phage-displaying clones were then tested for activity to AFBi-dextran and AFBi- 
BSA. The clones displayed very low levels o f activity towards the AFBi-dextran 
(data not shown). However, eight positives were obtained from the assay using the 
BSA-conjugate. Table 4.6 shows the absorbances obtained from the phage ELISA, 
while Figure 4.17 shows the results depicted as a 3-D bar graph. Seven o f the clones 
were re-grown on a 5 ml scale and tested for activity to free aflatoxin Bi. This was 
carried out using three different concentrations of aflatoxin Bi, 100, 50, and 1 (ig/ml 
respectively. Six of the clones showed recognition for free aflatoxin Bi. Figure 4.18 
shows this result. Non-specific interactions were minimal, as the clones did not 
recognise B SA  or milk-coated wells (data not shown).
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Table 4.6. Phage ELISA data of 96 randomly selected clones from the pre-immunised anti- 
AFBi phage-display library after three rounds of panning. Six positives were detected, with 
the numbers in bold being the clones that were chosen to be assayed for recognition free 
AFB,.
1 2 3 4 5 6 7 8 9 10 11 12
A 0.196 0.245 0.461 0.305 0.421 0.304 0.282 0.317 0.365 0.524 0.33 0.321
B 0.220 0.192 0.851 0.374 0.235 0.228 0.187 0.258 0.25 0.199 0.246 0.240
C 0.263 0.288 0.293 0.956 0.253 0.242 0.206 0.221 0.239 0.201 0.197 0.271
D 0.473 0.265 0.245 0.234 0.225 0.258 0.202 0.252 0.544 0.232 0.209 0.232
E 0.286 0.295 0.214 0.244 0.202 0.233 0.195 0.206 0.216 0.458 0.236 0.173
F 0.219 0.25 0.239 0.706 0.282 0.306 0.574 0.209 0.202 0.222 0.206 0.202
G 0.223 0.24 0.217 0.294 0.236 0.227 0.237 0.207 0.187 0.205 0.208 0.601
H 0.216 0.242 0.224 0.25 0.211 0.222 0.225 0.224 0.194 0.203 0.282 0.257
A bsorbance (492  
nm )
G
W ell R ow
Figure 4.17. Bar graph of phage ELISA analysis from the pre-immunised anti-AFB, library. 
The bars with flags represent the seven positive clones that correlate with the clones shown 
in Table 4.6.
W ell C olum n
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Figure 4.18. Competition phage-ELISA of seven clones selected after three rounds of 
panning for recognition to free AFB/. All seven of the positives were analysed for 
recognition to free AFB] by phage ELISA. Six of the clones selected showed recognition for 
the free toxin over the range I-100 ug/ml.
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4.2.7. P r o d u c t i o n  o f  s o l u b l e  s c F v  a n t i b o d i e s
4.2.7.1. Restriction enzyme digestion o f plasmidDNA andpAK 400
Once it was confirmed that the positive clones recognised free AFBi, three of them 
were chosen (B3, C4, & F4) for production as soluble scFv antibodies. In order to do 
this, the bacteria containing the ‘positive’ plasmid DNA was grown on 5 ml scale and 
the DNA was purified from the bacteria as described in section 2.17.1. The plasmid 
DNA was restriction enzyme digested using Sfil, and electrophoresed on a low-melt 
agarose gel. The cut 800 bp fragment separated on the gel, and was purified as 
described in section 2.15.5. Figure 4.19 shows a gel photograph of the restriction 
enzyme digestion of the three clones B3, C4, and F4, from pAK 100. Some of the 
vector remained uncut, and this was redigested overnight in order to obtain the 
maximum yield of positive DNA.
Figure 4.20 shows a gel photograph o f the restriction enzyme digestion on pAK 400. 
The cut vector (at approximately 4144 bp) and the tetracycline gene (2101 bp) which 
was cut from the vector can be easily differentiated on the photograph. A small 
amount of the vector also remained uncut, however, there was sufficient vector 
digested to gel-purify and use for the ligation reaction.
4.2.7.2. Ligation and transformation o f pAK 400 into JM  83 E. coli cells
The ‘positive’ scFv DNA was ligated into pAK 400 as described in section 2.17.3, 
and was successfully transformed into the non-suppressor E.coli strain JM 83.
Stocks of the transformed bacteria were made, and used to inoculate media for 
induction o f scFv production as described in section 2.17.6.
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U n cu t V ector  
C ut V ector
1500 bp  
S00 bp F ragm ent 
500 bp
Figure 4.19. Restriction enzyme digest of purified pAK 100 (using Sfil) containing the DNA 
of three ‘positive’ clones that recognised free AFBj. Lane 1: 100 bp ladder. Lanes 2-3: 
Clone B3. Lanes 4-5: Clone C4. Lanes 6-7: Clone F4. Due to the poor quality of the gel 
photograph (over-exposure of light) the cut DNA for clone F4 is not very visible, as is also 
the case with the uncut and cut vector from clone B3. However these were visible to the 
naked eye when the gel was visualised under UV light. It is possible to see that there was 
still some uncut vector in the samples, which was re-cut overnight.
1 2 3 4 5
U ncut P lasm id 6245 bp ^ w  
C ut P lasm id  4144 bp
C ut T etracycline G en e 2101 bp
1000 bp
Figure 4.20. Restriction enzyme digest o f pAK 400 using Sfil. Lane 1: 1 KB ladder. 
Lanes 2-5: pAK 400. It is clear from the gel photograph that partial digestion of the 
plasmid occurred with some uncut plasmid visible. However, there was sufficient cut 
plasmid to isolate and purify.
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4.2 .7 .3 . Induction o f  soluble scFv expression and analysis o f  cellular distribution 
Soluble scFv expression was induced on the transformed JM 83 cells as described in 
section 2.17.6. Culture supernatants and periplasmic lysates of the three clones were 
analysed for soluble expression o f the scFv fragments. Figure 4.21 shows the results 
of an ELISA, which analysed the culture supernatants and the periplasmic lysates 
from the three clones B3, C4, and F4. From the graph it can be seen that there is 
minimal secretion o f scFv clone-B3 into culture supernatant or periplasmic lysate. 
The scFv clone-C4 showed a high level of secretion into the supernatant with a 
moderate level o f secretion into the periplasm. Scfv clone-F4 showed an equal 
amount o f secretion o f antibody into both culture supernatant and the periplasm. It 
was decided to work with only one clone from this stage, and, therefore, scFv clone- 
C4 was chosen for production of soluble scFv antibodies on a large scale and to 
purify for further analysis.
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Figure 4.21. ELISA analysis of periplasmic lysates and culture supernatants of three 
soluble-expressed scFv anti-AFB/ clones. The periplasmic lysate data is represented as 
green markers surrounded by a blue line, while the culture supernatant data is represented 
as the blue and orange markers. The data shows that clone B3 neither secretes soluble 
scFv’s into the periplasm or the supernatant. Clone C4 secretes into both the periplasm and 
the supernatant, with a higher degree of secretion into the supernatant. Clone F4 also 
secretes into the periplasm and the supernatant.
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4.2 .7 .4 . Purification o f  soluble scFv fragments by IMAC
Culture supernatant containing scFv antibodies (clone C4) was concentrated five-fold 
as described in section 2.18.2. The concentrated supernatant was then passed through 
the IMAC column for purification (section 2.18.1). The purified scFv antibodies 
were dialysed into PBS and also concentrated five-fold. Figure 4.22 shows a SDS- 
PAGE of purified scFv antibody versus culture supernatant. It is apparent from the 
gel photograph that the purification procedure was not as effective as anticipated in 
the removal o f non-specific proteins from the sample when compared with the culture 
supernatant. In order to confirm the presence o f scFv antibody in the purified 
samples, a Western blot was carried out. Detection o f the scFv was achieved using 
an anti-FLAG antibody. Figure 4.23 shows a picture o f the Western blot. It can be 
seen that the 32 KDa fragment is quite clear and specific in the purified sample. 
However, it cannot be seen in the culture supernatant sample, as it may not be 
concentrated sufficiently.
1 2  3 4
45 K D a.
36.5 K D a.
T ------------------
32 K D a
Figure 4.22. SDS-PAGE analysis of IMAC-purification of C4 clone. Lanes 1 & 4: 
Molecular weight markers ranging from 6.5 KDa to 45 KDa. Lane 2: Supernatant. Lane 3: 
IMAC-purified supernatant. The 32 KDa protein fragment is more apparent in the purified 
fraction than the supernatant, mainly because the purified fractions were concentrated five­
fold after the purification procedure. The concentration of non-specific protein in the 
purified fractions is also quite high indicating the procedure was not as successful as 
anticipated.
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1 2  3 4
45 K D a
32 K D a _________ ^    29 K D a
20 K D a
6.5 K D a
Figure 4.23. Western blot analysis of IMAC-purification of C4 clone. Lanes 1 & 4: 
Coloured molecular weight markers. Lane 2: IMAC-purified supernatant. Lane 3: 
Supernatant. The 32 KDa protein fragment is more apparent in the purified fraction than the 
supernatant, mainly because the purified fractions were concentrated five-fold after the 
purification procedure.
4.2 .8 . ELISA analysis o f  soluble scFv antibodies
4.2 .8 .1 . Determination o f  working dilution o f scFv antibody in competitive ELISA 
fo r  AFBi
A checkerboard ELISA was carried out as described in section 2.19.1 in order to 
determine the optimal antibody dilution and conjugate concentration for use in 
competitive ELISA. Rows o f wells o f a 96-well microtitre plate were coated with 
concentrations o f AFBi-BSA ranging from 0 to 50 pg/ml, and blocked with 2 % 
(w/v) milk powder. Dilutions o f the purified scFv anti-AFBi antibody from 1/2 to 
1/32 were prepared and added to the plate. After incubation, anti-FLAG antibody 
was added followed by another incubation step. Enzyme-labelled anti-mouse 
antibody was then added followed by chromogenic substrate. Figure 4.24 shows the 
overlaid titre curves obtained for the scFv antibody. The antibody dilution that gave
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half the maximum absorbance was chosen, and the lowest conjugate concentration 
that provided sufficiently high absorbances was chosen. A 1/4 dilution o f antibody 
was used in the competition ELISA, with a conjugate concentration o f 12.5 pg/ml.
2.5
i<N
r tw
S
■fio
1.5
0.5
10 100
1/ Antibody Dilution
Figure 4.24. Determination of optimal conjugate loading density and antibody dilution. 
Wells of a microtitre plate were coated with AFBj-BSA conjugate at a range of 
concentrations between 0 and 50 /j.g/ml. Serial doubling dilutions of the IMAC-purified anti- 
aflatoxin scFv antibody (C4) were carried out and then added to the plate as described in 
section 2.19.1. The optimal conjugate concentration chosen was 12.5 /¿g/ml, and the optimal 
scFv antibody dilution (i.e. the one that gave half the maximum absorbance) was 1/4.
- 50 ug/ml 
-25 ug/ml 
12.5 ug/ml 
0 ug/ml
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4.2 .8 .2 . Competition ELISA fo r  the detection o f AFBi using scFv antibody 
A series o f standards of AFBi ranging in concentration from 98-1,560 ng/ml were 
prepared as described in section 2 .1 0 .1. 50 |il of each of these standards were then 
added to an AFBi-BSA coated plate (section 2.19.2). 50 (jJ/well o f the scFv anti- 
AFBi antibody was prepared at a 1/2 (1/4 final dilution) dilution and added to the 
plate. After incubation and washing, anti-FLAG antibody and enzyme-labelled anti­
mouse antibody were added followed by chromogenic substrate. The linear range of 
detection for the scFv antibody was 98 to 1,560 ng/ml. For intra-day assay variation, 
each concentration was assayed three times on the one day and the mean absorbance 
of bound antibody for each antigen concentration was plotted versus antigen 
concentration. Figure 4.25 shows the intra-day assay linear range of detection of 
AFBi for the scFv antibody, while Table 4.7 shows the coefficients of variation 
(C.V.’s) for the assay. Intra-day percentage C.V.’s for the assay were below 4.6 %. 
The inter-day assay variation was calculated by performing the assay over three 
separate days, and a separate calibration curve plotted for each normalised 
absorbance (absorbance/absorbance 0 (A/Ao)) value versus the respective AFBi 
concentration for each assay carried out on each day. The normalised mean values 
for the assay were calculated and plotted. Figure 4.26 shows the inter-day variability 
assay for the scFv antibody, while the percentage C.V.’s for the inter-day assay are 
shown in Tables 4.8. The percentage C.V.’s for the assay were less than 12 %.
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Table 4.7. Intra-day assay coefficients of variation for the determination offree AFB] using 
scFv anti-AFB; antibody (C4). Three sets of five standards were assayed the same day, and 
the C. V. ’s were calculated as the standard deviation (S.D.) expressed as a percentage of the 
mean values for each standard.
Aflatoxin B t concentration 
(ng/ml)
Calculated m ean ±  S.D. Coefficient of variation
(% )
1,560 0.852 ±0.039 4.59
780 1.081 ±0.027 2.54
390 1.435 ±0.022 1.57
195 1.665 ±0.056 3.39
98 2.044 ±0.068 3.36
2.5
2
as<NC\
§
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C oncentration  o f  free A FB 1 (ng/m l)
10000
Figure 4.25. Intra-day assay variation for competitive ELISA for AFB / using scFv anti-AFB / 
antibody (C4). The linear range of detection was 98 to 1,560 ng/ml. The error bars on each 
calibration point indicate the standard deviation of the mean of three measurements.
y = -0.4286Ln(x) + 
R2 = 0.99
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Table 4.8. Inter-day assay coefficients of variation for the determination offree AFBi using 
scFv anti-AFBj antibody (C4). Three sets of five standards were assayed on three different 
days, and C. V. ’s were calculated as the standard deviation expressed as a percentage of the 
mean normalised values for each standard.
Aflatoxin Bi concentration 
(ng/ml)
C alculated m ean ±  S.D. 
A/Ao
Coefficient o f variation 
(% )
1,560 0.404 ±  0.039 9.71
780 0.490 ±0.058 11.90
390 0.643 ±0.056 8.74
195 0.753 ±0.060 8.07
98 0.858 ±0.022 2.67
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Figure 4.26. Inter-day assay variation for competitive ELISA for AFB / using scFv anti-AFBj 
antibody (C4). The linear range of detection was 98 to 1,560 ng/ml. The error bars on each 
calibration point indicate the standard deviation of the mean of three measurements.
100 1000 
C oncentration  o f  free A F B I (ng/m l)
10000
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4.2 .8 .3 . Cross-reactivity studies
Cross reactivity studies were carried out on the scFv antibody to seven other 
structurally related aflatoxins, as described in section 2.19.3. Standard curves for each 
of the aflatoxins were produced as described previously in 4.2.8 .3. The results were 
normalised and plotted. The slope o f the line o f the standard curve for each toxin was 
expressed as a percentage o f the slope o f the line for binding to AFBi. Table 4.9 
shows the cross-reactions o f the scFv antibody, which showed a high level of cross­
reaction to the structurally related aflatoxins.
Table 4.9. Cross-reactions of scFv anti-AFBj antibody (C4) observed to seven other 
aflatoxins. Standard curves were produced for each of the aflatoxins in the same way as that 
for AFBi. Each concentration for each point on the standard curve was assayed in triplicate 
and the means plotted and normalised in order to construct standard curves.
A flatoxin scF v  
% C ross  
R eactiv ity
Bi 100
b 2 53.1
G, 75.6
g 2 67.9
M i 50.4
m 2 2 2 .8
B2a 17.8
G2a 21.7
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4.3. D iscussion
The work presented in this chapter showed the use o f  a pre-immunised antibody 
phage display library in order to produce soluble scFv antibodies, and their 
characterisation by ELISA. In order to produce the phage display library, Balb/c 
mice were immunised with an AFBi-BSA conjugate. Only one protein conjugate was 
commercially available, and was therefore used for both the immunisation and 
analytical steps. When carrying out antibody titres using this conjugate, the same 
controls as mentioned and explained in chapter 3.3 were included. These controls 
worked effectively, and it was apparent from them that there was a greater immune 
response to the AFBi portion, as opposed to the BSA  part o f the conjugate. The high 
antibody titre to the toxin-protein conjugate was indicative o f large quantities o f 
mRNA translating for specific AFBi-BSA antibodies. The spleen is rich in B-cells, 
and therefore rich in mRNA coding for these specific B-cells. As a result, once a 
sufficiently high enough specific antibody titre was obtained, the spleen was removed 
from the mice, and the RNA extracted from it.
Extraction o f  the RNA was successful, and good yields were obtained from the 
spleen. There was also a certain amount o f protein (as expected) in the samples. 
However, the quantity o f protein was not greater than the amount o f RNA present. A 
complementary strand o f DNA (cDNA) was synthesised from the RNA by reverse 
transcription, and this was used for amplification o f the heavy and light chains by 
PCR.
Amplification o f  the heavy and light chains was carried out using the extended primer 
mix (Chapter 2.15.4.), which incorporated all o f  the mouse Vh, V x ,  and VK sequences 
collected in the Kabat data base (Rabat et al., 1991). It also combined the extended 
primer sets described by Kettleborough et al. (1993), 0rum  et al. (1993), and Zhou et 
al. (1994). This ensured that a larger repertoire o f DNA coding for the mouse heavy 
and light chains was effectively and specifically amplified, and as a result a larger 
population o f  antibodies available for selection during the screening process. It can
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be seen (Figure 4.6) that the heavy and light chains were specifically amplified, using 
an annealing temperature o f 63° C.
Once the Vh and Vl fragments were amplified, they were densiometrically analysed, 
to determine the concentration o f DNA for optimisation of the SOE-PCR. A greater 
quantity o f heavy chain DNA was amplified compared to the light chain. However, 
there was sufficient light chain to proceed with the SOE-PCR. Approximately 10 ng 
of each of the Vh and V l’s was used, and this was adequate for the reaction to work 
successfully (Figure 4.7). SOE-PCR produced an 800 bp fragment, as the heavy and 
light chains are approximately 400 bp long each.
Both the SOE-PCR product and the vector pAK 100 had to be restriction enzyme- 
digested prior to the ligation step. Sfil was the restriction enzyme used, and, as 
described in section 4.1, it is unique as it cuts two sites at once on a piece of DNA. It 
is also useful, as the sites at which it cuts at are quite rare in antibody sequences, and 
therefore it eliminates the possibility of internal digestion, and incorrect sequence 
lengths. Digestion o f the SOE product results in a very small change in weight of the 
piece o f DNA. It is therefore quite difficult to differentiate between cut and uncut 
DNA. In order to aid the visual differentiation, the samples were electrophoresed on 
a 2-2.5 % agarose gel, which improved the separation o f the fragments. Figure 4.8 
shows an agarose gel o f digested and undigested fragment, and it is just possible to 
differentiate between the two fragments on the gel, indicating the reaction was 
successful. Digestion o f the pAK 100 vector is visually easier to differentiate, as the 
cut tetracycline cassette is 2101 bp in length. This is easily visualised on the gel 
(Figure 4.9). It can also be seen on the gel that a certain amount of vector remained 
uncut. Possibly there was not enough Sfil to digest all-the vector present in the 
sample. However, it is more favourable to have ‘too-little’ enzyme rather than ‘too- 
much’, especially in the case of Sfil. In reactions, with the enzyme in excess of DNA 
sites, each site becomes loaded with Sfil tetramer, and thus preventing the protein 
from binding the two sites necessary for full activity. Hence, it is easier to re-digest a 
sample to obtain complete digestion, rather than add too much initially, and not 
achieve any or sufficient digestion.
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Once both the vector and the SOE product were digested, they were ligated and 
transformed into supercompetent E.coli XL-1 blue cells. An antibody phage display 
library consisting o f 5 x 103 clones was produced. This library would be considered
• > « • 7 8as very small in size, as it is possible to generate libraries consisting of 10 or 10 
clones. However, given the fact that the library was produced from RNA that 
originated from a pre-immunised mouse, it was decided to attempt panning from the 
library, rather-than repeating the transformation procedure to produce a larger library.
In order to select for small haptens from a phage display library it optimal to use 
more than one hapten-protein conjugate. Therefore a second AFBi conjugate needed 
to be synthesised. Amino-dextran was chosen as the carrier molecule, as previously, 
it has been shown to yield low background values in ELISA (Xiao et al, 1995). This 
feature of amino-dextran is optimal for use in the panning procedure, as it is 
necessary to keep background signals to a minimum to ensure a non-biased selection 
for positive clones recognising free hapten. AFBi was activated producing the 
compound AFBi O-carboxymethylhydroxylamine, which contained a COOH group 
on the cyclopentanone ring. The COOH group was then used for coupling to amino 
groups on the dextran using conventional carbodiimide coupling chemistry. Due to 
laboratory safety, it was unsuitable to analyse the conjugate by ultra-violet 
spectroscopy. BlAcore™ (1000) was therefore used to analyse the conjugate, as it 
was a rapid and safer method to use. The conjugate was preconcentrated onto a blank 
dextran surface in order to optimise the pH in acetate buffer for immobilisation. The 
pH used was 5.0, which was relatively high, indicating a low substitution ratio of 
toxin on the dextran molecule. Immobilisation of the conjugate onto the activated 
dextran gel surface resulted in 2,773 RU (1,000 RU = 1 ng/mm2) being immobilised. 
The two polyclonal antibodies described in chapter 3 were then injected over the 
surface. Both showed low levels of binding to the conjugate surface. The antibodies 
obtained from rabbit 1 gave 67 RU of binding, while the antibodies obtained from 
rabbit 2 resulted in 95 RU binding. The antibodies obtained from rabbit 1 showed a 
significantly better binding response to an AFBi-BSA conjugate (-350 RU) (Chapter
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5.2) at the same dilution (1/100). This also confirmed a relatively low substitution 
ratio on the dextran conjugate.
After producing phage from the library initially, a phage titre of 2.5 x 109 cfu/ml of 
phage was produced. Round 1 of panning was carried out using an AFBi-BSA 
conjugate coated onto an immunotube at 50 (ig/ml. This yielded a phage titre of 3.0 x 
105 cfu/ml o f phage. A lower phage titre after the first round was expected, as it 
selected out a large amount of non-specific phage display antibodies. 96 random 
clones were picked and grown to produce phage from them. They were tested for 
recognition to AFBi-BSA conjugate. The background signal was quite high, and it 
was difficult to completely differentiate between positive clones and background. 8 
of the clones shown a certain level o f recognition for the conjugate i.e. those that 
gave the highest absorbances. Three of these were then assayed for recognition of 
free AFBi, but none o f them were positive. Therefore, a further round o f panning 
needed to be carried out to select for phage display antibodies recognising AFBi.
After the first round o f panning, it is desirable to switch the carrier molecule on the 
conjugate for the second round. This ensures that non-specific phage recognising the 
protein (from the round 1 conjugate) are not re-selected and amplified. Instead, only 
phage generally recognising the hapten will be selected for, and thus increasing the 
chances of selecting and amplifying a specific phage-antibody to the hapten. As a 
result o f this, AFBi-dextran was used for round 2 o f panning. A high concentration 
of 2 0 0  (j.g/ml was used to coat the immunotube, due to the low substitution ratio on 
the conjugate. This yielded a phage titre of 2.8 x 107 cfu/ml, which was higher than 
the titre obtained from round 1. 96 random clones were then selected and assayed for 
recognition to AFBi-BSA conjugate, and ten clones were positive. In the case of this 
assay the backgrounds were significantly lower compared to the ELISA after round 1 
(Tables 4.4 and 4.5). Three of these positive clones were then assayed for 
recognition to free AFBi. However, none of them were positive, indicating there was 
still a large number o f non-specific phage in the population. This prompted a third
185
round of panning to be carried out, in order to make the selection conditions more 
stringent for the detection of positive clones.
AFBi-BSA conjugate was used for round 3, as the previous round ensured that non­
specific ‘BSA-binding’ phage antibodies were removed from the selection process. 
As the number o f rounds o f panning increase, the selection for a specific phage- 
antibody becomes more stringent, as each round (providing different conjugates are 
used) ensures a reduction in the amount of non-specific phage, and greater 
amplification of specific phage. Round 3 gave a phage titre of 2.4 x 107 cfu/ml, 
which was slightly less than that obtained from round 2. 96 random clones were 
picked and assayed for selection to AFBi-BSA conjugate. Seven clones showed 
good recognition for the conjugate, with significantly lower background levels 
compared to the round 2 ELISA (Table 4.6). The seven clones were then assayed for 
recognition to free AFBi, in which six o f them showed recognition over the range 1- 
50 H-g/ml. The panning process was highly successful, as selection o f phage 
antibodies to small haptens is generally quite difficult.
It has been mentioned elsewhere (Moghaddam et al, 2001) that selection of a large 
number of antibodies to low molecular weight haptens conjugated to BSA or 
biotinylated can often be unsuccessful for the detection o f antibodies that bind the 
non-derivatised form of the hapten. Moghaddam et al. (2001) screened for phage 
display scFv antibodies to AFBi from non-immunised human phage libraries, as well 
as semi-synthetic phage libraries. It was found that a large percentage of the 
antibodies isolated from the non-immunised (human) library specifically bound 
AFBi-BSA conjugate but did not bind free AFBi, and if so, had at least 100-times 
less affinity than for the BSA conjugated form. However, they did find that a 
percentage of the scFv antibodies that bound to both free toxin and conjugate 
dramatically increased, when free AFBi was used for elution o f phage from AFBi- 
BSA during the elution step of the panning. With respect to the semi-synthetic 
library, after three rounds o f panning using the same conjugate, antibodies with high 
affinities to free AFBi were detected. This is a similar finding to what is presented in
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this chapter, except that two different conjugates were used. However, they used 
AFBi for elution of the phage from the immunotube, which may have increased the 
stringency of the procedure.
Three o f the clones (B3, C4, and F4) that recognised free AFBi were then selected for 
expression as soluble scFv antibodies. Restriction enzyme digestion o f the pAK 100 
plasmid containing the ‘positive’ scFv fragment was successfully carried out, as was 
digestion of the high expression vector pAK 400, which contains the enhanced Shine- 
Dalgarno sequence. Ligation of the scFv fragments into the plasmid was carried out 
and these were then transformed into the non-suppressor E.coli strain JM 83, which 
enhances soluble scFv expression. Analysis o f the periplasmic lysates and the culture 
supernatants was carried out by ELISA. One of the clones (F4) did not show 
significant levels of secretion o f soluble scFv into the periplasm or the culture 
supernatant, indicating that the scFv antibodies were not secreting correctly from the 
intracellular compartment of E.coli. Due to the arduous task in obtaining intracellular 
scFv antibodies, it was decided not to pursue work with this particular clone. Clone 
B3 showed equal levels o f antibody secretion both into the periplasm, as well as the 
culture supernatant. Clone C4, however, demonstrated a larger degree of secretion 
into the supernatant rather than the periplasm. It was therefore decided to concentrate 
on working with clone C4, as there was a predominant form of expression and, 
therefore, a quicker route to obtaining and purifying the scFv’s.
After scFv antibodies were produced in culture supernatant, they were concentrated 
five-fold and then purified using ProBond™ resin, which is an IMAC-based column 
(Janknecht et al., 1989). This procedure did not work as effectively as anticipated. 
Figure 4.22 shows a SDS-PAGE of purified scFv antibody versus culture supernatant. 
With respect to purity, there is very little difference between the two samples as they 
both have a number o f bands common to each other. IMAC was only useful in 
isolating the antibodies from the culture supernatant, but not isolating them from the 
proteins in the supernatant. It may be possible to further optimise the procedure by 
dialysing the culture supernatant into column running buffer prior to passing it
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through the column. This would remove some of the non-specific proteins below the 
molecular weight cut-off of 10 KDa, and therefore improving antibody purity. Muller 
et al. (1998) state that if the protein of interest such as an scFv antibody is only 
present as a small fraction in the supernatant, several contaminating proteins can 
remain. These can bind to the IMAC column under certain purification conditions 
and co-elute. Certain proteins from E.coli have been identified which may bind to 
IMAC columns during purification. These include superoxide dismutase (8  histidines 
(his)), chloramphenicol acetyltransferase (12 his), cAMP receptor protein (6  his), heat 
shock protein (14 his), host factor-1 protein (5 his), and wondrous histidine-rich 
protein (18 his). Some of these proteins, therefore, may account for the impurities 
observed on the SDS-PAGE gel. The IMAC column used in this procedure used 
iminodiacetate (IDA) as the metal-chelating compound and nickel (Ni2+) as the 
binding-metal. Arnold (1991) states that due to the higher affinity of imidazole 
(elution compound used in IMAC) for copper (Cu2+), histidine containing proteins are 
more strongly bound to Cu (II)-IDA than to IDA chelates o f other metals. It may be 
therefore more favourable to use copper as the chelating metal, rather than nickel 
which was being used. Alternative methods of purification could also be implemented 
such as production o f an affinity column using an anti-FLAG antibody. However, 
given the quality o f the antibody available, and the expense, it was not feasible to 
produce such a column. It was also possible to produce an AFBi affinity column for 
purification o f the scFv antibodies, but this was not feasible given the hazards 
associated with AFBi. Both o f these affinity columns use low pH buffers for elution, 
and this may affect antibody activity. Hence, it was more favourable to use IMAC, as 
low pH elution was not required, with an accompanying greater chance of 
maintaining the integrity of the antibody.
Western blot analysis was also carried out to identify the scFv antibodies. Figure 
4.23 shows the Western blot, where a single band can be observed for purified sample 
indicating the presence o f scFv antibodies. No significant band was observed in 
culture supernatant. This is probably because the sample was not sufficiently 
concentrated for the anti-FLAG antibody to detect it in the blot.
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It was important to initially optimise the concentration o f AFBi-conjugate and scFv 
antibody for use in a competitive ELISA. A checkerboard ELISA was carried out for 
the scFv antibody as described in section 2.19.1. The antibody dilution used was 1/4 
with a conjugate loading density o f 12.5 (J.g/ml for the assay.
A competition ELISA was optimised for the scFv antibody using these parameters. 
The assay was relatively sensitive, with a limit of detection of 98 ng/ml. Inter-day 
assay variation studies were carried out by analysing three sets of standards across the 
respective linear ranges on three different days and calculating the C.V.’s as the 
standard deviation expressed as a percentage of the mean normalised values for each 
standard.
The assay was reproducible over three different days with the C.V.’s below 11.9 % 
(Table 4.8). Yuan et al. (1997) produced scFv antibodies to the mycotoxin 
zearalenone, and found that the soluble antibodies could detect as little as 14 ng/ml 
for 50 % inhibition of binding. The scFv antibodies produced by Moghaddam et al. 
(2001) could detect as little as 14 (iM AFBi in solution. It is clear that these 
antibodies are more sensitive than the scFv produced here. The polyclonal antibodies 
produced to AFBi discussed in Chapter 3 are also significantly more sensitive (limits 
of detection 12.2 & 24 ng/ml, respectively) than the anti-AFBi scFv antibody. 
However, it is thought that the assay could be further optimised if a more sensitive 
anti-FLAG antibody could be obtained. Enzyme-labelling the anti-FLAG antibody 
could also improve the sensitivity o f the assay, as it would reduce the number of 
incubation steps, as well as reduce the probability o f the enzyme-labelled anti-species 
antibody reducing the sensitivity.
Cross-reactivity studies were also carried out on the scFv antibody. The procedure is 
described as in section 2.19.3 and Table 4.9 shows the results o f the studies. The 
scFv antibody showed high degrees of cross reactivity, especially to AFGi> AFG2> 
AFB2> Mi (in decreasing order). These are similar findings to the polyclonal 
antibodies discussed in chapter 3, where they were also cross-reactive to AFGi as the
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major functional group which both compounds differ from is masked by the protein 
which is attached on the cyclopentanone ring. Moghaddam et al. (2001) analysed 
their scFv antibodies for cross reactivity using BIAcore. They found that the 
antibody was able to bind as effectively to AFGi as AFBi. This is a similar finding to 
what was observed with the scFv antibody reported here. However, the scFv did not 
show any recognition for AFMi or AFM2. It is favourable to produce specific 
antibodies for a particular hapten, but it could be advantageous from a regulatory 
viewpoint to apply this scFv antibody for the detection o f total aflatoxin 
concentration in a sample.
4.4. C onclusions
The production o f an antigen-specific antibody phage display library from the RNA 
obtained from a mouse pre-immunised with AFBi-BSA conjugate was successful. 
The stringency of the panning procedures using two toxin-carrier conjugates 
sequentially reduced the number o f non-specific phage after each round of panning. 
It resulted in the highly successful isolation of seven phage display clones, six of 
them recognising free AFBi in solution. Soluble production o f scFv antibodies 
(clone C4) was induced using the high expression vector pAK 400. After purification 
by IMAC, a competition ELISA was optimised for the scFv antibody. The assay was 
relatively sensitive, but it was thought it could be further optimised using a more 
sensitive anti-FLAG antibody. The scFv showed a high level o f cross-reactivity to 
structurally similar aflatoxins. The phage display system used was found to be highly 
robust, and generally straightforward for the production o f scFv antibodies. SOE- 
PCR was particularly useful, as it reduced the number of ligation steps, coupled with 
the ease of restriction enzyme digestion using Sfil. The use o f a number of expression 
vectors eliminated the problems associated with expression levels, and enabled the 
production o f highly stable scFv antibodies.
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5.1. In trod u ction
Biosensor development over the last few decades has grown enormously, and now, 
biosensors are an established and reliable analytical tool. A biosensor may be defined 
as any probe or transducer that incorporates a biological component as the key 
functional element in the overall transducer sequence (Vadgama & Crump, 1992). 
Both the transducer and biological element can then work together to relate the 
concentration o f analyte to a measurable electronic signal. The first biosensor 
reported (Clark & Lyons, 1962) incorporated an enzyme as the bio-component 
operating in combination with an electrochemical transducer for the detection of 
glucose in samples. Since then, interest in the biosensor area has grown substantially, 
and their development has been extensively reviewed elsewhere (Pancrazio et al, 
1999; Rogers, 2000). Trends in biosensor development today show miniaturised, 
chip-based, microarrays capable o f  multi-analyte detection (Ekins, 1998; de Wildt et 
al., 2 0 0 0 ).
5.1.1. Components o f a biosensor
In the design o f any biosensor, the biological component is an essential part and 
should possess a high degree of specificity and stability. It is also important that it 
should not contaminate the sample, as well as retain its biological activity when 
immobilised. The biologically sensitive components can be an enzyme, organelle, 
membrane component, a bacterial cell or whole cell, or an antibody or antigen (Sethi, 
1994). These materials are responsible for the recognition o f the test species in the 
mixture and provide the sensitivity and specificity for the entire device. When the 
biological molecules interact specifically and reversibly, a change in one or more 
physio-chemical parameters occurs. These changes may produce ions, electrons, 
gases, heat, mass or light, which are then converted into electrical signals by the 
transducers, that process and display the information in a suitable form. A number of 
different transducer elements are available for use in biosensors (Sethi, 1994). These 
include electrochemical, which measure conductance, piezo-electric, which measure 
mass change, and optoelectronic, which measure optical changes. Biosensors-based 
on optoelectronics often incorporate the phenomenon of surface plasmon resonance
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(SPR) as a method o f detection. SPR-based biosensors are important tools in the 
biotechnology industry, as they have the ability to generate large amounts of 
qualitative and quantitative data simultaneously. A number of SPR-based biosensors 
are commercially available which include; the BIAcore range of instruments 
(BIAcore AB), the IAsys instrument (Affinity Sensors), the Texas Instruments SPR 
device (TI-SPR), and BIOS-1 system (Windsor Scientific Ltd). This chapter will 
focus on surface plasmon resonance-based biosensors and their applications in the 
detection o f analytes.
5.1.2. Surface plasmon resonance
In order to explain the principle o f SPR, it will be described in the context of BIAcore 
instruments, which incorporate the SPR phenomenon to monitor biomolecular 
interactions in ‘real-time’. At an interface between two transparent media o f different 
refractive index such as glass and water, light coming from the side o f higher 
refractive index is partly reflected and partly refracted. Above a certain critical angle 
o f incidence no light is refracted across the interface and total internal reflection 
(TIR) occurs at the metal film-liquid interface. This is where light travels through an 
optically dense medium such as glass, and is reflected back through that medium at 
the interface with a less optically dense medium such as buffer. Although the 
incident light is totally reflected, the electromagnetic field component, termed the 
evanescent wave, penetrates a distance on the order of one wavelength into the less 
optically dense medium, in this case buffer. The evanescent wave generated at the 
interface between a glass prism (high refractive index) and a layer o f buffer (lower 
refractive index) is illustrated in Figure 5.1. If the interface between the media of 
higher and lower refractive indices is coated with a thin metal film (a fraction of the 
light wavelength), then the propagation of the evanescent wave will interact with the 
electrons on the metal layer. Metals contain electron clouds at their surface, which 
can couple with incident light at certain angles. These electrons are also known as 
plasmons, and the passage of the evanescent wave through the metal layer causes the 
plasmons to resonate, forming a quantum mechanical wave known as surface 
plasmon. Therefore, when surface plasmon resonance occurs, energy from the
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Figure 5.1. The evanescent wave. Light directed into a glass prism at an angle greater than 
the critical angle undergoes total internal reflection. At the interface between the prism 
(high refractive index) and the buffer (lower refractive index), an electromagnetic field 
component of the light, the evanescent wave propagates into the medium of lower refractive 
index on the non-illuminated side.
incident light is lost to the metal film resulting in a decrease in the reflected light 
intensity. The resonance phenomenon only occurs at an acutely defined angle o f the 
incident light. This angle is dependent on the refractive index o f the medium close to 
the metal-film surface. Changes in the refractive index o f the buffer solution (e.g. an 
increase in surface concentration o f solutes), to a distance o f about 300 nm from the 
metal film surface will therefore alter the resonance angle. Continuous monitoring of 
this resonance angle allows the quantitation o f changes in refractive index o f the 
buffer solution close to the metal-film surface. This is illustrated in Figures 5.2 to 5.4 
where binding o f the analyte shifts the SPR angle from position 1 to position 2.
The reflected light angle at which SPR occurs is determined by three main 
parameters, which include the properties o f the metal film (optical constants, 
thickness and uniformity etc.), the wavelength o f the incident light, and the refractive 
index o f the media on either side o f the metal film.
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Figure 5.2. Schematic basis of SPR technology with the BIAcore instrument.
(A) Antibody (Y) is immobilised on the gold surface using conventional coupling chemistry 
such as EDC/NHS. Plan polarised light is emitted from a high efficiency emitting diode, and 
is focused on the gold chip surface in the shape of a wedge-shaped beam using a glass prism, 
under conditions of total internal reflection. The reflected light is then measured by a two- 
dimensional photo-diode array. The evanescent wave penetrates into the medium of lower 
refractive index at the metal-coated interface under conditions of total internal reflection. 
The angle at which this occurs is known as the resonant angle (i.e. SPR angle = angle 1), and 
a sharp shadow or dip occurs in the reflected light at angle 1), designated by the blue line in 
the reflected light. The angle at which SPR occurs is dependent on a number of factors 
including the refractive index of the layer adjacent to the metal film. SPR is therefore used to 
probe and monitor the interactions occurring at the chip-surface in ‘real-time
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(B)
Figure 5.3. (B) Antigen ( • )  is then injected over the immobilised-antibody chip surface. 
Binding of the antigen to the immobilised antibody causes an increase in the mass bound at 
the sensor chip surface and a subsequent change in the refractive index at the sensor chip 
surface, causing a shift in the resonant angle of the reflected light (i.e. from angle 1 (Figure
5.2) to angle 2). The shift in the resonant angle is proportional to the change in the mass of 
analyte bound at the sensor chip surface.
(C)
Reflected Intensity Resonance signal (RU)
Figure 5.4. (C) Plot of the change in the resonant angle (9) measured in ‘real-time’ 
following antibody: antigen binding versus time. This is interpolated by the instrument 
software to generate the characteristic SPR response curve, where the change in the SPR 
angle is converted to arbitrary response units. The response signal measured is proportional 
to the concentration of bound analyte.
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In real-time BIA, the metal film properties, wavelength, and refractive index of the 
glass (denser medium) are all kept constant, and as a result SPR can be used to 
monitor the refractive index o f the aqueous layer immediately adjacent to the metal 
(gold) layer. As a result, any changes in mass in the buffer will cause a change in 
SPR angle, which is monitored in ‘real-time’ and quantified as a sensorgram. A mass 
change o f approximately 1 kRU (1,000 RU) corresponds to a mass change in surface 
protein concentration o f 1 ng/mm2, or about 6  mg/ml in bulk protein concentration. 
Typical responses for surface binding of proteins in BIA are of the order of 0.1-20 
kRU. A more extensive review of SPR has been carried out by Liedberg & 
Lundstrom (1993).
5 .I .2 .I . The sensor chip
The sensor chip incorporated in the BIAcore system is depicted in Figure 5.5. It 
consists of a glass substrate onto which a 50 nm-thick gold film is deposited. This 
gold film is derivatised with a monolayer of a long chain hydroxalkyl thiol, which 
serves a barrier to proteins and other ligands from coming into direct contact with the 
metal surface. A carboxy-methylated dextran layer is covalently deposited onto the 
hydroxalkyl thiol layer. This is approximately 100 nm thick, and serves to produce a 
hydrophilic layer suitable for macromolecular interaction studies as well as
containing functional groups (carboxyl groups) available for ligand immobilisation 
chemistries. Covalent attachment of biomolecules to the flexible dextran layer 
preserves a hydrophilic environment around the immobilised molecules and gives a 
high degree of accessibility to the molecular surfaces. Immobilisation of proteins on 
the sensor-chip surface results in 30-40 % of the carboxyl groups in the matrix being 
activated under typical immobilisation conditions using EDC/NHS coupling 
chemistry. The dextran matrix is chemically stable in most buffers used in
biomolecular interaction studies and can be exposed to extremes of pH for short
periods without deterioration. Direct immobilisation o f proteins onto the gold surface 
itself can result in significant denaturation o f the immobilised protein.
Carboxymethylation o f the dextran layer also places a net negative charge on the 
dextran, which is completely charged above pH 7. This allows for positively charged
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proteins (i.e. below their pi) to become electrostatically attracted to the bound dextran 
layer, and effectively ‘pre-concentrates’ the protein to the chip for subsequent 
immobilisation procedures.
Surface
Matrix
Linker
layer
Gold film
Glass
support
Figure 5.5. Surface of a CM 5 sensor chip consisting of three layers: glass, a thin gold film, 
and a matrix layer. The matrix is bonded to the gold film through an inert linker layer.
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5.1 .2 .2 . Interpreting the SPR signal
The SPR signal originates from changes in the refractive index o f a surface layer 
consisting o f both bulk solution and the surface matrix with adsorbed biomolecules. 
A typical sensorgram for binding o f a bimolecule to immobilised ligand is shown in 
Figure 5.6.
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Figure 5.6. A typical BIAcore sensorgram for binding of analyte to immobilised ligand. 
The initial steady baseline is due to running buffer flowing over the immobilised ligand 
surface. Injection of sample causes an initial sharp signal increase due to the difference in 
bulk refractive index. The binding of two interactants can then be seen as a gradual increase 
in signal. The signal falls sharply at the end of the sample injection, as the lower refractive 
index buffer flows over the surface. The difference in response units (RU) between the initial 
baseline and the signal after the sample injection represents the amount of analyte bound.
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5.1 .3 . Resonant mirror-based devices
An example o f a resonant mirror-based device is the Iasys system. It is also similar 
to the BIAcore device in that polarised light is totally internally reflected at the 
underside of the sensor surface. In this case, the sensor surface has the metal layer 
replaced by a dielectric resonant layer (Cush et al., 1993). It is approximately 100 
nm thick, and made o f titanium which is of high refractive index. This is separarated 
from the prism by a low index layer made of silica. Figure 5.7 shows a schematic 
diagram o f the system. Incident light of focused on the prism-silica interface which 
results in frustrated total internal reflection (FTIR). This evanescently couples light 
into the high index or wave guiding layer. Within this waveguiding layer, total 
internal reflection (TIR) occurs generating an evanescent field at the biointerface. 
Efficient coupling occurs only for certain incident angles where phase matching 
between the incident beam and the resonant modes of the high index layers is 
achieved. At the resonant point, light couples into the high index layer, and 
propagates along the sensing surface before coupling back into the prism. During 
resonance, a phase shift of the order of 2n in reflected light occurs and causes 
constructive interferance that produces sharp peaks o f light at resonance. These 
changes in angular position are monitored in real-time as they are directly related to 
changes in refractive index at the biointerface surface. The IAsys system has also 
utilised a cuvette-based design as opposed to a flow cell configuration, which 
continually stirs to reduce mass transport effects and has a much larger surface area 
than the BIAcore chip.
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Figure 5.7. Structure of resonant mirror sensing device. Incident light is directed through a 
prism, and frustrated total internal reflection occurs at the boundary with the low refractive 
index layer. An evanescent field is generated which couples light into the high refractive 
index waveguiding layer. The guided mode gives rise to an evanescent field at the 
biointerface. The incident angle at which resonance occurs is dependent on the refractive 
index at the biointerface surface. Binding interactions at this surface cause a shift in angle of 
reflected light, which are related to changes in mass at the sensor chip surface.
5.1.4. Minature Texas Instruments-SPR device
In 1996 Texas Instruments Incorporated developed and released a fully integrated and 
minature surface plasmon resonance sensor. The TISPR-1 contains a light emitting 
diode (LED), polarizer, thermistor (to allow for correction due to temperature 
fluctuations) and two 128 silicon photo diode arrays housed in an epoxy resin 
moulding which was designed in the form o f the Kretschmann geometry prism 
(Figure 5.8(a)). The device was developed for use as a non-destructive, low-cost, and 
small-sized smart sensor. The wedge shaped beam reflects off the SPR sensing layer 
onto the PDA array by means o f a mirror. The SPR minimum is then measured in 
‘real-time’ following dedicated signal processing (Kukanskis et al., 1999). The 
system offers the capability for ‘remote-sensing’ and is available in a hand-held 
pipette-style format called the Spreeta™ device. A schematic o f the device in 
illustrated in Figure 5.8(b) with the attached flowcell.
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Figure 5.8(a). Cross-section of miniature TI-SPR instrument. Mass changes are related to 
changes in the resonant angle and position of the reflectance minima, which are detected in 
‘real-time ’.
Figure 5.8(b). TI-SPR device fitted with flow-cell. The control box interfaces with the 
device, which allows it to be installed onto a PC. This, together with dedicated software 
(SPR-MINI MS-Windows software) allows control of data acquisition, processing and 
display as a virtual control panel as seen on the laptop.
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5.1.5. Applications o f  SPR-based biosensors
Antibodies have been extensively applied to SPR-based biosensors, as they are 
molecules that are highly sensitive and specific for their antigens. A biosensor which 
monitors antibody-antigen interactions may also be known as an immunosensor. An 
extensive range o f analytes have been detected and measured by immunosensors, and 
more specifically SPR-based immunosensors. These include drugs, proteins, 
hormones, as well as environmental contaminants such as pesticides and food 
contaminants. One of the main advantages of SPR-based immunosensors is the 
absence o f labelling requirements and the ability to investigate the kinetics of the 
antibody-antigen interaction. Another advantage is the re-usability o f the sensor-chip 
surface, due to a regeneration step which can remove bound antibody from 
immobilised antigen on the chip surface, or vice-versa. Some of the more recent 
applications of SPR-technology incorporating antibodies as a detection method are 
reviewed in the following sections.
5.1 .5 .1 . Detection o f  small molecules using BIAcore
In certain cases, molecules of low molecular weight (less than 2,000 daltons), may 
not show a mass change when binding to the sensor surface, as they are too small to 
give a significant change in refractive index, and hence change in SPR signal. As a 
result, when developing a quantitative method for detection of low molecular weight 
compounds, it is necessary to use an indirect sensing method. This can either be 
in h ib itive  - where sample is incubated together with antibody, and the mixture 
passed over an immobilised conjugate surface for binding o f remaining free antibody. 
It gives a change in relative response inversely proportional to the amount of analyte 
free in solution. Alternatively a com petitive  format can be used - in which standard 
samples and high molecular weight hapten-conjugate compete for binding sites on an 
immobilised antibody surface. The increase in SPR signal is due to binding of the 
high molecular weight hapten-conjugate, and, similar to the inhibitive method, is 
inversely proportional to the amount of analyte in the sample. Figure 5.9 shows a 
diagrammatic representation of both assay formats.
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Figure 5.9. Diagrammatic representation of inhibition and competitive BIAcore-based 
immunoassays for the detection of low-molecular weight haptens. Inhibition assay involves 
sample and antibody mixed together, and the mixture passed over an immobilised conjugate 
surface for binding of remaining free antibody. A competitive format consists of standard 
samples and high molecular weight hapten - conjugate competing for binding sites on an 
immobilised antibody surface.
Effective regeneration o f the sensor surface is necessary for both of these formats if 
they are to be used routinely. The antibody-antigen interaction can often be very 
strong, and therefore very difficult to dissociate, despite using strong chaotrophic 
reagents. When selecting an antibody for use in a regenerable immunosensor, it is 
necessary to choose one with a moderate affinity to allow easy regeneration o f the 
sensor surface. I f  the choice o f antibody is limited, alternative immobilisation 
strategies can be used (Quinn el ah, 1999).
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Inhibition immunoassays have been used for the detection of organophosphate 
pesticides by Alcocer et al. (2000(a)). Polyclonal antibodies were produced to 
phosphonic acid (trans-4-phosphono-2-butenic acid (TPB), with the aim of producing 
an antibody preparation that recognised a number of organophosphates. Parathion- 
BSA conjugate was immobilised on the sensor-chip surface, and antibody and free 
parathion were injected over the chip surface, which resulted in the free antibody in 
solution binding to the conjugate surface. Regeneration of the bound antibody from 
the immobilised conjugate surface was carried out using two one-minute pulses of 20 
mM HC1 and NaOH. The antibody population had a linear range o f detection of 
1.562 to 50 [xg/ml, and the assay was highly reproducible. Another example, where 
hapten-protein conjugates were immobilised on the chip surface for use in inhibition 
assays was carried out by Keating et al. (1999). They used a 7-hydroxycoumarin- 
BSA conjugate, for immobilisation, and found the assay had a measuring range of 0.5 -  
80 pg/ml for the detection of free 7-hydroxycoumarin. The BIAcore-based 
immunoassay was easily regenerable, reproducible, entailed no sample clean-up, and 
compared well to established methods o f analysis.
Direct immobilisation of hapten onto the CM-5 sensor-chip surface can also be used 
for an inhibition assay. Fitzpatrick (2001) employed the direct immobilisation method 
for warfarin. 140 consecutive regeneration cycles with a monoclonal anti-warfarin 
antibody were carried out on a 4'-aminowarfarin immobilised surface. The surface
was regenerated with two 30-second pulses o f 30 mM HC1. The binding responses 
demonstrated coefficients of variation of 0.82 % over the course of 140 cycles, and 
no decrease in the measured binding response over the course of the regeneration 
study. An inhibition assay was optimised using this sensor-chip surface. The linear 
range o f detection for the assay was 0.49 to 500 ng/ml, with inter-day coefficients of 
variation no greater than 9.5 %.
Crooks et al. (1998) directly immobilised the sulphonamide drugs-sulfamethazine 
and sulfadiazine onto the surface o f a CM-5 sensor-chip surface using conventional 
EDC/NHS coupling chemistry. The assay was used for the detection of these
respective drugs in pig-bile samples. Analysis o f 2,081 samples for both 
sulphonamide residues over an 8 -month period showed the method to be highly 
reproducible and reliable. Van der Gaag et al. (1999) have also used the direct 
immobilisation of hapten method for the detection of aflatoxin Bi. It was found that 
the assay was sensitive enough for detection o f aflatoxins in food and feed.
Direct immobilisation of haptens to a CM-dextran gel surface is only possible where 
an amino group (NH2) is present on the hapten, as it can bind to the carbodiimide 
activated COO “ groups on the CM-dextran gel surface. Alternative methods of 
direct immobilisation have been attempted (unpublished observations/studies), where 
ethylenediamine is immobilised onto the dextran gel surface, and a hapten containing 
a COO " group is EDC/NHS activated remote from the chip, and then injected over 
the ethylenediamine-immobilised surface. Although this method partially works, it 
also results in some of the EDC/NHS present in the activated hapten solution reacting 
with unreacted COO “ groups on the sensor chip surface. This causes the 
ethylenediamine to ‘cross-link’ to the activated COO “ groups, and hence the 
activated hapten cannot effectively bind to the dextran gel surface.
Analysis of other small molecular weight compounds such as hormones ( Mani et al., 
1997), and also enzyme inhibitors has been carried out. Markgren et al. (1998) 
immobilised the enzyme HIV-1 proteinase directly onto the sensor-chip surface. 
They then injected a variety o f inhibitors and non-interacting drugs over the sensor 
surface, and were able to select and rank the inhibitors based on their association and 
dissociation rates. Myszka & Rich (2000) used immobilised antibody surfaces for the 
direct detection of the hormone progesterone. They immobilised three flow-cell 
surfaces with three monoclonal antibodies (anti-progesterone, anti-testosterone, and 
anti-mouse Fc) within a BIAcore 2000. The fourth flow cell remained blank as a 
control surface to correct control bulk refractive index changes, as well as observe 
non-specific interactions. Progesterone (M.W.= 315 daltons) was then injected over 
the respective surfaces, and binding was observed between the progesterone and the 
anti-progesterone antibodies. A lower degree of binding was observed with the anti­
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testosterone antibodies while no binding was observed towards the anti-mouse Fc 
antibody. This example illustrates how multiple surfaces can be used to compare 
simultaneously a compound’s selectivity for different target ligands. This type of 
biosensor data can also be use for the estimation of kinetics by fitting the data to 
simple interaction models.
5.1 .5 .2 . Applications o f  BIAcore in antibody engineering
Analysis o f recombinant antibodies and phage displayed antibodies can be easily and 
effectively carried out using BIAcore. The biosensor was used in a number of 
applications including the screening process, kinetic selection of phage-displayed 
antibodies, as well as the characterisation and epitope mapping o f fragments.
When antibody fragments are produced from a phage-display library, thousands of 
different specificities are available for selection. These different phage-displaying 
antibodies are usually selected against antigen using ELISA. ELISA is an 
equilibrium method, and therefore candidates with high off rates may be lost. 
BIAcore, however, can be used to evaluate an entire binding pattern of a selected 
panning round. Bacterial culture supernatants can be directly injected over the the 
sensor surface, without further purification (Marks el al, 1992).
The phage selection proccess can also be aided by BIAcore. Malmborg and 
Borrebaeck (1995) selected for phage-displaying Fab fragments specific for 
lysozyme by injecting the phage population over an immobilised lysozyme surface. 
Phage particles specifically bound to the immobilised lysozyme, and were then 
eluted, and re-injected over the surface for a second round of selection.
BIAcore is also a useful tool for the determination of kinetics of respective antibodies 
and their respective fragments (Malmborg et al, 1996). Active antibody 
concentrations can also be determined using BIAcore (Abraham et al, 1995; 
Kazeimer et a l, 1996) under the conditions of mass transport limited binding. 
Recombinant antibody quality can sometimes be a problem in a given preparation 
from E.coli. A simple two-site BIA assay was developed to measure the
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concentration o f assembled Fab' in the presence of unassembled antibody chains and 
fragments (Lawson et al, 1997). The assay involved the initial capture of the Fab' 
antibody from a sample using an immobilised anti-heavy chain antibody (or anti-light 
chain antibody). This was followed by binding of a complementary antibody (anti­
light or heavy chain antibody) in a second step. The initial capture step detects heavy 
or light chains in the sample (depending on what antibody was first immobilised), as 
well as unassembled chains or fragments in the mixture. However the second step 
using the complementary antibody only measures intact Fab' antibodies, since light 
chains will not be identified by anti-heavy chains and vice-versa. By replacing one of 
the antibodies in the two-site assay with antigen, the same assay format can be used 
to determine the integrity and activity o f recombinant antibodies and constructs such 
as scFv-hinge-Fc. The assay can be applied with confidence to culture supernatant or 
crude extract, allowing the optimal harvest time for the culture to be determined.
5.1 .5 .3 . Proteomic applications
At present, proteome analysis is carried out using a combination of 2-D gel 
electrophoresis and matrix-assisted laser desorption/ionization time of flight mass 
spectrometry (MALDI/TOF-MS). Both o f these methods combined are widely 
accepted and powerful tools in proteome analysis. However, after these initial 
proteomic analyses, more questions arise about their interactions. Do the proteins in 
question interact with each other? What other kind of molecules could bind to 
proteins that are specifically expressed during certain biological events or diseases? 
BIAcore can be used to monitor these types o f interactions, as well as possessing the 
advantage of being capable o f high-throughput analysis. Alternatively, MS analysis 
can be carried out on protein samples after they have be analysed by BIAcore- 
provided the analysed species is retained after analysis. Krone et al. (1997) 
combined BIAcore and MALDI/TOF-MS for the analyis o f the peptide myotoxin a. 
Three flow-cells o f a CM-5 sensor chip were immobilised with polyclonal anti- 
myotoxin a antibodies, while the fourth flow-cell was used as a control. Samples of 
myotoxin a were then injected over the surface for analysis. The sensor chip was 
then removed from the machine, and prepared for MS analysis, where the proteins
208
could be analysed. Femtomole quantities of the peptide were detected by direct 
MALDI analysis o f the sensor chips used during BIAcore analysis. Epitope tagging 
of peptides has also been carried out prior to BIA/MS analysis (Nelson ei al., 2000). 
Tags were fused or inserted into nominally unknown genes for the purpose of 
tracking proteins throughout expression. Once the proteins were expressed, they 
were digested with trypsin, resulting in epitope tagged peptides. BIAcore was used to 
selectively isolate (using immobilised antibodies), detect and quantify the peptides 
from the digested media. The sensor chips were then analysed by MALDI-TOF in 
order to characterise the tagged peptides, and identify the protein resulting from the 
gene. This method was capable of detecting low-to sub-femtomole quantities of 
peptide, and shows that BIA/MS is a rapid method to isolate, detect and identify 
epitope-tagged proteins from complex biological mixtures.
5.1.6. Determination o f  antibody affinity constants
The strength o f the bond formed between an antibody and its specific antigen, is 
determined by a combination of different physical forces such as hydrophobic 
interactions, electrostatic binding, van der Waals forces, and hydrogen bonds 
(Tijssen, 1985).
Hydrophobic interactions occur when conjugation of non-polar groups in a binding 
site repel water molecules away from the binding site. Electrostatic binding occurs 
between oppositely charged groups on the antibody and antigen, and its effect is 
greatly enhanced by the removal of water molecules from the binding site, as a result 
o f hydrophobic interactions. Van der Waals forces are as a result o f the attraction of 
electron clouds on adjacent non-polar groups o f the binding partners to each other. 
Hydrogen bonds are formed when hydrogen atoms are shared between two separate 
atoms, and are stronger than van der Waals forces.
The individual bond energies o f these weak non-covalent interactions are minimal, 
especially in aqueous environments, and their effects are only significant in large 
numbers. Non-covalent interactions are also only effective over a small distance, 
making the ‘goodness o f fit’ between the epitope and the binding site on the antibody 
the significant factor in determining the strength of the bond.
209
The sum of the attractive and repulsive forces for a single antibody-antigen bond is 
known as the antibody affinity, and may be described in the following expressions:
Ka
[Ab] +[Ag] [Ab:Ag] (1)
[Ab] = Antibody 
[Ab] = Antigen
[Ab: Ag] = Antibody-antigen complex 
Ka = Association rate constant 
Kd = Dissociation rate constant
The overall affinity o f the antibody for an antigen is given by the equilibrium 
association rate constant,
K  = [Ab : Ag] _ Ka_ _ J__
A [Ab]: [Ag] Kd Kd
The affinity o f an antibody may also be referred to as the equilibrium dissociation 
rate constant, Kd, which is the reciprocal o f the K a value.
Two antibodies with similar affinity constants (KA) may possess completely different 
kinetic rate constants, and consequently vary considerably in their time taken to reach 
equilibrium, which can be a significant factor when choosing an antibody for a 
specific use, e.g. for use in a regenerable immunosensor, or ELISA. When choosing 
an antibody for use in a regenerable immunosensor such as BIAcore, it is desirable to 
have an antibody with a high association rate constant (Ka) and a moderate-to-high 
dissociation rate constant (Kd). However, when choosing an antibody for use in 
ELISA, it is desirable to choose on with a high association rate constant (Ka) and a 
low dissociation rate constant (Kd).
Various techniques are available for the determination o f antibody affinity constants, 
which include ELISA-based methods (Friguet et al., 1985). This method relies on the 
concentration measurement of free antibody in solution after equilibrium with antigen 
has been reached. BIAcore can also be used to determine equilibrium dissociation
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rate constants. The method employed utilises the same method as that employed in 
ELISA (Friguet et ah, 1985), but has several advantages over this technique. The 
short contact time of the antibody-antigen mixture in the flow cell (compared to 
incubation step in ELISA) and continual flow of fresh equilibrium mixture over the 
antigen-coated sensor surface limits the possibility of re-equilibration o f the antibody- 
antigen mixture, and subsequent under estimation of the affinity constant. The 
method also does not require additional labelling of either reagent, or the addition of 
secondary reagents, which may affect the intrinsic thermodynamic binding constants.
5.1.7. Chapter outline
This chapter describes the characterisation o f polyclonal and scFv anti-AFBi 
antibodies, by applying them for the detection of AFBi on a SPR-based biosensor. 
BIAcore 1000™ was used in the analysis o f the polyclonal antibody, while BIAcore 
3000™ was used for the analysis o f the scFv antibody. Both antibodies were also 
applied for the detection o f AFBi in spiked grain samples, and solution affinity 
analysis was carried out on the scFv antibody.
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5.2. Results
5.2.1. Preconcentration o f  AFBi-BSA conjugate
10 mM acetate buffer was prepared at a range o f incremental pH’s from 3.9 to 4.9. A 
solution o f 50 |ig/ml o f AFBi-BSA was prepared in acetate buffer at each pH. Each 
conjugate concentration was passed sequentially over an underivatised chip surface at 
5 (il/min for 2 minutes as described in section 2.20.1. The differing degree of 
preconcentration was measured by the response prior to the end of the injection for 
each conjugate solution at the various pH values. Following injection, the flow of the 
running buffer over the chip surface was sufficient to dissociate the electrostatic 
attraction between the protein and the CM-dextran gel surface. Figure 5.10 shows 
that an increase in preconcentration occurs at pH values below 4.1. The 
preconcentration studies showed the optimal pH for immobilisation of AFBi-BSA 
conjugate was 3.9 in 10 mM acetate buffer. This pH was thus used for all subsequent 
immobilisations.
5.2.2. Immobilisation o f  AFBi-BSA conjugate
EDC/NHS coupling chemistry was used for activation o f the CM-dextran gel surface 
for the immobilisation of AFBi-BSA conjugate, as described in section 2.20.2. 
Figure 5.11 shows a typical immobilisation sensorgram where 6,766 RU of AFBi- 
BSA conjugate was immobilised onto the sensor surface after capping with 1M- 
ethanolamine hydrochloride, pH 8.5. This deactivated any remaining NHS-esters, 
and eluted any non-covalently bound material.
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Figure 5.10. Preconcentration o f  AFB/-BSA conjugate onto a CM-dextran chip surface. 
Solutions o f  AFBi-BSA at 50 fig/ml in 10 mM acetate buffer at pH  increments between 3.9 
and 4.9 were passed over an unactivated CM-dextran surface at 5 jul/min fo r 2 minutes. The 
low ionic strength o f  the buffer used favours the electrostatic attraction between the 
negatively charged dextran layer and the positively charged protein (i.e. below the isoelectric 
point). The degree o f  ‘preconcentration ’ was measured from the response prior to the end o f  
each sample injection. The ionic strength o f  running buffer (150 mM NaCl) was sufficient to 
remove the electrostatically attracted conjugate from  the sensor chip surface. The optimal 
p H  for immobilisation o f  AFBr BSA onto the CM-dextran chip surface was calculated to be 
p H  3.9, and subsequently all immobilisations o f  AFB,-BSA were carried out in 10 mM  
acetate buffer, pH3.9.
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Figure 5.11. Immobilisation o f AFB/-BSA conjugate onto a CM-dextran chip surface:
1. HBS running buffer is passed over the chip surface and a baseline measurement is 
recorded.
2. After mixing, a solution containing 0.05 M  NHS and 0.2 M E D C  is injected over the chip 
surface to activate it. The large increase in SPR signal is mainly due to a bulk refractive 
index change.
3. An increase o f  approximately 200 RU is recorded following activation o f  the chip 
surface.
4. A solution containing 50 /.ug/ml o f AFBj-BSA conjugate in 10 mM acetate buffer (pH 3.9) 
is passed over the chip surface fo r  20 minutes.
5. The amount o f  bound conjugate adsorbed is recorded whilst most o f  the non-covalently 
bound protein is eluted.
6. Any remaining surface NHS-esters are deactivated by the addition o f 1 M  ethanolamine 
hydrochloride p H  8.5. This also elutes any non-covalently bound conjugate.
7. 6,766 RU o f  AFBi-BSA conjugate bound to the surface following the immobilisation 
procedure.
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5.2.3. Development o f  a SPR-based inhibition immunoassay fo r  AFBi
A number of parameters had to be optimised for the development of an inhibition 
assay for AFBi. These included removal of non-specific interactions, optimisation of 
antibody dilution for the assay, as well as effective regeneration conditions.
5.2.3.I. Regeneration conditions
Affinity-purified polyclonal anti-AFBi antibody was diluted to 1/100 in HBS running 
buffer and injected over the immobilised AFBi-BSA immobilised surface. Initial 
studies showed that the antibody bound to the toxin-protein conjugate with a high 
avidity, and very little dissociation of the antibody from the conjugate surface was 
observed. It was also found that regeneration of the antibody from the AFBi-BSA 
conjugate surface was not possible using HC1 or NaOH solutions. As a result of this, 
a regeneration solution consisting o f 1M ethanolamine with 20% (v/v) acetonitrile, 
pH 12.0, was used. An ELISA was initially carried out in order to determine the 
suitability o f this regeneration solution on an AFBi-BSA surface.
AFBi-BSA conjugate was coated onto wells of a microtitre plate, which were then 
blocked with 2% (w/v) casein protein. 100 (il/well of the affinity-purified polyclonal 
anti-AFBj antibody was then added to the wells, and incubated for 1 hour at 37° C. 
After washing, 100 (il of a range o f 1M ethanolamine solutions-containing varying 
percentages (v/v) of acetonitrile was added to appropriate wells, incubated for 10 
minutes at room temperature, and then aspirated. The affinity-purified polyclonal 
antibody was then added, followed by HRP-labelled anti-rabbit antibody and 
chromogenic substrate. The assay was then repeated with the regeneration solutions 
added to the plate after coating and before incubation with antibody. It could be seen 
that addition of increasing percentage-concentrations of acetonitrile (in the 1M 
ethanolamine solutions) resulted in increased regeneration, while pre-treatment of the 
conjugate surface did not significantly decrease the binding of polyclonal antibody at 
higher concentrations (Figure 5.12.).
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Figure 5.12. The effects o f regeneration with IM ethanolamine, pH  12.0, containing varying 
percentages (v/v) o f  acetonitrile on AFB/-BSA coated onto wells o f  a 96-well microtitre plate. 
Increasing concentrations o f  the regeneration solution were added to coaled wells before 
('Pretreatment') and after ('Regeneration') incubation with affinity-purified anti-AFB, 
antibody. The amount o f  bound polyclonal antibody was measured by ELISA, with addition 
o f  HRP-labelled anti-rabbit IgG. The results shown are the averages o f  five analyses.
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From the ELISA experiment, it was decided to use 1M ethanolamine with 20% (v/v) 
acetonitrile, pH 12.0, as the regeneration solution for removal of bound polyclonal 
antibody from the AFBi-BSA immobilised surface. A 2-minute pulse o f the solution 
at a flowrate of 10 |il/min was used, Although it was successful for regeneration of 
the surface, it did not remove all the bound antibody each time. However, the 
accumulation of this bound antibody did not significantly affect binding over a large 
number of injections. The efficiency o f the regeneration process was evaluated by 
performing multiple (i.e. 25) binding-regeneration cycles over the AFBi-BSA-coated 
surfaces (Figure 5.13.). The surface binding capacity o f the antibody oscillated 
slightly over the twenty-five cycles, but it did not significantly affect the performance 
of the assay.
Initial studies, using a 1/8 dilution in HBS o f scFv anti-AFBi antibody showed that it 
was easily regenerated from the AFBi-BSA immobilised surface using a 1-minute 
pulse of 10 mM NaOH. This completely removed all bound scFv antibody after each 
binding-regeneration pulse. As a result, it was not necessary to carry out an 
investigative ELISA to examine the efficiency o f regeneration using this regeneration 
solution. Figure 5.14 shows a graph of the reproducibility o f regeneration for the 
scFv antibody over fifty regeneration cycles. Binding of the scFv antibody to the 
conjugate surface was highly reproducible, with approximately 250 RU of antibody 
binding to the surface each time. The regeneration solution (10 mM NaOH) did not 
affect the binding throughout the regeneration study.
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Figure 5.13. Graph showing the reproducibility o f regeneration o f  a sensor chip immobilised 
with AFBi-BSA on the surface. Twenty-five consecutive regeneration cycles o f  a 4-minute 
binding pulse o f  polyclonal anti-AFBj were carried out. This was followed by a 2-minute 
injection o f  lM-ethanolamine containing 20%(v/v) acetonitrile p H  12.0, as the regeneration 
solution. Approximately 15% o f  the antibody bound remained on the surface after each 
regeneration cycle. This did not seem to significantly affect the reproducibility o f  the binding.
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Figure 5.14. Graph showing the reproducibility o f  regeneration o f  a sensor chip immobilised 
with AFBi-BSA on the surface. Fifty consecutive regeneration cycles o f  a 3-minute binding 
pulse o f  scFv anti-AFBj were carried out. This was followed by a 1-minute injection o f  10 
m M N aO H  as the regeneration solution. This completely removed all o f  the bound antibody 
after each binding cycle, which resulted in highly reproducible binding cycles, as no 
significant decrease in the measured binding response over the course o f  the regeneration 
study was observed.
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5.2.3.2. Assessment o f  non-specific binding
The degree o f non-specific binding o f the polyclonal and scFv antibodies to both the 
dextran layer, and the immobilised BSA portion o f the toxin-protein conjugate, was 
assessed. This was carried out, by passing the respective antibody at the requisite 
dilution (1/100 for the polyclonal antibody, and 1/8 for the scFv antibody) over a 
blank CM-dextran surface, as well as an immobilised BSA surface as described in 
section 2.20.3. Figure 5.15 shows overlaid sensorgrams of the injection o f polyclonal 
anti-AFBi antibody over an AFBi-BSA immobilised surface, a BSA immobilised 
surface, as well as a CM-dextran layer. There was negligible non-specific binding of 
the antibody to the BSA protein (< 5RU). The antibody solution did not have to be 
pre-incubated with B SA  as all of the BSA binding antibodies were removed by 
subtractive-immunoaffinity chromatography. It was found that pre-incubation of the 
sample with 100 [ig/ml o f carboxy-methylated dextran (CM-dextran) removed all 
non-specific interactions to the CM-dextran surface. This was subsequently used in 
all antibody dilution preparations.
Figure 5.16 shows overlaid sensorgrams of the injection of scFv anti-AFBi antibody 
over an AFBj-BSA immobilised surface, a BSA immobilised surface, as well as a 
CM-dextran layer. A negligible amount of non-specific binding (<5 RU) was 
observed to the BSA and CM-dextran surfaces, and as a result the antibody solution 
did not have to be pre-incubated with either BSA or CM-dextran.
2 2 0
600
AFBr BSA surface 
BSA surface 
Dextran layer
Figure 5.15. Injection of a 1/100 dilution of affinity-purified polyclonal anti-AFB] antibody 
over immobilised AFB/-BSA conjugate, BSA, as well as a CM-dextran gel layer at 10 /ul/min 
for 4 minutes. A negligible amount of binding of the antibody to the BSA and dextran 
surfaces (< 5 RU) was observed using 100 jug/ml of CM-dextran in the diluent buffer, while 
368 RU of antibody bound to the immobilised AFB ¡-BSA conjugate surface. The differences 
in SPR signal are due to changes in the bulk refractive index of the antibody solution.
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Figure 5.16. Overlaid sensor grams showing binding of a 1/8 dilution of anti-AFB} scFv 
antibody to an AFBr BSA surface, BSA surface, and a CM-dextran gel layer, at 10 /jl/min for 
3 minutes. A negligible amount of binding of the scFv antibody to the BSA and dextran 
surfaces (< 5 RU) was observed, while 245 RU of antibody bound to the immobilised AFBj- 
BSA conjugate surface. The differences in SPR signal are due to changes in the bulk 
refractive index of the antibody solution.
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5.2.3.3. The determination o f  working range o f  model inhibition assay in PBS
For determination o f the working range o f the inhibition immunoassays for both the 
polyclonal and scFv antibodies, dilutions of AFB, were firstly prepared as described 
in section 2.10.1. Dilutions o f AFBi were prepared in PBS-5 % (v/v) methanol 
ranging from 0.75 to 98 ng/ml for the polyclonal antibody inhibition assays, and 3 to 
195 ng/ml for the scFv inhibition assays. The polyclonal affinity-purified antibodies 
were mixed with the corresponding dilution of AFBi using the autosampler on the 
BIAcore, and allowed to equilibrate for 10 minutes at room temperature. In the case 
o f the scFv antibodies, they were manually pre-mixed with the respective 
concentrations o f AFBi and allowed to incubate for 1 hour at 37° C, before being 
injected over the conjugate-immobilised surface. This was carried out, as it was a 
more economical method of using scFv antibody. The samples for both antibodies 
were passed over an immobilised AFBi-BSA surface in random order, and 
regenerated using the appropriate pre-determined regeneration solution.
A typical antibody binding response curve for the polyclonal anti-AFBi antibody is 
illustrated in Figure 5.17. The response was measured following the binding of 
unbound antibody from the equilibrated antibody: antigen mixtures. A standard 
curve was constructed by plotting concentration of free AFBi versus amount of 
unliganded antibody bound in response units (RU). Figure 5.18 shows the intra-day 
assay plot for the polyclonal affinity-purified anti-AFBi antibody. The assay had a 
range o f detection between 0.75 and 98 ng/ml. Table 5.1 shows the intra-day C.V.’s, 
which are the standard deviation expressed as a percentage of the mean. These varied 
between 3.5 and 13.6 %. In order to determine the inter-day coefficients of variation 
the assay was carried out on three different days, and the binding response of each 
antigen concentration was divided by the antibody response determined in the 
presence of zero antigen concentration (R/Ro). The mean o f these normalised results 
for each of three assays were plotted, and the C.V’s between them were calculated. 
Figure 5.19 shows the inter-day assay plot, with a range of detection between 0.75 
and 98 ng/ml. Table 5.2 shows the inter-day coefficients of variation for the assay, 
which range between 2.5 and 17 %.
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Figure 5.17. Overlaid interaction curves for various polyclonal antibody-AFB/ 
concentrations equilibrated in PBS. The measured binding responses for each concentration 
were used to construct a calibration curve. The antibody bound showed minimal dissociation 
from the sensor chip, and was regenerated using 1 M ethanolamine containing 20 % (v/v) 
acetonitrile, pH 12.0.
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Table 5.1. Intra-day coefficients of variation for polyclonal anti-AFBj antibody. Three sets 
of eight standards were run on the same day and the coefficient of variation (C. V. ’s) were 
calculated as the standard deviation (S.D.) expressed as a percentage of the mean values for 
each standard.
Aflatoxin Bj concentration 
(ng/ml)
Calculated mean ±  S.D. 
(RU)
Coefficient of variation
(%)
98.0 43.70 ±2.50 5.73
48.0 62.60 ±7.18 11.48
24.0 84.03 ± 7.64 9.09
12.0 110.66 ±3.96 3.58
6.0 134.90 ±6.23 4.62
3.0 168.46 ± 15.23 9.04
1.5 198.10 ± 21.07 10.64
0.75 214.03 ±29.04 13.57
AFB1 concentration (ng/ml)
Figure 5.18. Intra-day assay curve for AFBj in PBS using polyclonal anti-AFBj antibody. 
The range of detection for the antibody was between 0.75 and 98 ng/ml. The calibration plot 
was constructed using BIAevaluation 3.1 software package. The results shown are the 
average of triplicate measurements.
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Table 5.2. Inter-day coefficients of variation for polyclonal anti-AFBi antibody. Three sets of 
eight standards were run on three different days, and the measured binding responses were 
used to calculate the normalised binding response values. From these, the C. V. ’s were 
calculated as the standard deviation expressed as a percentage of the mean normalised 
values for each standard.
Aflatoxin Br concentration 
(ng/ml)
Calculated mean ± S.D. 
(R/Ro)
Coefficient of variation
(%)
98.0 0.18 ±0.03 17.02
48.0 0.25 ± 0.02 9.56
24.0 0.34 ±0.01 5.26
12.0 0.44 ±0 .02 5.61
6.0 0.56 ±0.00 1.43
3.0 0.72 ±0.01 2.50
1.5 0.82 ±0.03 3.63
0.75 0.91 ±0.03 3.61
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Figure 5.19. Inter-day assay curve for AFBj in PBS using polyclonal anti-AFBi antibody. 
The range of detection for the antibody was between 0.75 and 98 ng/ml. The calibration plot 
was constructed using BIAevaluation 3.1 software package. The results shown are the 
average of triplicate measurements.
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A typical antibody binding response curve for the scFv anti-AFBi antibody is 
illustrated in Figure 5.20. A standard curve was constructed by plotting concentration 
of free AFBi versus the amount o f unliganded antibody bound in response units 
(RU). Figure 5.21 shows the intra-day assay plot for the scFv anti-AFBi antibody. 
The assay had a range o f detection between 3 and 195 ng/ml. Table 5.3 shows the 
intra-day C.V.’s, which varied between 0.16 and 1.0 %. In order to determine the 
inter-day coefficients o f variation, the assay was carried out on three different days 
and the binding response o f each antigen concentration was normalised, plotted, and 
the C.V.’s between them were calculated. Figure 5.22 shows the inter-day assay plot, 
with a range o f detection between 3 and 195 ng/ml. Table 5.4 shows the inter-day 
coefficients o f variation for the assay, which ranged between 3 and 20 %.
Time (seconds)
Figure 5.20. Overlaid interaction curves for various equilibrated scFv antibody-AFBj 
concentrations in PBS. The measured binding responses for each concentration were used to 
construct a calibration curve. The antibody bound began to dissociate from the sensor chip 
immediately after the injection was completed. Regeneration of surface was carried out 
using 10 mMNaOH.
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Table 5.3. Intra-day coefficients of variation for scFv anti-AFBj antibody. Three sets of 
eight standards were run on the same day and the C. V. ’s were calculated as the standard 
deviation expressed as a percentage of the mean values for each standard.
Aflatoxin Bt concentration
(ng/ml)
Calculated mean ±  S.D.
(RU)
Coefficient of variation
(%)
195 31.06 + 0.32 1.03
98 42.46 + 0.40 0.95
48 64.26 ± 0.32 0.50
24 125.40 + 0.43 0.35
12 210.86 + 0.30 0.14
6 288.73 +0.81 0.28
3 312.43+0.50 0.16
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Figure 5.21. Intra-day assay curve for AFBj in PBS using scFv anti-AFBj antibody. The 
range of detection for the antibody was between 3 and 195 ng/ml. The calibration plot was 
constructed using BIAevaluation 3.1 software package. The results shown are the average of 
triplicate results.
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Table 5.4. Inter-day coefficients of variation for scFv anti-AFB/ antibody. Three sets of eight 
standards were run on three different days, and the measured binding responses were used to 
calculate the normalised binding response values. From these the C. V. ’s were calculated as 
the standard deviation expressed as a percentage of the mean normalised values for each 
standard.
Aflatoxin Bi concentration 
(ng/ml)
Calculated mean ±  S.D. 
(R/Ro)
Coefficient of variation
(%)
195 0.09 ±0.01 11.06
98 0.14 ±  0.01 12.39
48 0.27 ±0.05 19.95
24 0.53 ±0.02 4.01
12 0.79 ±0.02 3.5
6 0.89 ±0.03 3.95
3 0.96 ±0.03 3.35
1 10 100 1000 
AFB1 Concentration (ng/ml)
Figure 5.22. Inter-day assay curve for AFB] in PBS using scFv anti-AFBi antibody. The 
range of detection for the antibody was between 3 and 195 ng/ml. The calibration plot was 
constructed using BIAevaluation 3.1 software package. The results shown are the average of 
triplicate results.
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5.2.3.4. Detection o f AFBi in spiked grain samples
Spiked grain samples were prepared as described in section 2.10.3, and were applied 
in inhibition assays for both the affinity-purified polyclonal anti-AFBi antibody, and 
the scFv anti-AFBi antibody, as described in section 2.20.4.
The affinity-purified polyclonal antibodies were mixed with concentrations of spiked 
AFBi between 0 and 98 ng/ml using the autosampler on the BIAcore, and allowed to 
equilibrate for 10 minutes at room temperature. They were then were passed over an 
immobilised AFBi-BSA surface in random order, and regenerated using the 
appropriate pre-determined regeneration solution. Figure 5.23 shows a typical 
binding response curve for the affinity-purified polyclonal anti-AFBi antibody, where 
the amount o f unliganded antibody bound to the conjugate surface was measured. 
The range of detection of the polyclonal antibody for the detection of AFBi in the 
spiked grain samples was between 0.75 and 98 ng/ml. Figure 5.24 shows a graph of 
the intra-day assay variation, while Table 5.5 shows the percentage C.V.’s for the 
intra-day assay. These varied between 0.9 and 5.7 %. The assay was also 
reproducible on three separate days, and Figure 5.25 shows the inter-day assay 
variation, which also had a linear range o f detection between 0.75 and 98 ng/ml. The 
inter-day C.V.’s were between 0.7 and 11.4 %, and these are shown in Table 5.6.
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Figure 5.23. Overlaid interaction curves for various equilibrated polyclonal antibody-AFBi 
concentrations in spiked grain samples. The measured binding responses for each 
concentration were used to construct a calibration curve. The antibody bound showed 
minimal dissociation from the sensor chip, and was regenerated using 1 M ethanolamine 
containing 20 % (v/v) acetonitrile. pH 12.0.
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Table 5.5. Intra-day assay coefficients of variation in grain samples spiked with AFBj using 
affinity-purified polyclonal anti-AFBi antibody. Three sets of eight standards were run on 
the same day and the C. V. ’s were calculated as the standard deviation expressed as a 
percentage of the mean values for each standard
Aflatoxin Bt concentration 
(ng/ml)
Calculated mean ±  S.D. 
(RU)
Coefficient of variation
(%)
98.0 49.16 ±2.45 5.00
48.0 74.96 ± 4.29 5.73
24.0 89.40 ±2.95 3.30
12.0 112.50 ±3.22 2.86
6.0 136.80 ±3.93 2.88
3.0 166.93 ±1.55 0.93
1.5 224.20 ± 3.86 1.72
0.75 264.63 ±5.99 2.26
350
300
250
-  200 
CO
ËD
© 150 <0 c0
1  100
50
1 10 100 
AFB1 Concentration (ng/ml)
Figure 5.24. Intra-day assay curve for AFBt in grain samples spiked with AFBI using 
affinity-purified polyclonal anti-AFB] antibody. The range of detection for the antibody was 
between 0.75 and 98 ng/ml. The calibration plot was constructed using BIAevaluation 3.1 
software package. The results shown are the average of triplicate results.
Table 5.6. Inter-day coefficients of variation in grain samples spiked with AFB; using 
affinity-purified polyclonal anti-AFBj antibody. Three sets of eight standards were run on 
three different days, and the measured binding responses were used to calculate the 
normalised binding response values. From these the coefficient of variation (C. V. ’s) were 
calculated as the standard deviation expressed as a percentage of the mean normalised 
values for each standard.
Aflatoxin Bi concentration
(ng/ml)
Calculated mean ± S.D.
(R/Ro)
Coefficient of variation
(%)
98.0 0.15 ±0.009 6.28
48.0 0.24 ± 0.02 10.36
24.0 0.31 ±0.01 4.48
12.0 0.42 ±  0.02 6.20
6.0 0.49 ± 0.02 4.29
3.0 0.60 ± 0.06 11.44
1.5 0.77 ±0.006 0.77
0.75 0.94 ±  0.02 2.40
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Figure 5.25. Inter-day assay curve for AFBi in grain samples spiked with AFBi using 
affinity-purified polyclonal anti-AFBj antibody. The range of detection for the antibody was 
between 0.75 and 98 ng/ml. The calibration plot was constructed using BIAevaluation 3.1 
software package. The results shown are the average of triplicate results.
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The scFv anti-AFBi antibodies were manually pre-mixed with the respective 
concentrations of spiked AFBi and allowed to incubate for 1 hour at 37° C, before 
being randomly injected over the conjugate immobilised surface. Regeneration was 
carried out using the appropriate pre-determined regeneration solution. Figure 5.26 
shows overlaid interaction curves for various equilibrated scFv antibody-AFBi 
concentrations in spiked grain samples. The amount of unliganded antibody bound to 
the immobilised conjugate surface was measured, and this was used to construct a 
standard curve. Figure 5.27 shows the intra-day assay curve for the range detection 
for the scFv antibody. This was between 0.75 and 48 ng/ml, with percentage C.V.’s 
between 0.1 and 16.5 %. Inter-day variation studies were also carried out by running 
the assay on three separate days, normalising the results, and calculating the 
percentage C.V.’s between the assays. Figure 5.28 shows the inter-day assay curve 
with a range o f detection for the scFv antibody between 0.75 and 48 ng/ml. Table 5.8 
shows the percentage C.V.’s which varied between 3.7 and 11.8 %.
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0 ng/ml
Time (seconds)
Figure 5.26. Overlaid interaction curves for various equilibrated scFv antibody-AFB/ 
concentrations in spiked grain samples. The measured binding responses for each 
concentration were used to construct a calibration curve. The antibody bound began to 
dissociate from the sensor chip immediately after the injection was completed. Regeneration 
of surface was carried out using 10 mM NaOH.
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Table 5.7. Intra-day assay coefficients of variation in grain samples spiked with AFBj using 
scFv anti-AFBj antibody. Three sets of eight standards were run on the same day and the 
C. V. ’s were calculated as the standard deviation expressed as a percentage of the mean 
values for each standard.
Aflatoxin Bi concentration 
(ng/ml)
Calculated mean ±  S.D. 
(RU)
Coefficient of variation
(%)
48.0 39.93 ±2.57 6.44
24.0 46.36 ±7 .66 16.53
12.0 61.03 ±2.54 4.16
6.0 90.03 ±4.81 5.35
3.0 132.96 ±0.23 0.17
1.5 168.43 ±  10.73 6.3
0.75 194.43 ± 12.29 6.32
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Figure 5.27. Intra-day assay curve for AFB] in grain samples spiked with AFBt using scFv 
anti-AFB] antibody. The range of detection for the antibody was between 0.75 and 48 ng/ml. 
The calibration plot was constructed using BIAevaluation 3.1 software package. The results 
shown are the average of triplicate results.
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Table 5.8. Inter-day coefficients of variation in grain samples spiked with AFBj using scFv 
anti-AFB] antibody. Three sets of eight standards were run on three different days, and the 
measured binding responses were used to calculate the normalised binding response values. 
From these the C. V. 's were calculated as the standard deviation expressed as a percentage of 
the mean normalised values for each standard.
Aflatoxin Bi concentration 
(ng/ml)
Calculated mean ±  S.D. 
(R/Ro)
Coefficient of variation
(%)
48.0 0.19 ±0.007 4.13
24.0 0.24 + 0.01 7.47
12.0 0.33+ 0.04 11.83
6.0 0.44 ±0.01 4.06
3.0 0.67 + 0.02 3.58
1.5 0.84 ±0.03 4.63
0.75 0.93 ± 0.03 3.75
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Figure 5.28. Inter-day assay curve for AFB; in grain samples spiked with AFB/ using scFv 
anti-AFB i antibody. The range of detection for the antibody was between 0.75 and 48 ng/ml. 
The calibration plot was constructed using BIAevaluation 3.1 software package. The results 
shown are the average of triplicate results.
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5.2.4. Solution phase steady state affinity determinations
BIAcore was also used to determine the dissociation rate constant of the scFv anti-
• ~8AFBi antibody. A known concentration of scFv anti-AFBi antibodies (2.09 x 10 
M) were serially doubly diluted in HBS buffer, and passed sequentially over an 
immobilised AFBi-BSA conjugate surface. The binding responses obtained were 
used to construct a standard curve of antibody concentration (bound to the 
immobilised toxin-protein conjugate) versus response units, as described in section
2.20.5. This is shown in Figure 5.29. A known concentration o f scFv antibody (1/8 
dilution = 2.6125 x 10'9 M) was then mixed with serial doubling dilutions of AFBi 
ranging in concentration from 1.5 to 390 ng/ml (9.62 x 10‘12 to 6.25 x 10'7 M). These 
were allowed to attain equilibrium. Each equilibrium mixture was then injected over 
an immobilised AFBi-BSA conjugate surface, for the detection of 'unligated' scFv
anti-AFBi antibodies. The concentration of free scFv antibody at equilibrium was
determined by reference to the standard curve. The model described below was used 
to calculate the solution equilibrium dissociation constant
+ (3)
Where Bfree = Free concentration of scFv anti-AFBi antibody
A = Total concentration o f AFBi 
B =  Total scFv anti-AFBi antibody concentration 
Kd = Equilibrium dissociation constant
The equilibrium dissociation constant was calculated by constructing a plot of free 
scFv anti-AFBi antibodies versus AFBi concentration as shown in Figure 5.30. 
Equation (3), which describes the model for solution phase affinity assumes that the 
antibodies are monovalently bound, which is the case with an scFv antibody. The 
dissociation rate constant for this monovalent model was found to be, Kd = 6.91 x 10'8
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ScFv antibody concentration (M)
Figure 5.29. Serial doubling dilutions of scFv anti-AFB i antibodies of known concentration 
(M) were passed sequentially over an AFB/-BSA -coaled sensor chip surface. A calibration 
plot was constructed ofscFv anti-AFB/ antibodies (M) versus response measured (RU). The 
calibration plot was then used to calculate the concentration of free scFv antibody at 
equilibrium. The results shown are singlet measurements.
238
8e-9 T
co
c©oc
oo>»■Oon
C<0
©it
1e-9 1e-8 1e-7
A FBI Concentration (M)
1e-6 1e-5
Figure 5.301 Determination of overall solution equilibrium affinity constant between scFv 
anti-AFRi antibody and AFBj on an AFB/-BSA-coated chip surface. AFB/ concentrations 
were plotted against free scFv anti-AFBi antibody concentration, determined by reference to 
a calibration plot of scFv anti-AFBi antibodies. A 1:1 interaction model was used to 
describe the interaction, and fitted to the data set using BlAevaluation software, deriving an 
equilibrium dissociation constant of KD= 6,91 x ItT8 M, for the interaction between the scFv 
antibody and AFBThe model described in equation 3 fitted to the data does not describe the 
interaction particularly well as can be seen from the plot.
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5.2.5. Results summary
Table 5.9 gives a summary o f the results found in this chapter for both the polyclonal 
and scFv antibodies.
Table 5.9. Summary of the results obtained from the polyclonal and scFv anti-AFBi 
antibodies in the different BIAcore-based inhibition assay set-ups. It was not possible to 
calculate an equilibrium dissociation rate constant for the polyclonal antibody population 
because of its heterogeneous nature.
Inhibition assay-type Affinity-purified 
polyclonal anti-AFBi 
antibody
ScFv anti-AFBi antibody
Range of detection in 
PBS (ng/mi)
0.75 - 98 3 -1 9 5
Range of detection in 
spiked grain m atrix 
(ng/ml)
0.75 - 98 0.75 - 48
Equilibrium  dissociation 
rate constant (KD) (M)
N/A 6.91 x 10‘8
2 4 0
5.3. Discussion
In order to achieve a successful immobilisation of toxin-protein conjugate onto a CM- 
dextran gel surface, it is essential to maximise the interaction between the CM- 
dextran and the conjugate (AFBi-BSA). When the pH is greater than 7, the CM- 
dextran surface has a net negative charge (negatively charged carboxyl groups), and 
proteins at pH values below their isoelectric point (pi) will have a net positive charge 
(protonated amine groups). As a result, the positively charged protein will be 
electrostatically attracted to the negatively charged CM-dextran layer. Low ionic 
strength buffers such as 10 mM sodium acetate are employed for protein 
immobilisation procedures as they favour such electrostatic interactions. As a result, 
a ‘preconcentration’ step has to be carried out in order to maximise this interaction 
for subsequent immobilisation procedures. For the native form of a protein such as 
BSA, preconcentration can be facilitated by adjusting the pH below the isolectric point 
(BSA pi = 4.4). However, modification of proteins by, for example, conjugation to 
hapten molecules often radically alters the pi. Therefore, when dealing with modified 
proteins, the correct pH for preconcentration needs to be determined experimentally. 
The AFBt-BSA conjugate used had a relatively high substitution ratio of 7-10 
molecules o f AFBi for every BSA molecule. This resulted in the p i of the conjugated 
BSA molecule being reduced to less than 4.4, as there were fewer positively charged 
amines available on the protein for preconcentration onto the negatively charged 
dextran layer. Hence, the pH for optimal pre-concentration of the toxin-protein 
conjugate was lower. The pH at which the toxin-protein conjugate preconcentrated 
onto the dextran gel surface was 3 .9. This was indicative of a protein containing a high 
substitution ratio of hapten.
EDC/NHS coupling chemistry was used to immobilise AFBi-BSA conjugate onto the 
CM-dextran surface. Water-soluble carbodiimide EDC transforms surface carboxyl 
groups into active ester groups in the presence of NHS. The surface NHS esters are 
then available for reaction with amine groups on the hapten-protein conjugate. The 
reaction works best between pH 6 and 9, and its efficiency decreases rapidly below pH
4.5. Immobilisation o f AFBi-BSA conjugate needed to be carried out in acetate buffer
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pH 3.9, and, as a result, the immobilisation procedure was not optimal. However, on 
average, a sufficient amount of conjugate (between 4,000 -  8,000 RU) could be 
immobilised onto the sensor surface to allow for efficient analytical studies.
When designing SPR-based immunoassays, an important factor in their design is the 
regenerability o f  the sensor-chip surface in order to carry out multiple analyses. 
Ideally it should be possible to carry out fifty or more regeneration cycles on a given 
immobilised surface, and ligand-binding capacity should be maintained within 20 % 
of positive control values (Wong et a l, 1997). Regeneration studies were carried out 
on both the polyclonal and scFv anti-AFBi antibodies for binding to an immobilised 
AFBi-BSA conjugate surface.
Initial studies with the affinity-purified polyclonal anti-AFBi antibody indicated that it 
was difficult to remove, after binding to the AFBi-BSA conjugate surface using HC1 
and NaOH. It was not possible to completely regenerate the surface without affecting 
the binding capacity o f the immobilised conjugate. ELISA was used as a method to 
investigate the effects o f regeneration on immobilised conjugate. The use of a novel 
regeneration solution, consisting of 1M ethanolamine, 20% (v/v) acetonitrile, pH 12.0, 
was assessed in ELISA. This solution combined high ionic strength and extreme pH as 
well as chaotrophic properties. It was found to be previously successful for use in 
surface regeneration o f high affinity molecules (Quinn et al, 1999). The studies 
showed that this regeneration solution did not significantly affect the integrity of the 
conjugate surface, as well as that increasing concentrations o f acetonitrile in the 1M- 
ethanolamine solution removed increasing amounts of antibody from the surface.
The combined properties of this solution enabled successful regeneration, and 
facilitated consistent binding of the polyclonal antibody to the AFBi-BSA surface each 
time (Figure 5.13.). The regeneration solution did not seem to completely remove all of 
the bound antibody, although there was consistent binding of the antibody after each 
injection. This was probably due to the ‘higher-affmity’ antibodies in the 
heterogeneous solution o f polyclonal antibody that were more difficult to regenerate. 
The use of high salt concentrations and organic solvents as regeneration solutions could
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also have resulted in false signals, as contraction o f the dextran gel can sometimes 
occur, giving rise to inappropriate detector responses. It is significant for future 
biosensor applications that compatibility o f the immobilised-chip surface (even if 
limited) for organic solvents was demonstrated. Consequently, the possibilities for 
using small proportions of such solvents to aid solubility of analytes will extend the 
range of contaminants that could be covered.
Regeneration studies involving the scFv antibody showed that it was easily regenerated 
from the AFBi-BSA immobilised surface using a 1-minute pulse of 10 mM NaOH. 
The binding responses were highly consistent throughout the regeneration study with a 
variation o f binding o f approximately 8 %. There was no decrease in measured binding 
response throughout the study (i.e. cycle 1= 244.7, cycle 49= 244.3). The was probably 
due to pre-treatment o f the conjugate surface with twenty 1-minute pulses of 10 mM 
NaOH, which would have removed any loosely bound conjugate from the immobilised 
surface. As a result, when scFv antibody was injected over the conjugate surface, no 
leeching o f scFv antibody-conjugate complex from the surface was observed. 
Therefore, a decrease in binding signal was not observed throughout the regeneration 
study, and the binding-regeneration pulses were true to the signal observed.
Non-specific interactions between the polyclonal antibody and the BSA portion of the 
protein conjugate were minimal, as subtractive immunoaffinity chromatography (using 
a BSA column) was carried out on the antibody solution. This removed all BSA- 
binding antibodies. As a result BSA did not have to be incorporated into the diluent 
buffer. The addition o f CM-dextran to the diluent buffer ensured that there were no 
non-specific interactions to the CM-dextran surface. The scFv antibody displayed no 
non-specific binding to BSA or the CM-dextran gel surface. This is probably due to 
the fact that it is monoclonal in nature, and therefore recognises only one epitope, 
which is present o f the AFBi molecule.
After optimising the binding capacity and the degree of non-specific binding of both 
the polyclonal and scFv antibodies, the working range of detection of the BIAcore-
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based assays were then evaluated. A standard curve for the polyclonal antibody of the 
relative response against the aflatoxin Bi concentration is shown in Figure 5.19. The 
limit of quantification o f the assay was 0.75 ng/ml, and the assay had a detection range 
between 0.75-98.0 ng/ml. Each sample was analysed in triplicate and in random during 
all analyses. Intra-day variability of the assay was assessed by running three sets of 
standards on one day, and determining the coefficients o f variation between the 
calculated concentrations for each set of three. The C.V. values ranged from 3.58 to 
13.57%, and are shown in Table 5.1. Inter-day variability tests were also carried out, in 
which three sets o f standards across the linear range were assayed on three different 
days. The C.V.-values for this are shown in Table 5.2, and ranged from 2.5 to 17.02%. 
The limit of quantification for the assay using the scFv antibody was 3 ng/ml, with a 
range o f detection between 3 and 195 ng/ml (Figure 5.21). Intra-day and inter-day 
variability studies were carried out in the same manner as that for the scFv antibody. 
The intra-day C.V.’s were between 0.16 and 1.03 % (Table 5.3), while the inter-day 
C.V.’s were between 3.35 and 19.95 % (Table 5.4).
Both antibodies showed a high level of sensitivity for the detection o f AFBi, with the 
polyclonal antibody being slightly more sensitive (Limit of detection = 0.75 ng/ml) 
than the scFv antibody (Limit of detection = 3 ng/ml). The assays are also 
reproducible with good levels o f precision, and reproducibility. However, with both 
assays some of the C.V.’s are above 10 %. In the case of the polyclonal antibody the 
C.V.’s may have been higher due to the use of such a harsh regeneration solution. As 
mentioned previously, contraction of the dextran gel can sometimes occur with the use 
of such harsh regeneration solutions, and as a result may have given rise to more 
variable detector responses. However, the assay was reproducible over three days. The 
scFv showed very high intra-day degrees of precision with only the highest C.V. at 
1.03 %. This was probably a result of stringent pre-treatment of the immobilised 
surface prior to assay analysis, as well as that it was a very mild regeneration solution. 
This in turn gave rise to accurate binding responses during a given assay. The C.V.’s 
for the scFv inter-assay were slightly higher at certain points, indicating only a 
moderate degree o f reproducibility. Findlay et al. (2000) say that since the basis of
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immunoassays is the antibody-antigen interaction, they may be less precise than 
chromatographic techniques, and as a result, existing methods with respect to degrees 
of assay precision are too stringent. They recommend minimal acceptance limits of 20 
% (25 % at the limits of quantification) for precision profiles. Wong el al. (1997) 
describe the validation of an assay using BlAcore 2000 for the detection and 
quantification o f humanised monoclonal antibody in mouse serum. The assay was also 
designed to detect the presence of antibodies against the humanised antibody in the 
serum samples. They examined degrees of precision, accuracy, specificity, sensitivity, 
linearity, and ligand stability within the assay. They state that their acceptance criteria 
for validation is applicable to all biosensor-based immunoassays used to determine the 
concentration of an analyte, or to determine the presence o f antibodies capable of 
binding to that agent. In addition, they stated that results should be quantitated within 
20 % C.V. as a measure of precision. When taking these requirements into 
consideration, both assays shown in this chapter are within the required acceptance 
limits, and can be deemed reproducible.
The polyclonal and the scFv antibody were also used for the detection of AFBi in 
spiked grain samples, using BlAcore. The polyclonal antibody showed the same range 
of detection in spiked grain as that for PBS (0.75-98 ng/ml) with good degrees of 
precision (Intra-day C.V.’s: 0.93 -5.73 %) and also a high degree o f reproducibility 
(Inter-day C.V.’s: 0.77-11.44 %). The scFv antibody was more sensitive for the 
detection of AFBi in grain samples compared to the model PBS assay, with a detection 
range between 0.75 and 48 ng/ml. The assay also showed good levels of precision 
(Intra-day C.V.’s: 0.17-16.53 %) and reproducibility (Inter-day C.V.’s: 3.75-11.83 %). 
Linskens et al. (1992) state that low concentrations o f methanol extraction solvent can 
enhance the performance of some assays, and hence this may give a possible reason for 
the scFv antibody being more sensitive for the detection of AFBi in grain samples. 
Van der Gaag et al. (1999) developed a BIAcore-based inhibition assay for the 
detection o f AFBi in spiked grain samples. They used a commercially available 
monoclonal antibody, and directly immobilised AFBi onto the sensor-chip surface. 
The assay could detect levels as low as 0.2 ppb (ng/ml). The assays shown in this
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chapter are not as sensitive as this, but are capable of detecting as low as the EU 
maximum residue level set for AFBi (3 ppb (ng/g)) in grain samples.
BIAcore was also used to determine the solution phase affinity constant of the scFv 
anti-AFBi antibody. The assay was based on the detection o f free unliganded scFv 
antibody after incubation with free drug concentrations of AFBi. The model describing 
the solution phase affinity assumed the antibodies were monovalently bound, which 
was the case with scFv antibodies. The equilibrium dissociation constant for the scFv 
antibody was KD = 6.91 x 10'8 M indicating the scFv antibody has a relatively high 
affinity constant.
5.4. Conclusions
Both of the polyclonal and scFv antibodies examined bound specifically to aflatoxin 
Bi-BSA with a high avidity. The use of organic solvents combined with high ionic 
strength was also assessed. This solution did not damage the conjugate surface, but it 
could not regenerate all of the different polyclonal antibodies in the given population. It 
was possible to develop an SPR-based inhibition immunoassay for both the polyclonal 
and scFv antibodies. These assays were then applied for the detection of AFBi in 
spiked grain samples. Both assay types showed a high level of sensitivity, being 
capable of detecting AFBi below the maximum residue levels designated by the EU. 
Solution-phase equilibrium analysis was also carried out on the scFv antibody 
demonstrating it had a high dissociation rate constant. The availability o f an ‘on-line’ 
antibody-based biosensors should have a significant impact on routine surveillance and 
analysis o f agri-food materials.
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Chapter 6
Synthesis of Organophosphate-Protein Conjugates and their 
Applications in Immunoassays
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6.1. Introduction
A pesticide is any substance used to control, repel, or kill any pest. Organophosphate 
(OP) pesticides were developed in the early nineteenth century, and since then they 
have been extensively used for the treatment of cotton, corn, wheat, and a large 
variety of other agricultural crops. Some of them are also administered orally to 
cattle for the control o f insect parasites. Others are used externally on cattle for the 
control of external parasites (e.g. Warble fly). OP’s are the most commonly used 
pesticides primarily because o f their low mammalian toxicity, they penetrate grain to 
a limited extent, and they decompose slowly in storage (Skerritt el al., 1992). 
However, a consequence of their widespread use in the agricultural industry is that 
OP’s are commonly detected as residues in a large number of food products, and 
therefore, there are growing concerns over possible adverse effects o f long term, low- 
level exposure to these compounds.
6.1.1. Organophosphate chemistry and structure
OP’s are distinguished by a central phosphorous atom and numerous side chains. A 
generalised structure is shown in the Figure 6.1 (a). The X on the structure is 
generally a leaving group of variable structure. Most of the pesticides are dimethoxy 
and diethoxy compounds. OP’s are usually categorised based on the atoms 
immediately surrounding the central phosphorous atom. Phosphates are the prototype 
for the entire class and are those compounds where all four atoms surrounding the 
phosphorous are oxygen (e.g. dichlorvos). A large number of the OP's have sulphur 
double bonded to the phosphorous in the place o f the oxygen. This is illustrated in 
Figure 6.1 (b). The X denotes the presence of an aromatic structure. Figure 6.1 (c) 
shows the structure o f pirimiphos, while Figure 6.1 (d) shows the structure of 
chlorpyrifos. Both o f these OP’s are commonly used on grain materials while in 
storage for processing into various products, and will be discussed in greater detail- 
later in the chapter.
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Figure 6.1. (a) Generic organophosphate structure, (b) Orgcinophosphate structure
showing sulphur bonded to the phosphorous, (c) Structure of the pirimiphos-methyl, which 
has an aromatic structure in place of the X. (d) Structure of chlorpyrifos, which also has an 
aromatic ring structure. (X= side chain specific for individual OP’s).
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6.1.2. Mode o f  action and toxicology
OP’s are metabolised in a similar way for insects as for mammals. Acetylcholine 
(ACh) is produced in nerve cells and allows the transfer of nerve impulses from one 
nerve cell to a receptor cell e.g. from a muscle cell to another nerve cell. When the 
nerve transmission is completed, an enzyme known as acetylcholinesterase (AChE) 
speeds up the breakdown of acetylcholine in order to stop the nerve transmission. 
OP’s render acetylcholinesterase inactive, and as a result the nerve transmission 
continues indefinitely. This causes a wide variety o f symptoms in mammals such as 
weakness or paralysis o f the muscle, which will eventually result in death. This is a 
particularly rapid process for insects. The inhibition of acetylcholinesterase results in 
over-stimulation o f the parts of the nervous system that contain acetylcholine. This 
mainly affects the para-sympathetic nervous system, as well as the central nervous 
system (O’ Malley, 1997).
In humans OP’s can be absorbed through the skin, inhaled, or digested. Skin 
absorption is a very slow process, and, therefore, significant absorption only occurs 
after prolonged exposure to the pesticide (Kamrin, 1997). However, if the skin is 
inflamed (e.g. if  one had dermatitis), absorption can happen significantly faster, as it 
is more susceptible to uptake of the pesticide.
OP’s vary considerably in their toxicity potency. The major determinant of potency 
is the binding affinity of the parent compound and/or its metabolic products for 
AChE. The binding affinity in-turn is determined by structural characteristics such as 
lability o f the P-X bond and overall hydrophobicity and steric characteristics of the 
molecule (Storm et al., 2000). P =0 compounds are generally more potent then P=S 
compounds. This is because o f the greater electronegativity o f the oxygen, which 
weakens the P-X bond, thereby enhancing binding to AchE.
OP’s are highly toxic by all routes o f exposure. Upon inhalation, the first effects are 
usually respiratory. The responses are quite allergic in nature, and therefore, 
common symptoms may include bloody or runny nose, coughing, chest discomfort,
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difficulty in breathing, and wheezing due to constriction or excess fluid in the 
bronchial tubes. Severe toxicity affects the central nervous system and the peripheral 
nervous system (Kamrin, 1997). Usually signs o f acute toxicity become noticeable 
when the normal activity o f acetyocholinesterase is reduced by one half. Death may 
occur if  enzyme activity falls to between 10-20% of normal functioning levels and 
may be caused by respiratory failure or cardiac arrest (Kamrin, 1997). Although 
hazardous, the majority of OP’s, with the exception of dichlorvos are not thought to 
be carcinogenic.
6.1.3. Environmental and ecological effects
The toxicity o f OP’s for birds varies from slight to highly toxic. However, the 
majority, such as dichlorvos and parathion are highly toxic to wild birds such as 
mallard ducks and pheasants. Fish also fall victim to the toxicity o f OP’s. The 96- 
hour lethal concentration 50 (LC50) of a number of OP’s in water is between 0.003- 
0.9 mg/1, showing that very low concentrations are required for dangerous levels to 
be reached.
The pesticides have a relatively short half-life under many field conditions, and 
therefore pose little threat to organisms found in soil or groundwater over a long-term 
period. Lakes and streams may be susceptible to pesticide ‘run-off if application 
occurs prior to rainfall. OP breakdown in water is only significantly achieved with 
high pH levels (Kamrin, 1997).
6.1.4. Pirimiphos and chlorpyrifos
Pirimiphos-methyl is generally used to treat grains post-harvest for pests such as rice 
weevil (Sitophilus orzyae), and red flour beetle (Tribolium castaneum) 
(Desmarchelier et ah, 1981). It is used to different extents in Australia, Europe, Asia, 
and North America, predominantly because of the different biological effectiveness 
against particular insects and mite species. It is one of the more persistent OP’s that 
remains during storage and cooking, as its mammalian toxicity is somewhat lower 
than other OP’s. Its LD50 in rats is 2000 mg/kg (Cremlyn, 1991). Pirimiphos is 
particularly effective against insects that have become resistant to organochlorine
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insecticides and malathion. It is fast acting and has both contact and fumigant action. 
The ethyl ester, pirimiphos-ethyl, is used as an insecticide in mushroom farms and 
greenhouses (Cremlyn, 1991).
Chlorpyrifos is a broad-spectrum OP, widely used for the control of various crop 
pests in soil and on foliage, household insects and animal parasites (Manclus et al., 
1994). These include cutworms, corn rootworms, cockroaches, and lice. It is also 
used on grain, cotton, field fruit, nuts and vegetable crops. The pesticide is poisonous 
both through skin contact and ingestion (Kamrin, 1997). It is moderately toxic to 
mammalian species but extremely toxic to a wide range of non-target aquatic 
organisms. Its toxicity is class II (moderately toxic), with a significantly lower LD50 
of 95-270 mg/kg compared to pirimiphos (Kamrin, 1997).
6.1.5. Detection o f  organophosphates
OP’s such as pirimiphos and chlorpyrifos are commonly found as residues in a large 
number of food products due to their wide use in the agricultural industry as 
insecticides and herbicides. This poses potential health hazards, and as a result, there 
is a requirement for monitoring and surveillance programs for these residues. 
Maximum residue limits for each pesticide in different products have been defined by 
the Codex Alimentarius Commission. However, individual countries and most 
companies usually prescribe ‘nil’ residue limits. This is usually understood to be 
<0.1 ppm (Skerritt etal., 1992).
6 .I.5 .I. Chromatographic techniques fo r  the detection o f  organophosphates
Chromatographic techniques have been the most common and reliable systems used 
for the detection of OP's in recent times. Although preparation time and sample 
clean-up procedures are time-consuming, they still offer a high level o f reliability and 
sensitivity for detection. Bottomly and Baker (1984) developed a multi-residue 
method for the determination o f a number of pesticides including pirimiphos in grain 
samples. The pesticides were extracted with acetone-methanol, and were separated 
from co-extractives by a partition process with dichloromethane and chromatography 
on an acidic aluminium oxide column. Quantitative determinations were made by a
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packed column gas-liquid chromatography using a flame photometric detector. The 
method gave 84% recovery of pirimiphos from fortified grain samples containing 
0. lmg kg _1 of the pesticide.
Grob & Kalin (1991) developed a modified gas chromatography (GC) method for the 
detection o f pesticides. It incorporated on-line Size Exclusion Chromatography-Gas 
Chromatography (SEC-GC). The method permitted automated integration of sample 
preparation into the GC analysis and eliminated the corresponding manual work. The 
method was suitable for analysing many strongly differing components at the same 
time, and because high molecular weight materials were removed, it allowed an on- 
column introduction into GC without contaminating the column inlet. This resulted 
in the development of a technique that was sufficiently sensitive for the analysis of 
pesticides.
The GC detectors used to analyse the organophosphates, such as flame photometric 
detectors and nitrogen/phosphorous detectors, are sensitive to phosphorous but are 
not specific to phosphorous. As a result they are prone to interferences from 
phosphorous containing compounds. Residues in cole crops such as cabbage and 
broccoli are particularly difficult to analyse (Stan & Kellner, 1989). This is because 
o f numerous volatile co-extractives containing nitrogen and sulphur that are found in 
the Brassica genus and are therefore sensed by these detectors. 31Phosphorous 
Nuclear Magnetic Resonance (31PNMR) can be used for the analysis of 
organophosphate pesticide residues (Mortimer & Dawson, 1991). The technique is 
useful, as extraction o f large samples and the prolonged use of NMR acquisition 
times are not required. Minimal clean-up of extracts was required, and samples only 
took 30 min for analysis. However, problems were observed with the influence of 
solvents on chemical shifts. This limited the number o f organophosphates that could 
be analysed using C D C I3 .
More recent chromatographic methods for the detection of OP’s include gas 
chromatography-pulse flame photometric detection-mass spectroscopy (GC-PFPD-
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MS). The PFMD indicates the exact chromatographic time of suspected peaks for 
their MS identification and then provides elemental information (Dagan, 2000). 
Automatic GC-MS analysis is another method used for the detection of OP’s. This 
entailed analysis o f a sample by GC, and if a suspect peak was observed, MS analysis 
was carried out to identify the peaks. However, it was found that GC-PFPD-MS was 
significantly more sensitive for the detection of OP’s compared to GC-MS (Dagan, 
2000).
GC is also useful for multi-residue analysis of pesticides in wine (Soleas et al., 2000). 
The method was capable o f simultaneous quantitation of 17 pesticides including 
chlorpyrifos. The widespread use of pesticides during grape production has led to a 
greater presence o f pesticide residues in wines, which are sold on the international 
markets. The method was capable of detecting pesticide levels as low as 2 p.g/1, with 
recovery from spiked samples greater than 80 %.
6.I.5.2. Immunoassay-based techniques fo r  the detection o f  organophosphates
The detection methods mentioned in section 6.1.5.1 usually have time-consuming 
clean-up procedures, with multiphase columns and several solvent manipulations. 
This has enhanced the need to develop more rapid and sensitive techniques for OP 
detection. Immunoassay technology offers an important tool for the development of 
such detection systems. It is possible to apply immunoassays directly to test portions, 
and hence quantitative data can be obtained significantly faster. They are relatively 
cheap to develop and can give very low degrees of sensitivity.
Solvent selection is one of the limiting factors in the development of immunoassays 
for pesticide detection, as antibodies generally work best in an aqueous environment. 
Most pesticides are only soluble in organic phases, or are only sparingly soluble in 
water. For the extraction of pesticides from solid foods, a variety of solvents have 
been tested, such as acetone, ether, petroleum ether, methanol, acetonitrile or hexane. 
Direct analysis o f extracts by immunoassay requires the use o f solvents that are 
miscible in water at low concentrations, as well as being non-denaturing to the
254
antibody. Immunoassays and antibodies tolerate solvents to different levels, and 
therefore, individual assays must be assessed for tolerance of varying concentrations 
of a given solvent (Dankwardt, 2000). Interference levels o f solvents must also be 
assessed by running appropriate controls and blanks in a given assay. Clean-up steps 
can also be introduced to reduce interference by separating the analyte o f interest 
from the matrix. This can be carried out by Cig columns or immunoaffmity 
chromatography (Aga et al., 1994; Marx et al., 1995). Strachan el al. (1999) 
developed a more novel way for antibodies to tolerate solvents. They produced scFv 
antibodies to the pesticide atrazine. They also found that stabilisation of the antibody 
fragment using an inter-domain disulphide bond significantly greatly improved its 
tolerance for solvent (i.e. methanol). This stabilised single chain antibody was 
referred to as a stAb. They found that the stAb’s could tolerate as much as 50 % 
(v/v) methanol in an assay, and up to 19 % (v/v) DMSO.
Radioimmunoassays (RIA’s) were some of the earliest immuno-based assays used for 
the detection of OP’s and pesticides in general. Ercegovich et al. (1981) developed a 
RIA for the detection of parathion, using polyclonal antibodies being raised to a 
parathion-BSA conjugate in rabbits. The assay had a lower limit of detection of 4 ng 
o f parathion in sample-free solutions, and between 10-120 ng in blood plasma and 
lettuce without any clean-up o f the sample extract.
ELISA’s have also been developed for the detection of OP’s. Coupling chemistries of 
the pesticide hapten to the carrier protein can influence the specificity and sensitivity 
o f an assay (M Adam  et al., 1992). Monoclonal and polyclonal antibodies were 
produced to the OP fenitrothion. It was coupled to the carriers through its phosphate 
group, which generated the most specific antibodies with the highest affinities (both 
monoclonal and polyclonal antibodies). The pesticide was also coupled via its 
aromatic nitro group following its reduction and amide formation with an adipic 
spacer arm. This produced monoclonal and polyclonal antibodies o f moderate 
affinity. This has led to the proposal that antibodies o f greater specificity and higher 
affinity were produced by conjugation of the pesticide through the thiophosphate
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group, as it exposed the functional groups unique to fenitrothion in the immune 
system. The antibodies generated could also detect fenitrothion in grain samples with 
a limit of detection of 3 ng (Hill et al., 1992).
Mc Adam & Skerritt (1993) developed a generic method for the production of a 
number of organophosphate conjugates (i.e. fenitrothion, chlorpyrifos-methyl and 
ethyl, and pirimiphos-methyl). It entailed the synthesis o f a bifunctional reagent that 
allowed coupling to carrier molecules through a derivatised phosphate ester. 
Immunoassays were successfully developed for these pesticides using the conjugates 
produced. The assays were highly sensitive with 3 ppb being detected for 
fenitrothion, 0.02 ppb for chlorpyrifos-methyl, and 0.2 ppb for pirimiphos (Skerritt et 
al., 1992). The antibodies used in these assays were also tested for reaction to other 
pesticides, as a variety of pesticides can be used to treat stored grain samples, in order 
to control different insects. They showed low levels of cross reactivity to other OP’s, 
indicating that the conjugation strategy used was successful for the development of 
highly specific antibodies.
Manclus et al. (1994) have also synthesised chlorpyrifos conjugates for the 
production o f monoclonal antibodies to chlorpyrifos. The conjugation strategy used 
here is simpler to that described by Mc Adam & Skerritt (1993). It entailed synthesis 
of a spacer arm on the aromatic ring by chlorine substitution. The assay developed 
was sensitive (limit o f detection = 1 .3  ng/ml) and specific for the detection of 
chlorpyrifos, with low levels o f cross reactivity to other OP’s.
Manclus and Montoya (1996) developed another assay for chlorpyrifos and for 3,5,6- 
trichloro-2-pyridinol (TCP). This is the major metabolite o f chlorpyrifos in water, as 
it undergoes chemical hydrolysis. TCP is charged at neutral pH, and, therefore, more 
leachable into groundwater and surface water than the parent molecule. Conjugate 
synthesis o f TCP was carried out in the same way as described by Manclus et al. 
(1994), except that once the activated chlorpyrifos hapten was synthesised, chemical 
hydrolysis was carried out to convert it to TCP (containing the activated spacer arm)
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(Figure 6.2). Monoclonal antibodies were produced to both haptens, with limits of 
detection in ELISA of 6 ng/ml for chlorpyrifos, and 0.034 ng/ml for TCP. The TCP 
assay was particularly useful, as no extraction steps or clean-up procedures were 
required for the analysis o f the environmental water samples.
ScFv antibodies have also been produced to chlorpyrifos (Alcocer et al, 2000(b)). 
Two chlorpyrifos hybridoma cell lines were used as the source o f immunoglobulin 
genes for the production of the recombinant scFv antibodies in E. coli. The cloning 
system was the same as that as described in Chapter 4. Functional scFv antibodies 
were detected without any prior selection, as the genes came from functional anti- 
chlorpyrifos hybridomas. The extended primer mix used (Rrebber et a l ,  1997) was 
also a factor in the success of the screening procedure. The scFv’s produced showed 
limits o f detection as low as their parental monoclonal antibodies (7 ng/ml).
SCH2CH2COOH
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Figure 6.2. Reaction scheme for the synthesis of chlorpyrifos hapten for the production of 
chlorpyrifos conjugates, as well as the reaction scheme for the synthesis o f 3,5,6-trichloro-2- 
pyridinol (TCP) hapten, the main transformation product of chlorpyrifos.
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Garrett et a l  (1997) produced scFv antibodies to the OP parathion. This was also 
produced from the genetic material o f a hybridoma cell line secreting anti-parathion 
monoclonal antibodies. The scFv and the parent monoclonal antibody showed 
similar characteristics when analysed in ELISA. The limits of detection for the 
monoclonal antibody and scFv-based ELISA’s were 1.6 and 2.3 ng/well, respectively. 
Both antibodies were also assessed by ELISA for stability in methanol extracted 
samples. The scFv antibody was stable in methanol concentrations up to 5 % (v/v), 
but this deteriorated in concentrations over 10 % (v/v). Similar results were found for 
its parent monoclonal antibody, indicating that scFv antibodies can be as useful as 
monoclonal (and polyclonal) antibodies for the detection o f food contaminants in 
samples.
6.I.5.3. Biosensor-based techniques fo r  the detection o f  organophosphates 
Piezoelectric-based biosensors have been used for the detection of the pesticide 
parathion (Ngwainbi et al., 1986; Horaceck et a l, 1998). Piezoelectric biosensors 
measure mass changes that result from antibody-antigen binding interactions. 
Piezoelectricity occurs when anistropic crystals are subjected to mechanical stress, 
causing the generation of an electric charge. If an AC voltage is applied to the 
resonance crystals, it results in oscillations. The optimal resonance frequency at 
which this takes place is dependent upon the mass at the crystal surface. The 
relationship between the change of mass at the crystal surface (Aw) and the change in 
the oscillating frequency (Af) is defined by the Sauerbrey equation.
A f= -K A m
Ngwainbi et a l  (1986) coated piezoelectric crystals with anti-parathion antibodies, 
which were used for detection of parathion in the gas phase. This caused a mass 
change on the crystals, and generated a frequency shift proportional to the 
concentration o f the pesticide. The antibodies could detect as little as 36 ppb of 
parathion in this assay format.
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Regeneration of these sensor surfaces is central to the development of biosensor- 
based assays, as it ensures the re-usability of a given surface. Horaceck et al. (1998) 
immobilised parathion to piezoelectric crystals using albumin and dextran as two 
different spacer/carrier molecules. However it was not possible to regenerate bound 
scFv from BSA-parathion-coated crystals. The dextran-parathion-coated crystals 
were easily regenerated using proteinase K. This is a useful regeneration solution, 
when not working with proteins on a sensor surface. In this case, the piezoelectric 
biosensor was actually used as an antibody characterisation tool, as opposed to a tool 
used for pesticide detection.
SPR-based biosensors have also been applied as a detection method for OP’s 
(Alcocer et a l, 2000(a)). Broad specificity polyclonal antibodies were produced 
against a group o f organophosphates using the hapten -  phosphonic acid (trans-4- 
phosphono-2-butenic acid; TPB) conjugated to keyhole limpet hemocyanin (KLH). 
The antibodies were used in a BIAcore-based inhibition assay for the detection of 
parathion using a parathion-BSA conjugate. The limit o f detection for the antibody in 
this assay format was 1.5 ng/ml, with good levels o f reproducibility.
Namera et a l  (2000) developed a direct colourmetric method for the detection of 
OP’s in urine. Many people die through suicidal ingestion of OP’s each year, and 
therefore rapid measurement of OP’s is important for the prompt medical 
management of suspected patients exposed to these compounds. The assay was 
based on detecting colour complexes, which resulted from reactions of OP’s and the 
chromogenic reagent 4-(4-nitrobenzyl)pyridine (NBP) in urine. NPB reacted with the 
thiophosphate group on the pesticide to form a purplish-blue colour. The coloured 
complex could then be determined spectrophotometrically. The detection limit for 
the assay in urine was 0.1-10 (ig/ml in urine. Approximately 27 OP’s were detected 
in urine samples using this method, including chlorpyrifos, which had a limit of 
detection of 0.3 [xg/ml.
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6.1.6. Chapter outline
This chapter describes the production of a pirimiphos hapten containing an amino 
group for conjugation to proteins. It also describes the production o f chlorpyrifos- 
BSA conjugates, their spectrophotometric characterisation, and application on 
BIAcore. A polyclonal anti-chlorpyrifos antibody preparation and a chlorpyrifos- 
dextran conjugate were obtained from collaborators at the Institute of Food Research, 
Norwich Research Park, Colney, Norwich, NR 4 7UA, U.K. These were used in a 
competitive ELISA for the detection of chlorpyrifos. An investigation of the 
development o f an inhibition-based BIAcore assay for the detection of chlorpyrifos, 
using this antibody population was also undertaken.
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6.2. Results
6.2.1. Pirimiphos hapten synthesis and characterisation fo r  conjugate production
6.2.1.1. Synthesis o f  amino-pirimiphos
Amino-pirimiphos was synthesised for use in the production o f pirimiphos-protein 
conjugates. Figure 6.3 shows the scheme of the reaction used. The two starting 
compounds for the reaction, 2-amino-4-hydroxy-6-methyl pyrimidin and dimethyl 
chlorothiophosphate, were purchased commercially. Sodium anhydride was used to 
treat 2-amino-4-hydroxy-6-methyl pyrimidin in order to deprotonate the H  from the 
OH group. This de-protonated hydrogen then formed hydrogen gas with the hydrogen 
from sodium anhydride. The deprotonated compound reacted with dimethyl 
chlorothiophosphate to form ‘amino-pirimiphos’. Chlorine was a by-product from 
the reaction and formed a salt with the sodium from sodium anhydride.
6.2.1.2. Nuclear magnetic resonance (NMR), and mass spectral analysis (MS) o f  
amino-pirimiphos
NMR analysis was carried out on the compound in order to confirm that the desired 
structure was synthesised. Figure 6.4 (a) shows the Hydrogen (H) NMR spectra of 
amino-pirimiphos, while Figure 6.4 (b) shows a structure o f amino pirimiphos with 
the hydrogen atoms labelled A-E corresponding to the peaks in Figure 6.4 (a). All of 
the peaks on the spectra can be correctly accounted for on the structure.
Carbon (C) NMR was also carried out on the compound to account for the correct 
number o f carbon atoms on the structure. Figure 6.5 (a) shows the C NMR spectra of 
amino-pirimiphos, and Figure 6.5 (b) shows the carbon atoms labelled on an amino- 
pirimiphos structures, which correspond to the peaks on Figure 6.5 (a). Once again 
all o f the peaks are correctly identified, indicating the desired synthetic reaction had 
occurred to produce amino-pirimiphos.
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Figure 6.3. Reaction scheme showing the synthesis of amino-pirimiphos. Sodium anhydride 
reacted with-2-amino-4-hydroxy-6-methylpyrimidin to de-protonate the hydrogen, which 
formed hydrogen gas with the H ' o f NaH. The deprotonated compound reacted with 
dimethyl chlorothiophosphate to form amino-pirimiphos with chlorine as a by-product. This 
formed a salt with the Na of NaH.
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Figure 6.4. (a) H NMR of amino-pirimiphos. All of the relevant peaks are labelled A-E. and 
correspond to the atoms labelled on the amino-pirimiphos molecule in Figure 6.4. (b).
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Figure 6.4. (h) Structure of amino-pirimiphos showing the corresponding hydrogen atoms on 
the H NMR in Figure 6.4 (a).
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Figure 6.5. (a) C NMR of am ino-p ir im iphos. All of the relevant peaks are labelled A-F, and 
correspond to the atoms labelled on the amino-pirimiphos molecule in Figure 6.5. (b).
Figure 6.5. (h) Structure of amino-pirimiphos showing the corresponding carbon atoms on 
the C NMR in Figure 6.5 (a)
MS analysis was carried out to confirm the correct molecular weight o f the 
compound, as well as to analyse it for the presence o f other partially synthesised 
products. Figure 6.6 shows the MS analysis o f  amino-pirimiphos. The two main 
molecular weight peaks identified are that for 249 Da, and 279 Da. The 249 Da peak 
corresponds to amino-pirimiphos, while the 279 Da peak indicates the presence of 
amino-pirimiphos intermediate compound.
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Figure 6.6. MS analysis o f amino pirimiphos molecule. The peak shown at 249 indicates the 
production o f the amino-pirimiphos molecule. The peak at 279 indicates the presence o f a 
higher molecular weight intermediate in the production o f amino-pirimiphos.
265
6.2.1.3. Diazonium coupling o f  amino-pirimiphos to BSA
Diazonium coupling of amino-pirimiphos to BSA was carried out as described in 
section 2.13.1, and the reaction scheme is shown in Figure 6.7. Briefly, amino- 
pirimiphos was activated in an acidified sodium nitrite solution to yield highly 
reactive diazonium ions. The activated diazonium ions then reacted with free amino 
groups on the protein to form a diazonium-coupled pesticide-protein conjugate. 
Conjugates containing diazonium bonds yield highly coloured complexes, and this is 
generally a good indication of whether the reaction was successful or not. In the case 
of amino-pirimiphos no change in the colour of the reaction mixture occurred. Figure 
6.8 shows spectrophotometric analysis o f BSA, diazo-coupled amino-pirimiphos and 
pirimiphos. The scan of the diazo-coupled amino-pirimiphos shows only one 
shoulder at 280 nm similar to that o f the BSA scan. This indicated the reaction was 
definitely unsuccessful, as a second shoulder would have been observed at 
approximately 310 nm for pirimiphos.
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Figure 6.7, Reaction scheme for the production of diazo coupled amino-pirimiphos-BSA 
conjugate as described in section 2.13.2.
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Figure 6.8. Spectrophotometric scan of (A) BSA, (B) Diazo coupled amino pirimiphos-BSA, 
(C) Pirimiphos. Comparison of amino-pirimiphos-BSA with BSA shows similar scans. The 
line on scan (B) is at 310 nm i.e. the optical density of pirimiphos (C). This indicates the 
conjugation was unsuccessful\ as a distinctly larger shoulder should he present on the 
conjugated scan beside the protein peak at 280 nm, which would indicate linkage of amino- 
pirimiphos to BSA.
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6.2.2. Development o f  an enzyme-linked immunosorbent assay fo r  chlorpyrifos 
Polyclonal anti-chlorpyrifos anti-sera and a chlorpyrifos-dextran conjugate were 
obtained from collaborators at the Institute of Food Research, Norwich, U.K. The 
anti-sera was purified and used for the development of a competitive ELISA for the 
detection of chlorpyrifos. An investigation of the development o f an inhibition-based 
BIAcore assay for the detection of chlorpyrifos, using this antibody population was 
also undertaken.
6.2.2.1. Purification and characterisation o f  polyclonal anti-chlorpyrifos antibodies 
from  serum
The serum was initially purified by saturated ammonium sulphate precipitation as 
described in section 2.5.1. It was further purified by protein G affinity- 
chromatography as described in section 2.5.2. IgG bound to the protein G column 
and was eluted after washing, by addition of glycine buffer. The presence of 
antibody in the collected fractions was monitored by determining absorbance at 280 
nm. A typical elution profile for the serum is shown in Figure 6.9. Fractions 2-13 
contained protein with absorbances above 0.37 nm, and these were deemed 
acceptable for collection. The samples were then pooled and dialysed overnight in 
order to remove any remaining ammonium sulphate, as well as adjust the pH to 7.0.
The purity o f the polyclonal antibody preparation was assessed by SDS-PAGE as 
described in section 2.7. The antibody preparation was electrophoresed under 
reducing conditions, with appropriate molecular weight markers. The presence of 
two single bands representing the heavy and light chains on the gel were used to 
assess the purity o f the antibody sample. Figure 6.10 shows the gel. One band is 
observed below the 48.5 kDa markers, indicating the presence of the heavy chain. 
However, the light chain is not visible on the sample, as it would be expected to be 
visible just below the 26.6 kDa marker. The figure does demonstrate, however, 
purification steps have worked effectively.
268
1.2
as
©00fS
e
-c
10
Fraction Number
15 20
Figure 6.9. Typical elution profile for polyclonal anti-chlorpyrifos antibody preparation 
from a 1 ml protein G affinity column. Saturated ammonium sulphate precipitated sample 
was passed through the column, followed by 20 column volumes of wash buffer. Bound 
antibody was then eluted using 0.1 M glycine, pH 2.7. 0.5 ml fractions were collected, and 
the protein content was measured by absorbance at 280 nm. Fractions 2-13, inclusive, were 
pooled as they contained the greatest proportion of anti-chlorpyrifos antibodies.
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26.6 kDa
Figure 6.10. SDS-PAGE showing (B) affinity-purified polyclonal anti-chlorpyrifos 
antibodies. The sample was electrophoresed under reducing conditions. Lanes A and C 
contained markers consisting of a.2 macroglobulin (180 kDa), J3 galactosidase (116 kDa), 
fructose-6-phosphate kinase (84 kDa), pyruvate kinase (58 kDa), fumarase (48.5 kDa), lactic 
dehydrogenase (36.5 kDa), and triosephosphate isomerase (26.6 kDa). The purified sample 
in lane B has one band below the 48.5 kDa markers, consistent with the presence of the heavy 
chain. The light chain at 25 kDa, however, is not visible on the gel.
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6.2.2.2. Determination o f  working dilution o f  antibodies in a competitive ELISA 
fo r  chlorpyrifos
A checkerboard ELISA was carried out as described in section 2.11.2 in order to 
determine the optimal antibody dilution and conjugate concentration for use in 
competitive ELISA. Rows of wells o f a 96-well microtitre plate were coated with 
concentrations o f chlorpyrifos-dextran ranging from 0 to 100 (ig/ml, and blocked with 
2 % (w/v) milk powder. Dilutions of the purified polyclonal anti-chlorpyrifos 
antibodies from 1/100 to 1/100,000 were prepared and added to the plate. After 
incubation, enzyme-labelled anti-rabbit antibody was added followed by 
chromogenic substrate. Figure 6.11 shows the overlaid titre curves obtained from the 
anti-chlorpyrifos antibodies. The antibody dilution that gave half the maximum 
absorbance was chosen, and the lowest conjugate concentration that provided 
sufficiently high absorbances was chosen. Therefore, 50 |ig/ml o f chlorpyrifos- 
dextran conjugate, and 1/600 dilution o f antibody were chosen as the parameters for 
use in the competitive ELISA.
6.2.2.3. Methanol concentration optimisation
Chlorpyrifos is a very hydrophobic molecule. Therefore, it was essential to 
incorporate methanol into the free pesticide standards. The limit o f detection of the 
antibody for chlorpyrifos can depend on the maximum amount of methanol the 
antibody and assay will tolerate. For this reason a competitive assay for chlorpyrifos 
was optimised using different methanol concentrations o f 5, 10, 20, and 30 % (v/v). A 
competitive assay was carried out using chlorpyrifos standards ranging from 20 to 
25,000 ng/ml with the four different methanol concentrations. Three of the 
concentrations-10, 20, and 30 % (v/v) methanol appeared to reduce the inhibitory 
effects of the free chlorpyrifos in the assay (Figure 6.12), while 5 % (v/v) o f methanol 
did not seem to have as much of an effect. Therefore, 5% methanol was used for 
subsequent work.
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Figure 6.11. Determination of optimal conjugate loading density and antibody dilution. 
Wells of a microtitre plate were coated with chlorpyrifos-dextran conjugate at a range of 
concentrations between 0 and 100 pg/ml. Serial doubling dilutions of the affinity-purified 
anti-chlorpyrifos antibody were carried out and then added to the plate as described in 
section 2.11.3. The optimal conjugate concentration chosen was 50 ¡ig/ml, and the optimal 
antibody dilution (i. e. the one that gave half the maximum absorbance) was 1/600.
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Figure 6.12. Competition ELISA for chlorpyrifos to determine the optimum methanol 
concentration for use in ELISA. Chlorpyrifos standards ranging from 20 to 25,000 ng/ml 
were prepared in methanol concentrations of 5, 10, 20 and 30 % (v/v) in PBS. 5 % (v/v) 
methanol appeared to have the least effect on the assay, although it was not suitably 
sufficient to maintain pesticide solubility above 1000 ng/ml. This can be seen from the graph, 
where the absorbances drop after this concentration.
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6.2.2.4. Competitive ELISA  fo r  the detection o f  chlorpyrifos
A series o f standards o f chlorpyrifos ranging in concentration from 49-25,000 ng/ml 
were prepared as described in section 2.10.2. 50 |il of each o f these standards were 
then added to a chlorpyrifos-dextran-coated plate (section 2.11.3). 50 (il/well o f the 
affinity-purified anti-chlorpyrifos antibodies, were prepared at a 1/300 dilution (final 
dilution o f 1/600) and added to the plate. After incubation and washing, enzyme- 
labelled anti-rabbit antibody was added followed by chromogenic substrate. The 
linear range o f detection for the antibody population was 49 to 25,000 ng/ml. For 
intra-day assay variation, each concentration was assayed five times on the one day 
and the mean absorbance of bound antibody for each antigen concentration was 
plotted versus antigen concentration. Figure 6.13 shows the intra-day assay linear 
range of detection for chlorpyrifos. Table 6.1 shows the C.V.’s for the assay. Intra­
day percentage C. V. ’s for the calibration plot o f the assay were all below 7.3 %.
The inter-day assay variation was calculated by performing the assay over five 
separate days, and a separate calibration curve plotted for each normalised 
absorbance (absorbance/zero absorbance (A/Ao)) value versus the respective 
chlorpyrifos concentration for each assay carried out on each day. The normalised 
mean values for the assay were calculated and plotted as one assay. Figure 6.14 
shows the inter-day variability assay for the affinity-purified anti-chlorpyrifos 
antibody preparation. The percentage C.V.’s for the assay are shown in Table 6.2, 
and are all less than or equal to 10 %.
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Table 6.1. Intra-day assay coefficients of variation for the determination offree chlorpyrifos 
using affinity-purified anti-chlorpyrifos antibody. Five sets of ten standards were assayed the 
same day, and the C. V. ’s were calculated as the standard deviation (S.D.) expressed as a 
percentage of the mean values for each standard.
Chlorpyrifos concentration 
(ng/ml)
Calculated mean ± S.D. Coefficient of variation
(%)
25,000 0.200 ±0.014 7.26
12,500 0.218 ±0.007 3.21
6,250 0.266 ±0.007 2.87
3,125 0.332 ±0.020 6.15
1,563 0.403 ±0.015 3.76
781 0.488 ±0.031 6.44
391 0.559 ± 0.027 4.92
195 0.651 ±0.014 2.26
98 0.674 ±0.001 0.23
49 0.742 ± 0.035 4.75
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Figure 6.13. Intra-day assay variation for competitive ELISA for chlorpyrifos using affinity- 
purified anti-chlorpyrifos antibodies. The linear range of detection was 49.0 to 25,000 
ng/ml. The error bars on each calibration point indicate the standard deviation of the mean 
of five measurements.
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Table 6.2. Inter-day assay coefficients of variation for the determination offree chlorpyrifos 
using affinity-purified anti-chlorpyrifos antibody. Five sets of twelve standards were assayed 
on five different days, and the C. V. ’s were calculated as the standard deviation expressed as 
a percentage of the mean normalised values for each standard.
Chlorpyrifos concentration 
(ng/ml)
Calculated mean ± S.D. Coefficient of variation
(% )
25,000 0.316 ±  0.010 3.42
12,500 0.361 ±0.036 10.07
6,250 0.400 ±0.021 5.35
3,125 0.482 ±0.024 5.10
1,563 0.594 ±  0.028 4.80
781 0.702 ± 0.037 5.38
391 0.814 ±0.021 2.63
195 0.927 ±0.035 3.79
98 0.981 ±0.038 3.94
49 1.079 ±0.027 2.57
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Figure 6.14. Inter-day assay variation for competitive ELISA for chlorpyrifos using affinity- 
purified anti-chlorpyrifos antibodies. The linear range of detection was 49.0 to 25,000 
ng/ml. The error bars on each calibration point indicate the standard deviation of the mean 
of five measurements.
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6.2.2.5. Cross reactivity studies
Cross reactivity studies were carried out on the antibody population to six other OP’s, 
as described in section 2.11.5. Standard curves for each o f the pesticides were 
produced as described previously in 6.2.2.6 . The results were normalised and plotted. 
The slope o f the line o f the standard curve for each OP was expressed as a percentage 
o f the slope o f the line for binding to chlorpyrifos. Table 6.3 shows the cross 
reactivity o f  the affinity-purified anti-chlorpyrifos antibody population. The antibody 
was very cross-reactive to parathion and fenitrothion, and less reactive to mevinphos. 
However, it showed negligible recognition for the OP’s, carbophenethion, and 
etrimfos.
Table 6.3. Cross-reactivity of affinity-purified anti-chlorpyrifos antibody observed to six 
other organophosphates. Standard curves were produced for each of the organophosphates 
in the same way as that for chlorpyrifos. Each concentration for each point on the standard 
curve was assayed in triplicate and the means plotted and normalised in order to construct 
standard curves.
Pesticide %  Cross reactivity
Chlorpyrifo s-methyl 100
Parathion 50
Fenitrothion 50
Carbophenethion 0.5
Mevinphos 25
Etrimfos 1
Dichlorvos 5
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6.2.3. Production and characterisation o f  chlorpyrifos-BSA conjugates 
The structure o f chlorpyrifos was modified in order to place a spacer arm on it for 
conjugation to proteins such as BSA. Figure 6.2 shows the reaction scheme for the 
synthesis o f this modified chlorpyrifos hapten. Two chlorpyrifos-BS A conjugates 
were produced, one with a 25 molar (M) excess o f pesticide per molecule of BSA and 
one with a 50 M  excess of pesticide per molecule of BSA. Figure 6.15 shows the 
spectrophotometric scans of both o f the pesticide-protein conjugates. Conjugation 
was successful in both cases, with shoulders at 280 nm (representing the protein- 
BSA) and at 310 nm representing chlorpyrifos. The presence of both of these 
shoulders indicated the conjugation had worked. The conjugate concentrations, and 
the substitution ratios o f pesticide molecules: protein molecules was calculated 
spectrophotometrically, and these are shown in Table 6.4. The 50 M excess 
conjugate was calculated to have 27 pesticide molecules per BSA molecule, while the 
25 M  excess conjugate had 6  pesticide molecules per BSA molecule.
Both conjugates were also analysed by competitive ELISA, using a conjugate coating 
concentration o f 50 (ig/ml, and a 1/600 dilution of the affinity-purified anti- 
chlorpyrifos antibody. The free chlorpyrifos standards ranged from 49 to 25,000 
ng/ml. Figure 6.16 shows a graph o f the competition ELISA’s using both conjugates. 
No competition was observed in the assay using the 25 M excess conjugate. 
However, competition was observed in the assay using the 50 M excess of conjugate.
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Figure 6.15. UV spectra of (A) chlorpyrifos-BSA conjugate containing a 50 M excess of 
pesticide, (B) chlorpyrifos-BSA conjugate containing a 25 M excess of pesticide. The 
absorbance at 320nm was read and used to calculate the chlorpyrifos concentration of the 
conjugates.
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Table 6.4. Characterisation of two chlorpyrifos-BSA conjugates, with 50 and 25 molar excess 
of pesticide to BSA. This table shows the conjugate concentration and the coupling ratio of 
pesticide-protein. These results were calculated in duplicate.
Conjugate Conjugate Degree of conjugation
concentration BSA: Chlorpyrifos
mg/ml
Chlorpyrifos-BSA 25 M excess 7.4 1 : 6
Chlorpyrifos-BSA 50 M excess 2.13 1:27
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Figure 6.16. Competitive ELISA’s carried out using the two chlorpyrifos-BSA conjugates. No 
competition is observed with the 25 molar excess conjugate. However, competition was 
observed with the 50 molar excess conjugate.
 1 1 1 1
100 1000 10000 100000 
Concentration of free chlorpyrifos (ng/ml)
279
6.2.4. Development o f  an inhibition BIAcore-based immunoassay fo r  the detection 
o f  chlorpyrifos
6.2.4.1. Preconcentration studies o f  chlorpyrifos-BSA conjugates
10 mM acetate buffer was prepared at a range o f incremental pH’s from 3.9 to 4.5. A 
solution of 50 (ig/ml o f the 25 and 50 M excess chlorpyrifos-BSA conjugates was 
prepared in acetate buffer at each pH. Each conjugate concentration was passed 
sequentially over an underivatised chip surface at 5 |ol/min for 2 minutes as described 
in section 2.20.1. The differing degree of preconcentration was measured by the 
response prior to the end of the injection for each conjugate solution at the various pH 
values. Following injection, the flow of the running buffer over the chip surface was 
sufficient to dissociate the electrostatic attraction between the protein and the CM- 
dextran gel surface. Table 6.5 shows the degree of preconcentration in response units 
for each pesticide-protein conjugate. The studies showed the optimal pH for 
immobilisation o f 25 M excess chlorpyrifos-BSA conjugate was 4.5, and the optimal 
pH for immobilisation of 50 M excess chlorpyrifos-BSA conjugate was 3.9 (both in 
10 mM acetate buffer). These pH’s were thus used for all subsequent 
immobilisations.
6.2.4.2. Immobilisation o f  AFBi-BSA conjugates
EDC/NHS coupling chemistry was used for activation o f the CM-dextran gel surface 
for the immobilisation o f chlorpyrifos-BSA conjugates, as described in section
2.20.2. Table 6 .6  shows the number of response units of each respective conjugate 
immobilised after capping with lM-ethanolamine hydrochloride, pH 8.5. For the 25 
M excess conjugate, 5,283.8 RU of conjugate were immobilised, while for the 50 M 
excess conjugate 9,826.9 RU were immobilised.
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Table 6.5. Pre-concentration conditions for both conjugates. The highlighted response 
represents the optimum pre-concentration and coupling pH for the corresponding conjugate. 
For subsequent immobilisations the conjugate was immobilised onto the sensor surface in 
acetate buffer wing the corresponding pH.
pH 25 molar excess 
(RU)
50 molar excess 
(RU)
4.5 3728.9 1249.8
4.4 2465.4 514.1
4.3 2619.7 1007.2
4.2 1680.2 750.1
4.1 2988.0 983.9
4.0 2714.9 1317.4
3.9 801.3 2673.7
3.8 326.8 2343.4
Table 6.6. Table showing the number of RU immobilised for each conjugate. Both conjugates 
were immobilised onto individual flow cells on the sensor chip using conventional 
carbodiimide coupling chemistry as described in section 2.20.2.
Conjugate Immobilised conjugate
Response Units (RU)
25 molar excess 5283.8
50 molar excess 9826.9
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6.2.4.3. Regeneration conditions
Both chlorpyrifos-BSA conjugates were assessed for binding o f the affinity-purified 
anti-chlorpyrifos antibodies on BIAcore. Figure 6.17 shows a diagram o f the overlaid 
binding curves that were obtained after injecting the antibody ( 1/2 dilution) over both 
conjugate surfaces for 15 minutes at 5 (il/min. Binding to the 25 M excess conjugate 
resulted in 376.4 RU of antibody bound, while binding to the 50 M excess conjugate 
resulted in 183.6 RU binding. It was therefore decided to further use the 25 M excess 
conjugate for the optimisation of regeneration conditions, and development of an SPR 
inhibition-based immunoassay for chlorpyrifos.
Regeneration studies, using a 1/2 dilution in HBS of affinity-purified anti- 
chlorpyrifos antibody showed that it was easily removed from the chlorpyrifos-BSA 
(25 M  excess) immobilised surface using a 1-minute pulse o f 30 mM HC1. This 
completely removed all bound antibody after each binding-regeneration pulse. Figure 
6.18 shows a graph of the reproducibility of regeneration for the antibody over forty 
regeneration cycles. Binding of the polyclonal antibody to the conjugate surface was 
highly reproducible, with approximately 150 RU of antibody binding to the surface 
each time. The regeneration solution (30 mM HC1) did not affect the binding 
throughout the regeneration study.
6.2.4.4. Assessment o f  non-specific binding
The degree o f non-specific binding o f the polyclonal antibody to both the dextran 
layer, and the immobilised BSA portion of the pesticide-protein conjugate, was 
assessed. This was carried out, by passing a 1/2 dilution of the polyclonal antibody 
over a blank CM-dextran surface, as well as an immobilised BSA surface as 
described in section 2.20.3. Figure 6.19 shows overlaid sensorgrams of the injection 
of polyclonal anti-chlorpyrifos antibody over a BSA immobilised surface, and a CM- 
dextran layer. There was negligible non-specific binding o f the antibody to the BSA 
protein or the CM-dextran surface (< 5RU). The antibody solution did not have to be 
pre-incubated with BSA, as the antibodies were produced using a chlorpyrifos-KLH 
conjugate. As a result the antibody solution did not have to be pre-incubated with 
either BSA or CM-dextran.
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Figure 6.17. Overlaid binding curves for affinity-purified anii-chlorpyrifos antibody (1/2 
dilution) binding to a chlorpyrifos-BSA conjugate with a 25 M excess of pesticide, and a 50 
M excess ofpesticide. Binding to the 25 M excess conjugate resulted in 376.4 RU of antibody 
bound, while binding to the 50 M excess conjugate resulted in 183.6 RU binding. Both 
injections were carried out at a flowrate of 5 /jl/min for 15 min. The differences in SPR 
signal are due to changes in bulk refractive index of the antibody solution.
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Figure 6.18. Graph showing the reproducibility of regeneration of a sensor chip immobilised 
with chlorpyrifos-BSA (25 M excess) on the surface. Forty consecutive regeneration cycles 
of a 4-minute binding pulse of polyclonal anti-chlorpyrifos antibody were carried out. This 
was followed by a 1-minute injection of 30 mM HCl as the regeneration solution. This 
completely removed all of the bound antibody after each binding cycle, which resulted in 
highly reproducible binding cycles, as no significant decrease in the measured binding 
response over the course of the regeneration study was observed.
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Figure 6.19. Overlaid sensorgrams showing binding of a 1/2 dilution of affinity-purified 
anti-chlorpyrifos antibody to a BSA surface, and a CM-dextran gel layer, at 5 pl/min for 4 
minutes (for the dextran control) and 5 film in for the BSA control. A negligible amount of 
binding of the antibody vtm observed to the BSA and dextran surfaces (< 5 RU). The 
differences in SPR signal are due to changes in bulk refractive index of the antibody solution.
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6.2.4.5. Determination o f  working range o f  inhibition assay in PBS  
For determination o f the working range of the inhibition immunoassay for the 
affinity-purified anti-chlorpyrifos antibodies, dilutions o f chlorpyrifos were firstly 
prepared as described in section 2.10.2. Dilutions of chlorpyrifos were prepared in 
PBS-5 % (v/v) methanol ranging from 49 to 25,000 ng/ml. The antibodies were 
manually pre-mixed with the respective concentrations of chlorpyrifos and allowed to 
incubate for 1 hour at 37° C, before being injected over the conjugate-immobilised 
surface. This was carried out as it was a more economical method of using the 
antibodies. The samples were passed over the immobilised chlorpyrifos-BSA surface 
in random order, and the surface was regenerated using the 30 mM HC1. The 
response was measured following the binding o f unliganded antibody from the 
equilibrated antibody: antigen mixtures. A standard curve was constructed by 
plotting concentration of free chlorpyrifos versus amount o f unliganded antibody 
bound in response units (RU). Figure 6.20 shows the curves obtained from the 
inhibition assays using both chlorpyrifos-BSA conjugate i.e. the 25 and 50 M excess 
conjugates. It is apparent from these curves that no inhibition was observed in either 
case. It was not possible to pursue this work any further due to the limited supply of 
polyclonal anti-serum available from our collaborators.
286
1.2
1.0
0.8
¡ 0 ,
0.4
0.2
0.0
10
-Assay using 25 M conjugate 
Assay using 50 M conjugate
100 1000 10000 
Concentration of free chlorpyrifos (ng/ml)
100000
Figure 6.20. Inhibition BIAcare-based assays for the detection of chlorpyrifos using affinity- 
purified anti-chlorpyrifos antibodies and chlorpyrifos-BSA conjugates with 25 and 50 M 
excesses of pesticide. No range of inhibition wav observed for the antibody using either 
chlorpyrifos-BSA conjugate. The assays were repeated to ensure the result was correct.
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6.3. Discussion
It was intended to produce both polyclonal and scFv antibodies to the OP pirimiphos. 
Therefore, it was necessary to conjugate the pesticide to a carrier molecule such as 
BSA in order to elicit an immune response in an animal. Pirimiphos contains no 
suitable functional groups for conjugation to a protein or carrier molecule. As a 
result, a synthetic strategy for the production of a pirimiphos hapten containing a 
suitable functional group for conjugation was developed. An optimised method for 
the production of such a hapten was already developed (M° Adam & Skerritt, 1993). 
It involved the synthesis o f a bifunctional reagent that couples through the 
thiophosphate group of pirimiphos. This compound contained the characteristic 
phosphorous and sulphur atoms of organophosphates. However, the method for 
synthesising this compound was extremely time-consuming, and required the full­
time commitment and expertise o f an organic chemist to carry out the work. 
Therefore an alternative, less time-consuming procedure needed to be developed. 
This was done with the help o f two organic chemists (section 2.13.1). Therefore, the 
compound amino-pirimiphos was produced, by reacting the two compounds 2 -amino- 
4-hydroxy-6-methyl-pyrimidin, and dimethyl-chlorothiophosphate together (Figure 
6.3). The resulting compound- amino-pirimiphos contained an amino group (NH2) in 
the place o f the amino-diethyl group (N(CH2CH3)2) on the two position of the pyridin 
ring. The reaction was successful, and C & H NMR analysis was carried out to 
confirm its structure (Figures 6.4-6.5). Mass spectral analysis was also performed to 
confirm the correct molecular weight o f the compound. This provided additional 
evidence that the correct structure was synthesised. Figure 6 .6  shows the MS of the 
compound, and it can be seen that two peaks o f relatively equal intensity are present; 
one at MW = 249, and one at MW = 279. The 249 peak is that of amino-pirimiphos, 
while the 279 peak is a non-specific by-product of the reaction. Figure 6.21 shows 
the possible structure of this compound. One of the methoxy groups on the 
thiophosphate group may have cleaved off and reacted with the amino group to form 
an amino-methoxy group at that position. The intensity o f the peak also indicates that 
this compound is equally abundant as amino-pirimiphos, if  not greater.
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Figure 6.21. Structure of compound that may have been a non-specific by-product of the 
reaction (MW= 279) for the synthesis of amino-pirimiphos.
It was hoped, to couple the pesticide to the protein at the amino position by 
diazonium coupling. This reaction is outlined in Figure 6.7. The method involved 
the diazotization of amino-pirimiphos in acid with sodium nitrate. This approach was 
not successful as is evident from Figure 6.8. Initially it was thought solubility of the 
compound in acid was a problem, and therefore the acid concentration was increased 
significantly. However, the test reactions carried out revealed that harsh conditions 
were required to achieve successful conversion to the diazonium salt (data not 
shown). Addition of protein to such a solution would denature it, and might prevent 
its conjugation to the pesticide. One option was to isolate the diazonium salt prior to 
addition of the protein, and dissolve it in a less harsh solution. However, diazonium 
salts are highly reactive and dangerous when isolated. It is also thought that the 
presence of the two nitrogens on the ring structure, and the adjoining phosphorous, 
oxygen, and sulphur atoms had an electronegative effect on the amino group. As a 
result the amino group was not available for conjugation. Another reason why the 
diazonium-coupling reaction may not have worked was the predominance of the by -  
product shown in Figure 6.21. In this form the amino group was already substituted, 
and therefore not reactive for diazonium coupling.
Alternative approaches to activate the amino-pirimiphos compound were also carried 
out, such as nucleophilic attack of the amino group using electrophilic compounds
such as ethyl chloroacetate, and trifluoroacetic acid. It was thought these methods 
might work, as the ‘electron rich’ amino group would nucleophilically attack the 
‘electron deficient’ compounds like ethyl chloroacetate, and trifluoroacetic acid, 
forming an amide group (Figure 6.22), and HC1 as a by-product. However, attempts 
using both of these compounds failed to work. Once again it is thought that the 
presence of the two nitrogens on the ring structure, and the adjoining phosphorous, 
oxygen, and sulphur atoms had electronegative effect on the amino group.
Figure 6.22. Structure of pirimiphos hapten with an amide group.
After all o f these attempts to synthesise a conjugable form of the pesticide failed, it 
was then decided to terminate the project, given the amount o f time and energy that 
had already been spent on it. Instead, analysis of anti-chlorpyrifos polyclonal serum 
was carried out. This serum was obtained from collaborators at the Institute of Food 
Research, Norwich, U.K., (Section 6.1.6).
Purification o f the anti-chlorpyrifos serum was carried out by ammonium sulphate 
precipitation, and protein G affinity-chromatography. This worked effectively, with 
all o f the bound immunoglobulin eluting easily from the protein G column. The low 
pH of the glycine buffer did not affect the integrity o f the eluted immunoglobulins, as 
each fraction tube contained 2 M  Tris, which neutralised the pH of the eluted 
antibodies. It was not necessary to carry out subtractive immunoaffinity 
chromatography as the rabbit was immunised with a chlorpyrifos-KLH protein 
conjugate. As a result, the antibody population did not recognise dextran or BSA
290
conjugated to chlorpyrifos, and were thus used for analysis o f the antibodies. SDS- 
PAGE was also carried out on the antibody population in order to determine its 
purity. It showed a high degree of purity, as indicated by the presence of only one 
band on the gel. However, the electropherogram (Figure 6.10) shows that the light 
chain band at 25 KDa is not visible. This may be due to the high voltage denaturing 
the sample. The sensitivity o f the staining also may not have been sufficiently 
sensitive to stain the light-chain band.
The conjugate loading density o f chlorpyrifos-dextran was optimised for application 
in a competitive ELISA. It was necessary to optimise the antibody concentration for 
use in the assay, as too high an concentration would result in an excess of free 
antibody in solution, and therefore, would be only suitable for the detection of high 
concentrations of free antigen in solution. A checkerboard ELISA was carried out for 
the antibody as described in section 2.11.2. The antibody dilution used was 1/600 
with a conjugate loading density o f 50 fig/ml for the assay.
Due to the hydrophobicity o f chlorpyrifos it was also essential to optimise the 
methanol concentration in the free chlorpyrifos standards. This was important in 
order to obtain a balance between pesticide solubility and assay tolerance of the 
solvent. 5% (v/v) methanol was chosen as the optimum concentration. 
Concentrations above 5% (v/v) inhibited the competition assay and concentrations 
below 5% (v/v) would have been unsuitable to prepare the free chlorpyrifos 
standards.
A competition ELISA was optimised for the antibody population using these 
parameters. The antibody was relatively sensitive with a range o f detection between 
49 and 25,000 ng/ml. The limit o f detection for the antibody was 49 ng/ml. Inter­
day assay variation studies were carried out by analysing five sets of standards across 
the linear range on five different days and calculating the C.V.’s as the standard 
deviation expressed as a percentage o f the mean normalised values for each standard.
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The assay was reproducible over five different days, as the C.V.’s were within the 
acceptance limits o f less than or equal to 10 %. The assay also demonstrated good 
precision profiles (i.e. the quantitative measure of the variation between 
measurements, usually the C.V.’s versus the nominal concentration of analyte in the 
sample). Mc Adam & Skerritt (1993) developed an immunoassay for chlorpyrifos 
using a conjugate synthesised as described in section 6 .1.5.2. Monoclonal anti- 
chlorpyrifos antibodies were produced after immunisation with the conjugate. The 
antibodies produced had a limit of detection of 0.2 ppb (ng/ml) in ELISA. Manclus el 
al. (1994) developed an immunoassay for chlorpyrifos using monoclonal anti- 
chlorpyrifos antibodies. The limit of detection for the assay was 1.3 ng/ml. Both of 
these assays are significantly more sensitive than the assay developed here. 
However, the antibodies used were monoclonal, and therefore a homogenous 
population. Although monoclonal antibodies are not always more sensitive than 
polyclonal antibodies, they often can be, due to their high avidity for one particular 
epitope on a hapten. Skerritt et al. (1992) state that individual countries commonly 
prescribe nil residue limits i.e. <0.1 ppb of pesticide in grain samples. The 
sensitivity o f this polyclonal antibody population therefore needs to be optimised 
further in an ELISA set-up, if it were to be used for the detection o f chlorpyrifos in 
contaminated grain samples.
Cross-reactivity studies were also carried out on the antibody population as described 
in section 2.11.5. Table 6.3 shows the results of the studies. The antibody showed 
high degrees o f cross reactivity to parathion and fenitrothion, with some recognition 
for mevinphos. However, it showed negligible recognition for the two remaining 
OP’s, carbophenethion and etrimfos. The monoclonal antibodies produced by 
Skerritt et al. (1992) were highly specific, and did not detect many other 
organophosphates or pesticides from other chemical groups. The antibodies produced 
by Manclus et al. (1994) were also highly specific showing minimal specificity for 
the other OP’s. Once again, the reason for such specific antibodies was probably due 
to the fact that they were monoclonal, and therefore specific for only one epitope on 
the chlorpyrifos molecule. This epitope may be exclusive to the chlorpyrifos
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molecule, and does not share any similarity on the other OP’s. The polyclonal 
antibodies mentioned here were produced using a chlorpyrifos-KLH conjugate, which 
was conjugated in the same as described in Figure 6.2. This conjugation resulted in 
the thiophosphate part of the pesticide being exposed, which was not chemically 
modified in the reaction. This part of the molecule is common to all OP’s and 
therefore antibodies produced using this conjugate may recognise this part of the 
hapten, and therefore other OP’s. This was the case found here.
In order to develop an inhibition BIAcore-based assay for the detection of 
chlorpyrifos using the polyclonal antibodies, conjugates needed to be produced, as 
there was only a limited supply of the chlorpyrifos-dextran conjugate. BSA was 
chosen as the carrier molecule. Chlorpyrifos was chemically modified for conjugate 
production as described by Manclus et al. (1994) as shown in Figure 6.2. Two 
conjugates were produced, one with a 25 M excess of pesticide, and a second one 
with a 50 M excess o f pesticide. The objective o f synthesising two conjugates was to 
ensure the development of a sensitive SPR-based immunoassay, as sometimes over­
substitution of a conjugate radically alters its pi below 4.0. If this occurs, it can be 
difficult to immobilise the conjugate using EDC/NHS coupling chemistry. Both 
conjugations were successful, and the molar substitution ratio o f both conjugates was 
calculated. The 25 M excess conjugate had 6 pesticide molecules per BSA molecule, 
while the 50 M excess conjugate had 27 pesticide molecules per BSA molecule. 
These ratios were estimated spectrophotometrically, and therefore are not completely 
accurate for the calculation of actual ratios. However, they give good indications as 
to the substitution ratios, and it can be seen that limiting the molar ratio of pesticide 
did alter substitution. The conjugates were also analysed in a competition ELISA 
using the same parameters optimised for the competition ELISA using the 
chlorpyrifos-dextran conjugate. No competition was observed using the 25 M excess 
conjugate, while competition was observed using the 50 M excess conjugate. It may 
have been necessary to further optimise the assay using the 25 M  excess conjugate in 
order to observe competition. However, it was apparent from the A/Ao values of the
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assay that the antibodies did recognise the conjugate, thus showing the conjugate was 
suitable for antibody-binding interaction studies.
Preconcentration studies were carried out on the conjugates, in order to determine the 
optimal pH for immobilisation to the CM-dextran gel surface. The 25 M excess 
conjugate preconcentrated onto the surface at pH 4.5. This was expected due to the 
relatively low substitution ratio o f the conjugate, and thus a larger number of free 
amines were available for preconcentration onto the dextran gel surface. As a result 
the pi o f the protein was not radically changed. The 50 M excess conjugate 
preconcentrated on the dextran gel surface at pH 3.9. This was also as expected due 
to the high molar substitution ratio o f pesticide on the protein, and, therefore, fewer 
free amines available for preconcentration onto the dextran gel surface. This high 
substitution reduced the pi of the protein, and hence pH 3.9 was required for 
immobilisation. Both conjugates were sufficiently immobilised onto the dextran gel 
surface, with 5,283.8 RU of the 25 M excess being immobilised, and 9,826.9 RU of 
the 50 M excess being immobilised.
In order to determine which pesticide-protein conjugate was the most suitable for use in 
the development o f an SPR-based immunoassay, an antibody-binding saturation curve 
analysis was carried out on both conjugates using the affinity-purified anti-chlorpyrifos 
antibody. Figure 6.17 shows the overlaid binding curves obtained. Binding to the 25 
M excess conjugate resulted in 376.4 RU of antibody bound, while binding to the 50 
M excess conjugate resulted in 183.6 RU binding. As a result, the 25 M excess 
conjugate was subsequently used for the development o f the assay.
Regeneration studies involving the affinity-purified anti-chlorpyrifos antibody 
showed that it was easily regenerated from the chlorpyrifos-BSA immobilised surface 
using a 1-minute pulse o f 30 mM HC1. The binding responses were consistent 
throughout the regeneration study (approximately 150 RU binding each time) with a 
variation of binding well within the 20 % limit as mentioned in Chapter 5. Pre­
treatment of the conjugate surface with ten 1-minute pulses o f 30 mM HC1, removed
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any loosely bound conjugate from the immobilised surface and therefore reduced 
leeching of antibody: conjugate complex from the surface giving regeneration. A 
significant decrease in binding signal was therefore not observed throughout the 
regeneration study. Non-specific interactions between the polyclonal antibody and the 
BSA part of the protein conjugate, and the CM-dextran gel surface were minimal, and 
there was no need to incorporate BSA or CM-dextran into the diluent buffer.
After optimising the regeneration conditions, and non-specific interactions of the 
polyclonal antibody binding to the conjugate surface, an attempt was made to develop 
an inhibition SPR-based assay. The same range of detection was chosen for the 
antibody as that optimised in the ELISA. However, as can be seen from Figure 6.20, 
no inhibition was observed. A lower range o f detection for the antibody was also 
attempted (data not shown), but this too resulted in no inhibition being observed. The 
assay was also carried out using the 50 M excess conjugate. However no inhibition 
was observed in this situation either. A number o f reasons may explain this result. 
Firstly, the range of detection o f the antibody for the detection of chlorpyrifos may 
have increased in the BIAcore-based assay, thus causing problems with pesticide 
solubility. Due to the hydrophobicity o f chlorpyrifos, it is only soluble in methanol at 
high concentrations. However, the antibodies used in this assay cannot tolerate high 
methanol concentrations (Figure 6.12). As a result of this problem, it was not 
possible to determine a range of detection for the antibodies at the higher 
concentrations, because the population would not be able to tolerate the high 
concentration of methanol.
Another reason this assay may not have worked was that the antibody had a high 
dissociation rate. Figure 6.17 shows the antibody saturation curves carried out, and it 
can be observed that after the injection the antibody did begin to rapidly dissociate 
from the immobilised conjugate surface. In the inhibition set-up, the antibodies may 
have bound to the free pesticide in solution, but, because of the high antibody 
dissociation rate, they dissociated from the free pesticide and, instead, bound-again to 
the conjugate surface. The conjugate surface contained a large amount o f pesticide, 
and therefore the antibody population favoured binding to this instead of the free
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pesticide. A possible solution to this problem was to make a conjugate with an even 
lower molar substitution ratio o f pesticide, in order to shift the equilibrium of the 
assay in favour of the free pesticide and not the conjugate. This was attempted by 
producing conjugates (data not shown) with 5 and 10 M excesses of pesticide. 
However, when they were immobilised onto the sensor surface, there was not enough 
of antibody binding to them in order to develop an inhibition-based assay.
Although it was demonstrated that this antibody detected free pesticide in ELISA, it 
must be noted that ELISA is a different system to that o f BIAcore. ELISA is 
equilibrium-based, and therefore the interaction between the antibody, the pesticide 
and the conjugate were allowed to reach a level o f equilibrium before the detection 
step. In the BIAcore set-up, only the antibody and the pesticide were allowed to 
reach equilibrium before being injected over the conjugate surface, and, as a result, 
when injected over the surface, the antibodies ‘recognise’ this large quantity of 
pesticide-conjugate immobilised. Thus inhibition is prevented.
The reason any o f  these problems were encountered was because the antibodies 
produced probably had a low affinity for the pesticide. Chlorpyrifos is very 
hydrophobic, and this can cause problems in eliciting an immune response in an 
animal. Fasciglione et al. (1996) have found that carrier proteins can specifically 
modulate the antibody titre and the specificity of an immune response. This in turn 
may affect the affinity o f the antibody. They do not recommend conjugating a 
hydrophobic hapten to a hydrophobic carrier (such as KLH, which was used in the 
production o f this polyclonal antibody population). They have found that after 
conjugating such molecules together, the haptens hide inside the protein carrier itself 
by interactions with hydrophobic domains. The result o f this interaction is the lack of 
any productive interaction/stimulation with specific B-cells. Therefore, it is more 
favourable to conjugate a hydrophobic hapten to a more hydrophilic carrier protein. 
This will reduce the number o f domains that the hapten can shield in, and make it 
more available for presentation to the immune system. This will result in more 
specific antibodies with higher affinities.
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6.3. Conclusions
Conjugation o f pirimiphos to a protein for use in the production o f specific antibodies 
was unsuccessful. It was not possible to conjugate the modified form of the 
pesticide-amino-pirimiphos due to the presence o f the two nitrogens on the ring 
structure, as well as the presence of the phosphorous, sulphur and oxygen atoms. 
These had an electronegative effect on the molecule, and made it impossible to 
activate the amino group.
The development o f a competition ELISA for the detection of chlorpyrifos using 
affinity-purified polyclonal anti-chlorpyrifos antibodies was successful. The 
antibody was found to be relatively sensitive in the assay with good levels of 
reproducibility. Production o f chlorpyrifos-BSA conjugates with different molar 
substitution ratios was also successful. These were used for the development of an 
inhibition BIAcore-based assay for the detection o f free chlorpyrifos. However, this 
was unsuccessful, with the antibodies showing no level of inhibition in the SPR- 
based assay set-up using either conjugate. It is thought that the range of detection for 
the antibody may have changed, or its dissociation rate was too high to allow for 
inhibition to occur in the SPR-based immunoassay.
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Chapter 7
Overall Conclusions
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7.1. Overall conclusions
The research described in this thesis is mainly concerned with the production of 
antibodies and antibody fragments to the mycotoxin, aflatoxin Bi. Following their 
characterisation, the antibodies were used for the development o f surface plasmon 
resonance-based immunoassays, for detection of aflatoxin Bi in spiked grain samples. 
Pesticide-protein conjugates were also produced, characterised and evaluated for use 
in different immunoassay formats.
The work described in Chapter 3 entailed the production of polyclonal antibodies to 
aflatoxin Bi, their subsequent purification and characterisation. Protein G affinity- 
chromatography and immunoaffmity chromatography were used to isolate the 
antibodies following ammonium sulphate precipitation o f relevant crude antiserum. 
Immunoaffmity chromatography was particularly successful in the removal of ‘BSA- 
specific’ antibodies, thus ensuring lower background signals when using the same 
toxin-protein conjugate for both immunisation and characterisation procedures. The 
polyclonal antibodies were relatively sensitive and specific to AFBi. The optimised 
assays for the detection of aflatoxin Bi were highly reproducible, and demonstrated 
good precision. Antisera was used for the detection of AFBi in spiked grain samples. 
However, the grain matrix affected the antibody’s performance in the assay, thus 
reducing its sensitivity.
In Chapter 4 the production o f single chain Fv antibodies to aflatoxin Bi from an 
antibody phage display library was examined in detail. The library was produced 
using RNA obtained from the spleen of a mouse immunised with aflatoxin Bi-BSA 
conjugate. This was used for reverse transcription of RNA to cDNA, which was 
subsequently used for the amplification of the genes encoding the heavy and light 
chains o f an antibody. SOE-PCR proved to be an efficient method for annealing the 
heavy and light chains, and, coupled with the ease o f restriction enzyme digestion 
using Sfil, it aided in simplifying ligation of the DNA into the plasmid pAK 100. A 
small combinatorial library was produced. However, given the fact that the library 
was produced from RNA obtained from a mouse that was pre-immunised with
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antigen, it was feasible to pursue screening from it. After three rounds of panning 
using two different toxin-protein conjugates, seven clones (six o f which recognised 
free AFBi) were successfully isolated. Soluble production of one of the scFv 
antibody clones was induced using the high expression vector pAK 400. After 
purification o f the scFv by IMAC, a competition ELISA was optimised. The assay 
was relatively sensitive (limit o f detection-98 ng/ml), but it was thought it could be 
further optimised using a more sensitive anti-FLAG antibody. The phage display 
system used was found to be highly robust with the use o f a number of vectors for 
expression, and generally straightforward for the production of scFv antibodies.
The polyclonal and scFv antibodies produced were then applied for use in SPR-based 
immunoassays (Chapter 5). Regeneration of bound polyclonal antibody from the 
immobilised aflatoxin Bi-BSA conjugate surface was difficult, and required the use 
of organic solvents combined with high ionic strength. Although this solution did not 
regenerate all of the antibody from the surface, it removed a sufficient amount to allow 
for the development o f an assay. The scFv antibody was easily removed from the 
immobilised conjugate surface, and demonstrated a high level o f reproducibility for 
binding. SPR-based inhibition immunoassays were developed for both antibodies, 
which were sensitive and reproducible. These assays were then applied for the 
detection of AFBi in spiked grain samples. Both assays were highly sensitive and were 
capable of detecting AFBi below the maximum residue levels designated by the EU. 
Solution-phase equilibrium analysis was also carried out on the scFv antibody 
demonstrating it had a high dissociation rate constant.
Chapter 6  described the attempted production of a pirimiphos derivative for 
conjugation to a protein. This was unsuccessful, due to the presence o f atoms on the 
pesticide ring structure having an electronegative effect on the molecule, thus making 
it impossible to activate for conjugation.
A competition ELISA was developed for the detection of chlorpyrifos, using affinity- 
purified polyclonal anti-chlorpyrifos antibodies (obtained from collaborators at IFR 
Norwich, U.K.). The antibody was found to be relatively sensitive in the assay with
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good levels of reproducibility. Chlorpyrifos-BSA conjugates with different molar 
substitution ratios were also synthesised and used for the development of an 
inhibition BlAcore-based assay for the detection o f free chlorpyrifos. However, this 
was unsuccessful, with the antibodies showing no level of inhibition in the SPR- 
based set-up using any of the conjugates.
In summary, this work highlights the potential use of immunoassays for the detection 
of food contaminants in samples. It shows that antibodies can be produced with 
relative ease to aflatoxin B t, although, in the case o f polyclonal antisera not all 
populations within a given antiserum are as sensitive as each other. The production 
of recombinant antibody fragments shows great promise, especially when derived 
from a mouse that was pre-immunised with antigen. It can also be seen that large 
library sizes are not necessarily essential when using pre-immunised libraries. Single 
chain Fv antibodies have been shown to be as sensitive as polyclonal antibodies for 
the detection of the aflatoxin in SPR-based assays. They also showed good solvent 
tolerance levels. This is significant for future biosensor applications that compatibility 
(even if  limited) for organic solvents was demonstrated.
Organophosphate pesticides have proven to be difficult molecules to produce 
antibodies against. This is due mainly because they are difficult to conjugate to 
proteins, as they do not always contain a suitable functional group. They are also very 
hydrophobic in nature, thus making it difficult to achieve optimal conditions for the 
pesticide and protein to react without compromising their respective solubilities.
Future work could entail optimisation of aflatoxin extraction from grain samples using 
immunoaffinity columns, for the development of more sensitive and reproducible 
assays. These could then be used for reliable and routine analysis of food samples. It 
may also be possible to apply the antibodies for use in a ‘on-site’ dipstick assay and this 
will be examined shortly.
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Appendix 1A
Glossary o f  terms and definitions commonly employed in Bioanalytical
Validation procedures 
The terms listed below were referred to for validation purposes of certain 
procedures carried out in this thesis. The criteria which they can be defined under 
have been reviewed elsewhere (Findlay et al., 2000).
M ean
Describes the average of replicate (x) measurements, (i.e. /*/+«2+  nx/x)
Precision
Is defined as the closeness of agreement, or variance between independent test 
results of multiple measurements of the same sample obtained under a set of 
specified analytical test conditions. It is normally expressed in terms o f the 
relative standard deviation (% R.S.D.), or the coefficient o f variation (% C.V.) of 
the determined concentration of a replicate number of assays. The degree of 
precision assessed between replicates (i.e. % C.V.) performed during a single 
assay batch, is commonly referred to as the intra-assay variation (also referred to 
as repeatability). The term inter-assay variation (also referred to as 
reproducibility) is used to describe the precision between assays when related to 
multiple batches.
Lim it o f  Detection (L. O.D.)
Defines the lowest analyte concentration that the analytical technique can 
differentiate from background signals and is usually determined as background 
noise ± 3 standard deviations.
Robustness:
Is a term used to describe the ability of an analytical technique to withstand 
fluctuations in the described analytical test conditions. For immunoassay 
procedures the term could be used to describe changes in the ionic strength of the 
matrix, as well as pH and temperature changes.
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Standard Curve:
This describes the relationship between the measured analyte response (i.e. 
absorbance, response units) and the analyte concentration.
Non-specific binding:
This describes matrix effects which affect the degree of binding of the 
antibody: antigen interaction, and can occur as a result of increased protein 
concentration and sample viscosity in the sample matrix (e.g. grain matrix ), and 
also as result of altered ionic composition (e.g. urine) o f the sample matrix.
Coefficient o f  Variation (% C. V)
A quantitative measure o f the precision of an analytical measurement expressed as 
a percent function o f the mean value, also referred to as the Relative Standard 
Deviation (% R.S.D.).
% C.V. = [S.D./Mean value] x 100
Precision profile:
A quantitative measure of the variation between measurements, usually the 
coefficient o f variation versus the nominal concentration of analyte in the sample.
Normalised Response Values:
The response recorded in response units (RU) at each particular antigen 
concentration divided by the response recorded in the presence o f zero antigen.
Normalised Response = Response measured at particular antigen concentration
Response measured at zero antigen concentration
Normalised Absorbance Values:
The absorbance recorded (AU) at each particular antigen concentration divided by 
the absorbance recorded in the presence of zero antigen.
Normalised Absorbance = Absorbance measured at particular antigen concentration
Absorbance measured at zero antigen concentration
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